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ABSTRACT 
The acyl-CoA dehydrogenase, ACAD, genes encode enzymes that are essential to cellular 
metabolism as evidenced by the identification in the past 20 years of genetic defects associated 
with nine members of this gene family. In total, these defects constitute the most common inborn 
errors of metabolism identified through newborn screening and so are concerns to public health. 
Recently, two new ACADs, ACAD10 and 11, of unknown function have been identified. This 
discovery raises the specter of additional unrecognized disorders since prior studies on these two 
ACADs suggested a novel role in metabolism. Recently, ACAD10 has been linked to type 2 
diabetes in Pima Indians, which draws additional attention to its role in metabolism and public 
health importance.  
Both ACAD10 and ACAD11 are highly conserved but with unique additional large 
protein domains compared to other ACADs, likely encoded from  multiple coding domains. 
ACAD10 antigen in mice is present in lung, muscle, kidney, and pancreas, and localized to 
mitochondria, while a weak signal is also observed in peroxisomes of mouse lung. Human 
tissues including lung, kidney, liver, muscle, and pancreas reveal antigen present in 
mitochondria, and a weak antigen signal in peroxisomes in kidney and pancreas.   
  To investigate the role of ACAD10 in metabolism further, I have generated an Acad10 
deficient mouse and have characterized it through pathological, biochemical, and molecular 
studies. Deficient animals are viable and fertile, but become obese. Pathological studies reveal 
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inflammatory liver disease and secondary splenic extramedullary hematopoiesis. Skeletal muscle 
findings were  abnormal, consistent with deficient mice have elevated creatine kinase when 
fasting, indicative of rhabdomyolysis. Metabolomics analysis identified elevated levels of a 
variety of acylcarnitine species in deficient mouse samples consistent with mild, global energy 
dysfunction. Most dramatically, animals develop a syndrome consistent with insulin insensitivity 
characteristic of type 2 diabetes mellitus in humans. A better understanding of the biochemical 
pathways and physiological role of ACAD10, as well as the pathophysiology of disorders 
occurring among this new ACAD family member will allow identification and treatment of 
patients with ACAD10 deficiency, as well as its role in obesity and type 2 diabetes. 
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 1.0  INTRODUCTION 
Mitochondrial β-oxidation of fatty acids is critical for maintaining energy balance in organisms. 
While fatty acids are essential components of membrane structure and energy storage, their 
functions in cellular signaling, protein activation, and regulation of inflammatory, immune and 
other stress responses are no less important. These other roles often involve unusual complex 
lipids that are strictly regulated, often through their acyl-CoA intermediates. The goal of this 
project was to characterize the role of acyl-CoA dehydrogenases 10 and 11 on the metabolism of 
acyl-CoAs, and to identify the consequences of its failure in a model organism. 
1.1 MITOCHONDRIAL FATTY ACID OXIDATION 
Fatty acid β-oxidation (FAO) is a series of enzymatic reactions that occurs in the mitochondria 
and peroxisomes of all living eukaryotic organisms. β-oxidation in mitochondria generates 
reducing equivalents that are tied to adenosine triphosphate (ATP) synthesis via the electron 
transport chain (ETC) (Atkinson, Kapralov et al.), whereas β-oxidation in peroxisomes is 
associated with the production of hydrogen peroxide (H2O2) (Coates and Tanaka 1992, Reddy 
and Hashimoto 2001). Mitochondrial β-oxidation allows generation of energy from the 
degradation of fatty acids when the cellular glucose supply is low (Houten and Wanders 2010). 
Fatty acid synthesis is tightly linked to dietary intake, and during fasting, fatty acid synthesis is 
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 halted, and in turn, fatty acid oxidation is induced (Lehninger 1982). During this process, a 
variety of substrate transporters and enzymes ultimately lead to the degradation of fatty acids, 
resulting in the production of FADH2 and NADH that provide reducing equivalents directly to 
the ETC, and acetyl-CoA, which is available to enter the Krebs cycle (tricarboxylic acid cycle, 
TCA) where additional reducing equivalents are generated for production of ATP. ATP is the 
main source of energy for the organism (Lehninger 1982). 
 
Figure 1.  Mitochondrial Fatty Acid β-Oxidation Pathway 
 
 
Fatty acids consist of a chain of carbons with a carboxyl group attached at one end that 
serves as a reactive group for incorporation of coenzyme A into the molecule (Houten and 
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 Wanders 2010). Coenzyme A (CoA) is a cofactor that destabilizes the carbon-to-carbon bonds, 
allowing for reactions to occur at the third carbon in the chain (Houten and Wanders 2010). Free 
fatty acids are released from body triglyceride stores, then transported to cells via carrier 
proteins, imported into cells, and imported into the mitochondrial matrix as an activated acyl-
CoA substrate (Vockley and Whiteman 2002). There, a series of four enzymatic steps removes 
an acetyl-CoA moiety from the carbon backbone and leaves an acyl-CoA molecule that is two 
carbons shorter.  
In the first step of β-oxidation within the mitochondrial matrix, acyl-CoA 
dehydrogenases convert acyl-CoA esters to trans-2-enoyl-CoA, reducing its FAD cofactor to 
FADH2 (Lehninger 1982, Swigonova, Mohsen et al. 2009). The trans-2-enoyl-CoA is hydrolyzed 
by enoyl-CoA hydratase forming a 3-hydroxyacyl-CoA (GallusReactome 2010). The third step 
involves a second oxidation; 3-hydroxyacyl-CoA is converted to 3-ketoacyl-CoA by 3-
hydroxyacyl-CoA dehydrogenase, generating a molecule of NADH  (GallusReactome 2010). 
Reducing equivalents captured in FADH2 and NADH enter the respiratory chain at complexes I 
and III, respectively. The final step of the cycle is catalyzed by a ketoacyl-CoA thiolase and 
releases the two-carbon acetyl-CoA and a 2-carbon shorter acyl-CoA ready for another round of 
β-oxidation (GallusReactome 2010). Acetyl-CoA has a variety of metabolic fates, one of which 
is utilization by the TCA cycle, leading, in turn, to the generation of additional reducing 
equivalents for energy production through oxidative phosphorylation (OXPHOS). Thus, the 18-
carbon substrate palmitic acid (C16:0) for example will cycle through this process a total of eight 
times to reach completion and can generate up to 123 molecules of ATP through oxidative 
phosphorylation.  
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 Acyl-CoA dehydrogenases catalyze the α,β-dehydrogenation of acyl-CoA esters, utilizing 
FAD to transfer electrons to electron transferring flavoprotein, and in turn to the ETC. Several 
acyl-CoA dehydrogenases function in fatty acid oxidation cycle, each with a unique substrate 
optimum. Very long, medium, and short chain ACDs (VLCAD, MCAD, and SCAD) catalyze the 
first step of mitochondrial β-oxidation in the mitochondrial matrix with substrate chain length 
optima of 16, 8, and 4 carbons, respectively (Coates and Tanaka 1992). In contrast to VLCAD, 
ACAD9 and LCAD are most active against unsaturated long and branched medium chain 
substrates, respectively (Coates and Tanaka 1992). Other highly homologous ACADs, 
isovaleryl-CoA (IVD), short/branched chain acyl-CoA (SBCAD), and isobutyryl-CoA 
dehydrogenases (IBD) (Ibdah, Paul et al.), catalyze the third step in leucine, isoleucine, and 
valine metabolism, respectively, while glutaryl-CoA dehydrogenase (GDH) functions in lysine 
and tryptophan catabolic pathways (Coates and Tanaka 1992). 
1.1.1 Structural aspects of ACADs 
The crystal structures of MCAD, Mega- losphaera elsendii butyryl-CoA dehydrogenase, GDH, 
IVD, SCAD, VLCAD, and IBD have been published and are highly conserved (Tiffany, Roberts 
et al. 1997, Battaile, Molin-Case et al. 2002, Battaile, Nguyen et al. 2004, McAndrew, Wang et 
al. 2008). In MCAD, the fatty acyl portion of the octanoyl-CoA substrate is buried inside the 
polypeptide chain and is surrounded by V259 and Y375 on opposite sides, E376 at the top, and 
the flavin ring at the bottom. The structure also reveals that the FAD has an extended 
conformation with interaction of the flavin ring C2 carbonyl oxygen with residue Thr136 of the 
mature peptide chain. The overall polypeptide fold of IVD and SCAD are similar to that of 
MCAD and to a bacterial SCAD. The identity of the catalytic base of IVD has been confirmed to 
 4 
 be E254, and the location of the catalytic residue together with a glycine at position 374, which 
is a tyrosine in all other members of the ACAD family, appears to be important for conferring 
the branched-chain substrate specificity of IVD. 
1.1.2 Mouse Models of ACAD Deficiencies 
In the literature, several mouse models of ACAD deficiencies have been developed to help 
characterize the disease (Houten and Wanders 2010). The majority of these models have been 
created by genetic manipulation, however, two of them contain spontaneous mutations (Houten 
and Wanders 2010). Table I. below defines several of these models and how they relate to the 
disease as observed in humans (Koizumi, Nikaido et al. 1988, Schiffer, Prochazka et al. 1989, 
Wood, Amendt et al. 1989, Kuwajima, Kono et al. 1991, Kurtz, Rinaldo et al. 1998, Cox, Hamm 
et al. 2001, Ibdah, Paul et al. 2001, Janssen and Stoffel 2002, Exil, Roberts et al. 2003, Nyman, 
Cox et al. 2005, Tolwani, Hamm et al. 2005, Ji, You et al. 2008, Miinalainen, Schmitz et al. 
2009, Houten and Wanders 2010).   
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Table 1. Comparison of FAO deficiencies in mouse models 
 
1.2 ACAD 10 AND 11 
1.2.1 Multiple transcripts from ACAD10 and ACAD11 genes 
The function of two additional genes annotated in the human genome and predicted to be 
ACADs (ACAD10 and 11) is unknown (Swigonova, Mohsen et al. 2009, He 2011). These two 
genes share 46% amino acid homology between each other and are widely conserved across 
evolution. ACAD10 and ACAD11 genes with homology to the ACAD, APH, and HDL domains 
Disease 
Human  
Deficiency Mouse Model Reference 
OCTN2/Primary  
carnitine  
deficiency + + 
Koizumi et al. 1988;  
Kuwajima et al. 1991 
CPT1a + § Nyman et al. 2005 
CPT1b § Ji et al. 2008 
LCHAD/MTP ++ ++ Ibdah et al. 2001 
VLCAD ++ ± 
Cox et al. 2001; Exil et  
al. 2003 
LCAD ? + Kurtz et al. 1998 
MCAD ± Tolwani et al. 2005 
SCAD ?(?) ± 
Wood et al. 1989;  
Schiffer et al. 1989 
DCI ? ± 
Janssen and Stoffel  
2002 
DECR ++(?) ± Miinalainen et al. 2009 
§ Embryonic lethal 
? Unknown 
? No phenotype or asymptomatic 
± Mild, + moderate, ++ severe 
 6 
 are still found in lower organisms, such as fungi (Swigonova, 2009). Both genes are located 
within complicated loci containing multiple predicted exons and protein domains. Upstream of 
the conserved ACAD domains, there is a putative aminoglycoside phosphotransferase (APH) 
domain in both ACAD10 and ACAD11, which also could be a homoserine kinase type II domain 
(Figure 2) (He, 2011). 
 
 
Figure 2. ACAD10 Map 
The human ACAD10  genes consists of multiple predicted domains, including an APH domain, mitochondrial 
targeting signal (M), ACAD N-terminal domain (ACDN), ACAD middle domain (ACDM), and ACAD C-terminal 
domain (ACDC). There is also a predicted hydrolase superfamily domain (HDL) identified at the N-terminus of 
some alternative protein forms of ACAD10. These domains are drawn as colored boxes with the number of 
associated amino acids specified.  
 
The N-terminus of ACAD10 is longer than ACAD11, and it contains a predicated 
hydrolase domain ahead of the APH/homoserine kinase type II domain. Database searches of 
transcribed sequences from these genes have identified the presence of multiple transcripts that 
differ mostly at either the 5’ or 3’ end (He, 2011).  
To examine the presence of these transcripts in vivo, real-time PCR with primer pairs 
targeted to unique exon junctions in the different transcripts was used to measure the expression 
level of alternative transcripts of ACAD10 and 11 in 21 different human tissues (He 2011).  
  Multiple transcripts from the ACAD10 gene were detected and the relative abundance of 
each transcript differed in the various human tissues (Figure 3; (He 2011)). Primer set 7/8 target 
the region corresponding to the predicted APH domain (He, 2011). Primers 13/14 target a region 
shared by most transcripts in the genetic databases at the junction between the APH domain and 
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 conserved ACAD N- terminal domain (He, 2011). Primers 21/22 amplified a region mapped to a 
conserved C-terminal ACAD domain containing the catalytic base (He, 2011). In contrast, 
primers 21/22’ target an alternatively spliced species that eliminate exon 22, leading to loss of 
the predicted ACAD catalytic domain (He, 2011). In all tissues, expression of the transcripts 
amplified by primers 7/8 was higher than those by primers 21/22 (He, 2011). Thus, a large 
portion of the transcripts that contain sequences for an APH domain at the N-terminus do not 
have sequences for the ACAD domain at the C-terminus (He, 2011). Expression of the fragment 
defined by p21/22 was much higher than p21/22’ showing that the majority of transcripts 
encoding ACAD domains contain sequences potentially supporting ACAD enzymatic function 
(He, 2011). Interestingly, in some tissues (e.g., small intestine and thymus) the expression level 
of transcripts containing fragment 7/8 was higher than those amplified by primers 13/14, 
suggesting that these tissues may express a previously unrecognized protein species comprised of 
only an APH domain without ACAD sequences (He, 2011). Figure 3 below represents the 
expression of each fragment.  
 
Figure 3. Relative expression of ACAD10 mRNA species vs. GUSB in 21 human tissues 
Each colored bar represents the expression of a fragment amplified by a different set of primers as indicated by the 
legend. The data represent the mean of three qPCR experiments with a robust %CV less than 1.35% 
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 1.2.2 Tissue distribution of ACAD10 and ACAD11 transcripts 
To begin to understand the in vivo functions of ACAD10 and 11, the tissue expression pattern of 
the two genes in 21 different human tissues was examined using real-time RT-PCR (He 2011). 
Information currently available on both genes in public databases proved to be incomplete, 
hindering the ability to quantitate each of the specific transcripts. Therefore probes p13/14 
(ACAD10) and p11/12 (ACAD11) were used to target the sequences that are common to most of 
the identified transcripts thus measuring the total expression of each gene. ACAD11 had the 
highest level of expression in adult brain, 1.3 times the expression of the housekeeping gene 
GUSB (used as the internal control) (He, 2011). Thereafter, expression levels in other tissues 
were normalized to the brain. ACAD11 additionally had significant levels of expression in adult 
liver, heart, and kidney. ACAD10 had much lower levels of expression than ACAD11 with the 
highest level in muscle (0.3 times the expression of GUSB). Figure 4 below shows the 
expression of ACAD10 in other tissues relative to muscle. Interestingly, ACAD10 was expressed 
more highly in fetal brain than adult, a pattern similar to that seen for LCAD and also was highly 
expressed in heart and kidney (He, 2011). 
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Figure 4. Distribution of ACAD10 and 11 mRNA and protein in human tissues 
Levels of ACAD11 (A) and ACAD10 (B) mRNA were measured in 21 human tissues by real-time RT-PCR and 
normalized to the relative level of expression in the highest expression tissue. Primers P11/12 were used for 
measuring ACAD11 expression level and primers P13/14 were used for measuring ACAD10 levels. Both probes 
target the common region among all the known transcripts. The highest expression tissue of ACAD11 was found in 
brain (ratio to the housekeeping gene GUSB = 1.3), and the highest expression of ACAD10 was in fetal brain 
(relative expression to GUSB = 1.5). 
1.2.3 Subcellular location and mitochondrial fractionation of ACAD11 protein isoforms 
The presence of multiple ACAD10 and 11 transcripts in various tissues raises the possibility that 
some might generate protein species that localize to different subcellular compartments (He 
2011). To examine this, two separate rabbit polyclonal antisera were raised against synthetic 
ACAD11 peptides corresponding to a portion of the sequence of the N-terminal domain of the 
mature mitochondrial ACAD11 (He, 2011). The peptide sequences are common to potential 
ACAD11 protein isoforms translated from all identified ACAD11 transcripts, but not 
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 homologous to other ACADs including ACAD10 (He, 2011). Western blot analysis with this 
antiserum identified an ACAD11 protein species corresponding in size to the mature 
mitochondria form seen in our in vitro import studies. This form primarily localized to the 
membrane fraction of mitochondria isolated from both human cerebellum and kidney, but not in 
the mitochondrial matrix fraction (Figure 5) (He, 2011).  
 
Figure 5. Immunoblotting of mitochondrial subfractions from different tissue lysates 
An antibody to an ACAD11 peptide gave the highest signal in human kidney and brain. It appeared mainly in 
mitochondrial membrane (Mb), rather than matrix fraction (Mx). 
 
Immunofluorescence staining of ACAD11 in human neuroblastoma and skin fibroblasts 
revealed a marked difference in subcellular location of ACAD11 proteins (Figure 6 A-J) (He, 
2011). ACAD11 protein in neuroblastoma cells co-localized with mitochondrial ATPase (Figure 
6 A-C) (He, 2011). In contrast, majority of the ACAD11 signal in fibroblasts did not colocalize 
with mitochondrial ATPase (Figure 6 D-F) (He, 2011). 
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Figure 6.  Immunofluorescent staining of ACAD11 in human neuroblastoma and skin fibroblast 
Fluorescent staining of human neuroblastoma (SK-N-SH) (A), skin fibroblast (D) with antibodies to an ACAD11 
peptide is shown in green. (B and E) Fluorescent staining of the same human cells against mitochondrial ATPase 
antibody is shown in red. C is the merged image of A and B, and F is the merged image of D and E. The nucleus is 
indicated by white arrows. Human skin fibroblast were also treated with digitonin to only dissolve only the outer 
membrane, and then stained with ACAD11 peptide antibody (H), mitochondiral ATPase antibody (I). J is the 
merged image of H and I, showing ACAD11 stains other single membrane organelles besides mitochondria. DAPI 
was used for nuclear staining in panels H-J. 
 
Interestingly, in both human skin fibroblast and human neuroblastoma, additional 
ACAD11 specific staining actually appeared near the cytoplasmic membrane with a punctate 
pattern typical of membrane associated vesicles, most prominently seen with digitonin treat- 
ment (which preferentially solubilizes the cytoplasmic membrane). Finally, ACAD11 antibodies 
strongly stained nuclei regardless of cell solubilization conditions (Figure 6 H-J), a pattern also 
seen for ACAD9 (He, 2011). The striking difference in subcellular location of ACAD11 among 
various cell and tissue types emphasizes that expression of the mitochondrial form of ACAD11 
as the product of alternative splicing is tissue specific, in agreement with RNA expression 
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 studies (He, 2011). Consistent with these observations, a global proteomic survey of subcellular 
organelles of six major organs in mouse localized predicted ACAD10 protein to the membrane 
(microsomal) fraction and mitochondria, while ACAD11 sequences were identified in 
peroxisomes and mitochondria (He, 2011). 
1.2.4 Computer modeling of ACAD10 and ACAD11 
Computer modeling of ACAD10 and ACAD11 predict that an amino acid change from 
glutamate to aspartate (Figure 7) occurred in the catalytic site of these two members of the 
ACAD family (He 2011). This change is predicted to lead to different substrate specificity than 
seen in the other ACADs. To examine this prediction, a fragment comprising the mature 
mitochondrial coding region was cloned and over expressed in a prokaryotic system.  
 
Figure 7. Comparison of the amino acid residues in the active site of ACAD11 
A predicted model and GCD crystal structural model. Amino acids in ACAD11 are shown as colored sticks. Dark 
green highlights the relative positions of Glu370, the catalytic residue common to many of the ACADs. 
 
Extracts expressing the mature ACAD10 insert were only active with R or S, 2 methyl- 
C15-CoA (R or S, 2- methyl-pentadecanoyl-CoA) among a broad series of other substrates 
including the optimum ones for all of the other ACADs. The measured activity (1.4 mU/mg at 
150 M substrate concentration) was considerably lower and required higher substrate 
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 concentration than that obtained with other expressed ACADs towards their optimum substrates, 
suggesting that the dehydrogenation reaction between ACAD10 and R or S, 2 methyl- C15-CoA 
is unlikely the optimal function for ACAD10 in vivo. 
1.3 PLANT ACADS 
Plants perform a variation of fatty acid oxidation localized to the peroxisomes utilizing acyl-coA 
oxidases, which is thus analogous to human peroxisomes (Zolman, Nyberg et al. 2007). Acyl-
CoA oxidases are structurally similar to ACAD enzymes except that they utilize water as the 
electron acceptor for the oxidized enzyme, generating hydrogen peroxide in the process. The 
auxin indole-3-butyric acid (IBA, a plant growth factor) has been identified as a substrate of 
peroxisomal fatty acid β- oxidation in plants. The metabolism of IBA has been shown to be 
dependent on a peroxisomal protein (IBR) homologous to the ACADs, specifically ACAD10 and 
11 (Zolman, Nyberg et al. 2007). The plant and mammalian proteins both contain an APH 
domain at the N-terminus and ACAD domain at the C-terminus (Zolman, Nyberg et al. 2007). 
The IBR ACAD domain is most similar to the ACAD domain found in MCAD and other 
branched chain acyl-CoA dehydrogenases active against substrates containing characteristic 
aromatic rings (Zolman, Nyberg et al. 2007). 
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 1.4 ACAD LOCALIZATION ON GLUT4-CONTAINING VESICLES 
In addition to their usual location in the mitochondrial matrix, acyl-CoA dehydrogenases have 
been shown to be associated with cytoplasmic GLUT4-containing vesicles where they interact 
with two dileucine motifs on insulin-regulated aminopeptidase (IRAP) (Katagiri, Asano et al. 
2002). Glucose transporter type 4 is a protein encoded by the GLUT4 gene, and is expressed 
primarily in fat and muscle tissues (Katagiri, Asano et al. 2002). In cells, glucose equilibrium is 
maintained by the GLUT4 response to insulin (Haga, Ishii et al. 2011). The IRAP containing 
GLUT4 vesicles respond to insulin stimulation by translocating to the cell surface. IRAP has a 
specific protein structure containing a dileucine motif. The dileucine motif in IRAP plays a 
critical role in regulating GLUT4 trafficking. Several ACADs have been identified as being 
associated with the dileucine motif portion of IRAP, including LCAD, MCAD, and SCAD 
(Katagiri, Asano et al. 2002). Mutation of the dileucine motif of IRAP (amino acids 55-82) 
destroys this interaction (Katagiri, Asano et al. 2002).  
While these findings potentially connect some of the ACADs with insulin dependent 
transportation of glucose within cells, the physiologic role of the ACAD proteins in this setting is 
unclear (Katagiri, Asano et al. 2002). Of note, ACAD10 has been linked to insulin resistance and 
lipid oxidation in the Pima Indian population, but its localization to GLUT4 vesicles has not been 
investigated (Bian, Hanson et al. 2010). ACAD10 was one of 30 genes further examined after 
demonstrating a significant signal for diabetes in a genome-wide association study (Bian, 
Hanson et al. 2010). In this GWAS, a single nucleotide polymorphism (SNP), rs632650, was 
found to map within intron 2 of ACAD10 (Bian, Hanson et al. 2010). A functional association of 
ACAD10 with GLUT4-containing vesicles could provide a possible link between this ACAD 
and an insulin-regulated pathway. 
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 2.0  EVIDENCE FOR INVOLVEMENT OF MEDIUM CHAIN ACYL-COA 
DEHYDROGENASE IN THE METABOLISM OF PHENYLBUTYRATE 
This work has been previously published in the following location, (Kormanik, Kang et al. 
2012). Copyright permission was obtained to include the manuscript in this thesis dissertation. 
Kormanik K, Kang H, Cuebas D, Vockley J, Mohsen AW. “Evidence for involvement of 
medium chain acyl-CoA dehydrogenase in the metabolism of phenylbutyrate.”  Mol 
Genet Metab. 2012 Dec;107(4):684-9. doi: 10.1016/j.ymgme.2012.10.009. Epub 2012 
Oct 18. 
2.1 ABSTRACT 
Sodium phenylbutyrate is used for treating urea cycle disorders, providing an alternative for 
ammonia excretion. Following conversion to its CoA ester, phenylbutyryl-CoA is postulated to 
undergo one round of β-oxidation to phenylacetyl-CoA, the active metabolite. Molecular 
modeling suggests that medium chain acyl-CoA dehydrogenase (MCAD; EC 1.3.99.3), a key 
enzyme in straight chain fatty acid β -oxidation, could utilize phenylbutyryl-CoA as substrate. 
Moreover, phenylpropionyl-CoA has been shown to be a substrate for MCAD and its 
intermediates accumulate in patients with MCAD deficiency. We have examined the 
involvement of MCAD and other acyl-CoA dehydrogenases (ACADs) in the metabolism of 
phenylbutyryl-CoA. Anaerobic titration of purified recombinant human MCAD with 
phenylbutyryl-CoA caused changes in the MCAD spectrum that are similar to those induced by 
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 octanoyl-CoA, its bona fide substrate, and unique to the development of the charge transfer 
ternary complex. The calculated apparent dissociationconstant (KD app) for these substrates was 
2.16 μM and 0.12 μM, respectively. The MCAD reductive and oxidative half reactions were 
monitored using the electron transfer flavoprotein (ETF) fluorescence reduction assay. The 
catalytic efficiency and the Km for phenylbutyryl-CoA were 0.2mM-1⋅ sec-1 and 5.3 μM 
compared to 4.0 mM-1⋅ sec-1 and 2.8 μM for octanoyl-CoA. Extracts of wild type and MCAD-
deficient lymphoblast cells were tested for the ability to reduce ETF using phenylbutyryl-CoA as 
substrate. While ETF reduction activity was detected in extracts of wild type cells, it was 
undetectable in extracts of cells deficient in MCAD. The results are consistent with MCAD 
playing a key role in phenylbutyrate metabolism. 
2.2 INTRODUCTION 
Impairment of urea synthesis in humans is caused by defects in the activity of enzymes in the 
urea cycle including carbamylphosphate synthetase, ornithine transcarbamylase, argininosuccinic 
acid synthetase, argininosucinate lyase, and arginase and leads to hyperammonemia. High levels 
of ammonia in blood may lead to encephalopathy and death (Diaz, Krivitzky et al. 2013). 
Sodium phenylbutyrate is the active ingredient in Buphenyl ® (Hyperion, Pharmaceuticals) and 
is currently used for treating primary hyperammonemia caused by certain urea cycle defects 
(Adam, Almeida et al. 2013). Sodium phenylbutyrate may also be useful in treating secondary 
hyperammonemia that accompanies other inborn errors. In addition, phenylbutyrate has been and 
is being investigated in numerous clinical settings including modulation of fetal hemoglobin 
gene expression in sickle cell and in thalassemia, treatment of myleodysplastic syndromes and 
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 acute myeloid leukemia, cerebral and liver ischemic injury protection, among others (SD Gore 
2001, M Vilatoba and JL 2005, G Egger 2007, Y Saito 2009). As of this writing >30 trials 
involving sodium phenylbutyrate are listed on the www.clinicaltrial.gov website.  The 
mechanism proposed for ammonia clearance by phenylbutyrate administration involves its 
activation to phenylbutyryl-CoA, conversion to phenylacetyl-CoA, and conjugation with 
glutamine (Figure 8) for excretion by the kidneys (X Qi 2004).  
 
Figure 8. Schematic showing a proposed overall pathway for metabolism of phenylbutyrate to its final 
metabolite 
 
The conversion of phenylbutyryl-CoA to phenylacetyl-CoA is presumed to occur through 
one cycle of β-oxidation in mitochondria. The first step in the β-oxidation cycle is the α,β-
dehydrogenation of fatty acid CoA esters catalyzed by members of the acyl-CoA dehydrogenase 
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 (ACAD) family of enzymes. Nine members of this enzyme family have been identified, each 
with characteristic substrate specificity profile (J Willard , Y Ikeda 1983, Y Ikeda 1983, K Ikeda 
1985, K Izai 1992, R Rozen 1994, J Zhang 2002, TV Nguyen 2002). Short, medium, long, 
saturated very long, unsaturated very long chain acyl-CoA dehydrogenases (SCAD, MCAD, 
LCAD, VLCAD and ACAD9) have substrate optima of C4, C8, C12, C16, and C16:1 
(unsaturated very long chain among others) acyl-CoA esters, respectively, but can utilize other 
substrates (Y Ikeda 1983, Y Ikeda 1985, Y Ikeda 1985, R Ensenauer 2005). The crystal 
structures of SCAD, MCAD, and VLCAD have been published, (PDB ID: 1JQI, 3MDE, and 
43B96, respectively) (J-J Kim 1993, KP Battaile 2002, RP McAndrew 2008). The remaining 
four enzymes in the family are involved in amino acid metabolism and their crystal structures 
have been published as well, (PDB ID: 1IVH, 1SIR, 1RX0, and 2JIF) revealing a relatively 
restrictive active sites, rendering them highly specific for their bonafide substrates (KA Tiffany 
1997, KP Battaile 2004, Z Fu 2004, ACW Pike 2007).  It has been observed that patients with 
MCAD deficiency characteristically accumulate both the glycine and carnitine conjugates of 
phenylpropionate, a bacterial metabolite from bowel flora that is absorbed into the blood stream 
(P Rinaldo 1988). Mass spectrometry based enzymatic assay of MCAD deficient patient 
fibroblast cells using phenylpropionyl-CoA as substrate showed lack of conversion to its α,β-
unsaturated product (TG Derks 2008). While the crystal structure of SCAD and VLCAD and 
homology 3D modeling of ACAD9 show that the active site would not accommodate the 
phenylbutyryl acyl moiety, the active site of MCAD would. These findings and the structural 
similarities between phenylpropionate and phenylbutyrate implicate MCAD in the metabolism of 
phenylbutyryl-CoA.  In this study we tested the ability of purified human recombinant ACADs 
to bind and use phenylbutyryl-CoA as a substrate. We demonstrate that MCAD indeed uniquely 
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 utilizes phenylbutyryl-CoA as a substrate. In addition, we show the inability of extracts prepared 
from MCAD-deficient fibroblast to act upon this substrate.  
2.3 MATERIALS AND METHODS 
2.3.1 Purification of recombinant human MCAD 
Expression and purification of recombinant human MCAD was performed as previously 
described for isovaleryl-CoA dehydrogenase with minor modifications (A-W Mohsen 1995).   E. 
coli JM105 cells (Amersham Biosciences Corp; Piscataway, NJ) containing the human MCAD 
high expression vector pKeMCAD (Y Matsubara 1989) and a GroEL/GroES expression plasmid 
were grown overnight in a 200-ml LB broth pre-culture that was used to inoculate 4 x 2-L 
cultures in 2-YT broth. The cells were left to grow overnight at 37˚C with shaking and MCAD 
expression was induced the next morning using IPTG at a final concentration of 0.5 mM for 3 
hrs. Cells were harvested by centrifugation and resuspended in 2:1 weight to volume of 100 mM 
potassium phosphate pH 8.0, 150 mM EDTA. Cells were then lysed by sonication on ice. 
Including high amounts of EDTA in the cell lysis buffer is for protecting residues with groups, 
e.g., cysteine thiols and methionine sulfide groups, vulnerable to modification by oxygen 
reactive species generated during sonication cell suspension. This was effective in improving 
enzyme preparations resulting higher specific activity and consistent kinetic behavior (A-W 
Mohsen 1999). Cellular debris was removed by centrifugation at 250,000 x g for 60 minutes. The 
final supernatant was dialyzed for 4 hours with vigorous stirring in 50 mM potassium phosphate 
pH 8.0, at 4˚C. The sample was then loaded on a 16 x 40 mm DEAE Sepharose FF column 
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 preequilibrated in 50 mM potassium phosphate pH 8.0, using an ÄKTA UPC-900 pump FPLC 
system (Amersham Biosciences Corp; Piscataway, NJ). After washing with 300 ml of 50 mM 
potassium phosphate pH 8.0, MCAD was eluted with a 300 ml linear gradient from 50 to 500 
mM potassium phosphate pH 8.0. Green fractions with a 270/447 nm ratio <12 containing 
MCAD were pooled, concentrated, and dialyzed against 25 mM potassium phosphate, pH 8.0. 
Pooled fractions of essentially pure MCAD (270/447 nm ratio = 5.5), were concentrated and 
stored at –80˚C. Other recombinant human ACADs were similarly purified except that the 
protocol was terminated after the DEAE-Sepharose column for LCAD as the enzyme was 
unstable. LCAD protein purity ~70% at this stage. 
2.3.2 The electron transfer flavoprotein (ETF) purification 
Porcine ETF was purified as previously published (J Vockley 2000), except that the dialysis 
buffer used after both the 40-60% ammonium sulfate fractionation and DE-52 cellulose anion-
exchange chromatography steps consisted of unbuffered 15 mM dibasic potassium phosphate and 
5% glycerol. 
2.3.3 Fibroblast cell culture and extract preparation 
Wild type and MCAD deficient cells (homozygous for the K304E mutation) with the designation 
GM085401 and GM07844, respectively, were obtained from Coriell Institute for Medical 
Research, Camden, NJ. Cells were cultured in DMEM medium supplemented with glutamine 
and ampicillin and streptomycin, and 20% fetal bovine serum. Cells were harvested from a T175 
flask by sonication with a buffer consisting of 50 mM Tris buffer and 10 mM EDTA, pH 8.0. 
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 The cell debris was removed by centrifugation and the cell free extract was assayed for protein 
and enzyme activity as described below. 
2.3.4 ETF fluorescence reduction assay 
The ETF reduction assay was performed using a Jasco FP-6300 spectrofluorometer (Easton, 
MD) with a cuvette holder heated with circulating water at 32˚C. The assay was otherwise 
performed as described  (FE Frerman 1985), at the indicated substrate concentrations. The 
enzyme was diluted 1200-fold into a buffer containing 50 mM Tris, pH 8.0, 5 mM EDTA and 
50% glycerol, and 10 μl were used for each assay. The ETF concentration in the reaction mixture 
was 2 μM. Spectra Manager 2 software (Jasco Inc) was used to collect data and calculate reaction 
rate and Microsoft Excel was used to calculate the kinetic parameters. 
2.3.5 Phenylbutyryl-CoA synthesis 
CoASH, octanoyl-CoA, C12-CoA and phenylbutyric acid were obtained from Sigma (St. Louis, 
MO.) 2,6-dimethylheptanoic acid was obtained from Matreya LLC (Pleasant Gap, PA). The 
phenylbutyryl-CoA and 2,6-dimethylheptanoyl-CoA esters were prepared by the mixed 
anhydride method as described previously (Schulz 1974) and was purified by HPLC using a 
Luna 5 μm C18(2) column (25 cm x 0.46 cm) and a linear gradient (10-60%) of acetonitrile into 
50 mM ammonium phosphate, pH 5.5, at a flow rate of 1.5 mL/min over 30 min. 
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 2.3.6 Monitoring the interaction of MCAD with substrates 
Formation of the charge transfer ternary complex was monitored by observing the increase in 
absorbance at the 570 nm area, concomitant with the decrease of absorbance at 447 nm area, of 
the purified MCAD in 120 mM potassium phosphate spectrum under anaerobic conditions using 
a JascoV-650 Spectrophotometer. Phenylbutyryl-CoA solution dissolved in water to 0.53 mM 
was titrated into the MCAD sample one μL at a time using a 50 μl Hamilton syringe attached to 
an automatic dispenser. Ten seconds of equilibration time were allowed after mixing before the 
sample was scanned at 250 to 800 nm. Final substrate concentrations varied as indicated in figure 
legends. All data were adjusted for the dilution resulting from substrate addition. Substrates were 
titrated, but with different final concentrations as indicated in the figure legends. The 
dissociation constant (KD app) was calculated with the Stockell equation as described previously 
(MC McKean 1979): 
 
where d is the total ligand concentration, e is the total molar concentration of enzyme, p is the 
fraction of enzyme sites that bind ligand multiplied by e, and n is the number of binding sites. 
The absorbance at 447 nm when all enzyme sites are occupied with ligand was determined 
separately by adding large excess of octanoyl-CoA and used to calculate the fraction of enzyme 
with bound ligand at various readings and assuming that at large excess of added substrate would 
equal to e. 
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 2.3.7 Molecular modeling 
Computer modeling of MCAD was performed using a Silicon Graphics Fuel workstation 
(Mountain View, CA) with the Insight II 2005 software package and MOE software, from 
Chemical Computing Group, Montreal, Canada, and the atomic coordinates of pig MCAD 
(3MDE) in the dimer form as a molecule (J-J Kim 1993). Carbon atoms at positions C5-C8 of 
the octanoyl-CoA ligand, which co-crystallized with MCAD, were replaced with a phenyl group. 
The phenylbutyryl-CoA ligand conformation in the active site was refined using the Discover 
module. Human LCAD 3D structure was modeled using MCAD atomic coordinates as template 
and the Insight II modeling software. 
2.4 RESULTS 
2.4.1 Interaction of MCAD with substrates, the reductive half-reaction 
Formation of the charge transfer complex, the reductive half-reaction, is evident from the 
spectral scans of MCAD at various phenylbutyryl-CoA concentrations (Figures 9 and 10, 
respectively).  
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Figure 9. Monitoring the formation of the charge transfer complex with purfified MCAD upon addition of 
increasing amounts of octanoyl-CoA. 
The absorbance maxima at ~370 nm and ~447 nm are reduced and a new peak centered at 570 nm appears with 
addition of increasing substrate. Selected scans are shown with octanoyl-CoA concentration at 0, 3.25, 7.1, 10.8, 
15.6, 18.0, 21.5, and 28.2 μM. The inset shows the kinetics of these changes. Equation for the decrease at 447 nm is: 
y = –1 x 10-9x6 + 1 x 10-7x5 – 2 x 10-6x4 + 2 x 10-5x3 – 0.0003x2 – 0.008x + 0.3489. Equation for the increase at 
570 nm is: y = 6 x 10-10 x6 – 5 x 10-8 x5 + 1 x 10-6 x4 – 2 x 10-5 x3 + 0.0003x2 + 0.0003x + 0.0008. Enzyme 
concentration was 25.2 μM. 
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Figure 10. Monitoring the formation of the charge transfer complex with purified MCAD upon addition of 
increasing amounts of phenylbutyryl-CoA. 
The absorbance maxima at ~370 nm and ~447 nm are reduced and a new peak centered at ~570 nm appears with 
addition of increasing substrate. Selected scans are shown with phenylbutyryl-CoA concentration at 0, 4.2, 8.3, 16.3, 
24.1, 31.6, 40.7, and 80.2 μM. The inset shows the kinetics of these changes. Equation for the decrease at 447 nm is: 
y = 5 x 10-10 x5 – 1 x 10-7 x4 + 9 x 10-6 x3 – 0.0002 x2 – 0.0061 x + 0.3707. Equation for the increase at 570 nm 
is: y = – 1 x 10-10 x5 + 3 x 10-8 x4 – 3 x 10-6 x3 + 7 x 10-5 x2 + 0.0012 x + 0.0036. Enzyme concentration was 25.2 
μM. 
 
The progressive decrease and increase of absorbance at 447 nm and 570 nm, respectively, 
are similar to those induced by octanoyl-CoA. The octanoyl-CoA binding curve is sigmoidal in 
contrast to the phenylbutyryl-CoA binding curve, possibly reflecting differences in enzyme 
mechanism of interaction. The plot of d/p versus 1/e-p (the Stockell plot) was nonlinear. A line 
drawn at the straight area of the curve where the substrate:subunit ratio was 1:1 estimates the 
apparent dissociation constant (KD app) being 0.12 μM and 2.16 μM for octanoyl-CoA and 
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 phenylbutyryl-CoA, respectively. Other mathematical derivatives of the absorbance data all 
indicated that the binding sites are non-equivalent. 
Table 2. Kinetic Constants of Recombinant Human MCAD Using Octanoyl-CoA and 
Phenylbutyryl-CoA as Substrates and the ETF Fluorescence Reduction Assay 
 
2.4.2 Interaction of MCAD: Substrate ternary complex with ETF, the oxidative half 
reaction 
Using ETF as the electron acceptor in the standard enzymatic assay detailed above, transfer of 
electrons was confirmed as evident from the reduction of ETF fluorescence in the presence of 
various concentrations of phenylbutyryl-CoA. The catalytic efficiency and Km for the 
phenylbutyryl-CoA were 0.2 mM-1⋅ sec-1 and 5.3 μM compared to 4.0 mM-1⋅ sec-1 and 2.8 μM for 
octanoyl-CoA, respectively. 
Molecular modeling of human LCAD shows possible accommodation of the acyl moiety 
of the phenylbutyryl-CoA, with the exception of residue L264, which would have one of its side 
chain methyl hydrogens ~1.3Å away from a phenyl ring hydrogen and so would hinder binding. 
To test if the LCAD active site has enough plasticity to accommodate this potential substrate, we 
measured its activity with LCAD using the ETF fluorescence reduction assay. While the partially 
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 purified recombinant human LCAD was active in the presence of various substrates including 
C12-CoA and 2,6-dimethylheptanoyl-CoA, it was not active in the presence of phenylbutyryl-
CoA. Purified SCAD, MCAD, and ACAD9 also showed no activity with phenylbutyryl-CoA as 
substrate. 
2.4.3 The ETF fluorescence reduction assay of cell extract 
ETF fluorescence reduction was observed using extracts from wild type fibroblast cells in the 
presence of 30 μM of phenylbutyryl-CoA, octanoyl-CoA, or palmitoyl-CoA. (The latter substrate 
was used as internal control and is a substrate of VLCAD.) Enzyme specific activity measured 
using these substrates was 3.41 (0.53), 4.01 (1.34), 9.10 (2.13) nmoles ETF reduced⋅ min-1⋅ mg-1, 
respectively. No activity was observed using similar amounts of extract from fibroblast cells 
deficient in MCAD with either phenylbutyryl-CoA or octanoyl-CoA. The measured enzyme 
specific activity of palmitoyl-CoA oxidation in extract from these cells was 3.91 (1.34) nmoles 
ETF reduced⋅ min-1⋅ mg-1. 
2.5 DISCUSSION 
Following the conversion of phenylbutyrate to the CoA ester, one cycle of β-oxidation is 
expected to result in phenylacetyl-CoA and acetyl-CoA as the final products (Figure 11).  
Phenylacetyl-CoA is hydrolyzed to phenylacetate, which becomes conjugated with glutamine 
and is excreted in urine (Figure 8). An analysis of this first step in the β-oxidation of 
phenylbutyryl-CoA is important because the first step in the β-oxidation of fatty acids is 
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 postulated to be rate-limiting (P Macheroux 1997), and thus the metabolism of Buphenyl to its 
active form, phenylacetate, may also be modulated by similar factors that affects energy 
metabolism at the same step.   
The effect of phenylbutyryl-CoA on the MCAD absorbance spectrum at relatively low 
concentrations is monitored via the decrease of absorbance at 447 nm and increase of absorbance 
at 570 nm. This confirms productive binding of phenylbutyryl-CoA to MCAD in the reductive 
half reaction with lack of product release. This effect is similar to that induced by octanoyl-CoA 
binding to MCAD, and indicative of the transfer of a proton and a hydride to the flavin ring and 
formation of the charge transfer complex, which is comprised of the enzyme, reduced FAD, and 
enoyl product and detected by the intense absorbance band centered at 570 nm (SM Lau 1987, S 
Ghisla 2004).   
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Figure 11. Detailed proposed pathway of metabolism of phenylbutyrate to its active form, phenylacetate 
 
The inset in Figure 9 shows a sigmoidal shaped curve when octanoyl-CoA, but not 
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 phenylbutyryl-CoA, was used as substrate. This may imply positive cooperativity between the 
first and second subunits with octanoyl-CoA binding that does not occur with phenylbutyryl-
CoA.  Although other interpretations of sigmoidal behavior in this setting are possible, including 
presence of various MCAD forms or other effector molecules, the argument is weakened by the 
fact that the only difference between the two reactions is the substrate itself. Impurities in the 
substrate preparation are also not likely to induce such an effect as such impurities would be 
present at ineffectively low concentrations at the low substrate concentrations range, between 
0.25-1 and 4:1substrate:MCAD tetramer ratio. 
Reduction of ETF by the charge transfer complex in the oxidative half-reaction shows 
that electrons from the bound phenylbutyryl-CoA can be efficiently transferred to ETF and that 
the product, phenylbutenoyl-CoA, is released to complete the reaction. In contrast, none of the 
other ACADs are capable of catalyzing this reaction. 
 
Figure 12. Stick representation of MCAD active site residues and ligands with phenylbutyryl-CoA modeled in 
place of octanoyl-CoA 
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 The crystal structure of pig MCAD with bound octanoyl-CoA (PDB: 3MDE, [20]) was used to create the model 
using MOE modeling software. The E376 carboxylate is the active site catalytic base responsible for the substrate 
C2 proton abstraction to initiate catalysis. 
 
Modeling of a phenylbutyryl moiety in the active site in place of the octanoyl moiety 
observed in the MCAD crystal structure shows the phenyl moiety accommodated in the acyl 
moiety binding site pocket with a conformation perpendicular to the aromatic ring of Y375 
(Figure 12). Other residues involved in binding the phenyl moiety include E99, A100, Leu103, 
and V259. Furthermore, modeling predicts that the phenyl ring para and/or meta positions are 
candidate expansion sites for adding a functional group that may improve binding, while addition 
at the ortho position would prevent the derivative from binding to MCAD. 
Based on the kinetic parameters of MCAD with phenylbutyryl-CoA as substrate, 
individuals with MCAD deficiency are likely to experience a functionally relevant decrease in 
the ability to metabolize the medication, though indications for use in these patients are likely to 
be rare. Of note, since octanoyl-CoA has been reported to provide thermal stability to the MCAD 
K304E mutant (I Nasser 2004), it is possible that phenylbutyryl-CoA would behave similarly and 
may be of benefit in vivo in patients carrying at least one copy of this mutation. This requires 
additional investigation in cellular or whole body systems. It is unknown if carriers for MCAD 
deficiency, a much more common situation, will display altered metabolism of phenylbutyrate. 
In other indications where the functional effects of phenylbutyrate are less well characterized, 
modulation of MCAD activity might be of benefit to alter drug metabolism and/or its half-life 
and increase its efficacy, depending on the mechanism of action of the medication in each 
disorder. Detailed biochemical studies to determine the drug’s mode of action and its 
pharmacokinetics for such indications are thus crucial. 
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 3.0  CLONING AND EXPRESSION OF ACAD10 IN E.COLI 
3.1 ABSTRACT 
Acyl-CoA dehydrogenases 10 (ACAD10) and 11 (ACAD11) transcripts encoding 1059-aa 
(118Kd) and 780-aa (87Kd) proteins predicted to be structurally related have been identified in 
databases but their function is unknown. A polymorphism in the ACAD10 gene has been linked 
to obesity in Pima Indians and hence the physiological role of both proteins draws interest. We 
cloned human ACAD10 and 11 full length coding transcripts in E. coli, but they failed to support 
production of identifiable protein. Expression of inserts coding for ACAD10 S637-I1059 and 
ACAD11 S355-I780 sequences representing the ACAD domain was successful. The purified 
proteins have absorbance spectra typical of flavoproteins but were unstable. Antibodies were 
generated against each protein and eight mouse tissues were surveyed for presence of antigens 
using western blotting and immunofluorescence staining. Rabbit anti-ACAD10 antibodies 
detected ~100Kd and ~125Kd-bands in extracts from pancreas and brain, respectively. Anti-
ACAD11 antibodies detected a 75Kd-band in all tissues, with kidney and lung showing the 
strongest signal. Subcellular localization (mitochondria or peroxisomes) was tissue specific. The 
ACAD11 antigen localized exclusively to to peroxisomes. Removing a predicted ACAD10 N-
terminus signal peptide from the full coding sequence resulted in production of a ~100Kd protein 
in E. coli, while expressing a sequence for the predicted 75Kd ACAD11 resulted in the 
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 production of a 65Kd antigen. Purification and characterization of the native forms of these 
proteins will provide key insights into their structure and function. 
3.2 INTRODUCTION 
The acyl-CoA dehydrogenase (ACAD) family of flavoproteins consists of nine enzymes that are 
similar in structure and function (Swigonova, Mohsen et al. 2009). Seven are homotetramers 
(~400-amino acids per monomer) and two are homodimers (~640-amino acids per monomer). 
They all catalyze the α,β-dehydrogenation of their corresponding acyl-CoA substrates. 
Deficiencies in these proteins are major causes of inborn errors of metabolism (Vockley and 
Whiteman 2002). Five of these enzymes, VLCAD, ACAD9, LCAD, MCAD, and SCAD, 
catalyze the first step in the fatty acid β-oxidation spiral with each tolerating some variation in 
the acyl carbon chain length specificity and branching (Swigonova, Mohsen et al. 2009). More 
recently, a new ACAD gene, ACAD10, has been reported. It is even more highly conserved 
across species than the other ACADs, suggesting an essential role in cellular metabolism (He 
2011). A study with a full-heritage Pima Indian population sample identified an association 
between ACAD10 variants and type 2 diabetes and lipid oxidation (Bian, Hanson et al. 2010)  
The ACAD10 gene maps to chromosome 12q24.1 and encodes a predicted transcript for a 
1059 or 1090 amino acid protein (Xin Ye 2004, Ensembl 2013). In contrast to other ACADs, 
ACAD10 has a unique gene structure with multiple coding domains that likely yield multiple 
functional proteins. The hypothetical protein consists of three primary domains: an N-terminus 
domain with hydrolase homology, a middle domain with protein kinase homology, and a 
conserved ~ 400-aa C-terminus domain that is highly homologous to ACAD. The ACAD C-
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 terminus domain shows conservation of key primary structural ACAD elements essential for 
FAD and CoA ligand binding. Two isoforms of ACAD10 have been identified in genetic 
databases; isoform a and isoform b (National Center for Biotechnology Information 2013). 
ACAD10 isoform a is the longest transcript produced and codes for the largest predicted protein 
while the protein encoded by isoform be is predicted to be shorter. A second novel ACAD, 
ACAD11, encodes a hypothetical protein that is only 780 aa in length and is homologous to the 
middle and C-terminus domain of ACAD10. The ACAD domain and the protein kinase-like, 
catalytic domain is highly conserved in a number of species including humans, rat, mouse, 
chimpanzee, Rhesus monkey, cattle, chicken, Arabadopsis thaliana and more (National Center 
for Biotechnology Information 2013). The lowest organism that contain all of the ACAD10 
protein domains is fungi (Swigonova, 2009 ). 
The purpose of this project was to use molecular cloning and prokaryotic expression 
studies to determine the functional forms of ACAD10 and characterize its biochemical and 
physical properties using an in vitro E. coli expression system. I hypothesized that in humans the 
ACAD10 gene will support the expression of at least two major proteins (one containing all 
domains and another consisting of just the ACAD domains) that will differ in their subcellular 
localization. Prior studies suggest that the ACAD10 proteins containing only the ACAD domain 
will be localized to mitochondria. I predict that a full domain ACAD10 protein will be targeted 
to peroxisomes. Such duel targeting would be unique among the ACADs. Expression, 
purification and characterization of the various isoforms of ACAD10 will allow a better 
understanding of role of this protein in normal cellular metabolism and physiology. 
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 3.3 MATERIALS AND METHODS 
3.3.1 Cloning and Expression 
For cloning and expression, kits from Qiagen (Valencia, CA) were used according to the 
manufacturer’s protocols. Briefly, MGC Fully Sequenced Human ACAD10 cDNA was purchased 
from ThermoFisher Scientific (Pittsburgh, PA) as template for PCR. ACAD10 specific sequences 
were amplified with the Hot Star HiFidelity PCR kit (Qiagen, Valencia, CA) using a variety of 
forward and reverse primers specific to the various predicted ACAD10 isoforms. For expression 
studies, PCR generated ACAD10 and 11 products were purified using QIAGEN Plasmid Mini or 
Midi kit, then ligated into either pKK223-3, (GE Healthcare BioSciences, Pittsburgh, PA) or 
pET21a+, some containing a His6 N-terminal tag (Novagen, Billerica, MA). The sequence of all 
constructs was verified by the University of Pittsburgh Genomics and Proteomics Core 
Laboratories. The sequencing data were visualized and confirmed using the MacVector software 
(MacVector, Inc, Cary, NC).  
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 Table 3. Human ACAD10 Plasmid Constructs  
Plasmid Name Description
ACD10 Plasmid_v19 Full length ACD10
ACD10 Plasmid_v18 Full length ACD10
ACD10 Plasmid_v17 Full length ACD10
ACD10 Plasmid_v16 Removed 12-mer@ N-terminus (PTSII)
ACD10 Plasmid_v15 Removed 18-mer @ N-terminus (PTSII) + His Tag
ACD10 Plasmid_v14 Removed 18-mer @ N-terminus (PTSII)
ACD10 Plasmid_v13 Sitedirected Mutagenesis to put stop codon btwn domains
ACD10 Plasmid_v12 (minus HRI) Adjusting pETv8 by cleaving residues HRI at C term
ACD10 Plasmid_11 (C-His) C-His tagged generated using SDM
ACD10 Plasmid_10 in pcDNA3.1 Transfected full length ACD10 into pcDNA3.1 system
ACD10 Plasmid_9 (N-His) N-His tagged generated using PCR cut & paste
ACD10 Plasmid_8 Full length ACD10 - NheI site instead of AgeI site (for N-His)
ACD10 Plasmid_7 aka Fragment 6 "Full length" ACAD10
Fragment 5 Short form of ACAD10 (ACD11-like mito form)
Fragment 4 Short form of ACAD10 (ACD11-like mito form)/ used for Ab 
ACAD10 PLASMIDS (human)
 
 
Table 4. ACAD10 Plasmid Primers 
Plasmid Name Primers
ACD10 Plasmid_v19 hACD10_29mito_sig_fw & hACD10_3273rv
ACD10 Plasmid_v18 hACD10_38mito_sig_fw & hACD10_3273rv
ACD10 Plasmid_v17 hACD10_61mito_sig_fw & hACD10_3273rv
ACD10 Plasmid_v16 hACD10_37fw & hACD10_3AgeI_946-940rv
ACD10 Plasmid_v15 hACD10_55AgeIHisfw & hACD10_3AgeI_946-940rv
ACD10 Plasmid_v14 hACD10_55AgeIfw & hACD10_3AgeI_946-940rv
ACD10 Plasmid_v13 D1D2_fwd & D1D2_rv
ACD10 Plasmid_v12 (minus HRI) hACD10_787bExon7_fw & hACD10_minusHRI_rv
ACD10 Plasmid_11 (C-His) hACD10_exon7_787bfw & hACD10_HisCter_rv
ACD10 Plasmid_10 in pcDNA3.1
ACD10 Plasmid_9 (N-His) hACD10_NterNheINHis_fw & hACD10_3AgeI_946-940_rv
ACD10 Plasmid_8 hACD10_NheI_fw & hACD10_NheI_rv
ACD10 Plasmid_7 aka Fragment 6
Fragment 5 hACD10_53mito_fw & pET_3MCS_rv
Fragment 4 hACD10_47mito_fw & pET_3MCS_rv
ACAD10 Plasmid Primers (human)
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Figure 13. Plasmid Map 
The ACAD10 plasmid map represents several ACAD10 expression plasmids constructed and expressed, including 
one 89Kd peptide. Full length ACAD10 isoform B was constructed by inserting the N-terminus domain coding 
region at the 5’-end of the 89Kd peptide coding region, which required re-engineering the restriction enzyme sites at 
the insertion site to Age I without changing amino acid sequence. 
 
3.3.2 Transient transaction and overexpression in HEK293T cells with pcDNA ACAD10 
Human embryonic kidney cells (HEK293T) cells were cultured in regular DMEM media 
supplemented with 10% FBS (fetal bovine serum) and 1% pencillin. Upon confluence, cells were 
collected by trypsinization, counted, and electroporated each of  20x106 cells/mL with 20ug of 
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 pcDNA ACAD10 test plasmid and pcDNA control, respectively. Electroporated cells were 
transferred to regular DMEM medium containing 450ug/mL neomycin and grown for 48 hours. 
A few flasks of transfected cells containing pcDNA ACAD10 and pcDNA control were induced 
using 5uM retinoic acid for 48 hours and the remaining cells were not induced. The cells were 
harvested and processed for western blotting and seeded for immunofluorescence staining. 
HEK293T pcDNA control, pcDNA10 uninduced and induced cells were seeded at a 
concentration of 5×104 cells/ml on tissue culture-treated glass cover slips and allowed to grow 
overnight at 37 °C in a 5% CO2, 95% humidity incubator. Cells were fixed in 4% 
paraformaldehyde for 10 minutes followed by 0.1% Triton X100 cell permeabilization and 
further blocked after brief washings in 5% donkey serum (Jackson ImmunoResearch, West 
Grove, PA) for 1 hour on ice. This was followed by triple primary antibody incubation with: 1) 
anti-ACAD10 antibody (lab made) and 2) anti cytochrome c oxidase subunit 4 antibody (Abcam, 
Cambridge, MA) and 3) anti catalase peroxisome specific marker (Santa Cruz Biotechnology, 
Inc., Dallas, TX) at 4 °C overnight. After brief washing, cells were further incubated with 
donkey anti-rabbit secondary antibody Alexa Fluor 488 (Invitrogen, Grand Island, NY) for 
ACAD10, and donkey anti-mouse secondary antibody Alexa Fluor 555 (Invitrogen) for 
cytochrome c oxidase subunit 4, and donkey anti-goat secondary antibody Alex Fluor 647. 
Nuclei were counterstained with DAPI. The cover slips were then mounted using mounting 
media before imaging. All the images were taken using an Olympus Confocal FluoView FV1000 
microscope at a magnification of 60X. 
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 3.3.3 His-Tag Protein Purification 
Protein purification was performed using Talon Metal Affinity resin column (Clontech 
Laboratories Inc, Mountain View, CA).    Approximately 1.5-1.9g of plasmid preparations were 
lysed and added to the purification column for fraction collection at 4°C.  Purified extracts were 
then dialyzed in 50mM Tris before performing a protein assay and running an SDS-PAGE gel 
used for expression of ACD10- & ACAD11-ACAD domains as His-tag proteins.  
3.3.4 Production and Purification of Anti-ACAD10 Antiserum 
Rabbit anti-mouse ACAD10 and 11 antibodies were produced to a peptide homologous to the 
ACAD homologous domain of the ACAD10 or 11 protein structures. Rabbit antiserum to 
purified ACAD9 was raised by Cocalico Biologicals, Inc. (Reamstown, PA) according to 
company protocols. Rabbits were given initial inoculations of each purified protein and boosted 
three to four times with the purified protein at 1- or 2-week intervals. Final serum activity was 
confirmed by Western blotting. 
Both antibodies were affinity purified using blotting methods. Immun-blot PVDF 
(Millipore, Billerica, MA) membrane strips (0.5x2.0 cm) were placed in methanol for 2-3 
minutes and then equilibrated in 1X TBS + 0.02% sodium azide buffer for 15 minutes. The 
membrane strips were placed in 0.75mL of ACAD10 antigen solution rotating at 4°C for 1 hour, 
washed with 70% ethanol, and dried for 30 minutes under the chemical fume hood. They were 
then rinsed in 5 mL of methanol for 2 minutes, 10 mL of TBS for 2 minutes, then 5 times in 15 
mL of PBS each for 10 minutes. Up to four strips were placed in 1 mL of ACAD10 antigen 
antiserum and rotated gently on a Nutator (TCS Scientific Corporation,New Hope, PA) at 4°C 
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 overnight. The next day the strips were removed, rinsed with water, and incubated in TB-TX 
buffer for 10 minutes. They were then washed 5 times in TBS-TX (1 0mL/wash) for 10 minutes 
each, and twice in 10 mL of TBS-EDTA for 10 minutes each. The strips were transfered to a 
tube containing 1 ml ice-cold 0.2 M glycine (pH 3.0), and glycine was pipetted over them for 2 
minutes whilecollecting the eluent. The eluted antibody was neutralized with the same volume of 
2 N NaOH. The eluting process was repeated a second time, then strips were washed with H2O, 
dried, and stored at 4°C. The elutes were combined into an Amicon concentrator (Millipore, 
Billerica, MA) and the glycine/antibody solution was diluted with 10 mL PBS-azide. The 
Amicon concentrator was centrifuged at 2500 x g until the solution was reduced to 1 mL. The 
antibody solution was diluted to 10 mL final volume in PBS-azide + 0.25% BSA, concentrated 
to 1 ml, then diluted again to make a total volume of 3mL. The antibody was aliquoted into 
0.3mL portions and stored at 4 °C or flash frozen in liquid nitrogen and stored at -80 °C. A 
western blot was performed to confirm final serum activity and determine a working dilution. 
3.3.5 Western Blot analysis   
To examine expression in E. coli, cultures of cells containing various ACAD10 plasmids were 
grown in LB broth at 37 °C, induced for 3 hours at 37 °C, then harvested by centrifugation. The 
cell pellets were lysed by sonication in 50 mM Tris buffer, pH 8.0 on ice, and the sonicates were 
cleared by centrifugation at 14,000 x g for 30 min at 4 °C. Human and mouse tissues were 
homogenized in ice cold PBS, and were cleared by centrifugation. One hundred μg of protein 
from extracts were subjected to electrophoresis with SDS-PAGE, using a pre-cast 4-15% TGX 
gel (BioRad), and proteins were transferred electrophoretically to an Immun-Blot PVDF 
membrane. Rabbit anti-mouse ACAD10 and 11 antibodies were produced to a peptide 
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 homologous to the ACAD homologous domain of the ACAD10 or 11 protein structures by 
Cocalico, Inc according to standard immunization protocols.  The peptide made for the antiserum 
was expressed and purified from plasmid “short form Fragment 4” found in Table 3. The 
membrane was probed overnight with rabbit antiserum to ACAD10 or 11 at 1:500 dilution as 
primary antibody, then washed extensively with 1X TBS Tween 20 at room temperature. 
Following incubation with alkaline phosphatase-coupled goat anti-rabbit IgG antibody, the 
antigens were detected with NBT/BCIP color developing solution (Promega, Madison, WI).  
 
3.3.6 Identification of Proteins by Tandem Mass Spectrometry (MS/MS)  
Identification of ACAD10 and ACAD11 gel bands was performed by the University of 
Pittsburgh Proteomics Core Laboratory. Briefly, SDS-PAGE gels were stained with Coomasie 
blue, and bands of interest were excised, reductively alkylated with DTT/IAA, and digested with 
trypsin. Peptides were analysed using nano RP-HPLC interfaced with an LTQ XL linear ion trap 
mass spectrometer (Thermo Fisher Scientific). Spectra were analysed by the MASCOT (Matrix 
Science) search engine and identified peptides and proteins were further statistically validated 
with the Scaffold software. 
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 3.4 RESULTS 
3.4.1 ACAD10 cDNA amplification and expression 
PCR amplified fragments of the predicted full length human ACAD10 and ACAD11 regions 
were cloned into BL21 GRO EL/ES vectors, respectively, and expressed in E coli, but neither 
protein was identifiable in cellular extracts. To examine the possibility that another isoform was 
in fact the bona fide active one, a variety of inserts containing different combinations of 
predicted proteins were created via PCR and tested for expression and function (Figure 14). 
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Figure 14.  ACAD10 Human Plasmid Constructs Map 
 
See the text for details regarding these constructs 
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To identify the substrate binding pocket and catalytic site,  recombinant His-tag form of 
the ACAD-like domains (ACAD10 S637-I1059 and ACAD11 Q353-I780; designated ACAD10-
C and ACAD11-C) were amplified, sub-cloned and expressed with an additional Met-His6 tag at 
the N-terminus. The purified domains (predicted molecular mass 47 Kd) were yellow and had a 
typical flavin spectrum scanned between 250-800 nm demonstrated a reading of 1.660 at 280nm, 
but proved to be unstable as the protein precipitated before the next reaction could begin. The 
identity of the purified proteins was confirmed using MS/MS, and they were used to generate 
polyclonal rabbit antiserum. These antibodies were then used to analyze additional samples by 
SDS-PAGE and western blotting (Figure 15).  
 
Figure 15. Expression of ACD10-ACAD & ACAD11-ACAD domains as His-tag proteins 
Western blot of a 4-15% SDS-PAGE gel. (A) Purified ACAD10-ACAD domain, 42 Kd form (0.5 µg) was 
visualized with anti-ACAD10 antiserum , (B) ACAD11-ACAD domain,  47 Kd form (0.5 µg) visualized with anti-
His tag antibodies  (C) ACAD11-ACAD domain, 47 Kd form (0.5 µg) visualized with anti-ACAD11 antiserum  
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 Expression of a truncated version of the ACAD10, missing the N-terminal domains 
including HDL, APH, and a part of the mitochondrial targeting domain that precede the ACAD 
domain led to production of an appropriate size protein band identified with western blotting 
(Figure 16).   
 
Figure 16. Expression of N-terminus truncated ACAD10 long version in E. coli 
Western blot of a 4-15% SDS-PAGE gel. (A) Purified ACAD10 long version (10 µg) ~100Kd form was visualized 
with anti-ACAD10 antiserum. 
 
Overexpression in HEK293T (human embryonic kidney) cells of ACAD10 in a 
pcDNA3.1 vector system revealed that ACAD10 protein colocalized to mitochondria as 
demonstrated by immunofluorescent staining (Figure 17). Anti-VLCAD antibody was used as an 
internal control in these overexpression experiments. 
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Figure 17. Overexpression of ACAD10 in HEK293 
Control HEK293T cells were permeabilized with Triton X-100 and immunostained (green fluorescence) with 
antibodies to an ACAD10 peptide. (A-D). Fluorescent staining of induced or unindeced HEK293T cells with 
antibodies to the mitochondrial marker MTCO1 (red); colocalization of ACAD10 with mitochondria appears 
yellow. (E-H). Fluorescent staining of induced and uninduced HEK293T with anit-VLCAD antibodies (green) and 
antibodies to the mitochondrial marker anti MTCO1 (red). Colocalization of ACAD10 to the mitochondria appears 
yellow. 
 
3.4.2 First half reaction 
Screening for binding of a panel of acyl-CoA compounds the purified ACAD10 short form 
protein (which contains primarily the ACAD domain) was performed using absorbance spectral 
scanning. Purified protein has spectral maxima at ~370 nm and ~447 nm. These decreased afer 
addition of glutaryl-CoA and HMG-CoA, evidence that these compounds were bound to the 
enzyme catalytic site and were able to, at least in part, establish the charge transfer complex 
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 characteristic of the first half reaction (Figures 18 and 19). Incubation with succinyl-CoA, 
malonyl-CoA, and acetoacetyl-CoA led to no changes in the absorbance maxima, indicating lack 
of productive interaction with the enzyme (Figures 20-22).  
 
 
Figure 18. Binding of glutaryl-CoA to ACAD10 short protein. 
An absorbance spectral scan from 300-700 nm. 
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Figure 19. Binding of HMG-CoA to ACAD10 short protein binding. 
An absorbance spectral scan from 300- 700 nm.  
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Figure 20. Binding of succinyl-CoA to ACAD10 short protein. 
An absorbance spectral scan from 300- 700 nm. 
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Figure 21. Binding of malonyo-CoA to ACAD10 short protein. 
An absorbance spectral scan from 300- 700 nm. 
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Figure 22. Binding of acetoacetyl-CoA to ACAD10 short protein. 
An absorbance spectral scan from 300- 700 nm. 
 
 
3.5 DISCUSSION 
The ACAD10 and 11 genes are unique among the ACADs in that each contains additional 
predicted domains other than those homologous to the ACAD coding region. Moreover, multiple 
versions of sequences from each gene are found in expression databases, consisting of variable 
combinations of the predicted protein domains (Ensembl 2013). Additionally, ACAD10 and 11 
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 proteins have been localized to both peroxisomes and mitochondria in undirected proteomics 
studies. To better characterize these novel ACADS, various coding forms of each have been 
expressed in prokaryotic system, antisera have been produced, and their native forms have been 
explored in mouse and human tissue extracts. Prokaryotic expression studies confirmed that each 
protein contained an expected FAD cofactor, but none of the purified proteins were active. The 
proteins were unstable on storage, making extensive characterization impossible. In fact, many 
of the vectors tested led to no identifiable protein following expression. The expression vectors 
were designed to generate a variety of different forms of ACAD10, some predicted to be that 
seen in peroxisomes and others in mitochondria. I began attempting to express the full length 
ACAD10 protein; however, it was unstable in the full length form. Because of multiple domains 
and alternative splicing in mammalian cells, it is possible that the form used for these was in fact 
not the native one. I also created several of these inserts with the addition of His6 tags to aid in 
expression, though none of these were stable either. I then began exploring the use of shorter 
ACAD10 protein fragments. I chose an ACAD domain insert specifically for its homology to the 
other ACADs, expecting it to behave in a similar manner when expressed. Unfortunately, all of 
these forms were unstable in the bacterial strains and rapidly degraded.  
Mitochondrial import is directed by an N-terminal signal sequence characterized by 
positively charged amino acid residues and other properties (Omura 1998). Upon examination of 
the ACAD10 gene, a potential mitochondrial targeting sequence is present, but it is not clear from 
database studies what form the transcript of a mitochondrial targeted protein might take, though 
my tissue studies clearly show that one is present. My prokaryotic expression studies failed to 
identify an active protein with ACAD activity, but not all possible combinations of exons were 
tested. Previous qPCR experiments were also unclear as to the nature of the mitochondrial form 
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 of ACAD10. RNAseq experiments might be helpful to identify additional candidate transcripts. 
The amino terminus of ACAD10 contains a sequence homologous to a peroxisomal targeting 
signal. It has been shown that in proteins containing both a mitochondrial and peroxisomal 
targeting signal, the mitochondrial one is dominant (Omura 1998). Thus, any ACAD10 variants 
containing a mitochondrial targeting sequence are likely to in fact target to mitochondria, 
whereas all of the other forms will localize to peroxisomes.  
ACAD11 has been confirmed to be a peroxisomal protein, though the existence of a 
small amount of a mitochondrial form cannot be excluded. Identification of an ACAD11 band at 
75 kDa in tissue western blot experiments in contrast to the expected molecular mass of 87kDa 
for a full length protein suggests the existence of a an shorter transcript generated by exon 
skipping of one or more protein domain, or alternative posttranslational modification including 
proteolytic processing of the full length protein. Additional tissue expression and prokaryotic 
expressions studies are necessary to differentiate these possibilities. The function of ACAD11 
remains unclear. As a peroxisomal protein, it is likely to be an oxidase rather than a 
dehydrogenase, but additional characterization must await expression and purification of a stable 
protein for further study. 
 55 
 4.0  CHARACTERIZATION OF AN ACAD10 DEFICIENT MOUSE MODEL: 
PATHOLOGICAL AND BIOCHEMICAL ANALYSES 
4.1 ABSTRACT 
Pima Indians have the highest incidence of insulin resistance (IR) and type-2 diabetes mellitus 
(T2DM) of any reported population, but the pathophysiologic mechanism is unknown. Genetic 
studies have linked the ACAD10 gene, among others, to this predisposition. ACAD10 is related to 
a family of flavoenzymes active in fatty acid oxidation (FAO). Dysregulation of FAO and an 
increase in plasma acylcarnitines is recognized as important in the pathophysiology of IR and 
T2DM. In Acad10 deficient mice, animals accumulate excess abdominal adipose tissue, develop 
an early inflammatory liver process, and exhibit fasting rhabdomyolysis. Skeletal muscle 
mitochondria are abnormal. Blood acylcarnitine analysis shows an increase in long chain species 
in older animals, as seen in adults with obesity and T2DM. Acad10 deficient mice show an 
abnormal glucose tolerance test with elevated insulin levels in response to the glucose challenge. 
Our results identify ACAD10 as an important genetic determinant of T2DM and provide a model 
to further explore pathophysiology and therapy. 
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 4.2 INTRODUCTION 
4.2.1 Mitochondrial fatty acid oxidation and diabetes 
In the last half of the 20th century, the incidence of T2DM, previously unrecognized in the Pima 
Indians, began to rise. Multiple factors were postulated to be responsible including 
environmental factors such as diet and resultant obesity, along with a number of genetic 
determinants (Baier and Hanson 2004). ACAD10 was one of 30 genes further examined after 
demonstrating a significant signal for diabetes in a genome-wide association study (Bian, 
Hanson et al. 2010). In this genome wide association scan (GWAS), a single nucleotide 
polymorphism (SNP), rs632650, was found to map within intron 2 of ACAD10 (Bian, Hanson et 
al. 2010). The hypothetical ACAD10 protein is structurally related to the acyl-CoA 
dehydrogenase (ACAD) family of mitochondrial flavoproteins, which consists of nine enzymes 
that are similar in structure and function as they catalyze the α,β-dehydrogenation of their 
corresponding acyl-CoA substrates. Seven of these ACADs, LCAD, MCAD, SCAD, IVD, IBD, 
2-methyl-BCAD, GDH, are homotetramers (~400-aa per monomer) and two, VLCAD and 
ACAD9, are homodimers (~640-aa per monomer). In addition to their usual location in the 
mitochondrial matrix, some ACADs including LCAD, MCAD, and SCAD have been shown to 
be associated with cytoplasmic GLUT4- containing vesicles where they interact with two 
dileucine motifs on insulin-regulated aminopeptidase (IRAP) (Katagiri, Asano et al. 2002). 
Mutation of the dileucine motif of IRAP (amino acids 55-82) eliminates this interaction 
(Katagiri, Asano et al. 2002). In cells, glucose equilibrium is maintained by the GLUT4 response 
to insulin (Haga, Ishii et al. 2011). The GLUT4 and IRAP containing vesicles respond to insulin 
stimulation by translocation to the cell surface. IRAP has a specific protein structure containing a 
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 dileucine motif. The dileucine motif in IRAP plays a critical role in regulating GLUT4 
trafficking. These findings connect some of the ACADs with insulin dependent transportation of 
glucose within cells, but the physiologic role of the ACAD proteins in this setting is unclear 
(Katagiri, Asano et al. 2002). 
While skeletal muscle patterns of fatty acid utilization during fasting conditions have 
been shown to be associated with obesity-related insulin resistance and altered mitochondrial 
energy metabolism, including fatty acid oxidation, it has also been shown to play an important 
role in the development of T2DM (Kelley, Goodpaster et al. 1999),(Goodpaster 2013). We have 
recently shown that the pattern of acylcarnitines (ACNs), key metabolic intermediates of fatty 
acid oxidation, in the blood of obese and T2DM participants fall into two distinct patterns. First, 
the T2DM and obese participants have a similar accumulation of long-chain ACNs that arise 
from activity in the initial rounds of β-oxidation, consistent with increased flux at entry into 
mitochondrial β-oxidation. Diabetic participants also displayed a secondary accumulation of 
various shorter chain ACNs suggestive of inefficient fatty acid oxidation or interactions between 
β-oxidation and ETC. They also showed an inability to efficiently switch from fat metabolism 
during insulin clamp, as reflected in their inability to lower their ACNs as effectively as either 
the lean or obese subjects. In contrast, this pattern was not present in obese adolescents, who 
instead showed metabolic findings suggestive of upregulation of fatty acid oxidation (Mihalik, 
Goodpaster et al. 2010).  
The function of two additional proteins annotated in the human genome and predicted to 
be ACADs (ACAD10 and 11) is unknown (Vockley , Swigonova, Mohsen et al. 2009, He 2011). 
These two genes share 46% homology and are widely conserved across evolution. Homology 
alignments have defined three domains. Both genes are located within complicated loci 
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 containing multiple predicted exons and protein domains, including an ACAD domain. Previous 
published results and experiments described in the previous chapter of this thesis describe 
potential functions for ACAD10 in the central nervous system, metabolism, and immunity. In 
addition to their usual location in the mitochondrial matrix, acyl-CoA dehydrogenases have been 
shown to be associated with cytoplasmic GLUT4- containing vesicles where they interact with 
two dileucine motifs on insulin-regulated aminopeptidase  (Katagiri, Asano et al. 2002). 
To characterize the physiologic role of ACAD10 in intermediary metabolism and its 
possible link to T2DM, we have characterized an ACAD10 gene trap knockout mouse model. 
Aging animals become obese on a normal diet and develop insulin resistant hyperglycemia in 
response to an intraperitoneal glucose challenge. Tissue and blood ACN profiles are similar to 
those previously described for adult humans with T2DM. Our findings identify ACAD10 as new 
monogenic cause of T2DM in mice, and provide valuable insight into its potential role in the 
development of T2DM in Pima Indians. 
4.3 MATERIALS AND METHODS 
4.3.1 Subcellular Location of ACAD10 Protein in Human Tissues 
A human tissue panel was obtained from the NIH’s Eastern Division of the Cooperative Human 
Tissue Network (CHTNED). Formalin Fixed Paraffin Embedded (FFPE) human tissues were 
sectioned to 5 µm thickness. The sections were deparaffinized, rehydrated, and subjected to 
antigen retrieval followed by cell permeablization, then briefly washed with PBS and blocked. 
Tissues were stained by overnight incubation with three primary antibodies: anti-ACAD10, anti-
cytochrome c oxidase subunit 4, and anti-catalase. ACAD10 purified antibody was used in a 
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 1:1000 dilution and anti-MTCO1 antibody as a mitochondrial marker (Abcam), and catalase (N-
17) (Santa Cruz Biotechnology, Inc.) were used in 1:250 dilutions for the lung. Two different 
antibody dilutions were used to obtain the best possible tissue images. ACAD10 purified 
antibody was used in a 1:500 dilution, and anti-MTCO1 antibody as a mitochondrial marker 
(Abcam), and catalase (N-17) (Santa Cruz Biotechnology, Inc.) were used in 1:250 dilutions for 
kidney, liver, muscle, and pancreas. After washing, sections were further incubated for 1 hour 
with secondary antibodies donkey anti-rabbit 488 for ACAD10, donkey anti-mouse Cy3 for 
mitochondria, and donkey anti goat Cy5. Nuclei were counterstained with DAPI. Aqueous anti-
fade fluorescent mounting medium was applied and imaged. Slides were analyzed using an 
Olympus FluoView FV1000 confocal microscope (Olympus). 
4.3.2 Subcellular Location of ACAD10 Protein in Mouse Tissues 
Crude peroxisomal, mitochondrial, and purified peroxisomal fractions from ~10 mg of fresh 
control mouse liver tissue were separated using the PEROX1 Kit (Sigma-Aldrich, St Louis, MO) 
as per the manufacturer protocol, and 15 µg of total protein from each fraction were separated on 
a 12% SDS polyacrylamide gel, transferred to a PVDF membrane, and immunostained and 
visualized with ACAD10 antibodies as above. A western blot survey of ACAD10 expression in 
various human tissues was performed by homogenizing approximately 100 mg tissue in ice cold 
PBS using a Virtis HandiShear homogenizer followed by sonication using a microtip sonicator, 
and centrifugation at 30 minutes, maximum speed, at 4 °C. The supernatants (100 µg protein) 
were loaded onto SDS-PAGE gels, transferred to Immun-Blot PDVF membrane, and probed 
with 1:500 dilution of ACAD10 F-11 mouse monoclonal primary antibody (Santa Cruz 
Biotechnology, Inc.). 
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 4.3.3 Generation of Mutant Mice 
A heterozygote Acad10 gene trap knockout mouse model generated in a total genome knockout 
mouse project was purchased from Taconic Laboratories (Bian, Kasumov et al. 2006).    Six- to 
8-week-old Acad10 deficient (Acad10‒/‒) 129SvEv/BL6 mice were purchased from Taconic 
(Germantown, NY). Heterozygous mice were viable and fertile. Genotyping was performed by 
isolating genomic DNA from the tail tip using standard methods followed by PCR with primers 
designed to specifically amplify an ACAD10 containing DNA fragment, and visualization using 
1% agarose gel electrophoresis. PCR was able to reliably differentiate the genotype as either 
wild type, heterozygous, or homozygous for the disrupted Acad10 gene. Wild type and 
homozygous lines were established by breeding to create experimental animals in the same 
SvEv129/BL6 mixed background strain. Mice were housed in pathogen-free conditions at 
Children’s Hospital of Pittsburgh, Pennsylvania. All of the animal studies were conducted with 
the approval of the University of Pittsburgh Institutional Animal Care and Use Committee. 
4.3.4 Clinical Characterization 
Regular visual observations and weight measurements using a digital balance were performed to 
monitor health status and behaviors of wild type and Acad10 deficient mice over time.  
4.3.5 Micro MRI Imaging 
Abdominal MRI was performed with a Horizontal bore 7-T MRI system (Bruker Biospin 
Corporation, Billerica, MA) 70/30 with full vital monitoring system to assess accumulation of 
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 adipose tissue content in wild type and Acad10 deficient mice. Briefly, animals were 
anesthetized with isoflurane and 100% oxygen gas via nose cone during MRI imaging. Animal 
body temperature, heart rate, respiratory rate, and arterial oxygen saturation were continuously 
monitored visually and with the real-time physiology monitoring system. Total scanning time 
was approximately 30 to 45 minutes per animal. 
4.3.6 Histopathology  
Wild type and Acad10 deficient mice were sacrificed by cervical dislocation. Tracheas of the 
mice were exposed and cannulated (Pociask, Scheller et al. 2013). Lungs were perfused by 
instillation of PBS, and tissues were immediately dissected, flash frozen in liquid nitrogen for 
metabolic analysis, or preserved in 2.5% gluteraldehyde or 4% paraformaldehyde for 
histopathology (Pociask, Scheller et al. 2013). Tissues harvested included lung, liver, spleen, 
pancreas, brain, heart, bone, muscle, bone marrow, eyes, testes, and kidney. After fixation, 
organs were dehydrated and embedded in paraffin; 10 μm sections were stained with 
hematoxylin and eosin, according to standard protocols. Gomorri staining was also performed on 
muscle tissue samples using standard techniques.  
4.3.7 Immunohistochemical and immunofluorescent staining of paraffin-embedded 
sections of mouse tissues 
Tissues were removed from mice and immersed in fixative overnight at 4 °C, samples were 
formalin-fixed, paraffin embedded, and 5 µm sections were prepared and mounted on glass 
slides by the Department of Pathology, Children’s Hospital of Pittsburgh..  
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 Immunohistochemical staining was performed using overnight incubation at 4 °C with primary 
antibody, followed by incubation for 1 hour at room temperature with fluorescently labeled 
secondary antibodies as described in the previous chapter. Primary antibodies included rabbit 
polyclonal antibody against ACAD10, mouse anti-MTCO1 antibody as a mitochondrial marker 
(Abcam), and goat polyclonal IgG anti- catalase (N-17) (Santa Cruz Biotechnology, Inc.) as 
marker for peroxisomes. Primary antibodies were used at dilutions of 1:500 and secondary 
antibodies at a dilution of 1:3,000. Slides were analyzed using an Olympus FluoView FV1000 
confocal microscope with a magnification of 60X (Olympus). 
 
4.3.8 Biochemical Analysis  
Acad10 deficient mouse tissues including heart, liver, lung, muscle, kidney, spleen, and pancreas 
were harvested and immediately flash frozen in liquid nitrogen. Samples were extracted and 
derivatized with pentafluorophenacyl trifluoromethanesulfonate. Acylcarnitine profiling by 
UHPLC MS/MS was performed as previously described (Minkler, Stoll et al. 2008). Values were 
quantified using 13 point calibration curves, and 72 acylcarnitines were reported.  
Blood samples, (approximately 50-100 µL) were collected in a serum separator tube (BD 
Microtainer) by performing a retroorbital bleed. After collection blood was subjected to 
centrifugation for four minutes at ~450 g. Serum was removed and frozen at -80 °C until use. 
Glucose and creatine kinase levels were determined by MS/MS by clinical laboratory in the 
Department of Pathology at the Children’s Hospital of Pittsburgh of UPMC. C-reactive protein 
and insulin were measured with commercially available ELISA kits (Alpco Diagnostics, Salem, 
NH) according to the manufacturer instructions. Samples were assayed in triplicate. A panel of 
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 23 cytokines was analyzed with a Luminex immunoassay kit (Bio-Rad, Austin, TX) according to 
the manufacturer’s instructions.  
Whole blood, plasma, urine, and various tissue samples were also collected and 
processed for acylcarnitine profiling. Whole blood, urine, and tissues were collected and 
immediately flash frozen prior to analysis. Plasma was flash frozen after separation from whole 
blood as described above. For analysis of (1) acylcarnitines (2) carnitine and butyrobetaine, and 
(3) total carnitine, samples were isolated by ion-exchange solid-phase extraction, derivatized 
with pentafluorophenacyl trifluoromethanesulfonate, separated by HPLC, and detected with an 
ion trap mass spectrometer (Minkler, Stoll et al. 2008). Acylcarnitines values were quantified 
using 13 point calibration curves, and approximately 72 acylcarnitines were reported. The 
internal standards used were d6-acetyl-, d3-propionyl-, undecanoyl-, undecanedioyl-, and 
heptadecanoylcarnitine (Minkler, Stoll et al. 2008). Tissues were reported in concentrations units 
of µmol/gram wet weight. Urine, plasma, and whole blood were reported in units of nmol/mL. 
4.3.9 Glucose and Insulin Regulation Studies 
An intraperitoneal glucose tolerance test (IPGTT) was performed as previously described 
(Rehman, Wang et al. 2005). Briefly, mutant animals and age-matched controls were fasted for 
approximately 5.5 hours followed by an intraperitoneal administration of sterile filtered D-
glucose at 2 g/kg body weight. The blood glucose levels were measured in tail blood samples at 
0 (prior to glucose administration), 15, 30, 60, and 120 minutes after glucose administration 
using a handheld Precision Xtra glucometer (Abbott, Alameda, CA).  Glucose levels of 70-150 
mg/dl under normal conditions is considered normal in mice.   
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 4.3.10 Microscopy 
Light microscopy was performed in the Mouse histology core laboratory by the Children’s 
Hospital of Pittsburgh of UPMC. Transmission electron microscopy was performed by the 
Center for Biologic Imaging at the University of Pittsburgh. 
4.3.11 Electron Transport Chain complexes 
4.3.11.1 Preparation of Mitochondria from Organs 
Three control and Acad10-/- mouse heart, brain, liver, and muscle tissues were harvested and 
placed in ice-cold PBS (1X) on ice at the time of harvest. The organs were washed twice with 
PBS and suspended in the mitochondrial separation buffer (Behboo, Carroll et al.) which consists 
of 0.25M sucrose, 1mM EDTA, 2.5% glycerol, 50mM phosphate buffer (pH 8.0) and freshly 
added protease inhibitor cocktail (Sigma, St Louis, MO). The organs were homogenized. The 
suspension was centrifuged at 2000 rpm for liver and brain, 1000 rpm for heart, and 1500 rpm 
for muscle in a Sorval SS34 rotor for 10 minutes. The supernatant was collected and centrifuged 
at 15,000 x g for 15 minutes at 4°C. The resulting pellet containing the mitochondria was washed 
twice with HB buffer, suspended in HB buffer and stored at -80 °C or in liquid nitrogen. The 
protein concentration of each sample was obtained using Bio-Rad DC Assay.   
4.3.11.2 Blue native gel electrophoresis (BNGE)  
Mitochondrial respiratory chain complexes and supercomplexes were characterized using BNGE 
(Graves, Wang et al. 2012). Eight mg of digitonin (MP Biomedicals, Solon,OH) were dissolved 
in 200 ml of 30 mM HEPES buffer, pH 7.4, 150 mM potassium acetate and 10% glycerol, heated 
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 at 95°C, then cooled on ice. One mg of mitochondria, isolated as described above, was lysed by 
the addition of digitonin to a final ratio of 1:8 protein:digitonin. Following incubation on ice for 
20 minutes, a Coomassie blue solution (5% Coomassie blue G250 in 750 mM 6-aminocaproic 
acid) was added (1/20 v/v), and the mixture was centrifuged at 14,0006 x g for 20 minutes at 4 
°C. The supernatant was then directly loaded onto a 3–12% Native PAGE Novex Bis-Tris gel 
(Invitrogen), and subjected to electrophoresis at 80 V for 4 hours at 4 °C in the buffer provided 
by the supplier. Following electrophoresis, gels were stained with Bio-Safe Coomassie G250 
(Bio-Rad, Hercules, CA) for 30 minutes and exhaustively de-stained with water. Stained gels 
were scanned and the images analyzed. For confirmation of native complex identities, individual 
bands were excised from the above gels, incubated in Laemmli SDS- sample buffer (Bio Rad) 
for 30 minutes at room temperature and electrophoresed on a Criterion pre-cast gel (Bio Rad) 
and electrophoresed at 80 V for 2 hours followed by silver staining (Sigma-Aldrich).  
4.3.11.3 Complex I and V gel in situ activity stain  
For Complex I activity measurements, the blue native gel was placed in 3-4 ml of 2 mM Tris-
HCl, pH 7.4 buffer containing 2.5 mg/ml nitrotertrazolinum blue chloride and freshly added 0.1 
mg/ml NADH (Graves, Wang et al. 2012). The gel was incubated at 37 °C for 1-2 hours and then 
subjected to densitometric analysis. An average value from 3 gels was calculated. To quantify 
the ATPase activity of Complex V, gels were incubated in 3-4 ml of 34 mMTris-glycine,pH 7.8, 
14 mM MgSO4, 0.2% Pb(NO3)2 with freshly added 8 mM ATP for 3 hours at 37 °C.  
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 4.3.12 qPCR Expression studies  
Wild type and ACAD10 deficient mouse tissues including liver, muscle, and fat were harvested 
and immediately flash frozen in liquid nitrogen. RNA extraction was performed on all samples 
using Qiagen RNeasy Fibrous Tissue Mini Kit for muscle, and RNeasy Lipid Tissue Mini Kit for 
liver and fat (Valencia, CA).  RNA concentration and quality was determined using Nanodrop. 
For cDNA synthesis and genomic DNA elimination in the RNA samples for use with the RT2 
Profiler PCR Arrays, the RT2 First Strand Kit (Qiagen, Valencia, CA) was used. An RT² 
Profiler™ PCR Array Mouse Insulin Signaling Pathway (Qiagen, Valencia, CA) gene panel was 
tested following manufacturer’s protocol. Real-time PCR was perfomed on an ABI 7900HT 
Sequence Detection System (PE Applied Biosystems, Foster City, CA) PCR assays were 
performed in 96 well optical plates following the manufacturer's recommendations.  
 
4.4 NEUROBEHAVIORAL TESTING 
4.4.1 Open Field Testing 
To examine the locomotor function and behaviors of mutant mice in a new environment, animals 
were placed for 30 minutes in an open-field chamber testing chamber (28 x 28 x 40 cm) with a 
floor divided into equal-sized square fields, and the frequency of a variety of behaviors was 
determined (Figure 23). The lighting was set to 15-20 lux, similar to standard housing. The 
animal was removed from its home cage and placed into one of the four corners of the open-field 
 67 
 chamber and allowed to explore the chamber freely for 30 minutes, following which, it was 
returned to its home cage. Testing parameters included (1) ambulatory distance, (2) velocity, (3) 
real vertical time, (4) real stereotypic time, (5) distance per trip, (6) real resting time, (7) real 
ambulatory time, (8) ambulatory counts, (9) stereotypic counts, and (10) vertical counts. 
 
Figure 23. Open field testing chamber 
4.4.2 DigiGait Testing 
A DigiGait (Mouse Specifics Inc, Quincy, MA) apparatus was used to examine locomotion on a 
motorized transparent treadmill belt with ventral plane treadmill videography to image the 
ventral view of animals as they walk (Figure 24). The motorized belt enabled numerous strides to 
be captured over a range of walking speeds (0.1 cm/s to 99.9 cm/s); goal boxes and other 
artifices to compel the animals to walk were not needed. Digigait software was used to compute 
the area of the advancing and retreating paws to quantify the spatial and temporal indices of gait, 
and reported >50 indices of gait for each limb a following the testing period (see Appendix B).   
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 On day 1 each mouse was acclimated to the DigiGait chamber. The lights were off in the room, 
but the belt and overhead lighting fixture on the chamber were on. Animal containment plates 
were at their widest points. The animals were brought into the room and their micro-isolator cage 
lids were placed half way off for five minutes to allow for passive air transfer.  Each animal was 
placed individually into the DigiGait chamber with the treadmill off for 10 minutes to explore. 
The mouse was then removed and put back to its cage. For days 2-5, each animal was acclimated 
to the DigiGait chamber in a similar fashion, except that belt speed was increased incrementally 
to 5 cm/s, 10 cm/s, 15 cm/s, and 29 cm/s on successive days. Ambulation was recorded on each 
day for 30 seconds, and the animal was returned to its home cage.  One clip of data was analyzed 
for each animal and parameters for best visualization were set.  
 
Figure 24. DigiGait testing equipment 
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 4.5 RESULTS 
4.5.1 ACAD10 Protein 
Immunohistochemical staining results on a variety of human tissues using ACAD10 and 
ACAD11 antibodies are shown in Figures 25-27.  
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Figure 25. Immunofluorescent staining of ACAD10 in human tissues 
Control human tissues (column A-M) were permeabilized with Triton X-100 and immunostained (green 
fluorescence) with antibodies to an ACAD10 peptide. Column (B-N) is fluorescent staining of the human tissues 
against anti-MTCO1 antibody is shown in red. Column (C-O) is the merged image of (A) and (B), and so on. There 
was significant co-localization of ACAD10 in mitochondria. 
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Figure 26. Immunofluorescent staining of ACAD10 in Human tissues 
Control human tissues (column A-M) were permeabilized with Triton X-100 and immunostained (green 
fluorescence) with antibodies to an ACAD10 peptide. Column (B-N) is fluorescent staining of the human tissues 
against peroxisomal catalase (N-17) antibody is shown in magenta. Column (C-O) is the merged image of (A) and 
(B), and so on. In a few of the tissues there was faint colocalization of ACAD10 in peroxisomes observed. 
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Figure 27.Western blot survey of human tissues for ACAD10 production  
Western blot survey of ACAD10 in human tissues are shown on a 4-15% SDS-PAGE gel. 100 µg of tissue extract 
was applied per lane. Bands at ~50Kd were visualized with ACAD10 Santa Cruz F-11 mouse monoclonal primary 
antibody. All tissues except muscle and pancreas identified a predicted 50 Kd protein. Molecular mass marker size is 
listed to the left of the gel image. 
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Figure 28. ACAD11 confocal microscopy on mouse liver and kidney 
(A) Immunofluorescent staining of human liver and kidney with antiserum to ACAD11 (left column), the 
mitochondrial marker anti-MTCO1 (middle column), and the merged image (right column). (A) Tissues failed to 
show co-localization of ACAD11 with the mitochondrial marker. (B) Liver and kidney were stained with antibodies 
to the peroxisomal marker catalase (left column). The right column shows the merged images, and identifies 
colocalization of ACAD11 to peroxisomes in liver and kidney. 
 
The function of ACAD10 protein is annotated in the human genome as an acyl-CoA 
dehydrogenase, but it has not been confirmed experimentally (Hashimoto, Fujita et al. 1999, 
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 Swigonova, Mohsen et al. 2009, He 2011). Database searches of transcribed sequences from 
these genes have identified the presence of multiple transcripts that differed mostly at either the 
5’ or 3’ end.  One of the largest transcripts predicts a full length ACAD10 protein of 119Kd. 
Subcellular fractionation and western blotting was performed on wild type mouse liver tissue, 
and western blotting with ACAD10 antiserum identified a 119 Kd band in a combined 
mitochondrial/peroxisomal (M/P) fraction not present in a more purified peroxisomal fraction (P) 
(Figure 29). A smaller species was present in both fractions, and thus likely to be peroxisomal 
We have noted 119, 100, 56, and 32 Kd ACAD10 isoforms are present in databases. We have 
observed bands at 119Kd in the mitochondrial fraction, but not in the pure peroxisomal fraction. 
 
Figure 29. Subcellular fractionation and western blotting of wild type mouse liver tissue 
ACAD10 purified antibody identified a predicted 119Kd full length ACAD10 protein in a combined 
mitochondrial/peroxisomal (M/P) fraction and a smaller protein in a more purified peroxisomal fraction (P). 
Molecular mass marker size is listed to the left of the gel image.  
 
To further examine the subcellular location of ACAD10, immunohistochemical analysis 
was performed on a variety of control mouse tissues. Immunohistochemical staining 
demonstrated the presence of ACAD10 in mitochondria of muscle and kidney (Figure 30A).  A 
faint ACAD10 signal was detected in mitochondria and peroxisomes of the lung and pancreas 
(Figure 30A and 30B), but was restricted to mitochondria in muscle and kidney (Figure 30A).  
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Figure 30. Subcellular localization of ACAD10 varies in different tissues 
(A) Immunofluorescent staining of lung, pancreas, muscle, and kidney from wild type mice with anitserum to 
ACAD10 (left column), the mitochondrial marker anti-MTCO1 (middle column), and the merged image (right 
column). All tissues showed co-localization of ACAD10 with the mitochondrial marker. (B) In addition, lung and 
pancreas were stained with antibodies to the peroxisomal marker catalase (left column). The right column shows the 
merged images, and identifies colocalization of ACAD10 to peroxisomes as well as mitochondria in lung and 
pancreas.  
4.5.2 Acad10 Deficient Mouse Model 
To determine the functional role of ACAD10, an Acad10 gene trap knockout model produced in 
a total genome knockout mouse project was purchased (Taconic Farms, Germantown, NY). 
Heterozygote animals were bred and PCR reactions using mouse genomic DNA to genotype 
offspring (Figure 31). Homozygous mutant animals proved to be viable and fertile. 
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Figure 31. PCR genotyping of mutant animals 
This is a 1% agarose gel electrophoresis of the larger fragment (195 bp) represents the wild type Acad10 allele and 
the smaller (154 bp) the mutant allele, stained with ethidium bromide and photographed under UV light. Wild type 
(+/+), heterozygous (+/–), or homozygous mutant (–/–) could be distinguished. 
4.5.3 Clinical Characterization 
The Acad10 deficient mice exhibited excess weight gain compared to wild type control animals, 
a difference that was more pronounced with age  and sex (males > females) (Figures 32 and 33). 
Micro-magnetic resonance imaging and pathologic evaluation demonstrated greater 
accumulation of white adipose tissue in deficient mice, especially intra-abdominally (Figure 33). 
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Figure 32. ACAD10‒/‒ and WT mice average body weight measured in grams (g) 
The graph shows the weight (grams) of wild type and mutant male (blue) and female (red) animals measured at 6-8 
months of age. The values are the mean and standard deviation of >7 animals each. The asterix indicate significance 
difference. The difference between wild type and mutant male animals was statistically significant (two-tailed p-
value=0.0006), as was the difference between the two female genotypes (two-tailed p-value=0.0007). 
 
 
Figure 33. Intrabdominal fat accumulation is increased in mutant mice 
Photograph of 2 male mice, age 10-15 months with abdominal incisions exposing the abdominal cavities. The liver 
(yellow arrow) is at the top of the figures. Intrabdominal fat (red arrows) is greatly increased in Acad10‒/‒ 
compared to wild type animals.  
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Figure 34. Micro-MRI imaging of Acad10 mouse abdominal cavity 
Mice were visualized using Horizontal bore 7-T MRI system, Bruker Biospin 70/30 with full vital monitoring 
system. (A) is a wild type mouse at 2-3 months old and (B) is an Acad10-/- mouse at 2-3 months old visualized 
using RARE-T2 Imaging. (C) is the same wild type mouse at 7-8 months old and (D) is the same Acad10-/- mouse 
at  7-8 months old visualized using FISP-3D Imaging. The cross-sectional images are whole, live, mouse abdomen 
sections 11 of 15 for (A) and (B), and sections 40 of 128 for (C) and (D). The Acad10 deficient mice visually show 
significant increase in adipose accumulation over time as compared to wild type control mice of the same 
background. 
 
Increased weight over time in the Acad10 deficient mice was not due to hyperphagia as 
they showed no significant differences in the amount of food consumed in wild type as compared 
to the mutants (Figure 35). 
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Figure 35. Mouse food intake  
In a five week period mouse food levels from 6-7 mice per group were weighed weekly using a standard lab 
balance. All wild type and Acad10 deficient mice were approximately 8 months old. The “WT pooled” and “Acad10 
deficient pooled” categories include combined data from both male and female mice. There were no significant 
differences in the amount of food consumed by wild type mice (any group) compared to Acad10 deficient mice (any 
group). 
 
4.5.4 Histopathology 
A complete pathologic survey was performed on fed Acad10 deficient mouse tissues from young 
(approximately 10-12 weeks old) and older (approximately 25-26 weeks and 1 year old) mice. 
Haematoxylin and eosin staining revealed morphological abnormalities in deficient mice, 
including small multifocal necroinflammatory lesions and early abscess formation in liver 
parenchyma, extramedullary hematopoiesis with prominent megakaryocytes in spleen, and 
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 multifocal extensive recent hemorrhage involving alveoli and bronchial tree in lung (Figure 
36A). Alkaline phosphatase staining of muscle showed peripheral nuclei indicative of chronic 
damage; Gomorri trichrome demonstrated an increase in fat accumulation in deficient animals; 
and NADH dehydrogenase staining showed an increased number of poorly staining muscle 
fibers (Figure 36B).  Acad10 deficient mouse tissue weights were significantly higher than the 
weights of tissues found in wild type animals (Figure 37), suggesting the Acad10 deficient mice 
tissue composition includes more fat.   
 
Figure 36. Histopathology of tissues from ACAD10 deficient mice 
(A) Light microscopy with hematoxylin and eosin staining of wild type liver (a) and lung (c) and Acad10 –/–liver 
(b), lung (d), and spleen (e) showed the formation of small necroinflammatory lesions with the formation of early 
abscesses in liver, acute focal hemorrhaging in lung, and extramedullary hematopoeisis with prominent 
megakaryoctyes in spleen. (B) Specialized staining techniques of wild type and deficient mouse tissues. a. & b.  
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 Alkaline phosphatase staining showed peripheral nuclei indicative of chronic damage; c. & d. Gomorri trichrome 
shows increased fat accumulation (purple color) in deficient animals; e. & f. NADH dehyrogenase staining shows an 
increased number of poorly staining muscle fibers. 
 
 
Figure 37. Organ tissue weights 
Mouse organ tissues from 6 mice per group were weighed using a standard lab balance. All wild type and Acad10 
deficient mice were approximately 1 year old. The Acad10 deficient (KO) demonstrated significant heavier tissues 
compared to wild type mice in (A) Liver, (B) Adipose, and (C) Heart.  
 
Antigen purified anti-ACAD10 was used for visualization of western blots of 4-15% SDS 
polyacrylamide gels of several mouse tissues including liver, lung, muscle, brain, heart, kidney, 
pancreas, and spleen. ACAD10 antigen was detected in pancreas, kidney, and brain at a 
molecular mass of 100 Kd rather than the expected 119 Kd for full length ACAD10 containing 
all domains (Figure 38).  
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Figure 38. Western blot survey of ACAD10 in mouse brain, pancreas, and kidney  
Western blot survey of ACAD10 in mouse tissue (only pancreas, kidney and brain are shown) of a 4-15% SDS-
PAGE gel. 100 µg of tissue extract were applied per lane. Bands at ~100Kd were visualized with ACAD10 purified 
anti-ACAD10-C to reduce background.  
 
MitoProfile Total OXPHOS Rodent WB antibody cocktail (Abcam, Cambridge, MA), 
ATP Citrate synthase (C-20) (Santa Cruz Biotech Inc, Dallas, TX) VLCAD, and MCAD were 
used for visualization of western blots of 4-15% SDS polyacrylamide gels of several mouse 
tissues including heart, liver, muscle, and brain. Antigen was detected in all tissues at the 
appropriate molecular mass using the mitochondrial cocktail (expected sizes Complex V 55Kd, 
Complex III 48Kd, Complex IV 40Kd, Complex II 30Kd, Complex I 20Kd) and MCAD 
(expected 42Kd)  (Figure 39). Similarly, ATP-citrate synthase (expected size 107Kd) was 
detected most highly in muscle tissue, while VLCAD (expected 62Kd) was observed in heart, 
liver, and muscle tissues. 
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Figure 39. Western blot survey of ACADs in mouse liver, heart, muscle, and brain 
A 4-15% SDS-PAGE gel with 50 µg of tissue extract applied per lane was visualized with antiserum to the indicated 
protein. (A) ~55kDa, 48kDa, 40kDa, 30kDa, and 20kDa were visualized in heart, liver, muscle, and brain using a 
mitochondrial cocktail. (B) Staining with ATP-citrate synthase revealed an ~107Kd band. (C) and (D) Western blots 
with anti VLCAD and MCAD antisera, respectively showing the appropriate protein sizes of 62Kd and 42Kd, 
respectively.   
 
Similarly, anti-ACAD11 antiserum was used to survey human and mouse tissue extracts 
including kidney, lung, liver, heart, muscle, pancreas, and spleen on western blots. ACAD11 
antigen was detected in all mouse tissues examined and human kidney and liver at ~75 kDa in 
contrast to the expected molecular mass of 87 kDa (Figure 40). The identity of this band as 
ACAD11 was confirmed using MS/MS. 
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Figure 40. Western blot survey of various mouse and human tissues for ACAD11 
Western blot survey of ACAD11 in (A) mouse and (B) human of a 4-15% SDS-PAGE gel. 100 µg of tissue extract 
were applied per lane. In mouse, bands at ~75kDa were visualized in all tissues with ACAD11 purified anti-
ACAD11-C to reduce background. In human, bands at ~75kDa were visualized in kidney and liver with the same 
antibody. 
4.5.5 Transmission Electron Microscopy 
Transmission electron microscopy performed at the Center for Biologic Imaging at the 
University of Pittsburgh identified lipid droplets in liver and muscle from Acad10 deficient 
animals (Figure 41). The formation of lipid droplets was present in Acad10 knockout liver and 
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 muscle tissues (E and H). Lung tissue was morphologically abnormal with the presence of red 
blood cells consistent with hemorrhaging (G), while kidney was unremarkable (B and F).  
 
Figure 41. Transmission electron microscopy of control and Acad10 deficient mouse tissues 
Transmission electron microscopy of wild type mouse liver (a), kidney (c), lung (e), and muscle (g) was 
unremarkable. Acad10 deficient liver (b) and muscle (h) showed the accumulation of lipid droplets (marked with 
yellow arrows) and enlarged mitochondria (white arrow). The kidney (d) was unremarkable, and lung (f) showed the 
presence of red blood cells (red arrow) and abnormal alveolar architecture. 
4.5.6 Biochemical Phenotype 
All other ACAD deficient mouse models exhibit characteristic patterns of blood and tissue 
acylcarntine elevations consistent with the known substrate specificity of the deficient enzyme 
and reflecting the findings in human patients. Thus, I began biochemical phenotyping of the 
Acad10‒/‒ mice with similar analyses. Blood, urine and tissue extracts were analyzed by the 
Biochemical Genetics Laboratory at Case Western Reserve University (Dr. C. Hoppel, director) 
for acylcarntine profiling. Levels of short, terminal branch chained acylcarnitines in blood and 
heart tissue in 3.9 and 5.7 month old animals were elevated (Figures 42). However, these 
patterns were not specific enough to allow identification of the optimum substrate for ACAD10.  
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Figure 42. Acylcarnitines in tissue and blood from wild type and deficient mice.  
Values of selected acylcarnitine species (average of two determinations) in heart measured at 3.9 and 5.7 months of 
age. 
 
In light of the association of ACAD10 variants with type 2 diabetes in Pima Indians, 
Acad10 deficient mice were evaluated for glucose control and their glucose-insulin axis. The 
level of glucose in fasting Acad10 knockout male mice was consistently slightly increased 
compared to wild type animals, but the difference was not statistically significant (Figure 43). 
Acad10 deficiency females showed slightly elevated blood glucose compared to wild type 
females, but was not statistically significant.  
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Figure 43. Glucose concentrations in wild type and Acad10-/- mouse serum 
Animals (8 months old) were fed ad lib and random blood glucose measurements were taken. Food was then 
removed form cages and blood glucose levels were measured after overnight fasting (~15 hours). The bars show the 
mean and standard deviation of 3-4 female mice and 5-6 male mice. Blue bars represent wile type animals and red, 
females. Glucose levels of each genotype and condition were compared to each other. While glucose concentration 
in fasted Acad10 deficient male mice was slightly higher than for wild type, the difference was not statistically 
significant using an upaired t-test (two-tailed p-vlaues). ACAD10 deficient females had significantly higher glucose 
levels than wild type females.  
 
Fed animals of both genotypes showed a physiologically appropriate decrease in insulin 
concentrations, while in the fasting state there was an increase in insulin concentration in Acad10 
deficient mice compared to wild type (Figures 44 and 45). 
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Figure 44. Insulin concentration in Acad10‒/‒ and wild type mice 
Animals (~4 months old) were fed ad lib, or food was removed from cages and blood was drawn after fasting 
overnight (~15 hours). Blue bars represent wild type animals and red Acad10−/−. Insulin levels of each genotype 
and condition were compared. Insulin concentration in fed and fasted Acad10 deficient male mice was slightly 
higher than for wild type.  
 
 
Figure 45. Insulin concentration in Acad10‒/‒ and wild type mice 
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 Animals (~1yr old) were fed ad lib, or food was removed from cages and blood was drawn after fasting overnight 
(~15 hours). Blue bars represent wild type animals and red Acad10−/−. Insulin levels of each genotype and 
condition were compared. Insulin concentration in fed and fasted Acad10 deficient male mice was slightly higher 
than for wild type.  
 
4.5.7 Intraperitoneal glucose tolerance test (IPGTT) 
Given the abnormalities in fasting glucose and insulin, an intraperitoneal glucose tolerance test 
was performed on the mutant and wild type mice. Acad10 deficient male mice demonstrated 
significantly elevated glucose compared to the wild type mice and returned to baseline levels 
more slowly (Figure 46-48). The Acad10 deficient mice do not appear to clear glucose as 
effectively as the controls. The Acad10 deficient female mice also demonstrated slightly less 
efficient glucose clearance than wild type females in the early time points of the IPGTT.  
 
 
Figure 46. Intraperitoneal glucose tolerance test on Acad10 deficient and wild type female mice 
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 An IPGTT was performed as described in the methods. Wild type (Liu, Wang et al.) females old and young are 
shown in blue and green, respectively. Acad10 deficient (–/–) old and young are shown in red and purple, 
respectively. Young Acad10 deficient female mice show a statistically significant delay in glucose clearance 
compared to the young wild type females of the same genetic background (two-tailed p-value=0.0377 and 0.0134, 
respectively) at time 0 and 15 minutes, indicated by an asterisk.  
 
 
Figure 47. Intraperitoneal glucose tolerance test on Acad10 deficient and wild type male mice 
An IPGTT was performed as described in the methods. Wild type (Liu, Wang et al.) males old and young are shown 
in green/light blue and dark blue, respectively. Acad10 deficient (–/–) old and young are shown in purple/orange and 
red, respectively. Young Acad10 deficient male mice show a statistically significant delay in glucose clearance 
compared to the young wild type males of the same genetic background (two-tailed p-value=0.0201 and 0.0122, 
respectively) at time 30 and 60 minutes, indicated by an asterisk.  
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Figure 48. Total blood glucose level in mice during IPGTT as determined by area under the curve 
Acad10 deficient (ACAD10–/–) and wild type (WT) old and young are shown in red and blue, respectively. Acad10 
deficient mice show a significantly larger area under the curve compared to wild type in both males and females, 
and across all age groups.  
4.5.8 Inflammation 
Inflammation has been shown to play a significant role in the development of insulin resistant 
diabetes. Recurrent rhabdomyolysis is a common finding in human patients with ACAD 
deficiencies and other disorders of energy metabolism; therefore, we examined serum creatine 
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 kinase (CPK) levels in Acad10 deficient animals. Fed levels of CPK were normal in mutant 
animals. However, adult male Acad10 deficient mice exhibited a dramatic increase in the CK 
levels with fasting (Figure 49).  
To examine the inflammatory status in Acad10 knockout mice, a highly sensitive ELISA 
assay was used to measure CRP (Figure 50). No significant difference was found between 
mutant and wild type animals.  A broad panel of cytokines was normal or even reduced in 
Acad10‒/‒ male and female animals (Figure 51). Acad10‒/‒ male mice also showed significantly 
reduced cytokine levels (Figure 52). Additionally, quantification of C-reactive protein (CRP) in 
serum provides information on diagnosis, prognosis, and monitoring of disease (Eckersal 2000). 
In total, these results suggest that the insulin resistance seen in Acad10‒/‒ animals is 
unrelated to an inflammatory process.  
 
 
Figure 49. Blood CPK level in fed and fasted Acad10‒/‒ and wilt type mice 
Creatine kinase (CK) concentration in fasting Acad10 deficient male mice shows a statistically significant increase 
(two-tailed p-value=0.0135) compared with other fed and fasted animals at 8 months of age. 
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Figure 50. C-reactive protein concentration in wild type and Acad10 deficient mice 
Animals (~8 months old) were fed ad lib or food was removed from cages and blood was drawn after fasting 
overnight (~15 hours). The bars show the mean and standard deviation of 3 female mice and 3 male mice. Blue bars 
represent wild type animals and red Acad10‒/‒ −/−. CRP levels of each genotype and condition were compared to 
each other. Values between groups are not statistically significant, indicating lack of a generalize inflammation or 
infectious process in the Acad10 deficient animals. Each group had 24 animals and the assay was performed in 
triplicate.  
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Figure 51. Cytokine levels in blood from wild type and deficient mice.  
Male and female animals were fed ad lib or food was removed from cages and blood was drawn after overnight 
fasting (~15 hours). The bars show the mean and standard deviation of 3-4 female mice and 7 male mice for each 
group. Blue bars represent wile type animals and red Acad10−/−. Cytokine levels of each genotype and condition 
were compared to each other. Values between groups with an asterisk are statistically significant. 
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Figure 52. Cytokine levels in blood from wild type and mutant  male mice 
Male animals were fed ad lib and blood was drawn. The bars show the mean and standard deviation of 7 male mice 
for each group. Blue bars represent wile type animals and red Acad10−/−. Cytokine levels of each genotype were 
compared to each other. Values between groups with an asterisk are statistically significant, indicating normal or 
reduced cytokine levels in the Acad10 deficient animals.   
 
4.5.9 Electron Transport Chain complexes (Liu, Wang et al.) 
ETC abnormalities have previously been described in humans with obesity and T2DM 
(Goodpaster 2013). To examine ETC function in Acad10 deficient mice, blue native gel 
electrophoresis (BNGE) was performed on mitochondrial extracts from heart, liver, muscle, and 
brain tissue (Figure 53). ETC complex I activity was found to be elevated in liver, muscle, and 
brain from deficient animals, suggestive of mitochondrial proliferation. Complex V activity was 
elevated in heart, liver and muscle, but decreased in brain, suggesting the possibility of as yet 
unrecognized neurologic problems. 
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Figure 53. Characterization of electron transport chain complexes by blue native gel electrophoresis 
(A) Blue native gel electrophoresis of heart, liver, muscle, and brain from mutant (MT) and wild type (Liu, Wang et 
al.). (B) Complex I (CI) in situ gel activity. Enzymatic activity staining was detected as isolated Complex I as well 
as the bands that represent higher order supercomplexes (SC). (C) Enzymatic Complex V (CV) in situ gel activity 
activity.”d” and “m” denote the active dimer and monomer forms of CV, respectively. All lanes contain ~0.06 µg of 
tissue extract. (CII, CIII, and CIV are respiratory chain complexes II, III< and IV, respectively. 
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 4.5.10 Quantitative PCR (qPCR) 
An insulin/T2D regulatory panel of genes was measured for expression in fat, liver, muscle, and 
brain. Analysis of fat tissues showed significant down regulation in expression of the genes 
Hnf1b, Glp1r, Hnf4a, Fbp1, and Aqp2 (Figure 54).  
 
Figure 54. Quantitative PCR in Acad10 deficient mouse fat tissue 
This figure shows data points representing each gene’s expression. Expression is relatively normal reasonably 
detected in all samples, except for the 5 highlighted in green, which are expressed at lower levels as described in the 
text.  
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Figure 55. Quantitative PCR in Acad10 deficient mouse muscle tissue 
This figure shows data points representing each gene’s expression. Expression is relatively normal for all samples, 
except for the 1 highlighted in red, which is expressed at a higher level.  
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Figure 56. Quantitative PCR in Acad10 deficient mouse liver tissue 
This figure shows data points representing each gene’s expression. Expression is essentially normal for all samples, 
except for the 2 highlighted in red, which are expressed at  higher levels.  
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Table 5. Fold change in gene expression in ACAD10 deficient fat tissue compared to control 
Gene Expression in ACAD10‒/‒ vs Control 
Plate Position Tissue Gene Symbol Fold Regulation Comments 
A07 Fat Aqp2 -4.4537 Down 
B05 Fat Fbp1 -5.1396 Down 
C01 Fat Glpr1 -29.0071 Down 
C05 Fat Hnf1b -118.3296 Down 
C06 Fat Hnf4a -17.9802 Down 
G04 Muscle Tnf 2.54 Up 
F05 Liver Serpine1 3.45 Up 
D03 Liver Il6 3.07 Up 
 
4.6 NEUROBEHAVIORAL ANALYSES 
4.6.1 Open Field Testing 
Acad10 shows significant expression in brain, but deficient animals showed no overt neurologic 
deficits. To better evaluate for subtle deficits, neurobehavioral testing was performed on mutant 
wild type mice. Open field testing parameters included (1) ambulatory distance, (2) velocity, (3) 
real vertical time, (4) real stereotypic time, (5) distance per trip, (6) real resting time, (7) real 
ambulatory time, (8) ambulatory counts, (9) stereotypic counts, and (10) vertical counts. 
 100 
 Analysis was performed be examining two different zones designated Zone 0 (box perimeter) 
and Zone 1 (box center) (Figure 57).  
 
Figure 57. Open ffield zones in testing chamber. 
Zone 0 is the outer perimeter of the testing chamber, where animals are expected to spend more time because they 
feel more protected by the surrounding walls. Zone 1 is considered a more dangerous zone because upon entering 
Zone 1 the animal is exposed on all sides. 
 
Overall, female Acad10 deficient animals demonstrate less activity in the center area of 
the open field testing box than wild type females suggesting higher anxiety. The mutants also 
demonstrated smaller measures of movement, consistent with animal hypoactivity. Reduced 
rearing (an act of exposing the underside of the body) is another indicator of anxiety and female 
Acad10 deficient mice spent significant less time performing this activity than wild type females.   
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Figure 58. Open field ambulatory measures in female mice 
Time (in seconds) or centimeters (cm) spent or traveled in each activity is depicted with wild type animals in blue 
and ACAD10‒/‒ deficientin red. The Acad10 deficient female mice showed a statistically significant decrease in 
movement measures in Zone 1 (two-tailed p-value=0.0004, p-value= 0.0002, and 0.0003, respectively), indicated by 
an asterisk, as compared to wild type control mice of the same background. The Acad10 deficient female mice show 
statistically significant decrease in movement measures in Zone 0 across time (two-tailed p-value=0.0230), indicated 
by an asterisk, as compared to wild type control mice of the same background.   
 
 
Figure 59. Open field vertical measures in female mice 
Time (in seconds) spent vertical is depicted with wild type (Liu, Wang et al.) animals in blue and Acad10‒/‒ 
deficient in red The Acad10 deficient female mice show a statistically significant decrease in rearing in Zones 0 and 
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 1 (two-tailed p-value= 0.0226, 0.0001 and p-value= 0.0075, <0.0001, respectively), indicated by an asterisk, as 
compared to wild type control mice of the same background.   
 
 
Figure 60. Open field measures of stereotypic movements in female mice 
Time (in seconds) spent in each activity is depicted with wild type (Liu, Wang et al.) animals in blue and Acad10‒/‒ 
deficient in red. The Acad10 deficient female mice show a statistically significant decrease in stereotypy in Zone 1 
(two-tailed p-value= 0.0176, 0.0156, respectively), indicated by an asterisk, as compared to wild type control mice 
of the same background.  Stereotypic behaviors are fine movements such as scratching and grooming. The animal is 
not moving to cover distance in the chamber, but it is breaking the infrared beams of the chamber, therefore is not 
motionless. Stereotypy in mice is an indicator the animal is relaxed and feels comfortable in its environment.  
 
 
 
Figure 61. Open filed resting measures in female mice 
Time (in seconds) spent resting in each zone is depicted with wild type (Liu, Wang et al.) animals in blue and 
Acad10‒/‒ deficient inred. The Acad10 deficient female mice show a statistically significant increase in resting time 
in Zone 0 (two-tailed p-value=0.0002), indicated by an asterisk, as compared to wild type control mice of the same 
background.   
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 4.6.2 Digigait Testing  
DigiGait testing identified subtle changes in gait dynamics and posture in the Acad10 deficient 
mouse model compared to controls. The DigiGait testing proved more sensitive than other 
available tests and provided detailed information on specific gait parameters. Acad10 deficient 
mice showed a statistically significant decrease in percentage of brake stride and brake stance 
movements, while there was a statistically significant increase in the percentage of propel stride 
and propel stance movements in hind limbs. Correlation of these two parameters suggests that 
the deficient animals spend less time braking and more time in propulsion to generate movement 
forward, characteristic of several different neuropathologic conditions (Figure 62). The results in 
Figure 63 indicate that deficient animals spend more time and effort getting into motion than 
stopping or slowing down motion (Mouse Specifics 2010).   
 
 
Figure 62. Digigait indices I 
Percentage of each activity in (A) Forelimbs and (B) Hindlimbs is depicted with wild type (Liu, Wang et al.) 
animals in blue and Acad10‒/‒ deficient in red. The Acad10 deficient mice show a statistically significant decrease 
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 in %BrakeStride (p=0.0116) and %BrakeStance(p=0.0001). The Acad10 deficient mice show a statistically 
significant increase in %PropelStride (p=0.0037)  and %PropelStance (p=0.0001).  
 
Decreased swing and braking strides (Figure 64) confirms that the deficient animals 
spend less time braking and more time in propulsion to generate movement forward. Acad10‒/‒ 
deficient animals also demonstrate a decrease in paw area at peak stance in forelimbs and an 
increase in paw area at peak stance in hind limbs, a relative non-specific finding with multiple 
interpretations.  
 
Figure 63. Digigait indices II 
Measure of each activity in forelimbs and hindlimbs is depicted with wild type (Liu, Wang et al.) animals in blue 
and Acad10‒/‒ deficient in red. The Acad10 deficient mice show a statistically significant decrease in swing (p= 
<0.0001) and paw area at peak stance in cm2 (p= 0.0065) in the forelimbs.  There is also a corresponding decrease in 
brake (p= 0.0269) and paw area at peak stance in cm2 (p= 0.0416).   
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 Decreased stride length variation (Figure 64) in Acad10‒/‒  deficient animals implies that 
they have good balance and stability. Thus, there does not appear to be significant motor 
impairment in the mutant mice.   
 
Figure 64. Digigait indices III 
Measures of each activity in forelimbs and hindlimbs are depicted with wild type (Liu, Wang et al.) animals in blue 
and Acad10‒/‒ deficient in red. The Acad10 deficient mice show a statistically significant decrease in stride length 
variation (SLVar) using unpaired t-test (two-tailed p-value = 0.0132).  
Decreased stride length covariance (Figure 65) in Acad10‒/‒ deficient mice confirms the 
lack of variation and motor impairment. The measure MAX dA/dT is the maximal rate of change 
of paw area in contact with the treadmill belt during the braking phase (Mouse Specifics 2010). 
This parameter measures how quickly the limb is loaded with the weight of the animal to a 
stance position, and also how quickly the animal is capable of decelerating (Mouse Specifics 
2010). MAX dA/dT is related to general muscle strength of the animal. The Acad10‒/‒ deficient 
animals show a statistically significant decrease in MAX dA/dT suggesting the presence of some 
muscle weakness (Figure 65).  Figure 65 also shows additional parameters that were measured. 
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Figure 65. Digigait indices IV 
Measures of each activity in forelimbs and hindlimbs is depicted with wild type (Liu, Wang et al.) animals in blue 
and Acad10‒/‒ deficient in red. The Acad10 deficient mice show a statistically significant decrease in stride length 
CV (p= 0.0302) and MAX dA/dT (p= 0.0139) in the forelimbs using unpaired t-test. The Acad10 deficient mice 
show a statistically significant increase in the number of steps taken (p= 0.0152).  
 
4.6.3 Micro-MRI Brain 
Because Acad10-/- mice exhibited subtle abnormalities on neurobehavioral testing, brain MRI 
scans were performed over a period of 6 months to identify any changes in morphology. No 
significant abnormalities were identified as the Acad10 deficient mice increased in age. Figure 
66 shows a representative scan. 
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Figure 66. Micro-MRI of mouse brain 
Mice were visualized using Horizontal bore 7-T MRI system, Bruker Biospin 70/30 with full vital monitoring 
system. (A) and (B) is the same wild type mouse at 2-3 months old and 7-8 months old, respectively, using RARE-
T1 Imaging. The coronal image is whole, live, mouse brain section 11 of 15. (C) and (D) is the same Acad10-/- 
mouse at 2-3 months old and 7-8 months old, respectively, using RARE-T1 Imaging. The coronal image is a 
representative whole, live, mouse brain section 11 of 15. The Acad10 deficient mice do not show any significant 
changes in brain structure and morphology over time as compared to wild type control mice of the same 
background. 
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 4.7 DISCUSSION 
Over the past 20 years, 9 inborn errors of metabolism caused by deficiencies in ACADs have 
been described causing significant morbidity and mortality in affected individuals. Recently, two 
new ACADs of unknown function have been identified, raising the specter of additional 
unrecognized disorders related to their dysfunction. Prior research on ACAD10 and 11 suggested 
a novel role in central nervous system metabolism and highlighted a possible role in the 
development of T2DK (Bian, Hanson et al. 2010, He 2011). The studies in this thesis were 
designed to determine the physiologic function of ACAD10 and 11. This knowledge will provide 
the opportunity to define clinical disorders related to deficiency of ACAD10 and 11, allow 
development of strategies for early diagnosis, and lead to rational intervention. 
Disorders in fatty acid oxidation are among the most frequent of the inborn errors of 
metabolism and lead to a variety of phenotypes that require optimal treatment for patients to 
thrive (Vockley, Singh et al. 2002, Wang, Mohsen et al. 2010). Valuable progress has been made 
in recent years in identifying ACDs and their mutations in patients. Studies have focused initially 
on those enzymes most highly expressed and with easily deducible functions. More recently, the 
additional enzymes described in this gene family have exhibited low level expression, including 
ACAD10 and 11, and/or restricted tissue distribution, making functional studies and 
identification of deficient patients more difficult. Thus, additional approaches are needed to 
determine the roles of novel proteins such as ACAD10, and their possible role in disorders of 
mitochondrial fatty acid oxidation. Research in Dr. Vockley’s lab suggests potential functions for 
ACAD10 in the central nervous system, metabolism, and immunity (He 2011). ACAD10 has also 
been genetically linked to type 2 diabetes, but functional studies have yet to be performed to 
provide feedback to these insights (Bian, Hanson et al. 2010). Results presented in this thesis 
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 provide the first opportunity to better understand the biochemical pathways and functional 
interactions of ACAD10. First and foremost, animals deficient in ACAD10 develop the insulin 
resistance hyperglycemia characteristic of T2DM. They also exhibit the same metabolic profile 
in muscle previously reported by our lab in adult humans with T2DM. This pattern suggests 
inefficient transfer of reducing equivalents from fatty acids to the electron transport chain, likely 
leading to subtle energy deficiency. This finding leads to new possibilities for designing 
therapeurtic agents to treat T2DM. Stabilization of the proteins as the interface of FAO and ETC 
by small molecule chaperonins could reverse the defect identifying in our mice and improve 
energy transfer. ACAD10 deficient mice also become obese. Characterization of the physiologic 
change responsible for this derangement would also be of great potential relevance to human 
disease. An ACAD10 polymorphism has been linked to the development of T2DM in Pima 
Indians. Thus, further exploration of ACAD10 sequence, expression and function may provide 
further insight into this devastating illness in this population.  
Finally, ACAD10 deficient mice demonstrate other clinical abnormalities of potential 
relevance to human disease. While they do not become hypoglycemic with fasting, the classic 
sign seen in other mouse models of FAOD, ACAD10 mice do exhibit fasting rhabdomyolysis. 
This condition is a common one in humans and roughly one third of them remain without a 
diagnosis after extensive evaluations. Analysis of ACAD10 in these patients is warranted. 
ACAD10 deficient mice also develop subtle neurobehavioral abnormalities. These findings are 
in keeping with neurologic expression of the gene. Thus human patient may also experience 
neuromuscular disease. Unfortunately, my expressions studies failed to yield a stable and active 
ACAD10 protein for direct enzymatic studies, so an understanding of its role in mitochondrial 
metabolism, T2DM, obesity, and other symptoms were not possible. A number of options are 
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 available to achieve this goal. Expressions system using mammalian cells, baculovirus, or yeast 
might all allow production of stable protein as they are more homologous to native processes 
than the prokaryotic system used. Additional exploration of the functional protein forms 
generated from this complex locus would also be useful.  
ACAD10 and 11 share 46% homology between each other and are widely conserved 
across evolution (Vockley , Swigonova, Mohsen et al. 2009, He 2011). Extensive sequence 
analysis indicates that they are more highly conserved across evolution than the other more 
highly expressed ACADs, suggesting critical functions for these novel enzymes. Both genes are 
located within complicated loci containing multiple predicted exons and protein domains, 
including the ACAD domain. Database searches of transcribed sequences from these genes have 
identified the presence of multiple transcripts that differed mostly at either the 5’ or 3’ end.  
Acyl-CoA dehydrogenases 10 (ACAD10) and 11 (ACAD11) transcripts encoding 1059-aa 
(119kDa) and 780-aa (87kDa) proteins predicted to be structurally related have been identified in 
databases but their function is unknown. My strategy was to initially clone and express ACAD10 
as recombinant protein for structural and enzyme studies and to generate antibodies to localize its 
presence in cells to further define its role, but I experienced difficulty in obtaining a full length 
clone. This difficulty may have arrisen as a result of the size or amino acid composition of the 
ACAD10 protein and/or the possibility for alternative splicing. After the full length ACAD10 
appeared to be unstable, I began to create a full length protein by cloning it into a plasmid in 
pieces. I was able to successfully develop a plasmid with the ACAD domain, expression and 
purification of this short form allowed generation of an ACAD10 antibody. To increase stability 
of other ACAD10 plasmids, I added His6-tag to several ACAD10 plasmid forms, including the 
short plasmid form that corresponded to the ACAD domain.Transcripts were expressed in E. 
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 coli, but production of these proteins failed. Expression of inserts coding for ACAD10 S637-
I1059 and ACAD11 S355-I780 sequences representing the ACAD domain was successful.  
Several of the plasmid constructs were specifically examined more extensively following protein 
purification. The purified proteins have absorbance spectra typical of flavoproteins but were 
inactive unstable. 
While the only transcripts, that include a 5’-end UTR, that have been published code for 
1059-aa and 1090-aa in length, recently our mRNA isolation from mouse lung has revealed the 
presence of a transcript missing 9 internal exons, which would code for 61.5 kDa protein. These 
experiments also revealed the presence of other fragments of the sizes that reflect the 
discrepancy in the reported genomic sequences in GenBank and Ensembl databases. In the latter, 
the ACAD10 gene is reported to include an additional exon between exons 8 and 9, compared to 
the GenBank reported genomic sequence. Further sequence determination will resolve the 
various sizes and confirm the existence of more than two ACAD10 transcripts that may possibly 
function in various organelles. 
Despite some small successes with cloning the ACAD10 protein, we still need to learn 
how to isolate the native forms of this protein, especially the full length protein, which is now 
crucial to elucidating structure and function. By investigating the subcellular location and 
substrate specificities of this major protein species of this newly identified ACAD, we have just 
began to determine a potential physiological function of these unique proteins, which in turn will 
facilitate further studies and to continue identification of ACAD10 protein function.  
According to our findings, ACAD10 is detectable in both mitochondria and peroxisomes 
depending on tissue, while ACAD11 is largely peroxisomal. Duel localization of ACAD10 is 
likely related to differential splicing of the full gene transcript. For mitochondrial import to occur 
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 a signal sequence at the N-terminus is needed, which if present is the dominant localization 
signal in the protein. If this signal is lost by alternative splicing, then the protein must default to 
another location. Cytoplasmic transport through endoplasmic reticulum generated vesicles with 
exocytosis is a possibility, but a peroxisomal targeting signal would interrupt this and redirect the 
protein to peroxisomes. A weak amino terminal peroxisomal targeting signal can be detected 
internal to the mitochondrial signal and may be activated by loss of the mitochondrial signal. A 
c-terminal peroxisomal signal is also present and may be sufficient to direct the protein to 
perxoisomes with loss of the mitochondrial signal. Additional subcellular fractionation and 
import studies will be necessary to characterize the peroxisomal variants of ACAD10 and 11. 
Alternative enzyme assays will also need to be employed as peroxisomes do not use ETF as an 
elctron acceptor. Rather, oxidases take the place of dehydrogenases in peroxisomal FAO, and 
thus ACAD10 protein within peroxisomes may be an oxidase.  
In this study, we have made significant progress towards identifying the role of ACAD10 
in physiology. ACAD10 is a complex protein containing multiple domains. It appears to localize 
to mitochondria in muscle, lung, and kidney. It also appears to localize to the peroxisomes in 
lung. The deficient mouse demonstrates obesity with T2DM, subtle neurologic abnormalities, 
elevated short, branched chain acylcarnitines in tissues, and fasting rhabdomyolysis with 
abnormal muscle mitochondria. Additional study of this novel ACAD will ultimately lead to a 
better understanding of its role in human physiology and disease.   
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 APPENDIX A:  TATN-1 MUTATIONS REVEAL A NOVEL ROLE FOR TYROSINE AS 
A METABOLIC SIGNAL THAT INFLUENCES DEVELOPMENTAL DECISIONS AND 
LONGEVITY IN CAENORHABDITIS ELEGANS 
This work has been previously published in the following location. Copyright permission was 
not needed to include the manuscript in this thesis dissertation. 
My role in this project primarily focused on the work performed in the section Tyrosine 
aminotransferase expression is controlled by diet and environment in the following manuscript.  
 
Ferguson AA1, Roy S2, Kormanik KN1, Kim Y3, Dumas KJ3, Ritov VB4, Matern D5, Hu PJ6, 
Fisher AL7.  “TATN-1 Mutations Reveal a Novel Role for Tyrosine as a Metabolic 
Signal That Influences Developmental Decisions and Longevity in Caenorhabditis 
elegans.”  PLoS Genet. 2013 Dec;9(12):e1004020. doi: 10.1371/journal.pgen.1004020. 
Epub 2013 Dec 19.  
 
Recent work has identified changes in the metabolism of the aromatic amino acid tyrosine as a 
risk factor for diabetes and a contributor to the development of liver cancer. While these findings 
could suggest a role for tyrosine as a direct regulator of the behavior of cells and tissues, 
evidence for this model is currently lacking. Through the use of RNAi and genetic mutants, we 
identify tatn-1, which is the worm ortholog of tyrosine aminotransferase and catalyzes the first 
step of the conserved tyrosine degradation pathway, as a novel regulator of the dauer decision 
and modulator of the daf-2 insulin/IGF-1-like (IGFR) signaling pathway in Caenorhabditis 
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 elegans. Mutations affecting tatn-1 elevate tyrosine levels in the animal, and enhance the effects 
of mutations in genes that lie within the daf-2/insulin signaling pathway or are otherwise 
upstream of daf-16/FOXO on both dauer formation and worm longevity. These effects are 
mediated by elevated tyrosine levels as supplemental dietary tyrosine mimics the phenotypes 
produced by a tatn-1 mutation, and the effects still occur when the enzymes needed to convert 
tyrosine into catecholamine neurotransmitters are missing. The effects on dauer formation and 
lifespan require the aak-2/AMPK gene, and tatn-1 mutations increase phospho-AAK-2 levels. In 
contrast, the daf-16/FOXO transcription factor is only partially required for the effects on dauer 
formation and not required for increased longevity. We also find that the controlled metabolism 
of tyrosine by tatn-1 may function normally in dauer formation because the expression of the 
TATN-1 protein is regulated both by daf-2/IGFR signaling and also by the same dietary and 
environmental cues which influence dauer formation. Our findings point to a novel role for 
tyrosine as a developmental regulator and modulator of longevity, and support a model where 
elevated tyrosine levels play a causal role in the development of diabetes and cancer in people. 
A.1 INTRODUCTION 
The aromatic amino acid tyrosine serves many metabolic roles including being a building 
block for protein synthesis, a source of energy, and a precursor for the synthesis of melanin and 
several neurotransmitters including dopamine and other catecholamines. Beyond these currently 
known functions for tyrosine, recent work has suggested that tyrosine could also play regulatory 
roles in both metabolism and the control of cell proliferation. Specifically, in people elevated 
serum tyrosine levels occur with obesity and represent a risk factor for the development of 
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 diabetes [1]–[6]. Additionally, the enzyme tyrosine aminotransferase (TAT), which acts to 
normally convert tyrosine to energy, has been identified as a tumor suppressor gene which acts to 
promote apoptosis and prevent the development of hepatocellular carcinoma [7]. How changes in 
tyrosine metabolism could contribute to these disease processes is currently unknown, but it is 
possible that levels of this amino acid could play a direct regulatory role for the behavior of 
specific cells and tissues. While consistent with the available data, direct evidence for this model 
is currently lacking. 
The nematode Caenorhabditis elegans normally progresses through four larval stages before 
developing into a reproductive adult animal. However specific cues, such as crowding, low food 
availability, or elevated temperature, can be sensed by the developing worm and lead to 
developmental arrest in a diapause state called a dauer larva [8]–[11]. Entry into dauer permits 
worms to delay the completion of development and the initiation of reproduction in 
environments which are not favorable, and instead the animals can survive as a dauer for up to 
several months before resuming normal development when conditions become favorable for 
reproductive success. This developmental decision requires a complicated interplay of sensory 
neurons with specific cGMP, TGF-β, and insulin-like signaling cascades controlling the choice 
of reproductive versus dauer development [9], [10]. 
In the worm, the daf-2 insulin/IGF-1 receptor (IGFR) signaling pathway is involved in both 
dauer development and adult longevity [12]–[14]. Active signaling through the pathway during 
development enables animals to reach reproductive adulthood whereas reductions in daf-2/IGFR 
signaling due to either environmental triggers or genetic mutations lead to arrest as a 
dauer [9], [14]. In adult worms, daf-2/IGFR signaling is a major modulator of longevity and 
mutations impairing the pathway can result in 100% increases in lifespan [13]. 
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 At a molecular level, the daf-2/IGFR pathway consists of daf-28 and other insulin-like peptides, 
which are thought to act as ligands for the DAF-2 insulin/IGF-1 receptor [15]–[18]. Downstream 
of daf-2/IGFR, is the age-1 PI3 kinase and a kinase cascade consisting of the phosphoinositide-
dependent kinase pdk-1 and the protein kinase B genes akt-1 and akt-2 (Figure 1A) [19]–[22]. 
Both akt-1 and akt-2 normally act to phosphorylate the DAF-16 FOXO transcription factor 
which leads to its retention in the cytoplasm [23]–[25]. Reductions in either daf-2/IGFR or 
combinedakt-1 and akt-2 activity result in the entry of DAF-16/FOXO into the nucleus and 
strong activation of DAF-16/FOXO target genes [23]–[25]. In contrast, loss of onlyakt-1 activity 
leads to the translocation of DAF-16/FOXO into the nucleus but a lesser increase in the 
expression of DAF-16/FOXO target genes (Figure 1A and Table S1) [26], [27]. This finding 
suggested that additional pathways could be involved in controlling the transcriptional activity of 
DAF-16/FOXO (Figure 1A). One group of potential regulators is the eak (enhancer of akt-1 null) 
genes, which were identified in a forward genetic screen and act in a non-cell autonomous 
manner to control the transcriptional activity of nuclear localized daf-16/FOXO (Figure 1A) 
[26]–[29]. The identified eak genes lack structural homology to one another and appear to lie in 
one or more poorly characterized pathways that act in parallel to akt-1. The identification of the 
eak genes suggests that additional novel pathways either downstream or parallel to insulin 
signaling may await discovery.  
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Figure 67. Diagram of daf-2/IGFR signaling pathway and tyrosine metabolic pathway 
(A) For dauer formation in C. elegans the daf-2/IGFR receptor lies upstream of a PI3 kinase signaling cascade 
consisting of age-1/PI3  kinase, the phosphoinoside-dependent kinase pdk-1, and the protein kinase B family kinases 
akt-1 and akt-2. Both AKT-1 and AKT-2 act to phosphorylate DAF-16/FOXO and prevent entry of this protein into 
the nucleus.  Inhibition of AKT-1 leads to entry of DAF-16/FOXO into the nucleus without the activation of DAF-
16 target genes.  This suggested that other pathways acted to control the transcriptional activity of nuclear DAF-
16/FOXO.  The eak genes are a group of structurally unrelated genes which act in a cell non-autonomous manner to 
restrain the transcriptional activity of nuclear DAF-16/FOXO through an undefined molecular mechanism.  (B) 
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 Tyrosine is degraded to fumarate and acetoacetate via a five step degradation pathway.  Shown are the names and 
structures of the intermediates as well as the names of the enzymes in the pathway that are studied in this work.   
 
In both vertebrates and worms, there is data suggesting a link between tyrosine metabolism and 
insulin signaling. TAT, which catalyzes the first step in a conserved degradation pathway that 
converts tyrosine to fumarate and acetoacetate (Figure 1B), has been well studied as a target of 
regulation by insulin signaling in vertebrates with insulin effects seen at both the transcriptional 
and translational level [30]–[38]. Further, in C. elegans the hpd-1 gene, which encodes the 
enzyme 4-hydroxyphenylpyruvate dioxygenase and lies immediately downstream of TAT in the 
tyrosine degradation pathway, is a target gene for the daf-16/FOXO transcription factor and 
positively regulated by daf-2/IGFR signaling [39]. The down-regulation ofhpd-1 in daf-2/IGFR 
mutants could lead to a reduction in tyrosine clearance and could, at least in part, account for the 
increases tyrosine levels observed in these animals [40]. Furthermore, the inhibition of hpd-1 by 
RNAi was shown to both extend lifespan and delay dauer exit through unknown 
mechanisms [39]. Hence, tyrosine metabolism appears to be actively controlled by insulin 
signaling though the consequences of this regulation are currently unclear. 
In our work, we identify tatn-1, which is the worm ortholog of TAT, to be a novel dauer 
formation regulator that is under the control of several dauer-inducing stimuli, including daf-
2/IGFR signaling, and ultimately regulates tyrosine levels in the worm. We further find that tatn-
1 mutations enhance the dauer-formation and lifespan phenotypes of both daf-2/IGFR 
and eak mutants suggesting that elevated tyrosine levels have inhibitory effects on insulin 
signaling. These effects require the aak-2/AMPK gene, and tatn-1 mutants have elevated levels 
of the activated phospho-AAK-2 protein consistent with activation of AAK-2 signaling in 
response to elevated tyrosine. The activation of AAK-2 may lead to effects on the downstream 
transcription factors daf-16/FOXO and crh-1/CREB. We see a partial dependence ondaf-
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 16/FOXO for some tatn-1 phenotypes and activation of daf-16/FOXO target genes, and the loss 
of crh-1/CREB, which is inhibited by activated aak-2, mimics some tatn-1 phenotypes. Together 
our findings establish a novel role for tyrosine as a metabolic signal that influences insulin 
signaling, development, and lifespan through effects on aak-2/AMPK signaling. While further 
study is necessary, our results also suggest that the recently observed associations between 
tyrosine metabolism and both diabetes and cancer are due to elevated tyrosine levels playing a 
direct causal role in disease pathogenesis. 
A.2 RESULTS 
A.2.1 Reduced tyrosine aminotransferase activity promotes dauer arrest 
The eak genes were identified in a genetic screen as enhancers of the weak dauer 
formation phenotype shown by akt-1 mutants, and these genes normally act to suppress the 
transcriptional activity of nuclear localized daf-16/FOXO [26]–[29]. To identify new genes that 
act in parallel to eak genes to control dauer formation, we performed a genome-wide RNAi 
screen for gene inactivations that enhance the weak dauer-constitutive phenotype of the eak-
4(mg348) mutant. Since RNAi of dauer-constitutive genes typically yields a weaker phenotype 
than the corresponding mutants, we constructed an eri-3(mg408); eak-4(mg348) double mutant 
to enhance the sensitivity of the eak-4 mutant to RNAi [41], [42]. Control experiments 
demonstrated that RNAi inhibition of daf-2/IGFR, akt-1, or the 14-3-3 gene ftt-2enhance dauer 
arrest by the eri-3; eak-4 mutants whereas RNAi inhibition of daf-7,daf-9, or daf-11, which 
encode components of TGF-β, dafachronic acid, and cGMP pathways, respectively, do not 
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 (Figure 2A). These data suggested that the screen could be enriched for genes that act in the daf-
2/IGFR pathway to control dauer arrest. 
 
 
Figure 68. Tyrosine aminotransferase mutations enhance eak dauer and lifespan phenotypes 
(A) Effect of treatment of eri-3(mg408); eak-4(mg348) mutants with RNAi clones for daf-2, ftt-2, akt-1, daf-7, daf-
9, daf-11, and tatn-1 on dauer arrest at 25°C.  Bars represent mean percentage of dauers observed in two trials, and 
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 the error bars represent standard deviation.  The empty vector RNAi vector was used as a negative control.  (B) 
Enhanced dauer formation by eak-4(mg348) or tatn-1(baf1) mutations alone.  **p<0.001 for pairwise Fisher’s exact 
test.  (C) tatn-1 mutations enhance dauer arrest by eak-3(mg344), sdf-9(mg337), and hsd-1(mg337) mutants.  ** 
p<0.001 for each double mutant compared to its respective eak single mutant by Fisher’s exact test.  (D) tatn-1 
enhances eak-7(tm3188) dauer arrest.  **p<0.001 for comparisons between eak-7; tatn-1 and either tatn-1 or eak-7 
alone.  (E)  tatn-1(baf1) extends the lifespan of both wild type and eak-7 worms.  Shown are survival curves for wild 
type N2, tatn-1(baf1), eak-7(3188), and eak-7(3188); tatn-1(baf1), with error bars showing the 95% confidence 
intervals for each point.  The mean survival for N2, tatn-1, eak-7, and eak-7; tatn-1 are 21.0, 23.0, 30.0, and 33.5 
days, respectively.  P<0.001 for all comparisons by log-rank test.   
 
Among the RNAi clones identified from the screen was tatn-1, which encodes the worm 
ortholog of tyrosine aminotransferase. Inhibition of tatn-1 by RNAi enhanced dauer arrest by eri-
3; eak-4 mutants to the same extent as akt-1 RNAi (Figure 2A)[43]. Tyrosine aminotransferase is 
the first enzyme in the conserved five step tyrosine degradation pathway present in worms and 
other eukaryotes, and this enzyme catalyzes the deamination of tyrosine to produce 4-
hydroxyphenylpyruvate (Figure 1B). The subsequent steps in the degradation pathway convert 4-
hydroxyphenylpyruvate into fumarate and acetoacetate which can be ultimately metabolized by 
the Krebs' cycle (Figure 1B). 
Similarly to the effects of tatn-1 RNAi, we also found that the tatn-1(baf1) mutation, which has a 
P224S mutation in a conserved region of the protein and is likely a partial loss of function 
allele [43], [44], also promoted dauer arrest by the eak-4(mg348)mutants (Figure 2B and Table 
S2). Interestingly, the interaction between tatn-1 andeak-4 was strongly influenced by worm diet 
with diets consisting of the E. coli K12-derived HT115 or K12-B hybrid HB101 bacterial strains 
showing the strongest interaction (Figure S1). Additionally, we observed that a second tatn-
1 allele, tatn-1(qd182), both enhanced dauer arrest by the eak-4 mutant and also had a weak 
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 effect on dauer formation in isolation (Figure S2). The tatn-1(qd182) allele encodes a protein 
with a G171E mutation affecting a highly conserved glycine residue (Figure S2). Together these 
findings demonstrate a novel role for tyrosine aminotransferase as a regulator of the dauer 
development decision. 
We then tested whether tatn-1 interacted with other eak genes via the construction of tatn-1; 
eak mutants. We found that tatn-1(baf1) enhanced the dauer-constitutive phenotype of 
all eak mutants tested, including eak-4(mg348), eak-3(mg344),eak-5/sdf-9(mg337), eak-2/hsd-
1(mg433), and eak-7(tm3188) (Figure 2C and 2D). eak-7 showed a particularly strong interaction 
with tatn-1, with 92.4% of the population forming dauers at 25°C (Figure 2D), and we observed 
dauers in eak-7; tatn-1 in cultures growing at lower temperatures or on other worm diets. These 
data suggest that tatn-1 is a general enhancer of dauer formation by eak mutants. 
In addition to enhancing dauer formation, eak-7 mutations, but not other eakmutations, extend 
the lifespan of wild-type and akt-1 mutant worms [27]. We tested whether a tatn-1 mutation also 
enhanced the lifespan of eak-7 mutants by conducting survival assays using wild type N2, tatn-
1(baf1), eak-7(tm3188), and eak-7(tm3188); tatn-1(baf1) worm populations. We found that tatn-
1, eak-7, and eak-7; tatn-1 mutants all showed increased longevity relative to N2 (mean survivals 
of 21.0, 23.0, 30.0, and 33.5 days, respectively) (Figure 2E and Table S3). Specifically, tatn-
1extends mean survival 10.4%, eak-7 extends mean survival 43.1%, and eak-7; tatn-1increases 
survival 59.2% over wild type (Figure 2E). These findings demonstrate a novel role for tatn-1 in 
modulating lifespan and also demonstrate that the effects of the eak-7 – tatn-1 genetic interaction 
also influence adult longevity. 
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 A.2.2 Tyrosine aminotransferase interacts with insulin signaling in worms 
Mutations in the eak genes enhance the dauer formation phenotype of loss-of-function mutations 
affecting genes in the daf-2/IGFR signaling pathway, so we tested whether tatn-1 mutations also 
enhanced daf-2/IGFR mutant phenotypes [28]. We used the daf-2(e1368) allele which has a 
strong dauer-constitutive phenotype when grown at 25°C but a weaker phenotype when grown at 
lower temperatures. Compared to tatn-1(baf1) and daf-2(e1368) alone, we found that daf-
2(e1368); tatn-1(baf1) mutants showed increased levels of dauer formation when grown at 23°C 
(Figure 3A). Further, we found that the tatn-1 mutation extends the adult lifespan of worms 
treated with daf-2 RNAi starting at day 1 of adulthood (Figure 3B). We used RNAi treatment 
due to the high levels of dauer arrest that we observed with the daf-2(e1368); tatn-
1(baf1) animals. In these RNAi experiments, the mean survival of worms were 22.0 days for N2 
on control RNAi, 24.0 days for tatn-1 on control RNAi, 30.5 days for N2 on daf-2 RNAi, and 
37.0 days for tatn-1 on daf-2 RNAi (Figure 3Band Table S3). Hence, while daf-2 RNAi 
treatment extends the survival of wild type N2 worms by 37.4%, the inclusion of the tatn-1 allele 
further extends the lifespan ofdaf-2(Mihalik, Gaborik et al.) treated worms by an additional 21%. 
These findings show a genetic interaction between tatn-1 and daf-2/IGFR with impaired tyrosine 
degradation enhancing the daf-2/IGFR dauer formation and lifespan phenotypes. 
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Figure 69. The tatn-1 mutant enhances dauer formation and lifespan of worms with impaired daf-2/IFGR 
signaling 
 
 (A) Enhanced dauer formation by daf-2(e1368); tatn-1(baf1) compared to daf-2(e1368) grown at 23C for 3 days.  
**p<0.01 by Fisher’s exact test.  (B)  tatn-1 extends the lifespan of worms treated with daf-2 RNAi from day 1 of 
adulthood.  The mean survival for N2 control RNAi, tatn-1(baf1) control RNAi, N2 daf-2(Mihalik, Gaborik et al.), 
and tatn-1(baf1) daf-2(Mihalik, Gaborik et al.) are 22.0, 24.0, 30.5, and 37.0 days, respectively. P<0.001 for N2 vs. 
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 tatn-1 on control RNAi and N2 daf-2(Mihalik, Gaborik et al.) vs. tatn-1 daf-2(Mihalik, Gaborik et al.) by log-rank 
test.  
 
 
A.2.3 Tatn-1 likely does not alter PI3 kinase or TGF-β signaling 
Since the eak mutations interact with akt-1 mutations to enhance dauer formation, the 
effects of tatn-1 mutations could be due to inhibition of the PI3 kinase signaling pathway (Figure 
1A) [20]–[22], [28], [45]. To test this possibility, we looked for genetic interactions between 
loss-of-function and gain-of-function mutations affecting the PI3 kinase pathway with tatn-1. 
First, we constructed tatn-1 mutants containing the loss-of-function mutations affecting the PKB 
genes akt-1 and akt-2, and the related kinase sgk-1. We found that none of these genes interacts 
strongly with atatn-1 mutation to enhance dauer arrest (Figure 4A). This finding suggests 
that tatn-1 is not an upstream regulator of either akt-1 or akt-2. To further test whether tyrosine 
affected the PI3 kinase signaling cascade, we tested whether the eak-4(mg348); tatn-
1(baf1) interaction was blocked by gain-of-function mutations in either pdk-1 or akt-1. These 
mutations were identified in genetic screens as suppressors of the dauer-constitutive phenotype 
of an age-1/PI3K null mutant [20], [21]. We constructed both eak-4(mg348); pdk-1(mg142), 
tatn-1(baf1) and eak-4(mg348); akt-1(mg144); tatn-1(baf1) mutants and examined the effects of 
these mutations on dauer formation. We found that pdk-1(mg142), which is a dominant gain-of-
function allele of 3-phosphoinositide-dependent kinase and lies upstream of akt-1, akt-2, and 
sgk-1, had little effect on dauer formation by the eak-4(mg348); tatn-1(baf1) mutants (70% with 
pdk-1(mg142) versus 75% without) (Figure 4B). We further found that akt-1(mg144) had at 
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 most a modest effect on dauer formation by eak-4(mg348); tatn-1(baf1) mutants (51% with akt-
1(mg144) versus 77.6% without) (Figure 4C). Together these results suggest that the interaction 
between eak-4 and tatn-1 likely does not involve changes in the PI3 kinase signaling cascade. 
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 Figure 70. tatn-1 effects on development do not require changes in PI3 kinase signaling 
(A) tatn-1(baf1) does not augment dauer arrest by mutants with loss-of-function mutations in the protein kinase 
B genes akt-1, akt-2, or sgk-1. (B) The pdk-1(mg142) gain-of-function allele minimally affects dauer formation by 
eak-4(mg348); tatn-1(baf1) mutants. % dauers observed was 75.6% in eak-4; tatn-1 and 70.7% in eak-4; pdk-
1(mg142); tatn-1. ** p,0.001 by Fisher’s exact test. (C) The akt-1(mg144) gain-of-function allele weakly inhibited 
dauer formation by eak-4(mg348); tatn-1(baf1) mutants. % dauers observed was 77.6% in eak-4; tatn-1 and 51% in 
eak-4; akt-1(mg144); tatn-1.  
 
In addition to the daf-2/IGFR signaling pathway, dauer formation in worms is also regulated by a 
TGF-β signaling pathway [9]–[11]. While traditionally these two pathways are viewed as 
independent, more recent work has indicated that cross-talk between the pathways may occur. 
Specifically, genes in one pathway, such as sdf-9/eak-5 or pdp-1, have been shown to augment 
the dauer formation phenotypes of genes in the other pathway [46], [47]. Notably, the pdp-
1 phosphatase was identified from an RNAi screen using daf-2/IGFR pathway mutants as 
was tatn-1. To test whether tatn-1 could act in the TGF-β signaling pathway, we blocked this 
pathway with either the daf-3/SMAD or daf-5/Sno mutations [41], [48], [49]. We found that 
neither mutant reduced dauer formation by the eak-4; tatn-1 mutants (Figure S3), which is 
consistent with tatn-1 acting independently of the TGF-β pathway. 
A.2.4 AAK-2/AMPK is activated in tatn-1 mutants and required for effects on dauer 
formation and longevity 
Since tatn-1 did not interact with akt-1, akt-2, or sgk-1, we looked for alternate signaling 
pathways that could be activated by a tatn-1 mutation, and then interact with the daf-2/IGFR 
signaling pathway. The AMP-activated protein kinase (AMPK) ortholog AAK-2 was considered 
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 as a candidate because aak-2 interacts with daf-2 signaling, plays roles in dauer development, 
modulates worm longevity, and acts in part through the daf-16/FOXO transcription factor which 
is part of the daf-2/IGFR signaling pathway [50]–[53]. To test the involvement of aak-2/AMPK, 
we compared dauer formation between eak-4(mg348); tatn-1(baf1) and eak-4(mg348); tatn-
1(baf1), aak-2(gt33) mutants. We found that loss of aak-2 strongly reduced dauer arrest from 
84.7% to 10.7% (Figure 5A and Table S2). The aak-2 mutation also reduced dauer formation by 
an eak-4(mg348); tatn-1(qd182) mutant though to a lesser degree than with the tatn-
1(baf1) allele (Figure S4). This may be due to thetatn-1(qd182) allele being a stronger loss-of-
function allele than tatn-1(baf1) as suggested by the developmental delay phenotype shown 
by tatn-1(qd182) and the higher tyrosine levels found in this mutant (Figure S4 and below). 
Together these findings support a necessary role for aak-2/AMPK for worms to respond to 
reductions in tatn-1 activity, especially with weaker alleles. 
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Figure 71. aak-2 activity is necessary and sufficient for tatn-1 effects on development and longevity 
(A) The effects of tatn-1(baf1) on dauer formation require the aak-2/AMPK gene. ** p,0.001 by Fisher’s exact test. 
(B) Activation of aak-2 with the AMPK agonist AICAR (0.125 mM) mimics the effects of tatn-1 on eak-4(mg348) 
mutants. The effect of AICAR depends on aak-2/AMPK because an eak-4; aak-2 mutant fails to respond to AICAR. 
** p,0.001 for comparison of eak-4 with and without AICAR by Fisher’s exact test. (C) Levels of phospho-AAK-2 
are increased in eak-4(mg348); tatn-1(baf1) L2 larval worms or N2 L2 larval worms treated with 1 mM AICAR 
compared to untreated N2 L2 larval worms. Levels of phospho-AAK-2 was detected using an anti-phospho-T172 
specific antibody, and actin was a loading control. The ratio represents the level of phospho-AMPK normalized for 
the actin level in each lane. N2 larval worms treated with 10 mM sodium azide to deplete ATP levels and the AMPK 
positive control extract (+) (Cell Signaling Technologies) were included as positive controls. (D) aak-2 is required 
for tatn-1 effects on lifespan. Mean survival for N2, tatn-1(baf1), aak-2(gt33), and tatn-1(baf1); aak-2(gt33) were 
18.0, 21.0, 14.0, and 13.0 days, respectively. p,0.001 for all pairwise curve comparisons by log-rank test. 
 
To further explore the role of aak-2/AMPK in dauer formation, we treated worms with the 
AMPK agonist AICAR. Treatment of wild-type N2 worms with 0.125 mM AICAR had no effect 
on development or dauer formation, but eak-4 mutants treated with AICAR showed a significant 
increase in dauer formation compared to an untreated control (Figure 5B). This effect 
required aak-2/AMPK as an eak-4(mg348); aak-2(gt33) mutant failed to respond to AICAR 
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 (Figure 5B). These findings demonstrate that aak-2 activity is both necessary and sufficient to 
promote dauer formation by eak-4 mutants. 
Our findings could suggest that AAK-2 is activated in the tatn-1 mutants. To test this possibility 
we used western blotting to measure levels of AAK-2 phosphorylated on the activating 
Thr243 residue, which is analogous to Thr172 in the vertebrate orthologs. We found that treatment 
of N2 wild-type animals with either sodium azide which inhibits mitochondrial function and 
depletes ATP levels by approximately 50% at this dose or with 1 mM AICAR leads to increases 
in phosphorylated AAK-2 levels compared with untreated L2 larval N2 worms grown in parallel 
(Figure 5C) [54]. Furthermore levels of phospho-AAK-2 were also increased in eak-4; 
tatn1 mutant L2 larvae compared to the N2 control larvae (Figure 5C). Importantly, the phopho-
AAK-2 signal was lost in aak-2(gt33) mutants confirming the identity of this band as AAK-2 
(Figure 5C). These findings demonstrate that both tatn-1 mutations and AICAR treatment serve 
to activate AMPK in C. elegans, and that this activation of AAK-2 is required for the effects 
of tatn-1 mutations on development. 
The requirement for aak-2/AMPK for the effects of tatn-1 could reflect impaired tyrosine 
degradation leading to reduced production of the TCA cycle precursors fumarate and 
acetoacetate and a consequent decrease in energy production. To test this possibility we analyzed 
worm lysates for levels of AMP and ATP. We found thateak-4(mg348); tatn-1(baf1) mutants 
had a lower AMP/ATP ratio than N2 worms grown in parallel (Figure S5). This suggests that 
the role of aak-2/AMPK does not reflect reduced energy production in the tatn-1 mutants. 
Finally, we tested whether the effect of tatn-1(baf1) on adult lifespan requires aak-2activity, and 
we found that a tatn-1 mutation increased wild-type lifespan by 17.8%, but decreased aak-
2(gt33) lifespan by 8.9% compared to aak-2(gt33) alone (N2 mean survival 18.0 days, tatn-
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 1(baf1) 21.0 days, aak-2(gt33) 14.0 days, and tatn-1(baf1), aak-2(gt33) 13.0 days) (Figure 
5C and Table S3). Hence aak-2 is both required for the tatn-1 lifespan increase and may even 
play a protective role in animals with reduced tatn-1 activity. 
A.2.5 tatn-1 acts by daf-16/FOXO dependent and independent pathways 
Since the effects of eak genes on dauer formation are dependent on both the FOXO transcription 
factor DAF-16 and the nuclear hormone receptor DAF-12, we tested whether these genes are 
required for dauer formation by eak-4(mg348); tatn-1(baf1) mutants through the construction of 
daf-16(mgDf47); eak-4(mg348); tatn-1(baf1) and eak-4(mg348); tatn-1(baf1), daf-12(rh61rh411) 
mutants [26]–[28]. We found that the genetic interaction is completely dependent on daf-12 
(Figure 6A). However, we identified both daf-16 dependent and independent effects of tatn-1. 
The tatn-1 effects on dauer formation are largely blocked by the daf-16(mgDf47) mutation, but a 
small percentage of worms still form dauers (Figure 6A). This daf-16 independent pathway was 
also seen in experiments using the stronger tatn-1(qd182) allele (Figure S6). These findings 
suggest that daf-16/FOXO does play a vital role in the interaction between eak genes and tatn-1, 
but that daf-16/FOXO independent pathways are also involved. 
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Figure 72. tatn-1 acts by daf-16/FOXO dependent and independent mechanisms 
(A) Mutations in daf-16 (daf-16(mgDf47)) or daf-12 (daf-12(rh61rh411)) inhibit dauer formation by eak-4(mg348); 
tatn-1(baf1) mutant worms. ** p,0.001 by Fisher’s exact test. (B) The daf-16(mgDf50) mutation also inhibits dauer 
formation by eak-4; tatn-1(baf1) mutants, and a transgene expressing the DAF-16A isoform largely rescues dauer 
formation by daf-16(mgDf50); eak-4; tatn-1 mutants while a transgene expressing the DAF-16DF isoform only 
weakly rescues. (C) eak-4; tatn-1 mutants activate expression of the daf-16 target gene sod-3 as indicated by 
expression of a sod-3p:GFP reporter gene in L2 larvae, and this induction requires the aak-2/AMPK gene. * p,0.05 
for t-test comparisons of eak-4 vs. eak-4; tatn-1, and eak-4; tatn-1 vs. eak-4; tatn-1; aak-2. (D) Induction of the 
endogenoussod-3 gene in eak-4; tatn-1 mutants is seen by quantitative RT-PCR, and this induction also depends on 
the aak-2/AMPK gene. (E) DAF-16A:GFP is not nuclear localized in either L2 stage WT or eak-4; tatn-1 larvae, but 
exposure to a 1 hour 35uC heat shock produces clear nuclear localization of DAF-16A:GFP (arrow). (F) tatn-1 
effects on lifespan are daf-16 independent. Treatment of N2 and tatn-1(baf1) mutants with daf-16 RNAi reduces 
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 mean survival, but tatn-1(baf1) still lives longer than N2. The mean survival of N2 control RNAi, tatn-1 control 
RNAi, N2 daf-16(Mihalik, Gaborik et al.), tatn-1 daf-16(Mihalik, Gaborik et al.) are 21.0, 24.0, 14. 
 
The daf-16/FOXO gene encodes multiple isoforms which have been recently shown to have 
differential modes of regulation and have distinct effects on development and longevity [24], 
[55], [56]. For dauer development, three isoforms appear to be involved with DAF-16A being 
the predominant isoform, DAF-16DF playing a somewhat lesser role, and DAF-16B playing a 
modest role, at best [55]. As a result, we tested whether the developmental effects of eak-4 and 
tatn-1 are dependent on particular daf-16 isoforms through the use of isoform-specific transgenes 
to rescue the dauer-constitutive phenotypes lost in daf-16/FOXO mutants (Figure 6B). We found 
that a transgene encoding a DAF-16A:mRFP fusion protein was able to strongly rescue the 
formation of dauers by a daf-16(mgDf50); eak-4(mg348); tatn-1(baf1) mutant, whereas a 
transgene encoding a DAF-16DF:GFP fusion protein only weakly rescued dauer formation 
(Figure 6B). These data suggest that the daf-16a isoform is most involved in the developmental 
effects produced by tatn-1 mutants. 
To further explore the role of daf-16/FOXO in tatn-1 phenotypes, we examined the effects of 
eak-4 and tatn-1 mutations on both daf-16/FOXO target gene expression and DAF-16 subcellular 
localization. We used a sod-3:GFP transgene to examine the effects of eak-4 and tatn-1 
mutations on expression of the daf-16 target gene sod-3, which encodes a manganese superoxide 
dismutase enzyme [57], [58]. We generated combinations of eak-4(mg348) and tatn-1(baf1) with 
the transgene, and examined GFP expression in L2 larvae. We found that the combination of 
eak-4 and tatn-1 mutations resulted in the highest expression of sod-3:GFP even prior to dauer 
formation (Figure 6C). Furthermore, aak-2/AMPK was required for this enhanced activation of 
the sod-3:GFP reporter (Figure 6C). Similar effects of tatn-1 and eak-4 on sod-3 expression were 
also seen when mRNA levels for the endogenous gene were measured by Q-PCR in L2 larvae, 
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 and this effect on sod-3 expression also required aak-2/AMPK (Figure 6D). Together these 
findings demonstrate that tatn-1 and eak-4 act in an aak-2/AMPK dependent manner to promote 
at least some aspects of daf-16/FOXO transcriptional activity. 
Since the eak genes act to inhibit DAF-16/FOXO within the nucleus, a possible explanation for 
the enhancement of dauer formation in eak; tatn-1 double mutants may be explained by the tatn-
1 allele causing increased nuclear localization of DAF-16 as do mutations affecting akt-1 [26]. 
We tested for changes in DAF-16 localization via the use of transgenic animals expressing a 
DAF-16A:GFP fusion protein [59]. We found that eak-4; tatn-1 mutants failed to show clearly 
visible nuclear localization of DAF-16:GFP in synchronized L2 worms grown at 25°C (Figure 
6E). In contrast, exposure of animals to a 1 hour heat-shock at 35°C led to strong nuclear 
localization of DAF-16A:GFP (Figure 6E). Together these findings suggest that the tatn-1 
enhancement of the eak dauer formation phenotype could be due to an increase in daf-16 
transcriptional activity without an accompanying significant change in DAF-16 subcellular 
localization.   
We then used daf-16 RNAi treatment to test whether daf-16/FOXO is required for the lifespan 
extension of tatn-1 mutants. We found that silencing of daf-16 through RNAi results in a 
shortened lifespan for both tatn-1 and wild-type N2 worms compared to control RNAi treatment 
(Figure 6F). However in daf-16 RNAi treated worms, tatn-1 still produces lifespan extension 
over wild type (mean survival for N2 control RNAi 21.0 days, tatn-1(baf1) control RNAi 24.0 
days, N2 daf-16(Mihalik, Gaborik et al.) 14.5 days, and tatn-1(baf1) daf-16(Mihalik, Gaborik et 
al.) 17.0 days). Specifically, tatn-1(baf1) produced a 13.7% increase in lifespan in control RNAi 
treated worms, but a 17.8% increase in lifespan in daf-16 RNAi treated worms. These data 
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 suggest that the increased lifespan resulting from tatn-1 is either independent of daf-16 or occurs 
in a site resistant to the effects of daf-16 RNAi. 
A.2.6 crh-1/CREB shows overlapping gene expression and phenotypes with tatn-1 
To explore the effects of impaired tyrosine metabolism in C. elegans, we performed whole 
transcriptome RNA sequencing (RNA-seq) to identify genes that are differentially regulated in 
the tatn-1 mutants. To maximize the gene expression changes seen, we used the stronger tatn-
1(qd182) allele and compared its transcriptome to that of wild-type N2 animals. Using ANOVA 
testing with a false-discovery rate of 5%, we identified 890 up-regulated and 3732 down-
regulated genes in the tatn-1(qd182) mutant relative to N2 (Table S4). 
To understand how the tatn-1 mutants might affect the daf-2/IGFR pathway, we used this data 
set to examine whether changes in the expression of genes in pathway are seen. We found that 
there was no change in the expression of daf-2/IGFR, daf-16/FOXO, aak-2/AMPK, eak-4, or 
akt-2 (Table S4). However we did find that levels of the age-1 PI3-kinase are reduced almost 
76% and levels of akt-1 are reduced almost 70% compared to N2 while levels of the daf-
18/PTEN tumor suppressor, which normally inhibits signaling through the PI3-kinase signaling 
pathway, is reduced almost 95% compared to wild-type animals (Table S4). Despite the 
observed changes in the expression of genes in the PI3-kinase signaling pathway, there is likely 
little net effect on the regulation of downstream targets by the pathway as we failed to observe 
differences in DAF-16:GFP localization, which would translocate to the nucleus if the pathway 
was inhibited (Figure 6E). 
We then used both the DAVID program and the Panther database both to identify biologic 
themes within the up-regulated and down-regulated genes by testing for over-represented gene 
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 classes based on structural and functional annotations and to visualize the gene classes seen in 
both groups of genes (Figure S7 and Table S5) [60], [61]. Within the up-regulated set, we found 
that genes involved in tyrosine metabolism and neuropeptide signaling were strongly over-
represented (7–10 fold) (Table S5). Specifically, we found that every gene in the tyrosine 
degradation pathway is up-regulated in the tatn-1(qd182) mutant suggesting that the altered 
metabolism is detected and leads to a compensatory change in expression of the pathway (Table 
S4). The significance of the changes in neuropeptide signaling gene expression is currently 
unclear, but could suggest that impaired tyrosine metabolism or the resulting increased in AAK-
2/AMPK activity produces direct changes in neuronal activity or that these changes could be the 
direct downstream effectors responsible for the tatn-1 phenotypes. Graphically, we saw a greater 
percentage of genes which were expressed in the extracellular compartment and had catalytic or 
receptor activity among the up-regulated genes compared to those that were down-regulated in 
the tatn-1 mutants (Figure S7). In contrast, within the down-regulated genes, we identified over-
representation of a broad range of genes involved in germline development, cell cycle, DNA 
replication, and larval development (Table S5). Further, these genes were more likely to be 
expressed in the intracellular compartment and to have regulatory effects on translation or 
enzyme activity (Figure S7). The expression changes in genes involved in cell cycle regulation 
and development could perhaps account for the developmental delay observed in the tatn-
1(qd182) mutant compared to N2 (Figure S4). 
 
Given the requirement we found for daf-16/FOXO for aspects of the tatn-1 phenotypes, we used 
Gene Set Association Analysis (GSAA) to test for enrichment of genes known to be regulated by 
daf-16/FOXO in the context of daf-2/IGFR signaling [62], [63]. Via this approach, we found 
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 both the up-regulated and down-regulated daf-16/FOXO target genes identified by Murphy et. al. 
to be enriched within the tatn-1(qd182) transcriptome (Figure 7A). This suggests that the 
expression of a subset of daf-16/FOXO target genes is altered by changes in tyrosine 
metabolism. 
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Figure 73. tatn-1 mutants and crh-1/CREB mutants share gene expression profiles and effects on dauer 
formation 
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 (A) Shot-gun whole transcriptome sequencing (RNA seq) was used to used to characterize and measure the 
transcriptome of N2 and tatn-1(qd182) mutants. From these experiments a total of 20,408 mRNA and other RNA 
transcripts were detected. To test for evidence of a daf-16/FOXO gene expression signature in the tatn-1(qd182) 
mutants Gene Set Association Analysis (GSAA) was used to determine whether the expression of daf-16/FOXO 
target genes regulated in the context of daf-2/IGFR signaling are associated with the tatn-1(qd182) mutant gene 
expression profile. GSAA calculates a differential expression score for each gene in the entire 20,408 gene RNA-seq 
dataset, and then uses a running weighted Kolmogorov-Smirnov test to examine association of an entire gene set 
with each phenotypic class. The strength of the association is measured by the association score (AS) where positive 
scores indicate association of the gene set with the phenotype, and statistical significance is measured by a false 
discovery rate (FDR) that is adjusted for multiple testing. From 225 genes down-regulated in daf-2/IGFR mutants, 
140 showed association with the tatn-1(qd182) profile, and from 230 genes up-regulated in daf-2/IGFR mutants, 120 
showed evidence of association by GSAA analysis. AS represents the association score with positive values 
indicating association, and FDR represents the false discovery rate for the association. (B) To test for evidence of a 
crh-1/CREB gene expression signature in the tatn-1(qd182) mutants Gene Set Association Analysis (GSAA) was 
used to determine whether the expression of crh-1/CREB target genes identified through microarray studies using 
wild-type and crh-1 mutant worms associate with the tatn-1(qd182) expression profile. From 534 genes down-
regulated in crh-1/CREB mutants, 315 showed evidence of association, and from 544 genes up-regulated in crh-
1/CREB mutants, 323 showed evidence of association by GSAA analysis. AS represents the association score with 
positive values indicating association, and FDR represents the false discovery rate for the association. (C) crh-
1/CREB mutants enhance dauer formation by eak-4 mutants but not by tatn-1 mutants. 
 
Since our genetic studies suggested the involvement of a daf-16-independent pathway, we also 
used GSAA to test whether target genes recently identified for the CREB transcription 
factor crh-1 are enriched in the tatn-1(qd182) mutant [53]. We chose to focus on crh-1 because 
recent work has demonstrated that crh-1/CREB lies downstream of aak-2/AMPK [53]. crh-
1/CREB and aak-2/AMPK are mechanistically linked because AAK-2 directly phosphorylates 
and inactivates thecrh-1/CREB coactivator crtc-1, and as a result both aak-2/AMPK over-
expressing and crh-1/CREB mutant animals are long-lived and share gene expression 
profiles[53]. We found that in the tatn-1(qd182) mutants, there is differential expression of both 
genes up-regulated and genes down-regulated in crh-1/CREB mutants (Figure 7B). This suggests 
that altered tyrosine metabolism could lead to changes incrh-1 target gene expression and could 
suggest a role for crh-1/CREB in the tatn-1phenotypes. To test for crh-1/CREB involvement, we 
combined the crh-1(tz2) null allele with tatn-1 and eak-4 and examined the effects on dauer 
formation. We found that crh-1 showed a similar interaction as tatn-1 with eak-4, but did not 
promote dauer formation by the tatn-1 mutant (Figure 7C). Together these findings suggest 
that tatn-1 mutants share phenotypes and gene expression profiles with crh-1/CREB mutants and 
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 could be consistent with crh-1/CREB acting as an additional downstream effector of the 
response to impaired tyrosine metabolism. 
A.2.7 Tyrosine aminotransferase expression is controlled by diet and environment 
In vertebrates, tyrosine aminotransferase has been reported to be an insulin target gene with 
insulin treatment leading to reduced expression [32]–[35], [38]. As a result, we asked whether 
tatn-1 could also be regulated by daf-2/IGFR signaling in worms. To test the effects of daf-2 
signaling on tatn-1 expression, we generated transgenic worms with an integrated transgene 
expressing a TATN-1:GFP fusion protein under the control of the tatn-1 promoter. This 
transgene rescues the tatn-1(baf1) mutation and blocks dauer formation by eak-4(mg348); tatn-
1(baf-1) mutants, which demonstrates that the fusion protein is both functional and expressed in 
the correct anatomical locations (Figure 8A).   
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Figure 74. Control of TATN-1 protein expression by daf-2/IGFR signaling, diet and temperature 
 (A) Rescue of tatn-1 mediated dauer arrest by a tatn-1p:tatn-1 cDNA:GFP transgene (bafIs131). (B) daf-2 signaling 
positively regulates TATN-1:GFP expression. Box and whiskers plot showing comparison of GFP fluorescence 
between day 1 adult wild-type and daf-2(e1368) mutants expressing the TATN-1:GFP transgene and grown on 
OP50-1 bacteria. N$15 worms, ** p,0.001 by t-test. (C) Bacterial food source and temperature regulate TATN-
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 1:GFP expression. Wild-type worms expressing the TATN-1:GFP transgene were grown on the indicated bacteria 
until adulthood and then either kept at 20uC or shifted to 25uC overnight. 
 
GFP fluorescence representing the TATN-1:GFP fusion protein is observed in the intestine and 
hypodermis of worms (Figure 8E). When we crossed the transgene into the daf-2(e1368) mutant, 
and we found that the presence of the daf-2/IGFR mutation led to a 20% decline in GFP 
expression in adult worms grown on OP50-1 at 20° (Figure 8B and Figure 8E). This is consistent 
with daf-2/IGFR signaling acting positively to promote TATN-1 expression in adult worms. 
Interestingly, the effect ofdaf-2/IGFR signaling on TATN-1 expression likely occurs either at the 
translational or protein stability level because Q-PCR experiments demonstrated almost a 50% 
increase in tatn-1 mRNA expression in the daf-2 mutant animals (Figure S8). As a result of the 
divergent regulation of tatn-1 mRNA and protein levels, we focused on TATN-1:GFP expression 
in our subsequent experiments. 
Beyond daf-2/IGFR signaling, we found that both diet and environmental temperature affected 
TATN-1 levels to a similar or even greater degree. Specifically, adult worms grown on OP50-1, 
HB101, or HT115 show decreases in TATN-1:GFP expression when shifted from 20°C to 25°C 
for 24 hours with worms grown on OP50-1 showing a 26.2% decrease, on HB101 a 44.7% 
decrease, and on HT115 a 24.2% decrease (Figure 8C and Figure 8E). Further, we found that the 
OP50-1 fed worms showed greater TATN-1:GFP expression compared to HB101 and HT115 fed 
worms. This difference was especially apparent in worms grown at 25°C, due to the variability 
of GFP intensity seen at 20°C, with HB101 and HT115 fed animals showing a 25.3% and 17.3% 
decrease, respectively, compared to OP50-1 fed worms (Figure 8C and Figure 8E). 
The effects of diet on TATN-1:GFP expression suggests that the E. coli bacterial strains vary in 
nutrient composition in a way that can be detected by the worms. Prior work has demonstrated 
that protein is the primary component of these bacteria but that the overall protein levels are not 
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 significantly different between strains [64]. However, this work also suggested that specific 
amino acids could vary between the strains and account for differences in fat content in worms 
fed each strain. Specifically,pept-1 mutants, which lack an intestinal peptide transporter, fail to 
show the expected differences in fat content when fed different bacterial strains [64]. In 
vertebrates, tyrosine aminotransferase expression is controlled by dietary amino acid intake, 
most notably for tryptophan [65]–[67]. To test whether dietary amino acid intake could affect 
TATN-1:GFP expression, we supplemented HB101 spotted NGA plates spotted with either 
tyrosine or tryptophan at a final concentration of 1 mg/mL, and compared TATN-1:GFP 
expression to worms fed HB101 alone or OP50-1. This concentration is 8 times the level found 
in standard NGA media (0.125 mg/mL). We found that the addition of tyrosine or tryptophan 
increases the GFP expression level in HB101 fed worms up to that seen in worms grown on 
OP50-1 (Figure 8D and Figure 8E). Together these data demonstrate that TATN-1 levels are 
dynamic and under the control of both daf-2/IGFR signaling as well as dietary and 
environmental cues. Importantly many of these signals that control TATN-1 expression 
also influence dauer formation suggesting that tatn-1 could be a regulated modulator ofdaf-
2/IGFR signaling and developmental decisions. 
A.2.8 Tyrosine mediates the effects of tatn-1 mutations 
Since TATN-1 is the first enzyme in the tyrosine degradation pathway, decreased activity should 
both increase the levels of tyrosine and also decrease the levels of the downstream metabolites 
(Figure 1B). The tatn-1 mutant phenotypes could be a direct result of changes in the level of a 
particular metabolite. For example, elevated fumarate levels are known promote hypoxia 
inducible factor (HIF) activity in certain renal cancers [68]. Alternately, tatn-1 could have a 
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 novel function that is independent of its metabolic activity. For example, subunits of the 
phenylalanine hydroxylase enzyme are known to have an additional, non-enzymatic role as a 
transcriptional co-activator [69]. To explore whether either of these models accounts for the tatn-
1phenotypes, we tested for interactions between eak-4 and mutant alleles of other enzymes in the 
tyrosine degradation pathway (Figure 1B) by constructing pah-1; eak-4 and hpd-1; eak-
4 mutants. These mutants lack pah-1, which encodes the enzyme phenylalanine-4-hydroxylase 
that converts phenylalanine into tyrosine, orhpd-1, which encodes 4-hydroxyphenylpyruvate 
dioxygenase and catalyzes the step immediately downstream of tatn-1 [39], [43], [70]. We found 
that pah-1 did not enhance dauer arrest by the eak-4 mutants (Figure 9A) whereas both tatn-
1 andhpd-1 increased dauer formation. Lower numbers of eak-4; tatn-1 dauers were seen 
because the experiment was scored after 3 days due to the slower development of thehpd-
1 mutant. Additionally, when we used the pah-1 mutant to block the synthesis of tyrosine in 
a tatn-1; eak-4 mutant, we found that this reduced dauer formation (Figure 9B). These results 
suggested that the effects of tatn-1 on dauer formation were directly linked to the metabolic 
effects of tatn-1, and that the accumulation of tyrosine instead of deficiency of a downstream 
metabolite could be responsible for thetatn-1 phenotype.   
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 Figure 75. tatn-1 acts by increasing tyrosine levels 
 (A) Both tatn-1 and hpd-1 mutations augment dauer arrest by eak-4(mg348) mutants after three days at 25uC, 
whereas a pah-1 mutation does not. ** p,0.001 for comparisons between eak-4 and eak-4; tatn-1, and hpd-1; eak-4 
by Fisher’s exact test. (B) Inhibiting tyrosine synthesis with the pah-1 mutation reduces dauer formation by eak-4; 
tatn-1 mutants. (C) tatn-1(baf1) has a higher concentration of tyrosine compared to wild type N2. The bars represent 
the mean tyrosine concentration from four independent samples, and the error bars show the standard error of the 
mean. ** p,0.001 by t-test. (D) tatn-1(qd182) and tatn-1(baf1) have higher tyrosine levels compared to wild 
type N2. (E) tatn-1(qd182) has higher tyrosine levels than N2 and tatn-1(baf1) when the measured tyrosine levels 
are normalized to the levels of nonaromatic amino acids in each sample. (F) Treatment of eak-4(mg348) mutants but 
not N2 with tyrosine results in dauer arrest. ** p,0.001 for comparison of eak-4 + and - tyrosine using Fisher’s exact 
test. (G) Tyrosine (1 mg/mL) is more potent than other amino acids in producing dauer arrest by eak-4(mg348) 
mutants. ** p,0.001 for comparison between eak-4 vs eak-4+tyrosine and eak-4+tyrosine and eak-4+asparagine 
using Fisher’s exact test. (H) Impaired dopamine synthesis in cat-2(e1112) mutants does not block the effect of tatn-
1 on dauer formation. (I) Impaired tyramine and octopamine synthesis in tdc-1(ok914) mutants does not block the 
effect of tatn-1 on dauer formation. 
 
As a result, we measured the levels of amino acids in wild-type N2, tatn-1(baf1), andtatn-
1(qd182) larval animals grown at 25°C on HB101 plates by liquid chromatography mass 
spectrometry (LC-MS/MS). We found that wild-type N2 worms contained an average of 78.1 
pmol of tyrosine per 100 worms whereas tatn-1(baf1) worms contained 237.4 pmol per 100 
worms (Figure 9C). Hence the tatn-1(baf1) mutation produced a roughly three fold increase in 
tyrosine levels in the mutant animals. Further to compare the effects of tatn-1(qd182) on tyrosine 
levels compared to tatn-1(baf1), we measured tyrosine levels in additional samples grown and 
prepared in parallel. We found in these samples that wild-type N2 worms contained an average 
of 99.6 pmol of tyrosine per 100 worms, tatn-1(baf1) contained an average of 327.2 pmol per 
100 worms, and tatn-1(qd182) contained an average of 470.2 pmol per 100 worms, which is an 
43.7% increase over tatn-1(baf1) (Figure 9D). However, we noted that the tatn-1(qd182) worms 
were smaller than N2 or tatn-1(baf1) and the levels of many other amino acids measured in 
parallel were lower intatn-1(qd182) compared to tatn-1(baf1). This suggested that the tatn-
1(qd182)samples may have contained less overall biomass, and hence our normalization to worm 
counts alone may underestimate the effect of the tatn-1(qd182) mutation on tyrosine levels. To 
correct for this difference, we normalized tyrosine levels to the levels of all non-aromatic amino 
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 acids in the samples with the assumption that the net effect of these mutations on the levels of 
these amino acids is neutral. After normalization, we found that tatn-1(baf1) produced a 3.4 fold 
increase in tyrosine levels compared to N2 whereas tatn-1(qd182) produced a 12.6 fold increase 
compared to N2, which is also a 3.7 fold increase over tatn-1(baf1) levels (Figure 9E). These 
findings demonstrate that both tatn-1 alleles increase tyrosine levels compared to wild-type 
animals, and that the stronger phenotypes of the tatn-1(qd182) allele are likely due to the further 
increases in tyrosine levels observed. 
To directly test whether elevated tyrosine levels are responsible for the tatn-1phenotype, we 
treated worms with exogenous tyrosine cast into the NGA plates at 1 mg/mL. This treatment 
results in tyrosine levels in the worms that are elevated compared to untreated animals, but lower 
than those seen in the tatn-1 mutants (Figure S9). We found that supplementation had no effect 
on the development of wild-type worms but lead to dauer arrest by the eak-4 mutants (Figure 
9F). These results directly demonstrate changes in tyrosine levels alter the development of eak-
4mutant worms and are responsible for the tatn-1 phenotype. 
Amino acids are known to antagonize insulin actions in vertebrates, so our results could 
represent either the non-specific effects of any amino acid or a tyrosine-specific effect [71], [72]. 
To test these possibilities we directly compared the ability of a variety of amino acids to enhance 
dauer formation by eak-4 mutants. We grew eak-4mutants on HB101 spotted NGA 
supplemented with tyrosine, glycine, leucine, isoleucine, glutamate, glutamine, asparagine, or 
aspartate, each at the concentration of 1 mg/mL. Since tyrosine is the largest of these amino 
acids, this resulted in worms being treated with higher molar equivalents of the other amino acids 
compared to tyrosine. We found that while other amino acids do increase the formation of dauers 
by eak-4 mutants, none was as potent as tyrosine (Figure 9G). This suggests that the effect on 
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 dauer formation shows selectivity for the presence of tyrosine. The effects of tyrosine and to a 
lesser extent the other amino acids is not due to a toxic effect of the amino acid supplementation 
as treated worms showed a similar lifespan to untreated worms (Figure S9). 
Besides being a building block for proteins, tyrosine serves as a precursor for the synthesis of 
catecholamine neurotransmitters. In vertebrates, there is evidence that the levels of tyrosine as a 
precursor influences the synthesis of these neurotransmitters [73]. Hence, one possibility is 
that tatn-1 mutations raise tyrosine levels and facilitate its conversion into the neurotransmitters 
dopamine, octopamine, or tyramine which could produce the observed phenotypes. To test this 
possibility, we blocked dopamine synthesis with the cat-2 mutation, which affects the worm 
tyrosine hydroxylase gene, and we blocked octopamine and tyramine synthesis with the tdc-
1mutation, which removes the enzyme tyrosine decarboxylase [74], [75]. We found that 
both cat-2; eak-4; tatn-1 and tdc-1; eak-4; tatn-1 mutants are similar to eak-4; tatn-1 mutants 
with regards to the formation of dauers (Figure 9H and Figure 9I). These data demonstrate that 
excessive synthesis of dopamine, octopamine, or tyramine is not responsible for the tatn-
1 phenotype. Instead tyrosine is directly sensed by the worms and acts as a developmental 
regulator. 
A.3 DISCUSSION 
A.3.1 Tyrosine as a modulator of daf-2 insulin/IGF-1 signaling effects. 
Together our results identify tyrosine and tyrosine aminotransferase activity as a modifier of daf-
2/IGFR effects in C. elegans (Figure 10). While the control of tyrosine aminotransferase 
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 expression and activity has been extensively studied as a target of insulin signaling in 
vertebrates [30]–[34], [36], [38], a connection between tyrosine aminotransferase or tyrosine 
metabolism and insulin action has not been demonstrated. Prior work in C. elegans has suggested 
that the hpd-1 gene, which encodes 4-hydroxyphenylpyruvate dioxygenase, is repressed in daf-
2 mutants and that knock-down of hpd-1 by RNAi delayed dauer exit and extended lifespan [39]. 
However, the mechanism involved has been unclear. Our work shows that both tatn-1, and 
likely hpd-1, impact on daf-2/IGFR signaling through increasing tyrosine levels in the animal. 
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Figure 76. Model for the regulation of TATN-1 expression, tyrosine levels, and the resulting effects of tyrosine 
effects on cell signaling pathways 
 
Shown is the daf-2/IGFR signaling pathway and eak genes from Figure 1A with the addition, shown in blue, of the 
effects of tyrosine identified in this work and the control of TATN-1 expression by daf-2/IGFR signaling and by 
dietary and environmental cues as demonstrated in Figure 8. In summary, worms sense the available diet and 
environmental temperature and these factors both contribute to the dauer decision and the regulation of TATN-1 
protein levels. Conditions which promote the dauer decision also tend to reduce the expression of TATN-1. The 
reductions in TATN-1 expression lead to reduced removal of tyrosine through degradation and increase free tyrosine 
levels in the animal. These increases in tyrosine activate aak-2/AMPK and disrupt the effects of normal daf-2/IGFR 
signaling through positive effects on daf-16/FOXO and perhaps inhibitory effects on crh-1/CREB. The effects of 
tyrosine are particularly pronounced when the daf-2/IGFR pathway is compromised, such as through mutations 
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 in the daf-2/IGFR gene or the eak genes which lie in a parallel pathway. This may be due to further reductions in 
TATN-1 expression or reductions in inhibitory regulators of daf-16/FOXO activity. 
 
We find the effects of tyrosine on daf-2/IGFR signaling to be complex with roles for both 
the daf-16/FOXO transcription factor and the aak-2/AMPK seen (Figure 10). One way that high 
tyrosine levels could interact with daf-2/IGFR signaling would be for tyrosine to somehow 
activate aak-2/AMPK. AMP kinases are a known regulator of both daf-16 and the vertebrate 
homolog FOXO3 [51], [76]. AMPK regulates FOXO transcriptional activity through the 
phosphorylation of up to six sites on these proteins. In our work, aak-2/AMPK mutations 
suppress the dauer promoting effects of tatn-1 mutations, treatment of worms with the AMPK 
agonist AICAR is able to mimic the effects of tyrosine, and increases in the active 
phosphorylated form of AAK-2 are seen in the tatn-1 mutant. These findings demonstrate that 
elevated tyrosine levels activate aak-2/AMPK which could then phosphorylate daf-16/FOXO. 
This phosphorylation event could then interfere with the inhibitory effects of an intact daf-
2/IGFR pathway on daf-16/FOXO activity. Further work would be needed to test this model, and 
the ability of mutants lacking aak-2/AMPK or daf-16/FOXO to still respond to elevated tyrosine 
levels also supports the presence of alternate, currently unknown downstream pathways. 
These alternate pathways could either lie in parallel to daf-16/FOXO or could be the dominant 
response pathway with daf-16/FOXO only playing a permissive role, especially at lower tyrosine 
levels. One possible alternate pathway involves the CREB transcription factor crh-1 (Figure 10). 
The crtc-1 co-activator for the CREB transcription factors has been shown to be a target of 
regulation by aak-2/AMPK, and in vertebrates, CRTC co-activators are known to interact with 
insulin signaling in mediating the hepatic metabolic adaptation to the fed versus fasting 
state [53], [77],[78]. We find that tatn-1(qd182) mutants show evidence of crh-1/CREB-
regulated gene expression, and a crh-1/CREB mutant mimics the interaction of eak-4 and tatn-1. 
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 Perhaps elevated tyrosine levels lead to the activation of aak-2/AMPK which then results in the 
activation of daf-16/FOXO and inhibition of crtc-1 and crh-1/CREB (Figure 10). The presence 
of paired downstream pathways could explain the partial requirement for daf-16/FOXO, 
especially at higher tyrosine levels. 
Beyond effects on daf-16/FOXO and crh-1/CREB, elevated tyrosine, especially at high levels, 
could also have hormetic effects via changing cellular redox status, producing ER stress, or 
perturbing the protein folding environment [79]. These effects could account for the positive 
effects of increased tyrosine on longevity, and some of the genes involved in sensing hormetic 
stresses, such as the HSF-1 orthologhsf-1, also interact with daf-16/FOXO and play roles in 
dauer formation [80]–[82]. Alternately, tyrosine could act via a novel pathway that operates 
independently ofdaf-16/FOXO or crh-1/CREB, especially at higher levels. For example, the 
vertebrate calcium-sensing receptor, PPARγ nuclear receptor, and aryl hydrocarbon receptor 
(Agarwala, Cano et al. 2007) have all been shown to respond to aromatic amino acids, though 
their connection to insulin action is currently unclear [83]–[85]. The recent finding that Akt and 
Foxo1 are largely dispensable for the control of hepatic metabolism by insulin in vivo has 
suggested that FOXO- independent pathways exist and play important roles in metabolic 
control [86]. 
Our work also provides insights into the eak genes which are known to act via unclear 
mechanisms to reduce daf-16/FOXO transcriptional activity while not significantly affecting the 
subcellular localization of DAF-16/FOXO [26], [27], [29]. We find that beyond enhancing the 
inhibitory effects of akt-1 on daf-16/FOXO activity, the eakgenes also suppress the effects of 
amino acids and AMPK activity on daf-16/FOXO activity. Additional work will be needed to 
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 understand if the eak genes normally represent a control point where the effects of these 
metabolic signals on insulin signaling can be enhanced or suppressed. 
A.3.2 The complex control of tyrosine aminotransferase. 
We find that the regulation of tatn-1 expression in worms is complex with daf-2activity, diet, and 
environmental conditions each contributing to the expression level (Figure 10). In vertebrates, 
tyrosine aminotransferase has also been shown to undergo regulation at the transcriptional, 
translation, and degradation levels in response to hormonal and nutritional cues [66]. We find 
that daf-2/IGFR activity inhibits tatn-1gene transcription but raises TATN-1 protein levels. This 
is consistent with work in vertebrates showing that insulin shows complex effects on tyrosine 
aminotransferase expression with actions at both the transcriptional and translational level [30]–
[34],[36], [38]. Nutritional cues appear to also be an important regulator because we find that 
the E. coli strain used as food has a powerful effect on the expression of tatn-1and these effects 
parallel the effects of the weaker tatn-1(baf1) allele on dauer formation. In rats, the activity of 
hepatic tyrosine aminotransferase varies several-fold during the day with a peak during the 
evening and nadir in the early morning [87]. Studies of the cyclic variation have demonstrated 
that dietary protein intake is a prime inducer of tyrosine aminotransferase levels [65]. Feeding 
animals a protein-free diet results in a constant low level of tyrosine aminotransferase, whereas 
feeding animals protein meals at differing times produces corresponding shifts in enzyme 
production. Among amino acids, some such as tryptophan are potent inducers of tyrosine 
aminotransferase expression [66]. The mechanisms accounting for the dietary effects of amino 
acids on tyrosine aminotransferase are currently unclear. This could suggest a role for additional 
nutrient sensitive pathways which may well be conserved as we find that both tryptophan and 
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 tyrosine act as tatn-1 inducers in worms. Finally, we find a novel role for environmental 
conditions on tatn-1 expression as lower temperatures promote expression and higher 
temperatures inhibit it. How changes in temperature translate into the observed effects is unclear 
but perhaps hormonal changes mediated by the cytochrome P450 daf-9 and the nuclear hormone 
receptor daf-12 or changes mediated by thermosensory neurons are involved [88]. Together this 
suggests that the control of tyrosine aminotransferase activity, which modulates tyrosine levels, 
could be controlled via a complex network of internal and external cues. Our finding that 
changes in tyrosine levels alter both signaling pathways and gene expression patterns could 
suggest that carefully controlling tyrosine metabolism and ultimately tyrosine levels plays an 
important role in overall homeostasis (Figure 10). 
A.3.3 Aromatic acids in human disease. 
Recent work has suggested that levels of specific amino acids, particularly branched chain and 
aromatic amino acids, could influence insulin sensitivity in people and mice [1]–[6]. While the 
exact role of aromatic amino acids in metabolic disease is unknown, our results suggest that 
these could play a causal role in either insulin-resistance or the development of diabetes [89]. 
Given the complex nature of tyrosine aminotransferase regulation, subtle changes in hormone 
levels, diet, and perhaps other factors could lead to changes in hepatic tyrosine metabolism and 
contribute to changes in serum aromatic amino acid levels. There may also be significant 
changes during the day due to dietary intake or release from internal stores such as muscle. As 
tyrosine levels increase, it is possible that, as in worms, the increases modify responses to insulin 
signaling and augment pre-existing insulin resistance in a harmful way (Figure 10). The 
connection between insulin signaling and tyrosine metabolism could potentially even lead to a 
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 vicious cycle of reduced insulin signaling producing elevated tyrosine levels which then lead to a 
further reduction in insulin signaling. 
Tyrosine aminotransferase has also been found to be a tumor suppressor gene in human 
hepatocellular carcinoma (HCC) [7]. The human tyrosine aminotransferase gene is located on 
16q, which is frequently deleted in HCC, and analysis of tumors reveals that gene deletion or 
silencing via hypermethylation is common [7]. Consistent with an inhibitory role in the 
pathogenesis of liver cancer, transfection of HCC cancer cell lines with a tyrosine 
aminotransferase transgene suppressed malignant behavior such as growth in soft agar and the 
formation of tumors in nude mice. In these cells, tyrosine aminotransferase expression also acted 
to inhibit tumor formation via the stimulation of apoptosis, but the exact molecular events are 
still unclear [7]. Our data would suggest that the activation of AMPK or the downstream effects 
of AMPK on FOXO transcription factors, such as FOXO3, or CREB would be attractive targets 
for future study. Alternately, we also saw down-regulation of genes involved in DNA repair so 
the elevated tyrosine levels could also promote the accumulation of additional cancer promoting 
mutations (Table S5). Together these findings suggest that extracellular or intracellular tyrosine 
levels could act as signaling molecules involved in the control of cell growth, differentiation, and 
physiology. 
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 A.4 MATERIALS AND METHODS 
A.4.1 C. elegans strains and maintenance 
All C. elegans strains were propagated on standard nematode growth agar (NGA) plates 
containing streptomycin (200 µg/mL) and spotted with OP50-1, as previously described [90]. 
For specific experiments, worms were fed HB101, OP50, or HT115 E. coli strains using NGA 
containing streptomycin (HB101) or no antibiotics (OP50 and HT115). 
The following C. elegans mutants were obtained from the C. elegans Genetics Center, which is 
supported in part by NIH Office of Research Infrastructure Programs (P40 OD010440): daf-
16(mgDf50) I, cat-2(e1112) II, pah-1(ok687) II, tdc-1(ok914) II, crh-1(tz2) III, daf-2(e1368) III, 
hpd-1(ok1955) III, unc-119(ed3) III, akt-1(mg144) V, akt-1(mg306) V, aak-2(gt33) X, akt-
2(ok393) X, daf-12(rh61rh411) X, pdk-1(mg142) X, sgk-1(ok538) X, muIs84[pAD76(sod-
3::GFP)], lpIs14 [daf-16f::GFP+unc-119(+)], and lpIs12 [daf-16a::RFP+unc-119(+)]. tatn-
1(baf1) X has been described previously, and tatn-1(qd182) was identified in an unrelated 
mutagenesis screen and is a gift from Daniel Pagano and Dennis Kim [43], [44]. muIs109[daf-
16::GFP] X has been described previously and is a gift from Malene Hansen [59]. daf-
16(mgDf47), hsd-1(mg433) I, eak-3(mg344) III, eak-4(mg348) IV, eak-7(tm3188) IV, sdf-
9(mg337) V have been described previously [26]–[28], [91]. Double and triple mutants were 
generated by standard genetic crosses, and the genotypes of strains were confirmed by PCR 
using oligos which detect gene deletions or RFLP's associated with the mutation (Table S6). 
Throughout this work tatn-1 is implied to refer to the tatn-1(baf1) allele except specifically as 
noted otherwise. 
 158 
 A.4.2 Dauer assays 
Worm embryos were isolated by sodium hypochlorite treatment, and eggs were transferred to 
plates, and grown at the indicated temperature in a designated incubator. The plates were scored 
two or three days later under a dissecting microscope for the presence of L2, dauer, and L3/L4 
and older worms. We conducted control experiments to determine the robustness and 
reproducibility of visual scoring by having several scorers evaluate a series of still images and 
corresponding movies of larvae of different developmental stages. We then compared the 
correlation between the scorers for the entire series via the use of a kappa statistic [92]. These 
experiments indicated that scoring was consistent between raters within the lab with all 
comparisons showing “substantial” to “almost perfect” agreement (Table S7) [92]. 
For each assay, approximately 100 worms were scored from each of two to three plates set up in 
parallel for each genotype used in an experiment. This resulted in 200 to, more typically, 300 
animals being scored for each genotype within an experiment. Each experiment was repeated at 
least once with comparable results, which resulted in between 400–600 worms being scored per 
genotype in total. The percentages of each stage were graphed using Prism5 software, and the 
graphs show pooled data from a single trial. To perform pairwise comparisons between mutant 
strains, a contingency table was set up using the counts for L2, dauer, and L3/L4 categories, and 
p-values were calculated using Fisher's exact contingency test within SAS version 9.3. To 
determine SDS resistance, worms were washed from plates with 1% SDS, and then incubated for 
20 minutes with gentle rocking. Worms were then pelleted and washed with water. Aliquots 
were scored for survival as demonstrated by movement, and each experiment was repeated at 
least once. The percentages of living worms were graphed with Prism5. 
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 A.4.3 Lifespan assays 
Lifespan asays were conducted as previously described at 20°C using either NGA or RNAi 
plates containing 50 µM FUDR [93]. Lifespan assays for N2, tatn-1(baf1), eak-7(tm3188), 
and eak-7(tm3188); tatn-1(baf1) used NGA plates spotted with HB101, and worms were grown 
from eggs at 16°C to minimize larval arrest. Lifespan assays for N2, tatn-1(baf1), aak-2(gt33), 
and tatn-1(baf1), aak-2(gt33) used NGA plates spotted with HB101. Lifespan assays for amino 
acid treated N2 worms used either NGA plates or NGA plates supplemented with 1 mg./mL 
tyrosine, glycine, or isoleucine, and then spotted with HB101. Lifespan assays using daf-
2 and daf-16RNAi treatment used NGA media supplemented with carbenicillin (50 µg/mL) and 
isopropyl β-d-thiogalactopyranoside (IPTG, 1 mM). RNAi treatment for daf-16 was started at 
egg hatching while daf-2 RNAi treatment started on day 1 of adulthood with larval development 
occurring on NGA plates spotted with HB101 at 20°C. 
For all lifespan assays three plates containing 40 worms each, for each genotype were set up, as 
well as an extra plate, with worms to replace worms that had crawled off the plate, bagged, or 
exploded, to reduce the number of censored events. Prism5 (Graphpad Software) was used to 
generate graphs and perform log-rank testing for curve comparisons. SAS was used to create 
lifetables and calculate mean survival. 
A.4.4 Amino acid supplementation 
Amino acids (Sigma-Aldrich) were dissolved as 45 mg/mL stock solutions in water, and then 
added to molten NGM to obtain a 1 mg/mL final concentration. These plates were dried and 
spotted with HB101 before use. 
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 A.4.5 Amino acid analysis 
Worms were Worms were grown on HB101 spotted NGM plates for two days at 25°C before 
being washed from the plates and then being rinsed twice with miliQ water. For Figure S9A, 
NGM plates either with or without 1 mg./mL tyrosine cast into the agar were used to grow the 
worm culture. To normalize the samples for worm number, a 5 µL aliquot was removed and 
scored for worm number. Amino acids were then extracted using aqueous methanol and crushing 
with a mortar and pestle as previously described [94]. The methanol solution was removed by 
evaporation and the residue stored frozen at −80°C. Amino acid analysis was performed via 
liquid chromatography tandem mass spectrometry following reconstitution of the residue in 0.1 
mL water as described previously for urine [95]. Amino acid content was then either normalized 
to total worm number in the sample (Figure 9B, Figure 9C, and Figure S9A) or normalized to the 
levels of individual non-aromatic amino acids and then divided by the average normalized level 
observed in the wild-type N2 samples (Figure 9D).   
A.4.6 AICAR treatment 
Aliquots from a 250 mM AICAR solution dissolved in water (Cell Signaling Technology) were 
spotted onto NGA plates spotted with HB101 to give a final concentration of 0.125 mM 1 hour 
before eggs were added to the plates. A comparable volume of water alone was used as a 
negative control. 
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 A.4.7 AMP and ATP measurements 
Worms  embryos were isolated by sodium hypochlorite treatment from N2 and eak-4(mg348); 
tatn-1(baf1) adults, and the eggs were transferred to NGA plates spotted with HB101. The plates 
were incubated at 25°C for 24 hours so most of the population was L2 larvae. The worms were 
washed from plates with water and washed with water to remove bacteria. Nucleotides were then 
extracted from the worms as previously described [50]. The resulting extract was stored at −80°C 
until analysis. ATP, ADP, and AMP levels were measured by HPLC with UV detection of 
individual nucleotides. 
A.4.8 Fluorescent imaging 
Images of worms were obtained with a BX51 fluorescence microscope and quantified using 
ImageJ software as previously described [44]. 
A.4.9 Quantitative RT-PCR 
For sod-3 expression, worm embryos were isolated by sodium hypochlorite treatment, and eggs 
were transferred to NGA plates spotted with HB101 and incubated at 25°C for 24 hours. The 
worms were washed from plates in water, pelleted by centrifugation, washed with water, and 
frozen for storage. RNA extraction, reverse transcription, and quantitative PCR were performed 
as previously described [27], [44]. The geometric mean level of the control genes pmp-3, cdc-42, 
and Y45F10D.4 were used to normalize the samples, and the relative levels of sod-3 expression 
were determined using the 2−ΔΔCt approach [96], [97]. 
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 For tatn-1 expression, N2 and daf-2(e1368) embryos were isolated by sodium hypochlorite 
treatment, and eggs were transferred to S-basal to arrest the worms at the L1 stage. L1 larvae 
were added to NGA plates spotted with OP50-1 and the plates were incubated at 20°C for 3 
days. Adult worms were washed from plates and RNA was isolated as described above. The 
geometric mean level of the control genes pmp-3, cdc-42, and Y45F10D.4 were used to 
normalize the samples, and the relative levels of tatn-1 expression were determined using the 
2−ΔΔCt approach [96], [97]. 
The oligos used to detect pmp-3, cdc-42, and Y45F10D.4 have been previously described [98]. 
The expression of sod-3 was detected using the oligos 5′-
CCAACCAGCGCTGAAATTCAATGG-3′ and 5′-GGAACCGAAGTCGCGCTTAATAGT-3′ 
[99]. The expression of tatn-1 was detected using 5′-CTTGATCAGAGAAGAATCAGTG-3′ and 
5′-GAGTGTTGATTGAAGTTGCG-3′. These oligos were designed to cross intron-exon 
boundaries using the PerlPrimer program [100]. 
 
A.4.10 Whole transcriptome RNA sequencing 
N2 wild-type control and tatn-1(qd182) mutant worms were synchronized via the use of 
hypochlorite treatment and grown on HB101 spotted NGM plates at 25°C for 2 days. These 
conditions and time point correspond to the conditions used for the amino acid analysis 
separately performed using these strains. The worms were washed from the plates and were then 
washed twice with miliQ water. The worm pellet was then suspended in QIAzol lysis reagent 
(Qiagen, Valencia, CA) and frozen at −80°C. Total RNA was isolated using the Qiagen 
miRNeasy mini kit and the RNA yield was measured by spectrophotometry. Total RNA was sent 
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 to Expression Analysis (Durham, NC) for analysis including bioanalyzer electrophoresis to 
ensure RNA quality followed by library preparation using the Illumina TruSeq RNA sample prep 
kit. The resulting library was subjected to high-throughput 50 nucleotide paired end sequencing 
using an Illumina sequencer at a depth of 17 million reads per sample. 
The resulting sequence data was clipped using internally developed software from Expression 
Analysis and matched to the C. elegans genome using RSEM [101]. The resulting transcript 
counts were then normalized using the upper quartile normalization approach [102]. 
Differentially expressed genes were then identified through the use of ANOVA testing and genes 
with a FDR score of 5% or lower were considered to be differentially expressed. This lead to the 
identification of 4622 genes as being differentially expressed (890 up-regulated and 3732 down-
regulated) between tatn-1(qd182) and wild-type N2. 
Over-represented gene classes were identified in the up-regulated and down-regulated genes 
through the use of DAVID [60]. Analysis of the transcriptome data for daf-16/FOXO and crh-
1/CREB regulated genes was performed using the Gene Set Association Analysis for RNA-seq 
program (available at http://gsaa.unc.edu/login/index.html) [63]. GSAA calculates a differential 
expression score for each gene in the entire RNA-seq dataset, 20408 genes in all, and then uses a 
running weighted Kolmogorov-Smirnov test to examine association of an entire gene set with 
each phenotypic class. The strength of the association is measured by the association score (AS) 
where positive scores indicate association of the gene set with the phenotype, and statistical 
significance is measured by a false discovery rate (FDR) that is adjusted for multiple testing. The 
daf-16/FOXO regulated genes were from previously published microarray data from Murphy et. 
al., and the crh-1/CREB regulated genes were from recently published microarray data from 
Mair et. al. [53], [62]. 
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 A.4.11 Generation of TATN-1:GFP transgenic animals 
Clones for the tatn-1 promoter and cDNA where purchased from Open Biosystems and verified 
by sequencing [103], [104]. A tatn-1p:tatn-1 cDNA:GFP transgene was generated using Gateway 
cloning and the vector pDEST-MB14 [104]. The resulting transgene or punc-119cbr, which 
contains the unc-119 gene from Caenorhabditis briggsae, was used to bombard HT1593 (unc-
119(ed3)) as previously described [105], [106]. From bombardment we obtained bafIs130 from 
punc-119cbr, which carries the unc-119 gene from Caenorhabditis briggsae, and bafIs131 from 
the tatn-1p:tatn-1 cDNA:GFP transgene [106]. Both transgenes were outcrossed with N2 and 
then mated with eak-4(mg348); tatn-1(baf1) to test for rescue of the dauer formation phenotype. 
The bafIs131 transgene was also crossed into a daf-2(e1368) mutant to generate daf-2(e1368); 
bafIs131. 
 
A.4.12 Anti-phospho AMPK western blotting 
Worm embryos were isolated by sodium hypochlorite treatment, and eggs were transferred to 
NGA plates spotted with HB101 and incubated at 25°C for 24 hours. For treatment with AICAR, 
the plate was spotted 1 hour before adding the eggs with aliquots from a 250 mM AICAR stock 
that was dissolved in water. As a positive control, N2 wild-type worms were grown as above, 
washed off in S-basal, and then exposed to 10 mM sodium azide in S-basal. This dose of S-basal 
has been previously shown to result in a 50% decrease in ATP concentrations in treated worms 
[54]. The worms were washed from plates in water, pelleted by centrifugation, washed with 
water, and suspended in 1× LDS loading buffer (Invitrogen) before being heated to 70°C in a 
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 Bransonic sonicator waterbath (Branson) for 30–40 minutes [107]. After heating the samples 
were centrifuged and the supernatant retained for analysis. The protein levels were measured 
using the CB-X protein assay kit (G-Biosciences), and 30 µg of protein was run on a 10% 
Nupage SDS-PAGE gel (Invitrogen) and blotted to a nitrocellulose membrane. Phospho-AAK-2 
was detected using a rabbit monoclonal antibody (Cell Signaling Technology #2535), and actin 
was detected using a rabbit anti-actin antibody (Cell Signaling Technology #4967) followed by 
detection by an anti-rabbit HRP secondary antibody and visualization using chemiluminescence 
(Bio-Rad). The resulting X-ray film was scanned and quantified using gel analysis tools in 
ImageJ [108]. 
A.5 SUPPORTING INFORMATION 
All supporting information can be found in the published manuscript.  
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Fisher AL7.  “TATN-1 Mutations Reveal a Novel Role for Tyrosine as a Metabolic 
Signal That Influences Developmental Decisions and Longevity in Caenorhabditis 
elegans.”  PLoS Genet. 2013 Dec;9(12):e1004020. doi: 10.1371/journal.pgen.1004020. 
Epub 2013 Dec 19.  
A.5.1 Figure S1  
The interaction between tatn-1 and eak-4 is modified by bacterial diet. Shown are the effects of 
HB101, HT115, OP50, or OP50-1 bacterial diets on dauer formation by eak-4(mg408); tatn-
1(baf1) mutants. These results represent one of two trials, and the shadings represent the 
percentages of L2, Dauer, or L3/L4 or older animals within each population. ** p,0.001 for 
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 pairwise Fisher’s exact contingency tests comparing OP50 versus HB101 or HT115 and OP50-1 
versus HB101 or HT115. (EPS) 
A.5.2 Figure S2 The tatn-1(qd182) allele enhances dauer formation by eak-4 mutants.  
(A) The point mutation in the tatn-1(qd182) allele produces a G to E change in a conserved 
residue of tyrosine aminotransferase as indicated by the arrow. This change is predicted to have 
an .89% chance of impairing protein function based on analysis using the coding SNP scoring 
tool available at the Panther database. (B) Enhanced dauer arrest by the eak-4; tatn-1(qd182) 
mutant compared to eak-4 or tatn-1(qd182) alone, or the N2 wild type strain. ** p,0.001 for 
pairwise Fisher’s exact test. (EPS) 
A.5.3 Figure S3  
Tatn-1 acts independently of the TGF-b signaling pathway. Inhibiting the TGF-b-like signaling 
pathway involved in dauer formation with mutations affecting daf-3/SMAD or daf-5/Sno genes 
does not block dauer formation by the eak-4; tatn-1 mutants. (EPS) 
A.5.4 Figure S4 The effects of the tatn-1(qd182) allele on dauer formation depend on aak-
2/AMPK.  
(A) The effects of tatn-1(qd182) on dauer formation also require aak-2. ** p,0.001 by Fisher’s 
exact test. (B) The tatn-1(qd182) allele is likely stronger than tatn-1(baf1) because the tatn-
1(qd182) allele shows delayed development compared to tatn-1(baf1) and wild type N2 worms.  
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 The curves show the percentage of adults present at each timepoint after synchronization. (C) 
SDS selection, which kills animals which have not fully completed dauer development including 
synthesis of the dauer cuticle and cessation of pharyngeal pumping, reveals a stronger effect of 
aak-2/AMPK mutations on dauer formation by the eak-4(mg348); tatn-1(qd182) mutants 
compared with scoring based on morphology. (EPS) 
A.5.5 Figure S5 
 Tatn-1 mutations do not impair energy production and increase the AMP/ATP ratio. L2 larval 
wild-type N2 and eak-4(mg348); tatn-1(baf1) worms were collected and nucleotides were 
extracted for measurement using HPLC with UV detection. Shown is the average AMP/ATP 
ratio for three separately grown worm preparations (N2 mean 0.036 and eak-4; tatn-1 mean 
0.029, p = 0.73 by t-test). (EPS) 
A.5.6 Figure S6.  The effects of the tatn-1(qd182) allele on dauer formation depend on daf-
16/FOXO. 
 (A) Loss of daf-16 in the daf-16(mgDf47) mutant partially inhibits dauer formation by eak-4(mg348); tatn-1(qd182) based on morphology, but SDS selection, which kills larvae which 
have not fully completed dauer development (B) reveals a stronger inhibitory effect of the daf-16(mgDf47) mutation on dauer formation.  (EPS) 
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 A.5.7 Figure S7  
Pie charts representing gene ontology categories of differentially expressed genes in the tatn-1(qd182) mutant compared to wild type N2. Genes as being differently expressed where divided 
into up-regulated and down-regulated groups and then analyzed using the tools within the 
Panther database. Pie charts were generated for each group using the ‘‘biologic process’’, 
‘‘cellular component’’, and ‘‘molecular function’’ gene ontology perspectives. (EPS) 
 
A.5.8 Figure S8.  daf-2/IGFR signaling inhibits the expression of tatn-1 mRNA.  
Measurement of tatn-1 mRNA levels in N2 and daf-2(e1368) mutants reveals that the daf-2 
mutants show a 40–50% increase in tatn-1 expression compared to N2. Shown are the results of 
two independent trials using RNA isolated from daf-2 and N2 adult animals. (EPS) 
 
A.5.9 Figure S9.  Tyrosine supplementation raises tyrosine levels but does not affect worm 
lifespan.  
(A) Growth of N2 worms on NGA supplemented with 1 mg./mL tyrosine leads to an increase in 
tyrosine levels as shown by liquid chromatography and tandem mass spectrometry. The 
untreated N2 average is 74.3 mmol per 100 worms and the tyrosine treated average is 163.6 mmol 
per 100 worms, which is a 2.2 fold increase. (B) Lifespan assays performed with N2 worms 
supplemented with tyrosine, glycine, or isoleucine show no effect of tyrosine supplementation on 
lifespan compared to untreated N2 animals (Untreated N2 mean survival 19.5 days, tyrosine 
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 treated 20.0 days, glycine treated 19.0 days, and isoleucine treated 21.5 days). The isoleucine 
treatment produces a small, but consistent effect on worm lifespan in two separate trials.  (EPS) 
A.5.10 Table S1. Function and human homologs for genes studied. 
Table showing the function and human homolog identified using HomoloGene, or Wormbase if 
not hits were identified, for each of the genes studied.  (DOCX) 
 
A.5.11 Table S2. Effects of tatn-1 on dauer formation.  
Excel spreadsheet showing the genetic and dauer formation assay data used to create each panel. 
(ZIP) 
 
A.5.12 Table S3. Effects of tatn-1 on longevity.  
Excel spreadsheet showing the lifetable analysis for lifespan experiments shown in Figure 2, 3, 
5, and 6.  (ZIP)  
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 A.5.13 Table S4. Genes differentially expressed between tatn-1(qd182) mutants and N2 
worms.  
Excel spreadsheet showing genes identified as up-regulated or down-regulated at a 5% false 
discovery rate through RNA-seq experiments with three tatn-1(qd182) and three wild-type N2 
RNA samples.  (ZIP) 
 
A.5.14 Table S5  
Gene classes identified as enriched via use of the DAVID program. The lists of up-regulated and 
down-regulated genes where searched for evidence of enriched functional or structure gene 
classes via use of the DAVID computer program. Shown is an Excel spreadsheet showing the 
DAVID output for each gene list.  (ZIP) 
 
A.5.15 Table S6. List of oligos and enzymes used to genotype progeny of crosses.  
Excel spreadsheet containing the oligo sequences and when needed restriction enzymes used to 
genotype the progeny of crosses involving the listed mutations. For all experiments, multiple 
rounds of self-fertilization and PCR genotyping were used to identify progeny homozygous for 
all mutations.  (ZIP) 
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 A.5.16  Table S7  
Correlation between raters for a set of control images depicting worm larval stages. A group of 
raters independently viewed a series of 60 images and accompanying movies of larval worms of 
differing developmental stages in random order. Raters scored each animal as L2 or below, 
dauer, or L3 or above.  Correlation between the raters was determined via the kappa statistic. 
Note that one rater had never previously worked with C.elegans and learned to perform scoring 
via a brief tutorial prior to scoring the image set.  (DOCX) 
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 APPENDIX B: QUANTITATIVE PCR 
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   Figure 77. qPCR raw data for ACAD10 deficient mouse fat tissue 
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            Figure 78. qPCR raw data for ACAD10 deficient mouse muscle tissue 
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        Figure 79. qPCR raw data for ACAD10 deficient mouse liver tissue 
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 APPENDIX C: DIGIGAIT IMAGING SYSTEMS - INDICES 
DIGIGAIT IMAGING SYSTEM - INDICES 
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APPENDIX D: ACYLCARNITINE MS/MS SPECTRA FOR MOUSE WHOLE BLOOD 
AND HEART SAMPLES 
Figure 80. Wild type Mouse Whole Blood Acylcarnitine Chromatogram I 
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Figure 81. Acad10-/- Mouse Whole Blood Acylcarnitine Chromatogram I 
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Figure 82. Wild type Mouse Whole Blood Acylcarnitine Chromatogram II 
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Figure 83. Acad10-/- Mouse Whole Blood Acylcarnitine Chromatogram II 
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Figure 84. Wild type Mouse Heart Acylcarnitine Chromatogram I 
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Figure 85. Acad10-/- Mouse Heart Acylcarnitine Chromatogram I 
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 APPENDIX E: COMPLETE ACYLCARNITINE RAW DATA 
 
Sample CompoundName Sample Prep I Sample Prep II Sample Prep III 
 ACD 10 KO  Urine acetylcarnitine 20.73 16.01 21.216 
 ACD 10 KO  Urine propionylcarnitine 0.37 0.50 0.528 
 ACD 10 KO  Urine butyrylcarnitine 0.52 0.75 0.442 
 ACD 10 KO  Urine isobutyrylcarnitine 0.22 0.19 0.292 
 ACD 10 KO  Urine R-3-hydroxy-butyrylcarnitine 0.02 0.09 0.003 
 ACD 10 KO  Urine S-3-hydroxy-butyrylcarnitine 0.02 0.06 0.000 
 ACD 10 KO  Urine valerylcarnitine 0.01 0.02 0.011 
 ACD 10 KO  Urine isovalerylcarnitine 0.07 0.07 0.032 
 ACD 10 KO  Urine 3-hydroxy-isovalerylcarnitine 0.67 0.62 0.684 
 ACD 10 KO  Urine 2-methyl-butyrylcarnitine 0.07 0.07 0.089 
 ACD 10 KO  Urine tigloylcarnitine 0.03 0.03 0.026 
 ACD 10 KO  Urine 3-methyl-crotonylcarnitine 0.00 0.00 0.001 
 ACD 10 KO  Urine hexanoylcarnitine 0.08 0.06 0.024 
 ACD 10 KO  Urine R-3-hydroxy-hexanoylcarnitine 0.02 0.02 0.009 
 ACD 10 KO  Urine S-3-hydroxy-hexanoylcarnitine 0.03 0.02 0.017 
 ACD 10 KO  Urine phenylacetylcarnitine 0.01 0.00 0.001 
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  ACD 10 KO  Urine phenylpropionylcarnitine 0.01 0.01   
 ACD 10 KO  Urine 4-phenyl-butyrylcarnitine 0.01 0.00   
 ACD 10 KO  Urine benzoylcarnitine 0.08 0.30 0.214 
 ACD 10 KO  Urine 4-methyl-hexanoylcarnitine 0.01 0.01 0.002 
 ACD 10 KO  Urine octanoylcarnitine 0.03 0.03 0.005 
 ACD 10 KO  Urine R-3-hydroxy-octanoylcarnitine 0.00 0.02 0.003 
 ACD 10 KO  Urine S-3-hydroxy-octanoylcarnitine 0.01 0.02 0.006 
 ACD 10 KO  Urine branched-chain C8 0.01 0.01 0.000 
 ACD 10 KO  Urine 
cis-3,4-methylene-
heptanoylcarnitine 0.03 0.02 0.011 
 ACD 10 KO  Urine 4-methyl-octanoylcarnitine 0.01 0.02 0.003 
 ACD 10 KO  Urine 2,6-dimethyl-heptanoylcarnitine 0.02 0.02 0.001 
 ACD 10 KO  Urine decanoylcarnitine 0.01 0.00 0.005 
 ACD 10 KO  Urine cis-4-decenoylcarnitine 0.01 0.01 0.009 
 ACD 10 KO  Urine 
cis-3,4-methylene-
nonanoylcarnitine 0.04 0.04 0.034 
 ACD 10 KO  Urine R-3-hydroxy-decanoylcarnitine 0.00 0.01 0.002 
 ACD 10 KO  Urine S-3-hydroxy-decanoylcarnitine 0.02 0.02 0.002 
 ACD 10 KO  Urine 5-decynoylcarnitine 0.02 0.01 0.009 
 ACD 10 KO  Urine lauroylcarnitine 0.01 0.01   
 ACD 10 KO  Urine trans-2-dodecenoylcarnitine 0.00 0.01   
 ACD 10 KO  Urine R-3-hydroxy-lauroylcarnitine 0.01 0.00   
 ACD 10 KO  Urine S-3-hydroxy-lauroylcarnitine 0.00 0.01   
 ACD 10 KO  Urine myristoylcarnitine 0.00 0.01   
 ACD 10 KO  Urine myristoleoylcarnitine 0.02 0.02   
 ACD 10 KO  Urine cis-5-tetradecenoylcarnitine 0.00 0.01   
 ACD 10 KO  Urine trans-2-tetradecenoylcarnitine 0.00 0.02   
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  ACD 10 KO  Urine 
cis,cis-5,8-
tetradecadienoylcarnitine 0.01 0.02   
 ACD 10 KO  Urine R-3-hydroxy-myristoylcarnitine 0.00 0.01   
 ACD 10 KO  Urine S-3-hydroxy-myristoylcarnitine 0.01 0.00   
 ACD 10 KO  Urine hydroxy-C14:1 0.00 0.01   
 ACD 10 KO  Urine palmitoylcarnitine 0.01 0.02   
 ACD 10 KO  Urine palmitoleoylcarnitine 0.00 0.01   
 ACD 10 KO  Urine trans-2-hexadecenoylcarnitine 0.00 0.02   
 ACD 10 KO  Urine R-3-hydroxy-palmitoylcarnitine 0.02 0.02   
 ACD 10 KO  Urine S-3-hydroxy-palmitoylcarnitine 0.00 0.01   
 ACD 10 KO  Urine hydroxy-C16:1 0.00 0.01   
 ACD 10 KO  Urine stearoylcarnitine 0.05 0.01   
 ACD 10 KO  Urine oleoylcarnitine 0.00 0.00   
 ACD 10 KO  Urine linoleoylcarnitine 0.02 0.03   
 ACD 10 KO  Urine alpha-linolenoylcarnitine 0.00 0.01   
 ACD 10 KO  Urine gamma-linolenoylcarnitine 0.00 0.02   
 ACD 10 KO  Urine R-3-hydroxy-stearoylcarnitine 0.01 0.02   
 ACD 10 KO  Urine S-3-hydroxy-stearoylcarnitine 0.01 0.01   
 ACD 10 KO  Urine hydroxy-C18:1 0.01 0.01   
 ACD 10 KO  Urine hydroxy-C18:2 0.01 0.01   
 ACD 10 KO  Urine hydroxy-C18:3 0.01 0.01   
 ACD 10 KO  Urine malonylcarnitine 2.14 2.95 2.252 
 ACD 10 KO  Urine succinylcarnitine 1.83 2.57 2.435 
 ACD 10 KO  Urine methyl-malonylcarnitine 0.74 1.34 1.347 
 ACD 10 KO  Urine ethyl-malonylcarnitine 0.03 0.02 0.005 
 ACD 10 KO  Urine glutaroylcarnitine 2.12 3.05 2.096 
 ACD 10 KO  Urine adipoylcarnitine 2.65 2.37 2.008 
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  ACD 10 KO  Urine 3-methyl-glutaroylcarnitine 0.23 0.31 0.240 
 ACD 10 KO  Urine suberoylcarnitine 1.05 0.88 1.135 
 ACD 10 KO  Urine sebacoylcarnitine 0.26 0.31 0.351 
 WT  Urine acetylcarnitine 42.63 21.40 8.690 
 WT  Urine propionylcarnitine 0.83 0.83 0.320 
 WT  Urine butyrylcarnitine 1.39 0.88 0.237 
 WT  Urine isobutyrylcarnitine 0.37 0.30 0.281 
 WT  Urine R-3-hydroxy-butyrylcarnitine 0.04 0.13 0.002 
 WT  Urine S-3-hydroxy-butyrylcarnitine 0.04 0.08 0.000 
 WT  Urine valerylcarnitine 0.05 0.01 0.011 
 WT  Urine isovalerylcarnitine 0.22 0.04 0.053 
 WT  Urine 3-hydroxy-isovalerylcarnitine 1.42 0.73 0.372 
 WT  Urine 2-methyl-butyrylcarnitine 0.19 0.07 0.042 
 WT  Urine tigloylcarnitine 0.06 0.03 0.020 
 WT  Urine 3-methyl-crotonylcarnitine 0.00 0.00 0.001 
 WT  Urine hexanoylcarnitine 0.23 0.04 0.020 
 WT  Urine R-3-hydroxy-hexanoylcarnitine 0.16 0.01 0.009 
 WT  Urine S-3-hydroxy-hexanoylcarnitine 0.03 0.02 0.007 
 WT  Urine phenylacetylcarnitine 0.01 0.00 0.002 
 WT  Urine phenylpropionylcarnitine 0.01 0.01   
 WT  Urine 4-phenyl-butyrylcarnitine 0.01 0.00   
 WT  Urine benzoylcarnitine 0.12 0.43 0.002 
 WT  Urine 4-methyl-hexanoylcarnitine 0.01 0.01 0.001 
 WT  Urine octanoylcarnitine 0.20 0.02 0.000 
 WT  Urine R-3-hydroxy-octanoylcarnitine 0.05 0.01 0.002 
 WT  Urine S-3-hydroxy-octanoylcarnitine 0.07 0.02 0.002 
 WT  Urine branched-chain C8 0.01 0.01 0.000 
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  WT  Urine 
cis-3,4-methylene-
heptanoylcarnitine 0.10 0.03 0.006 
 WT  Urine 4-methyl-octanoylcarnitine 0.05 0.02 0.001 
 WT  Urine 2,6-dimethyl-heptanoylcarnitine 0.06 0.02 0.002 
 WT  Urine decanoylcarnitine 0.08 0.00 0.005 
 WT  Urine cis-4-decenoylcarnitine 0.18 0.00 0.008 
 WT  Urine 
cis-3,4-methylene-
nonanoylcarnitine 0.17 0.03 0.028 
 WT  Urine R-3-hydroxy-decanoylcarnitine 0.03 0.01 0.001 
 WT  Urine S-3-hydroxy-decanoylcarnitine 0.04 0.02 0.001 
 WT  Urine 5-decynoylcarnitine 0.03 0.02 0.007 
 WT  Urine lauroylcarnitine 0.03 0.01   
 WT  Urine trans-2-dodecenoylcarnitine 0.00 0.01   
 WT  Urine R-3-hydroxy-lauroylcarnitine 0.01 0.00   
 WT  Urine S-3-hydroxy-lauroylcarnitine 0.01 0.01   
 WT  Urine myristoylcarnitine 0.02 0.01   
 WT  Urine myristoleoylcarnitine 0.06 0.02   
 WT  Urine cis-5-tetradecenoylcarnitine 0.04 0.01   
 WT  Urine trans-2-tetradecenoylcarnitine 0.04 0.02   
 WT  Urine 
cis,cis-5,8-
tetradecadienoylcarnitine 0.02 0.02   
 WT  Urine R-3-hydroxy-myristoylcarnitine 0.00 0.01   
 WT  Urine S-3-hydroxy-myristoylcarnitine 0.01 0.00   
 WT  Urine hydroxy-C14:1 0.01 0.01   
 WT  Urine palmitoylcarnitine 0.08 0.02   
 WT  Urine palmitoleoylcarnitine 0.02 0.01   
 WT  Urine trans-2-hexadecenoylcarnitine 0.05 0.01   
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  WT  Urine R-3-hydroxy-palmitoylcarnitine 0.02 0.02   
 WT  Urine S-3-hydroxy-palmitoylcarnitine 0.00 0.01   
 WT  Urine hydroxy-C16:1 0.00 0.01   
 WT  Urine stearoylcarnitine 0.08 0.01   
 WT  Urine oleoylcarnitine 0.01 0.00   
 WT  Urine linoleoylcarnitine 0.03 0.02   
 WT  Urine alpha-linolenoylcarnitine 0.02 0.01   
 WT  Urine gamma-linolenoylcarnitine 0.01 0.01   
 WT  Urine R-3-hydroxy-stearoylcarnitine 0.01 0.02   
 WT  Urine S-3-hydroxy-stearoylcarnitine 0.01 0.01   
 WT  Urine hydroxy-C18:1 0.01 0.01   
 WT  Urine hydroxy-C18:2 0.02 0.01   
 WT  Urine hydroxy-C18:3 0.01 0.01   
 WT  Urine malonylcarnitine 8.73 1.47 1.718 
 WT  Urine succinylcarnitine 5.80 1.52 1.513 
 WT  Urine methyl-malonylcarnitine 4.29 0.57 0.789 
 WT  Urine ethyl-malonylcarnitine 0.00 0.01 0.001 
 WT  Urine glutaroylcarnitine 5.91 1.66 2.220 
 WT  Urine adipoylcarnitine 7.45 1.56 2.539 
 WT  Urine 3-methyl-glutaroylcarnitine 0.94 0.29 0.201 
 WT  Urine suberoylcarnitine 2.59 0.85 0.812 
 WT  Urine sebacoylcarnitine 0.68 0.13 0.250 
 ACD 10 KO Plasma acetylcarnitine 22.65 15.03 20.850 
 ACD 10 KO Plasma propionylcarnitine 0.92 0.63 0.548 
 ACD 10 KO Plasma butyrylcarnitine 0.68 0.39 0.726 
 ACD 10 KO Plasma isobutyrylcarnitine 0.20 0.10 0.109 
 ACD 10 KO Plasma R-3-hydroxy-butyrylcarnitine 0.06 0.05 0.022 
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  ACD 10 KO Plasma S-3-hydroxy-butyrylcarnitine 0.16 0.08 0.066 
 ACD 10 KO Plasma valerylcarnitine 0.03 0.01 0.008 
 ACD 10 KO Plasma isovalerylcarnitine 0.20 0.09 0.100 
 ACD 10 KO Plasma 3-hydroxy-isovalerylcarnitine 0.11 0.08 0.033 
 ACD 10 KO Plasma 2-methyl-butyrylcarnitine 0.09 0.08 0.102 
 ACD 10 KO Plasma tigloylcarnitine 0.01 0.01 0.005 
 ACD 10 KO Plasma 3-methyl-crotonylcarnitine 0.00 0.00 0.000 
 ACD 10 KO Plasma hexanoylcarnitine 0.06 0.04 0.038 
 ACD 10 KO Plasma R-3-hydroxy-hexanoylcarnitine 0.00 0.00 0.003 
 ACD 10 KO Plasma S-3-hydroxy-hexanoylcarnitine 0.01 0.00 0.005 
 ACD 10 KO Plasma phenylacetylcarnitine 0.01 0.00 0.000 
 ACD 10 KO Plasma phenylpropionylcarnitine 0.03 0.01   
 ACD 10 KO Plasma 4-phenyl-butyrylcarnitine 0.01 0.00   
 ACD 10 KO Plasma benzoylcarnitine 0.00 0.00 0.004 
 ACD 10 KO Plasma 4-methyl-hexanoylcarnitine 0.01 0.01 0.000 
 ACD 10 KO Plasma octanoylcarnitine 0.02 0.02 0.000 
 ACD 10 KO Plasma R-3-hydroxy-octanoylcarnitine 0.01 0.01 0.003 
 ACD 10 KO Plasma S-3-hydroxy-octanoylcarnitine 0.02 0.02 0.009 
 ACD 10 KO Plasma branched-chain C8 0.01 0.01 0.000 
 ACD 10 KO Plasma 
cis-3,4-methylene-
heptanoylcarnitine 0.01 0.01 0.001 
 ACD 10 KO Plasma 4-methyl-octanoylcarnitine 0.01 0.02 0.000 
 ACD 10 KO Plasma 2,6-dimethyl-heptanoylcarnitine 0.02 0.01 0.000 
 ACD 10 KO Plasma decanoylcarnitine 0.02 0.00 0.011 
 ACD 10 KO Plasma cis-4-decenoylcarnitine 0.02 0.00 0.006 
 ACD 10 KO Plasma 
cis-3,4-methylene-
nonanoylcarnitine 0.01 0.00 0.002 
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  ACD 10 KO Plasma R-3-hydroxy-decanoylcarnitine 0.01 0.01 0.003 
 ACD 10 KO Plasma S-3-hydroxy-decanoylcarnitine 0.02 0.02 0.008 
 ACD 10 KO Plasma 5-decynoylcarnitine 0.01 0.00 0.000 
 ACD 10 KO Plasma lauroylcarnitine 0.03 0.02 0.007 
 ACD 10 KO Plasma trans-2-dodecenoylcarnitine 0.00 0.01 0.001 
 ACD 10 KO Plasma R-3-hydroxy-lauroylcarnitine 0.01 0.00 0.001 
 ACD 10 KO Plasma S-3-hydroxy-lauroylcarnitine 0.00 0.01 0.002 
 ACD 10 KO Plasma myristoylcarnitine 0.03 0.03 0.032 
 ACD 10 KO Plasma myristoleoylcarnitine 0.02 0.02 0.017 
 ACD 10 KO Plasma cis-5-tetradecenoylcarnitine 0.01 0.03 0.018 
 ACD 10 KO Plasma trans-2-tetradecenoylcarnitine 0.00 0.02 0.001 
 ACD 10 KO Plasma 
cis,cis-5,8-
tetradecadienoylcarnitine 0.01 0.03 0.011 
 ACD 10 KO Plasma R-3-hydroxy-myristoylcarnitine 0.01 0.01 0.000 
 ACD 10 KO Plasma S-3-hydroxy-myristoylcarnitine 0.02 0.00 0.002 
 ACD 10 KO Plasma hydroxy-C14:1 0.01 0.01 0.005 
 ACD 10 KO Plasma palmitoylcarnitine 0.12 0.08 0.132 
 ACD 10 KO Plasma palmitoleoylcarnitine 0.00 0.02 0.038 
 ACD 10 KO Plasma trans-2-hexadecenoylcarnitine 0.00 0.01 0.002 
 ACD 10 KO Plasma R-3-hydroxy-palmitoylcarnitine 0.02 0.02 0.000 
 ACD 10 KO Plasma S-3-hydroxy-palmitoylcarnitine 0.00 0.01 0.004 
 ACD 10 KO Plasma hydroxy-C16:1 0.00 0.01 0.003 
 ACD 10 KO Plasma stearoylcarnitine 0.08 0.03 0.032 
 ACD 10 KO Plasma oleoylcarnitine 0.06 0.06 0.122 
 ACD 10 KO Plasma linoleoylcarnitine 0.04 0.06 0.057 
 ACD 10 KO Plasma alpha-linolenoylcarnitine 0.01 0.01 0.006 
 ACD 10 KO Plasma gamma-linolenoylcarnitine 0.00 0.02 0.002 
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  ACD 10 KO Plasma R-3-hydroxy-stearoylcarnitine 0.01 0.02 0.006 
 ACD 10 KO Plasma S-3-hydroxy-stearoylcarnitine 0.01 0.01 0.001 
 ACD 10 KO Plasma hydroxy-C18:1 0.01 0.01 0.008 
 ACD 10 KO Plasma hydroxy-C18:2 0.01 0.01 0.004 
 ACD 10 KO Plasma hydroxy-C18:3 0.01 0.01 0.002 
 ACD 10 KO Plasma malonylcarnitine 0.03 0.01 0.008 
 ACD 10 KO Plasma succinylcarnitine 0.05 0.03 0.016 
 ACD 10 KO Plasma methyl-malonylcarnitine 0.02 0.02 0.005 
 ACD 10 KO Plasma ethyl-malonylcarnitine 0.01 0.00 0.000 
 ACD 10 KO Plasma glutaroylcarnitine 0.03 0.02 0.009 
 ACD 10 KO Plasma adipoylcarnitine 0.03 0.02 0.010 
 ACD 10 KO Plasma 3-methyl-glutaroylcarnitine 0.00 0.01 0.000 
 ACD 10 KO Plasma suberoylcarnitine 0.01 0.02 0.010 
 ACD 10 KO Plasma sebacoylcarnitine 0.01 0.01 0.002 
 WT  Plasma acetylcarnitine 16.85 17.79 26.232 
 WT  Plasma propionylcarnitine 0.41 0.53 1.489 
 WT  Plasma butyrylcarnitine 0.23 0.74 0.774 
 WT  Plasma isobutyrylcarnitine 0.08 0.10 0.191 
 WT  Plasma R-3-hydroxy-butyrylcarnitine 0.04 0.06 0.040 
 WT  Plasma S-3-hydroxy-butyrylcarnitine 0.08 0.08 0.048 
 WT  Plasma valerylcarnitine 0.00 0.01 0.013 
 WT  Plasma isovalerylcarnitine 0.07 0.07 0.181 
 WT  Plasma 3-hydroxy-isovalerylcarnitine 0.09 0.07 0.080 
 WT  Plasma 2-methyl-butyrylcarnitine 0.06 0.07 0.124 
 WT  Plasma tigloylcarnitine 0.01 0.01 0.008 
 WT  Plasma 3-methyl-crotonylcarnitine 0.00 0.00 0.000 
 WT  Plasma hexanoylcarnitine 0.05 0.04 0.020 
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  WT  Plasma R-3-hydroxy-hexanoylcarnitine 0.00 0.00 0.002 
 WT  Plasma S-3-hydroxy-hexanoylcarnitine 0.00 0.00 0.004 
 WT  Plasma phenylacetylcarnitine 0.01 0.00 0.002 
 WT  Plasma phenylpropionylcarnitine 0.01 0.01   
 WT  Plasma 4-phenyl-butyrylcarnitine 0.01 0.00   
 WT  Plasma benzoylcarnitine 0.00 0.01 0.000 
 WT  Plasma 4-methyl-hexanoylcarnitine 0.01 0.01 0.000 
 WT  Plasma octanoylcarnitine 0.02 0.02 0.000 
 WT  Plasma R-3-hydroxy-octanoylcarnitine 0.01 0.01 0.002 
 WT  Plasma S-3-hydroxy-octanoylcarnitine 0.02 0.02 0.007 
 WT  Plasma branched-chain C8 0.01 0.01 0.000 
 WT  Plasma 
cis-3,4-methylene-
heptanoylcarnitine 0.01 0.01 0.000 
 WT  Plasma 4-methyl-octanoylcarnitine 0.01 0.02 0.000 
 WT  Plasma 2,6-dimethyl-heptanoylcarnitine 0.02 0.01 0.000 
 WT  Plasma decanoylcarnitine 0.02 0.00 0.007 
 WT  Plasma cis-4-decenoylcarnitine 0.02 0.00 0.005 
 WT  Plasma 
cis-3,4-methylene-
nonanoylcarnitine 0.01 0.00 0.000 
 WT  Plasma R-3-hydroxy-decanoylcarnitine 0.01 0.01 0.002 
 WT  Plasma S-3-hydroxy-decanoylcarnitine 0.04 0.03 0.005 
 WT  Plasma 5-decynoylcarnitine 0.01 0.00 0.000 
 WT  Plasma lauroylcarnitine 0.03 0.02 0.008 
 WT  Plasma trans-2-dodecenoylcarnitine 0.01 0.01 0.000 
 WT  Plasma R-3-hydroxy-lauroylcarnitine 0.01 0.00 0.001 
 WT  Plasma S-3-hydroxy-lauroylcarnitine 0.00 0.01 0.000 
 WT  Plasma myristoylcarnitine 0.04 0.04 0.029 
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  WT  Plasma myristoleoylcarnitine 0.02 0.03 0.003 
 WT  Plasma cis-5-tetradecenoylcarnitine 0.03 0.03 0.001 
 WT  Plasma trans-2-tetradecenoylcarnitine 0.00 0.01 0.001 
 WT  Plasma 
cis,cis-5,8-
tetradecadienoylcarnitine 0.02 0.03 0.009 
 WT  Plasma R-3-hydroxy-myristoylcarnitine 0.00 0.01 0.000 
 WT  Plasma S-3-hydroxy-myristoylcarnitine 0.01 0.00 0.002 
 WT  Plasma hydroxy-C14:1 0.01 0.01 0.004 
 WT  Plasma palmitoylcarnitine 0.15 0.11 0.117 
 WT  Plasma palmitoleoylcarnitine 0.02 0.02 0.007 
 WT  Plasma trans-2-hexadecenoylcarnitine 0.00 0.01 0.001 
 WT  Plasma R-3-hydroxy-palmitoylcarnitine 0.02 0.02 0.001 
 WT  Plasma S-3-hydroxy-palmitoylcarnitine 0.00 0.01 0.004 
 WT  Plasma hydroxy-C16:1 0.00 0.02 0.001 
 WT  Plasma stearoylcarnitine 0.08 0.04 0.036 
 WT  Plasma oleoylcarnitine 0.11 0.09 0.047 
 WT  Plasma linoleoylcarnitine 0.06 0.06 0.034 
 WT  Plasma alpha-linolenoylcarnitine 0.01 0.01 0.003 
 WT  Plasma gamma-linolenoylcarnitine 0.00 0.01 0.002 
 WT  Plasma R-3-hydroxy-stearoylcarnitine 0.02 0.03 0.005 
 WT  Plasma S-3-hydroxy-stearoylcarnitine 0.01 0.01 0.001 
 WT  Plasma hydroxy-C18:1 0.01 0.01 0.003 
 WT  Plasma hydroxy-C18:2 0.01 0.01 0.004 
 WT  Plasma hydroxy-C18:3 0.01 0.01 0.002 
 WT  Plasma malonylcarnitine 0.04 0.02 0.026 
 WT  Plasma succinylcarnitine 0.04 0.02 0.013 
 WT  Plasma methyl-malonylcarnitine 0.03 0.01 0.004 
 217 
  WT  Plasma ethyl-malonylcarnitine 0.01 0.00 0.000 
 WT  Plasma glutaroylcarnitine 0.00 0.01 0.015 
 WT  Plasma adipoylcarnitine 0.03 0.02 0.017 
 WT  Plasma 3-methyl-glutaroylcarnitine 0.01 0.01 0.000 
 WT  Plasma suberoylcarnitine 0.01 0.03 0.012 
 WT  Plasma sebacoylcarnitine 0.01 0.01 0.002 
 ACD 10 KO Whole Blood acetylcarnitine 32.15 22.37   
 ACD 10 KO Whole Blood propionylcarnitine 0.82 0.57   
 ACD 10 KO Whole Blood butyrylcarnitine 0.47 0.27   
 ACD 10 KO Whole Blood isobutyrylcarnitine 0.19 0.09   
 ACD 10 KO Whole Blood R-3-hydroxy-butyrylcarnitine 0.10 0.08   
 ACD 10 KO Whole Blood S-3-hydroxy-butyrylcarnitine 0.24 0.16   
 ACD 10 KO Whole Blood valerylcarnitine 0.02 0.01   
 ACD 10 KO Whole Blood isovalerylcarnitine 0.20 0.09   
 ACD 10 KO Whole Blood 3-hydroxy-isovalerylcarnitine 0.16 0.14   
 ACD 10 KO Whole Blood 2-methyl-butyrylcarnitine 0.08 0.07   
 ACD 10 KO Whole Blood tigloylcarnitine 0.01 0.01   
 ACD 10 KO Whole Blood 3-methyl-crotonylcarnitine 0.00 0.00   
 ACD 10 KO Whole Blood hexanoylcarnitine 0.04 0.03   
 ACD 10 KO Whole Blood R-3-hydroxy-hexanoylcarnitine 0.00 0.01   
 ACD 10 KO Whole Blood S-3-hydroxy-hexanoylcarnitine 0.01 0.01   
 ACD 10 KO Whole Blood phenylacetylcarnitine 0.01 0.00   
 ACD 10 KO Whole Blood phenylpropionylcarnitine 0.02 0.01   
 ACD 10 KO Whole Blood 4-phenyl-butyrylcarnitine 0.01 0.00   
 ACD 10 KO Whole Blood benzoylcarnitine 0.00 0.00   
 ACD 10 KO Whole Blood 4-methyl-hexanoylcarnitine 0.01 0.01   
 ACD 10 KO Whole Blood octanoylcarnitine 0.04 0.04   
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  ACD 10 KO Whole Blood R-3-hydroxy-octanoylcarnitine 0.00 0.01   
 ACD 10 KO Whole Blood S-3-hydroxy-octanoylcarnitine 0.02 0.02   
 ACD 10 KO Whole Blood branched-chain C8 0.01 0.01   
 ACD 10 KO Whole Blood 
cis-3,4-methylene-
heptanoylcarnitine 0.01 0.01   
 ACD 10 KO Whole Blood 4-methyl-octanoylcarnitine 0.01 0.02   
 ACD 10 KO Whole Blood 2,6-dimethyl-heptanoylcarnitine 0.02 0.01   
 ACD 10 KO Whole Blood decanoylcarnitine 0.03 0.01   
 ACD 10 KO Whole Blood cis-4-decenoylcarnitine 0.03 0.01   
 ACD 10 KO Whole Blood 
cis-3,4-methylene-
nonanoylcarnitine 0.00 0.00   
 ACD 10 KO Whole Blood R-3-hydroxy-decanoylcarnitine 0.01 0.01   
 ACD 10 KO Whole Blood S-3-hydroxy-decanoylcarnitine 0.03 0.03   
 ACD 10 KO Whole Blood 5-decynoylcarnitine 0.01 0.00   
 ACD 10 KO Whole Blood lauroylcarnitine 0.03 0.04   
 ACD 10 KO Whole Blood trans-2-dodecenoylcarnitine 0.00 0.01   
 ACD 10 KO Whole Blood R-3-hydroxy-lauroylcarnitine 0.01 0.01   
 ACD 10 KO Whole Blood S-3-hydroxy-lauroylcarnitine 0.01 0.01   
 ACD 10 KO Whole Blood myristoylcarnitine 0.08 0.10   
 ACD 10 KO Whole Blood myristoleoylcarnitine 0.03 0.02   
 ACD 10 KO Whole Blood cis-5-tetradecenoylcarnitine 0.03 0.03   
 ACD 10 KO Whole Blood trans-2-tetradecenoylcarnitine 0.01 0.02   
 ACD 10 KO Whole Blood 
cis,cis-5,8-
tetradecadienoylcarnitine 0.01 0.03   
 ACD 10 KO Whole Blood R-3-hydroxy-myristoylcarnitine 0.01 0.01   
 ACD 10 KO Whole Blood S-3-hydroxy-myristoylcarnitine 0.01 0.01   
 ACD 10 KO Whole Blood hydroxy-C14:1 0.01 0.01   
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  ACD 10 KO Whole Blood palmitoylcarnitine 1.06 0.86   
 ACD 10 KO Whole Blood palmitoleoylcarnitine 0.02 0.03   
 ACD 10 KO Whole Blood trans-2-hexadecenoylcarnitine 0.00 0.02   
 ACD 10 KO Whole Blood R-3-hydroxy-palmitoylcarnitine 0.02 0.02   
 ACD 10 KO Whole Blood S-3-hydroxy-palmitoylcarnitine 0.00 0.02   
 ACD 10 KO Whole Blood hydroxy-C16:1 0.00 0.01   
 ACD 10 KO Whole Blood stearoylcarnitine 0.27 0.35   
 ACD 10 KO Whole Blood oleoylcarnitine 0.36 0.31   
 ACD 10 KO Whole Blood linoleoylcarnitine 0.14 0.14   
 ACD 10 KO Whole Blood alpha-linolenoylcarnitine 0.03 0.04   
 ACD 10 KO Whole Blood gamma-linolenoylcarnitine 0.00 0.02   
 ACD 10 KO Whole Blood R-3-hydroxy-stearoylcarnitine 0.02 0.03   
 ACD 10 KO Whole Blood S-3-hydroxy-stearoylcarnitine 0.01 0.01   
 ACD 10 KO Whole Blood hydroxy-C18:1 0.02 0.01   
 ACD 10 KO Whole Blood hydroxy-C18:2 0.01 0.01   
 ACD 10 KO Whole Blood hydroxy-C18:3 0.01 0.01   
 ACD 10 KO Whole Blood malonylcarnitine 0.13 0.08   
 ACD 10 KO Whole Blood succinylcarnitine 0.41 0.39   
 ACD 10 KO Whole Blood methyl-malonylcarnitine 0.11 0.07   
 ACD 10 KO Whole Blood ethyl-malonylcarnitine 0.02 0.00   
 ACD 10 KO Whole Blood glutaroylcarnitine 0.01 0.01   
 ACD 10 KO Whole Blood adipoylcarnitine 0.04 0.01   
 ACD 10 KO Whole Blood 3-methyl-glutaroylcarnitine 0.01 0.01   
 ACD 10 KO Whole Blood suberoylcarnitine 0.02 0.02   
 ACD 10 KO Whole Blood sebacoylcarnitine 0.01 0.01   
WT  Whole Blood acetylcarnitine 24.14 21.97   
WT  Whole Blood propionylcarnitine 0.42 0.50   
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 WT  Whole Blood butyrylcarnitine 0.13 0.37   
WT  Whole Blood isobutyrylcarnitine 0.07 0.08   
WT  Whole Blood R-3-hydroxy-butyrylcarnitine 0.06 0.07   
WT  Whole Blood S-3-hydroxy-butyrylcarnitine 0.16 0.14   
WT  Whole Blood valerylcarnitine 0.00 0.01   
WT  Whole Blood isovalerylcarnitine 0.06 0.06   
WT  Whole Blood 3-hydroxy-isovalerylcarnitine 0.13 0.12   
WT  Whole Blood 2-methyl-butyrylcarnitine 0.05 0.06   
WT  Whole Blood tigloylcarnitine 0.01 0.01   
WT  Whole Blood 3-methyl-crotonylcarnitine 0.00 0.00   
WT  Whole Blood hexanoylcarnitine 0.03 0.03   
WT  Whole Blood R-3-hydroxy-hexanoylcarnitine 0.00 0.01   
WT  Whole Blood S-3-hydroxy-hexanoylcarnitine 0.01 0.01   
WT  Whole Blood phenylacetylcarnitine 0.01 0.00   
WT  Whole Blood phenylpropionylcarnitine 0.01 0.01   
WT  Whole Blood 4-phenyl-butyrylcarnitine 0.01 0.00   
WT  Whole Blood benzoylcarnitine 0.00 0.00   
WT  Whole Blood 4-methyl-hexanoylcarnitine 0.01 0.01   
WT  Whole Blood octanoylcarnitine 0.04 0.04   
WT  Whole Blood R-3-hydroxy-octanoylcarnitine 0.00 0.01   
WT  Whole Blood S-3-hydroxy-octanoylcarnitine 0.02 0.02   
WT  Whole Blood branched-chain C8 0.01 0.01   
WT  Whole Blood 
cis-3,4-methylene-
heptanoylcarnitine 0.01 0.01   
WT  Whole Blood 4-methyl-octanoylcarnitine 0.00 0.02   
WT  Whole Blood 2,6-dimethyl-heptanoylcarnitine 0.02 0.01   
WT  Whole Blood decanoylcarnitine 0.02 0.01   
 221 
 WT  Whole Blood cis-4-decenoylcarnitine 0.02 0.01   
WT  Whole Blood 
cis-3,4-methylene-
nonanoylcarnitine 0.01 0.00   
WT  Whole Blood R-3-hydroxy-decanoylcarnitine 0.01 0.01   
WT  Whole Blood S-3-hydroxy-decanoylcarnitine 0.03 0.03   
WT  Whole Blood 5-decynoylcarnitine 0.01 0.00   
WT  Whole Blood lauroylcarnitine 0.03 0.03   
WT  Whole Blood trans-2-dodecenoylcarnitine 0.00 0.01   
WT  Whole Blood R-3-hydroxy-lauroylcarnitine 0.01 0.01   
WT  Whole Blood S-3-hydroxy-lauroylcarnitine 0.01 0.01   
WT  Whole Blood myristoylcarnitine 0.07 0.09   
WT  Whole Blood myristoleoylcarnitine 0.01 0.03   
WT  Whole Blood cis-5-tetradecenoylcarnitine 0.03 0.03   
WT  Whole Blood trans-2-tetradecenoylcarnitine 0.01 0.02   
WT  Whole Blood 
cis,cis-5,8-
tetradecadienoylcarnitine 0.01 0.03   
WT  Whole Blood R-3-hydroxy-myristoylcarnitine 0.00 0.01   
WT  Whole Blood S-3-hydroxy-myristoylcarnitine 0.02 0.01   
WT  Whole Blood hydroxy-C14:1 0.01 0.02   
WT  Whole Blood palmitoylcarnitine 0.94 0.99   
WT  Whole Blood palmitoleoylcarnitine 0.03 0.05   
WT  Whole Blood trans-2-hexadecenoylcarnitine 0.00 0.02   
WT  Whole Blood R-3-hydroxy-palmitoylcarnitine 0.02 0.02   
WT  Whole Blood S-3-hydroxy-palmitoylcarnitine 0.00 0.02   
WT  Whole Blood hydroxy-C16:1 0.00 0.02   
WT  Whole Blood stearoylcarnitine 0.20 0.30   
WT  Whole Blood oleoylcarnitine 0.40 0.39   
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 WT  Whole Blood linoleoylcarnitine 0.16 0.12   
WT  Whole Blood alpha-linolenoylcarnitine 0.03 0.03   
WT  Whole Blood gamma-linolenoylcarnitine 0.00 0.01   
WT  Whole Blood R-3-hydroxy-stearoylcarnitine 0.02 0.03   
WT  Whole Blood S-3-hydroxy-stearoylcarnitine 0.01 0.01   
WT  Whole Blood hydroxy-C18:1 0.02 0.01   
WT  Whole Blood hydroxy-C18:2 0.01 0.01   
WT  Whole Blood hydroxy-C18:3 0.01 0.01   
WT  Whole Blood malonylcarnitine 0.12 0.06   
WT  Whole Blood succinylcarnitine 0.42 0.29   
WT  Whole Blood methyl-malonylcarnitine 0.06 0.06   
WT  Whole Blood ethyl-malonylcarnitine 0.00 0.00   
WT  Whole Blood glutaroylcarnitine 0.01 0.01   
WT  Whole Blood adipoylcarnitine 0.02 0.02   
WT  Whole Blood 3-methyl-glutaroylcarnitine 0.01 0.01   
WT  Whole Blood suberoylcarnitine 0.01 0.02   
WT  Whole Blood sebacoylcarnitine 0.01 0.01   
 ACD 10 KO  Muscle  acetylcarnitine 147.79 135.75 67.982 
 ACD 10 KO  Muscle  propionylcarnitine 2.96 2.89 0.549 
 ACD 10 KO  Muscle  butyrylcarnitine 3.10 3.00 1.705 
 ACD 10 KO  Muscle  isobutyrylcarnitine 0.35 0.44 0.715 
 ACD 10 KO  Muscle  R-3-hydroxy-butyrylcarnitine 1.20 1.56 0.191 
 ACD 10 KO  Muscle  S-3-hydroxy-butyrylcarnitine 5.16 6.13 1.310 
 ACD 10 KO  Muscle  valerylcarnitine 0.27 0.16 0.036 
 ACD 10 KO  Muscle  isovalerylcarnitine 1.33 0.43 2.266 
 ACD 10 KO  Muscle  3-hydroxy-isovalerylcarnitine 1.44 1.76 0.716 
 ACD 10 KO  Muscle  2-methyl-butyrylcarnitine 0.84 0.79 0.556 
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  ACD 10 KO  Muscle  tigloylcarnitine 0.41 0.25 0.132 
 ACD 10 KO  Muscle  3-methyl-crotonylcarnitine 0.14 0.04 0.005 
 ACD 10 KO  Muscle  hexanoylcarnitine 0.57 0.47 0.321 
 ACD 10 KO  Muscle  R-3-hydroxy-hexanoylcarnitine 0.06 0.14 0.019 
 ACD 10 KO  Muscle  S-3-hydroxy-hexanoylcarnitine 0.40 0.15 0.057 
 ACD 10 KO  Muscle  phenylacetylcarnitine 0.24 0.04 0.000 
 ACD 10 KO  Muscle  phenylpropionylcarnitine 0.23 0.34   
 ACD 10 KO  Muscle  4-phenyl-butyrylcarnitine 0.28 0.09   
 ACD 10 KO  Muscle  benzoylcarnitine 0.03 0.04 0.004 
 ACD 10 KO  Muscle  4-methyl-hexanoylcarnitine 0.24 0.24 0.003 
 ACD 10 KO  Muscle  octanoylcarnitine 0.41 0.46 0.000 
 ACD 10 KO  Muscle  R-3-hydroxy-octanoylcarnitine 0.46 0.34 0.031 
 ACD 10 KO  Muscle  S-3-hydroxy-octanoylcarnitine 0.57 0.47 0.112 
 ACD 10 KO  Muscle  branched-chain C8 0.20 0.17 0.000 
 ACD 10 KO  Muscle  
cis-3,4-methylene-
heptanoylcarnitine 0.32 0.32 0.007 
 ACD 10 KO  Muscle  4-methyl-octanoylcarnitine 0.21 0.48 0.000 
 ACD 10 KO  Muscle  2,6-dimethyl-heptanoylcarnitine 0.57 0.39 0.000 
 ACD 10 KO  Muscle  decanoylcarnitine 0.26 0.00 0.122 
 ACD 10 KO  Muscle  cis-4-decenoylcarnitine 0.23 0.00 0.006 
 ACD 10 KO  Muscle  
cis-3,4-methylene-
nonanoylcarnitine 0.13 0.00 0.000 
 ACD 10 KO  Muscle  R-3-hydroxy-decanoylcarnitine 0.09 0.29 0.022 
 ACD 10 KO  Muscle  S-3-hydroxy-decanoylcarnitine 0.65 0.71 0.037 
 ACD 10 KO  Muscle  5-decynoylcarnitine 0.16 0.11 0.000 
 ACD 10 KO  Muscle  lauroylcarnitine 0.31 0.38 0.003 
 ACD 10 KO  Muscle  trans-2-dodecenoylcarnitine 0.05 0.31 0.000 
 224 
  ACD 10 KO  Muscle  R-3-hydroxy-lauroylcarnitine 0.34 0.16 0.002 
 ACD 10 KO  Muscle  S-3-hydroxy-lauroylcarnitine 0.48 0.26 0.018 
 ACD 10 KO  Muscle  myristoylcarnitine 0.23 0.60 0.325 
 ACD 10 KO  Muscle  myristoleoylcarnitine 0.68 0.53 0.098 
 ACD 10 KO  Muscle  cis-5-tetradecenoylcarnitine 0.00 0.31 0.000 
 ACD 10 KO  Muscle  trans-2-tetradecenoylcarnitine 0.30 0.51 0.000 
 ACD 10 KO  Muscle  
cis,cis-5,8-
tetradecadienoylcarnitine 0.13 0.58 0.055 
 ACD 10 KO  Muscle  R-3-hydroxy-myristoylcarnitine 0.08 0.29 0.000 
 ACD 10 KO  Muscle  S-3-hydroxy-myristoylcarnitine 0.20 0.11 0.013 
 ACD 10 KO  Muscle  hydroxy-C14:1 0.00 0.25 0.022 
 ACD 10 KO  Muscle  palmitoylcarnitine 1.45 1.84 1.817 
 ACD 10 KO  Muscle  palmitoleoylcarnitine 0.00 0.43 0.107 
 ACD 10 KO  Muscle  trans-2-hexadecenoylcarnitine 0.20 0.48 0.009 
 ACD 10 KO  Muscle  R-3-hydroxy-palmitoylcarnitine 0.45 0.59 0.000 
 ACD 10 KO  Muscle  S-3-hydroxy-palmitoylcarnitine 0.00 0.55 0.069 
 ACD 10 KO  Muscle  hydroxy-C16:1 0.00 0.42 0.019 
 ACD 10 KO  Muscle  stearoylcarnitine 2.04 1.05 0.646 
 ACD 10 KO  Muscle  oleoylcarnitine 0.51 1.44 1.712 
 ACD 10 KO  Muscle  linoleoylcarnitine 0.75 1.65 1.430 
 ACD 10 KO  Muscle  alpha-linolenoylcarnitine 0.31 0.34 0.107 
 ACD 10 KO  Muscle  gamma-linolenoylcarnitine 0.01 0.41 0.014 
 ACD 10 KO  Muscle  R-3-hydroxy-stearoylcarnitine 0.29 0.58 0.003 
 ACD 10 KO  Muscle  S-3-hydroxy-stearoylcarnitine 0.21 0.34 0.023 
 ACD 10 KO  Muscle  hydroxy-C18:1 0.32 0.40 0.174 
 ACD 10 KO  Muscle  hydroxy-C18:2 0.22 0.46 0.070 
 ACD 10 KO  Muscle  hydroxy-C18:3 0.20 0.27 0.051 
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  ACD 10 KO  Muscle  malonylcarnitine 1.02 0.40 0.360 
 ACD 10 KO  Muscle  succinylcarnitine 0.89 0.76 0.293 
 ACD 10 KO  Muscle  methyl-malonylcarnitine 0.14 0.42 0.078 
 ACD 10 KO  Muscle  ethyl-malonylcarnitine 0.14 0.10 0.000 
 ACD 10 KO  Muscle  glutaroylcarnitine 0.08 0.19 0.078 
 ACD 10 KO  Muscle  adipoylcarnitine 0.22 0.27 0.016 
 ACD 10 KO  Muscle  3-methyl-glutaroylcarnitine 0.00 0.33 0.000 
 ACD 10 KO  Muscle  suberoylcarnitine 0.08 0.36 0.000 
 ACD 10 KO  Muscle  sebacoylcarnitine 0.14 0.23 0.000 
WT  Muscle acetylcarnitine 113.43 127.63 137.438 
WT  Muscle propionylcarnitine 2.90 2.77 2.263 
WT  Muscle butyrylcarnitine 1.72 3.56 1.562 
WT  Muscle isobutyrylcarnitine 0.44 0.43 0.150 
WT  Muscle R-3-hydroxy-butyrylcarnitine 1.19 1.70 0.369 
WT  Muscle S-3-hydroxy-butyrylcarnitine 3.26 6.51 2.297 
WT  Muscle valerylcarnitine 0.32 0.15 0.062 
WT  Muscle isovalerylcarnitine 0.58 0.38 0.000 
WT  Muscle 3-hydroxy-isovalerylcarnitine 1.54 1.67 1.020 
WT  Muscle 2-methyl-butyrylcarnitine 0.81 0.76 0.217 
WT  Muscle tigloylcarnitine 0.32 0.26 0.061 
WT  Muscle 3-methyl-crotonylcarnitine 0.05 0.05 0.003 
WT  Muscle hexanoylcarnitine 0.73 0.55 0.177 
WT  Muscle R-3-hydroxy-hexanoylcarnitine 0.04 0.16 0.033 
WT  Muscle S-3-hydroxy-hexanoylcarnitine 0.32 0.15 0.078 
WT  Muscle phenylacetylcarnitine 0.25 0.05 0.000 
WT  Muscle phenylpropionylcarnitine 0.23 0.37   
WT  Muscle 4-phenyl-butyrylcarnitine 0.30 0.09   
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 WT  Muscle benzoylcarnitine 0.07 0.04 0.013 
WT  Muscle 4-methyl-hexanoylcarnitine 0.25 0.25 0.001 
WT  Muscle octanoylcarnitine 0.55 0.47 0.000 
WT  Muscle R-3-hydroxy-octanoylcarnitine 0.45 0.33 0.032 
WT  Muscle S-3-hydroxy-octanoylcarnitine 0.68 0.51 0.087 
WT  Muscle branched-chain C8 0.20 0.18 0.000 
WT  Muscle 
cis-3,4-methylene-
heptanoylcarnitine 0.33 0.36 0.009 
WT  Muscle 4-methyl-octanoylcarnitine 0.12 0.52 0.006 
WT  Muscle 2,6-dimethyl-heptanoylcarnitine 0.42 0.43 0.000 
WT  Muscle decanoylcarnitine 0.23 0.00 0.151 
WT  Muscle cis-4-decenoylcarnitine 0.24 0.00 0.005 
WT  Muscle 
cis-3,4-methylene-
nonanoylcarnitine 0.16 0.00 0.000 
WT  Muscle R-3-hydroxy-decanoylcarnitine 0.15 0.32 0.020 
WT  Muscle S-3-hydroxy-decanoylcarnitine 0.72 0.75 0.048 
WT  Muscle 5-decynoylcarnitine 0.15 0.13 0.000 
WT  Muscle lauroylcarnitine 0.27 0.44 0.018 
WT  Muscle trans-2-dodecenoylcarnitine 0.08 0.30 0.000 
WT  Muscle R-3-hydroxy-lauroylcarnitine 0.34 0.17 0.002 
WT  Muscle S-3-hydroxy-lauroylcarnitine 0.00 0.28 0.016 
WT  Muscle myristoylcarnitine 0.51 0.57 0.288 
WT  Muscle myristoleoylcarnitine 0.83 0.61 0.105 
WT  Muscle cis-5-tetradecenoylcarnitine 0.00 0.29 0.000 
WT  Muscle trans-2-tetradecenoylcarnitine 0.19 0.49 0.019 
WT  Muscle 
cis,cis-5,8-
tetradecadienoylcarnitine 0.23 0.58 0.023 
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 WT  Muscle R-3-hydroxy-myristoylcarnitine 0.11 0.32 0.000 
WT  Muscle S-3-hydroxy-myristoylcarnitine 0.31 0.15 0.029 
WT  Muscle hydroxy-C14:1 0.00 0.26 0.015 
WT  Muscle palmitoylcarnitine 2.23 2.11 1.620 
WT  Muscle palmitoleoylcarnitine 0.00 0.60 0.204 
WT  Muscle trans-2-hexadecenoylcarnitine 0.10 0.58 0.015 
WT  Muscle R-3-hydroxy-palmitoylcarnitine 0.46 0.66 0.020 
WT  Muscle S-3-hydroxy-palmitoylcarnitine 0.00 0.57 0.154 
WT  Muscle hydroxy-C16:1 0.00 0.46 0.055 
WT  Muscle stearoylcarnitine 1.96 1.18 0.687 
WT  Muscle oleoylcarnitine 1.73 1.85 1.183 
WT  Muscle linoleoylcarnitine 1.35 1.39 0.907 
WT  Muscle alpha-linolenoylcarnitine 0.32 0.38 0.076 
WT  Muscle gamma-linolenoylcarnitine 0.02 0.45 0.027 
WT  Muscle R-3-hydroxy-stearoylcarnitine 0.31 0.64 0.017 
WT  Muscle S-3-hydroxy-stearoylcarnitine 0.23 0.37 0.084 
WT  Muscle hydroxy-C18:1 0.35 0.49 0.225 
WT  Muscle hydroxy-C18:2 0.31 0.39 0.104 
WT  Muscle hydroxy-C18:3 0.30 0.25 0.024 
WT  Muscle malonylcarnitine 0.96 0.48 0.689 
WT  Muscle succinylcarnitine 0.84 0.68 1.024 
WT  Muscle methyl-malonylcarnitine 0.07 0.49 0.153 
WT  Muscle ethyl-malonylcarnitine 0.04 0.13 0.000 
WT  Muscle glutaroylcarnitine 0.03 0.12 0.000 
WT  Muscle adipoylcarnitine 0.34 0.29 0.021 
WT  Muscle 3-methyl-glutaroylcarnitine 0.00 0.36 0.000 
WT  Muscle suberoylcarnitine 0.08 0.41 0.000 
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 WT  Muscle sebacoylcarnitine 0.20 0.24 0.000 
ACD 10 KO  Liver  acetylcarnitine 68.17 90.74 77.053 
ACD 10 KO  Liver  propionylcarnitine 5.70 9.11 13.448 
ACD 10 KO  Liver  butyrylcarnitine 0.97 1.81 3.709 
ACD 10 KO  Liver  isobutyrylcarnitine 0.84 1.55 0.559 
ACD 10 KO  Liver  R-3-hydroxy-butyrylcarnitine 2.77 3.11 0.978 
ACD 10 KO  Liver  S-3-hydroxy-butyrylcarnitine 1.67 2.68 0.676 
ACD 10 KO  Liver  valerylcarnitine 0.19 0.12 1.426 
ACD 10 KO  Liver  isovalerylcarnitine 0.88 0.53 0.503 
ACD 10 KO  Liver  3-hydroxy-isovalerylcarnitine 0.90 1.48 0.448 
ACD 10 KO  Liver  2-methyl-butyrylcarnitine 0.69 1.06 0.704 
ACD 10 KO  Liver  tigloylcarnitine 0.25 0.22 0.016 
ACD 10 KO  Liver  3-methyl-crotonylcarnitine 0.04 0.06 0.003 
ACD 10 KO  Liver  hexanoylcarnitine 0.28 0.15 0.498 
ACD 10 KO  Liver  R-3-hydroxy-hexanoylcarnitine 0.04 0.21 0.047 
ACD 10 KO  Liver  S-3-hydroxy-hexanoylcarnitine 0.32 0.29 0.085 
ACD 10 KO  Liver  phenylacetylcarnitine 0.22 0.04 0.002 
ACD 10 KO  Liver  phenylpropionylcarnitine 0.33 0.75   
ACD 10 KO  Liver  4-phenyl-butyrylcarnitine 0.24 0.09   
ACD 10 KO  Liver  benzoylcarnitine 0.03 0.03 0.004 
ACD 10 KO  Liver  4-methyl-hexanoylcarnitine 0.21 0.26 0.041 
ACD 10 KO  Liver  octanoylcarnitine 0.31 0.43 0.000 
ACD 10 KO  Liver  R-3-hydroxy-octanoylcarnitine 0.38 0.38 0.035 
ACD 10 KO  Liver  S-3-hydroxy-octanoylcarnitine 0.50 0.55 0.048 
ACD 10 KO  Liver  branched-chain C8 0.17 0.19 0.000 
ACD 10 KO  Liver  
cis-3,4-methylene-
heptanoylcarnitine 0.29 0.39 0.009 
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 ACD 10 KO  Liver  4-methyl-octanoylcarnitine 0.07 0.54 0.000 
ACD 10 KO  Liver  2,6-dimethyl-heptanoylcarnitine 0.35 0.47 0.000 
ACD 10 KO  Liver  decanoylcarnitine 0.15 0.00 0.030 
ACD 10 KO  Liver  cis-4-decenoylcarnitine 0.15 0.00 0.001 
ACD 10 KO  Liver  
cis-3,4-methylene-
nonanoylcarnitine 0.19 0.00 0.004 
ACD 10 KO  Liver  R-3-hydroxy-decanoylcarnitine 0.05 0.36 0.008 
ACD 10 KO  Liver  S-3-hydroxy-decanoylcarnitine 0.56 0.80 0.000 
ACD 10 KO  Liver  5-decynoylcarnitine 0.16 0.11 0.000 
ACD 10 KO  Liver  lauroylcarnitine 0.19 0.35 0.000 
ACD 10 KO  Liver  trans-2-dodecenoylcarnitine 0.05 0.26 0.000 
ACD 10 KO  Liver  R-3-hydroxy-lauroylcarnitine 0.29 0.16 0.001 
ACD 10 KO  Liver  S-3-hydroxy-lauroylcarnitine 0.44 0.26 0.000 
ACD 10 KO  Liver  myristoylcarnitine 0.02 0.24 0.000 
ACD 10 KO  Liver  myristoleoylcarnitine 0.65 0.53 0.006 
ACD 10 KO  Liver  cis-5-tetradecenoylcarnitine 0.00 0.32 0.000 
ACD 10 KO  Liver  trans-2-tetradecenoylcarnitine 0.13 0.51 0.018 
ACD 10 KO  Liver  
cis,cis-5,8-
tetradecadienoylcarnitine 0.09 0.54 0.000 
ACD 10 KO  Liver  R-3-hydroxy-myristoylcarnitine 0.07 0.32 0.000 
ACD 10 KO  Liver  S-3-hydroxy-myristoylcarnitine 0.20 0.05 0.000 
ACD 10 KO  Liver  hydroxy-C14:1 0.00 0.25 0.020 
ACD 10 KO  Liver  palmitoylcarnitine 0.33 0.56 0.297 
ACD 10 KO  Liver  palmitoleoylcarnitine 0.00 0.32 0.000 
ACD 10 KO  Liver  trans-2-hexadecenoylcarnitine 0.12 0.52 0.000 
ACD 10 KO  Liver  R-3-hydroxy-palmitoylcarnitine 0.39 0.64 0.000 
ACD 10 KO  Liver  S-3-hydroxy-palmitoylcarnitine 0.00 0.39 0.012 
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 ACD 10 KO  Liver  hydroxy-C16:1 0.00 0.45 0.015 
ACD 10 KO  Liver  stearoylcarnitine 1.36 0.40 0.407 
ACD 10 KO  Liver  oleoylcarnitine 0.00 0.00 0.000 
ACD 10 KO  Liver  linoleoylcarnitine 0.28 0.78 0.297 
ACD 10 KO  Liver  alpha-linolenoylcarnitine 0.00 0.26 0.000 
ACD 10 KO  Liver  gamma-linolenoylcarnitine 0.00 0.36 0.000 
ACD 10 KO  Liver  R-3-hydroxy-stearoylcarnitine 0.26 0.65 0.006 
ACD 10 KO  Liver  S-3-hydroxy-stearoylcarnitine 0.24 0.32 0.033 
ACD 10 KO  Liver  hydroxy-C18:1 0.24 0.30 0.063 
ACD 10 KO  Liver  hydroxy-C18:2 0.20 0.27 0.018 
ACD 10 KO  Liver  hydroxy-C18:3 0.18 0.25 0.000 
ACD 10 KO  Liver  malonylcarnitine 2.29 2.21 1.625 
ACD 10 KO  Liver  succinylcarnitine 0.74 0.65 0.465 
ACD 10 KO  Liver  methyl-malonylcarnitine 0.05 0.53 0.073 
ACD 10 KO  Liver  ethyl-malonylcarnitine 0.20 0.13 0.000 
ACD 10 KO  Liver  glutaroylcarnitine 2.26 4.27 3.456 
ACD 10 KO  Liver  adipoylcarnitine 1.70 2.97 2.081 
ACD 10 KO  Liver  3-methyl-glutaroylcarnitine 0.14 0.46 0.011 
ACD 10 KO  Liver  suberoylcarnitine 0.07 0.62 0.064 
ACD 10 KO  Liver  sebacoylcarnitine 0.18 0.34 0.044 
 WT Liver  acetylcarnitine 106.78 107.49 76.101 
 WT Liver  propionylcarnitine 8.94 13.02 6.053 
 WT Liver  butyrylcarnitine 0.57 0.93 5.906 
 WT Liver  isobutyrylcarnitine 1.25 1.31 0.768 
 WT Liver  R-3-hydroxy-butyrylcarnitine 4.20 3.90 2.816 
 WT Liver  S-3-hydroxy-butyrylcarnitine 2.18 2.63 1.192 
 WT Liver  valerylcarnitine 0.20 0.12 0.610 
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  WT Liver  isovalerylcarnitine 0.57 0.57 0.139 
 WT Liver  3-hydroxy-isovalerylcarnitine 1.18 1.25 0.471 
 WT Liver  2-methyl-butyrylcarnitine 0.92 1.46 0.615 
 WT Liver  tigloylcarnitine 0.31 0.22 0.008 
 WT Liver  3-methyl-crotonylcarnitine 0.07 0.09 0.000 
 WT Liver  hexanoylcarnitine 0.27 0.13 0.877 
 WT Liver  R-3-hydroxy-hexanoylcarnitine 0.09 0.20 0.047 
 WT Liver  S-3-hydroxy-hexanoylcarnitine 0.36 0.28 0.101 
 WT Liver  phenylacetylcarnitine 0.20 0.05 0.002 
 WT Liver  phenylpropionylcarnitine 0.28 0.54   
 WT Liver  4-phenyl-butyrylcarnitine 0.25 0.10   
 WT Liver  benzoylcarnitine 0.04 0.06 0.012 
 WT Liver  4-methyl-hexanoylcarnitine 0.22 0.24 0.029 
 WT Liver  octanoylcarnitine 0.33 0.36 0.000 
 WT Liver  R-3-hydroxy-octanoylcarnitine 0.29 0.34 0.035 
 WT Liver  S-3-hydroxy-octanoylcarnitine 0.53 0.45 0.071 
 WT Liver  branched-chain C8 0.17 0.16   
 WT Liver  
cis-3,4-methylene-
heptanoylcarnitine 0.28 0.33 0.000 
 WT Liver  4-methyl-octanoylcarnitine 0.19 0.49 0.007 
 WT Liver  2,6-dimethyl-heptanoylcarnitine 0.48 0.37 0.006 
 WT Liver  decanoylcarnitine 0.16 0.00 0.082 
 WT Liver  cis-4-decenoylcarnitine 0.21 0.00 0.000 
 WT Liver  
cis-3,4-methylene-
nonanoylcarnitine 0.12 0.00 0.000 
 WT Liver  R-3-hydroxy-decanoylcarnitine 0.07 0.29 0.030 
 WT Liver  S-3-hydroxy-decanoylcarnitine 0.55 0.64 0.038 
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  WT Liver  5-decynoylcarnitine 0.13 0.12 0.000 
 WT Liver  lauroylcarnitine 0.19 0.32 0.000 
 WT Liver  trans-2-dodecenoylcarnitine 0.05 0.26 0.000 
 WT Liver  R-3-hydroxy-lauroylcarnitine 0.29 0.16 0.005 
 WT Liver  S-3-hydroxy-lauroylcarnitine 0.00 0.23 0.028 
 WT Liver  myristoylcarnitine 0.00 0.21 0.161 
 WT Liver  myristoleoylcarnitine 0.46 0.43 0.019 
 WT Liver  cis-5-tetradecenoylcarnitine 0.00 0.15 0.000 
 WT Liver  trans-2-tetradecenoylcarnitine 0.15 0.44 0.000 
 WT Liver  
cis,cis-5,8-
tetradecadienoylcarnitine 0.08 0.47 0.005 
 WT Liver  R-3-hydroxy-myristoylcarnitine 0.07 0.28 0.000 
 WT Liver  S-3-hydroxy-myristoylcarnitine 0.16 0.07 0.029 
 WT Liver  hydroxy-C14:1 0.00 0.20 0.031 
 WT Liver  palmitoylcarnitine 0.22 0.44 1.330 
 WT Liver  palmitoleoylcarnitine 0.00 0.30 0.121 
 WT Liver  trans-2-hexadecenoylcarnitine 0.13 0.47 0.004 
 WT Liver  R-3-hydroxy-palmitoylcarnitine 0.41 0.55 0.003 
 WT Liver  S-3-hydroxy-palmitoylcarnitine 0.00 0.33 0.097 
 WT Liver  hydroxy-C16:1 0.00 0.34 0.010 
 WT Liver  stearoylcarnitine 1.52 0.29 0.895 
 WT Liver  oleoylcarnitine 0.00 0.00 0.993 
 WT Liver  linoleoylcarnitine 0.29 0.65 0.576 
 WT Liver  alpha-linolenoylcarnitine 0.00 0.22 0.048 
 WT Liver  gamma-linolenoylcarnitine 0.00 0.35 0.000 
 WT Liver  R-3-hydroxy-stearoylcarnitine 0.31 0.54 0.023 
 WT Liver  S-3-hydroxy-stearoylcarnitine 0.25 0.26 0.036 
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  WT Liver  hydroxy-C18:1 0.35 0.23 0.149 
 WT Liver  hydroxy-C18:2 0.27 0.24 0.136 
 WT Liver  hydroxy-C18:3 0.26 0.20 0.020 
 WT Liver  malonylcarnitine 1.84 1.70 1.212 
 WT Liver  succinylcarnitine 0.76 0.79 0.516 
 WT Liver  methyl-malonylcarnitine 0.05 0.45 0.032 
 WT Liver  ethyl-malonylcarnitine 0.23 0.11 0.000 
 WT Liver  glutaroylcarnitine 3.09 4.27 2.640 
 WT Liver  adipoylcarnitine 2.84 2.43 2.165 
 WT Liver  3-methyl-glutaroylcarnitine 0.00 0.41 0.000 
 WT Liver  suberoylcarnitine 0.16 0.45 0.059 
 WT Liver  sebacoylcarnitine 0.18 0.26 0.058 
 ACD 10 KO  Whole Brain acetylcarnitine 49.38 58.09 30.024 
 ACD 10 KO  Whole Brain propionylcarnitine 3.09 3.35 1.221 
 ACD 10 KO  Whole Brain butyrylcarnitine 1.33 1.59 1.048 
 ACD 10 KO  Whole Brain isobutyrylcarnitine 0.37 0.50 0.167 
 ACD 10 KO  Whole Brain R-3-hydroxy-butyrylcarnitine 0.74 1.07 0.088 
 ACD 10 KO  Whole Brain S-3-hydroxy-butyrylcarnitine 1.11 1.50 0.312 
 ACD 10 KO  Whole Brain valerylcarnitine 0.33 0.12 0.040 
 ACD 10 KO  Whole Brain isovalerylcarnitine 1.41 0.78 0.176 
 ACD 10 KO  Whole Brain 3-hydroxy-isovalerylcarnitine 1.04 1.25 0.415 
 ACD 10 KO  Whole Brain 2-methyl-butyrylcarnitine 0.71 0.63 0.263 
 ACD 10 KO  Whole Brain tigloylcarnitine 0.26 0.14 0.012 
 ACD 10 KO  Whole Brain 3-methyl-crotonylcarnitine 0.03 0.02 0.001 
 ACD 10 KO  Whole Brain hexanoylcarnitine 0.36 0.18 0.069 
 ACD 10 KO  Whole Brain R-3-hydroxy-hexanoylcarnitine 0.08 0.10 0.025 
 ACD 10 KO  Whole Brain S-3-hydroxy-hexanoylcarnitine 0.28 0.07 0.026 
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  ACD 10 KO  Whole Brain phenylacetylcarnitine 0.23 0.01 0.000 
 ACD 10 KO  Whole Brain phenylpropionylcarnitine 0.19 0.29   
 ACD 10 KO  Whole Brain 4-phenyl-butyrylcarnitine 0.25 0.06   
 ACD 10 KO  Whole Brain benzoylcarnitine 0.03 0.01 0.002 
 ACD 10 KO  Whole Brain 4-methyl-hexanoylcarnitine 0.22 0.20 0.000 
 ACD 10 KO  Whole Brain octanoylcarnitine 0.33 0.33 0.000 
 ACD 10 KO  Whole Brain R-3-hydroxy-octanoylcarnitine 0.33 0.28 0.002 
 ACD 10 KO  Whole Brain S-3-hydroxy-octanoylcarnitine 0.50 0.35 0.006 
 ACD 10 KO  Whole Brain branched-chain C8 0.17 0.16 0.000 
 ACD 10 KO  Whole Brain 
cis-3,4-methylene-
heptanoylcarnitine 0.30 0.29 0.001 
 ACD 10 KO  Whole Brain 4-methyl-octanoylcarnitine 0.22 0.43 0.008 
 ACD 10 KO  Whole Brain 2,6-dimethyl-heptanoylcarnitine 0.52 0.34 0.000 
 ACD 10 KO  Whole Brain decanoylcarnitine 0.19 0.00 0.050 
 ACD 10 KO  Whole Brain cis-4-decenoylcarnitine 0.23 0.00 0.011 
 ACD 10 KO  Whole Brain 
cis-3,4-methylene-
nonanoylcarnitine 0.12 0.00 0.000 
 ACD 10 KO  Whole Brain R-3-hydroxy-decanoylcarnitine 0.05 0.24 0.010 
 ACD 10 KO  Whole Brain S-3-hydroxy-decanoylcarnitine 0.57 0.57 0.002 
 ACD 10 KO  Whole Brain 5-decynoylcarnitine 0.15 0.08 0.000 
 ACD 10 KO  Whole Brain lauroylcarnitine 0.24 0.33 0.060 
 ACD 10 KO  Whole Brain trans-2-dodecenoylcarnitine 0.07 0.21 0.003 
 ACD 10 KO  Whole Brain R-3-hydroxy-lauroylcarnitine 0.31 0.12 0.000 
 ACD 10 KO  Whole Brain S-3-hydroxy-lauroylcarnitine 0.03 0.19 0.003 
 ACD 10 KO  Whole Brain myristoylcarnitine 0.84 1.07 0.842 
 ACD 10 KO  Whole Brain myristoleoylcarnitine 0.57 0.46 0.136 
 ACD 10 KO  Whole Brain cis-5-tetradecenoylcarnitine 0.00 0.19 0.000 
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  ACD 10 KO  Whole Brain trans-2-tetradecenoylcarnitine 0.23 0.46 0.000 
 ACD 10 KO  Whole Brain 
cis,cis-5,8-
tetradecadienoylcarnitine 0.08 0.43 0.000 
 ACD 10 KO  Whole Brain R-3-hydroxy-myristoylcarnitine 0.10 0.24 0.000 
 ACD 10 KO  Whole Brain S-3-hydroxy-myristoylcarnitine 0.26 0.02 0.000 
 ACD 10 KO  Whole Brain hydroxy-C14:1 0.00 0.20 0.015 
 ACD 10 KO  Whole Brain palmitoylcarnitine 1.95 2.38 3.335 
 ACD 10 KO  Whole Brain palmitoleoylcarnitine 0.00 0.57 0.349 
 ACD 10 KO  Whole Brain trans-2-hexadecenoylcarnitine 0.15 0.47 0.000 
 ACD 10 KO  Whole Brain R-3-hydroxy-palmitoylcarnitine 0.38 0.52 0.000 
 ACD 10 KO  Whole Brain S-3-hydroxy-palmitoylcarnitine 0.00 0.32 0.000 
 ACD 10 KO  Whole Brain hydroxy-C16:1 0.00 0.35 0.004 
 ACD 10 KO  Whole Brain stearoylcarnitine 2.33 0.81 0.840 
 ACD 10 KO  Whole Brain oleoylcarnitine 1.20 1.52 2.988 
 ACD 10 KO  Whole Brain linoleoylcarnitine 0.32 0.79 0.080 
 ACD 10 KO  Whole Brain alpha-linolenoylcarnitine 0.00 0.26 0.000 
 ACD 10 KO  Whole Brain gamma-linolenoylcarnitine 0.00 0.36 0.000 
 ACD 10 KO  Whole Brain R-3-hydroxy-stearoylcarnitine 0.26 0.52 0.008 
 ACD 10 KO  Whole Brain S-3-hydroxy-stearoylcarnitine 0.18 0.21 0.000 
 ACD 10 KO  Whole Brain hydroxy-C18:1 0.28 0.24 0.057 
 ACD 10 KO  Whole Brain hydroxy-C18:2 0.19 0.21 0.006 
 ACD 10 KO  Whole Brain hydroxy-C18:3 0.17 0.22 0.000 
 ACD 10 KO  Whole Brain malonylcarnitine 0.55 0.40 0.280 
 ACD 10 KO  Whole Brain succinylcarnitine 0.31 0.32 0.267 
 ACD 10 KO  Whole Brain methyl-malonylcarnitine 0.01 0.34 0.100 
 ACD 10 KO  Whole Brain ethyl-malonylcarnitine 0.15 0.09 0.000 
 ACD 10 KO  Whole Brain glutaroylcarnitine 0.29 0.50 0.068 
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  ACD 10 KO  Whole Brain adipoylcarnitine 0.28 0.24 0.008 
 ACD 10 KO  Whole Brain 3-methyl-glutaroylcarnitine 0.00 0.31 0.000 
 ACD 10 KO  Whole Brain suberoylcarnitine 0.06 0.31 0.000 
 ACD 10 KO  Whole Brain sebacoylcarnitine 0.18 0.20 0.000 
WT Whole Brain acetylcarnitine 60.42 60.95 49.166 
WT Whole Brain propionylcarnitine 3.64 3.90 1.643 
WT Whole Brain butyrylcarnitine 1.18 1.55 1.252 
WT Whole Brain isobutyrylcarnitine 0.44 0.52 0.355 
WT Whole Brain R-3-hydroxy-butyrylcarnitine 0.83 1.18 0.147 
WT Whole Brain S-3-hydroxy-butyrylcarnitine 1.33 1.59 0.308 
WT Whole Brain valerylcarnitine 0.27 0.13 0.044 
WT Whole Brain isovalerylcarnitine 0.88 0.60 0.453 
WT Whole Brain 3-hydroxy-isovalerylcarnitine 1.10 1.36 0.376 
WT Whole Brain 2-methyl-butyrylcarnitine 0.66 0.71 0.340 
WT Whole Brain tigloylcarnitine 0.28 0.15 0.017 
WT Whole Brain 3-methyl-crotonylcarnitine 0.05 0.02 0.001 
WT Whole Brain hexanoylcarnitine 0.35 0.19 0.088 
WT Whole Brain R-3-hydroxy-hexanoylcarnitine 0.12 0.11 0.019 
WT Whole Brain S-3-hydroxy-hexanoylcarnitine 0.25 0.08 0.017 
WT Whole Brain phenylacetylcarnitine 0.20 0.01 0.000 
WT Whole Brain phenylpropionylcarnitine 0.19 0.33   
WT Whole Brain 4-phenyl-butyrylcarnitine 0.25 0.07   
WT Whole Brain benzoylcarnitine 0.03 0.01 0.000 
WT Whole Brain 4-methyl-hexanoylcarnitine 0.20 0.22 0.000 
WT Whole Brain octanoylcarnitine 0.30 0.40 0.000 
WT Whole Brain R-3-hydroxy-octanoylcarnitine 0.19 0.28 0.004 
WT Whole Brain S-3-hydroxy-octanoylcarnitine 0.33 0.38 0.020 
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 WT Whole Brain branched-chain C8 0.17 0.18 0.000 
WT Whole Brain 
cis-3,4-methylene-
heptanoylcarnitine 0.27 0.32 0.003 
WT Whole Brain 4-methyl-octanoylcarnitine 0.25 0.46 0.000 
WT Whole Brain 2,6-dimethyl-heptanoylcarnitine 0.46 0.39 0.003 
WT Whole Brain decanoylcarnitine 0.20 0.00 0.065 
WT Whole Brain cis-4-decenoylcarnitine 0.09 0.00 0.017 
WT Whole Brain 
cis-3,4-methylene-
nonanoylcarnitine 0.05 0.00 0.009 
WT Whole Brain R-3-hydroxy-decanoylcarnitine 0.04 0.29 0.015 
WT Whole Brain S-3-hydroxy-decanoylcarnitine 0.60 0.66 0.001 
WT Whole Brain 5-decynoylcarnitine 0.16 0.09 0.000 
WT Whole Brain lauroylcarnitine 0.32 0.42 0.167 
WT Whole Brain trans-2-dodecenoylcarnitine 0.04 0.24 0.000 
WT Whole Brain R-3-hydroxy-lauroylcarnitine 0.29 0.13 0.000 
WT Whole Brain S-3-hydroxy-lauroylcarnitine 0.43 0.21 0.001 
WT Whole Brain myristoylcarnitine 0.81 1.77 1.519 
WT Whole Brain myristoleoylcarnitine 0.44 0.55 0.220 
WT Whole Brain cis-5-tetradecenoylcarnitine 0.00 0.26 0.000 
WT Whole Brain trans-2-tetradecenoylcarnitine 0.06 0.53 0.007 
WT Whole Brain 
cis,cis-5,8-
tetradecadienoylcarnitine 0.07 0.50 0.005 
WT Whole Brain R-3-hydroxy-myristoylcarnitine 0.09 0.27 0.000 
WT Whole Brain S-3-hydroxy-myristoylcarnitine 0.23 0.02 0.000 
WT Whole Brain hydroxy-C14:1 0.00 0.22 0.012 
WT Whole Brain palmitoylcarnitine 2.26 3.65 3.712 
WT Whole Brain palmitoleoylcarnitine 0.00 0.77 0.550 
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 WT Whole Brain trans-2-hexadecenoylcarnitine 0.09 0.42 0.005 
WT Whole Brain R-3-hydroxy-palmitoylcarnitine 0.37 0.57 0.000 
WT Whole Brain S-3-hydroxy-palmitoylcarnitine 0.00 0.35 0.008 
WT Whole Brain hydroxy-C16:1 0.00 0.35 0.028 
WT Whole Brain stearoylcarnitine 2.08 0.74 0.567 
WT Whole Brain oleoylcarnitine 1.33 2.56 2.678 
WT Whole Brain linoleoylcarnitine 0.54 0.86 0.174 
WT Whole Brain alpha-linolenoylcarnitine 0.25 0.22 0.000 
WT Whole Brain gamma-linolenoylcarnitine 0.00 0.32 0.022 
WT Whole Brain R-3-hydroxy-stearoylcarnitine 0.28 0.59 0.031 
WT Whole Brain S-3-hydroxy-stearoylcarnitine 0.18 0.25 0.001 
WT Whole Brain hydroxy-C18:1 0.22 0.26 0.028 
WT Whole Brain hydroxy-C18:2 0.15 0.23 0.004 
WT Whole Brain hydroxy-C18:3 0.16 0.23 0.022 
WT Whole Brain malonylcarnitine 0.07 0.81 0.147 
WT Whole Brain succinylcarnitine 0.33 0.38 0.138 
WT Whole Brain methyl-malonylcarnitine 0.02 0.40 0.047 
WT Whole Brain ethyl-malonylcarnitine 0.13 0.11 0.000 
WT Whole Brain glutaroylcarnitine 0.69 0.48 0.248 
WT Whole Brain adipoylcarnitine 0.34 0.28 0.020 
WT Whole Brain 3-methyl-glutaroylcarnitine 0.01 0.35 0.000 
WT Whole Brain suberoylcarnitine 0.07 0.35 0.000 
WT Whole Brain sebacoylcarnitine 0.14 0.22 0.000 
KO Heart total_carnitine   1183.29 507.785 
KO Heart free_carnitine   731.44 310.147 
KO Heart butyrobetaine   19.03 7.532 
KO Heart acetylcarnitine   308.83 153.214 
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 KO Heart propionylcarnitine   14.66 2.146 
KO Heart butyrylcarnitine   4.14 4.757 
KO Heart isobutyrylcarnitine   0.47 0.418 
KO Heart R-3-hydroxy-butyrylcarnitine   3.40 1.551 
KO Heart S-3-hydroxy-butyrylcarnitine   12.72 4.532 
KO Heart valerylcarnitine   0.59 0.152 
KO Heart isovalerylcarnitine   0.42 0.240 
KO Heart 3-hydroxy-isovalerylcarnitine   2.75 1.295 
KO Heart 2-methyl-butyrylcarnitine   1.14 0.364 
KO Heart tigloylcarnitine   0.35 0.169 
KO Heart 3-methyl-crotonylcarnitine   0.04 0.002 
KO Heart hexanoylcarnitine   0.70 0.476 
KO Heart R-3-hydroxy-hexanoylcarnitine   0.22 0.059 
KO Heart S-3-hydroxy-hexanoylcarnitine   0.37 0.208 
KO Heart phenylacetylcarnitine   0.02 0.000 
KO Heart phenylpropionylcarnitine   0.48   
KO Heart 4-phenyl-butyrylcarnitine   0.10   
KO Heart benzoylcarnitine   0.09 0.015 
KO Heart 4-methyl-hexanoylcarnitine   0.33 0.000 
KO Heart octanoylcarnitine   0.67 0.000 
KO Heart R-3-hydroxy-octanoylcarnitine   0.55 0.057 
KO Heart S-3-hydroxy-octanoylcarnitine   1.02 0.157 
KO Heart branched-chain C8   0.24 0.000 
KO Heart 
cis-3,4-methylene-
heptanoylcarnitine   0.47 0.018 
KO Heart 4-methyl-octanoylcarnitine   0.69 0.007 
KO Heart 2,6-dimethyl-heptanoylcarnitine   0.56 0.000 
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 KO Heart decanoylcarnitine   0.00 0.189 
KO Heart cis-4-decenoylcarnitine   0.00 0.005 
KO Heart 
cis-3,4-methylene-
nonanoylcarnitine   0.00 0.000 
KO Heart R-3-hydroxy-decanoylcarnitine   0.64 0.048 
KO Heart S-3-hydroxy-decanoylcarnitine   1.99 0.128 
KO Heart 5-decynoylcarnitine   0.14 0.004 
KO Heart lauroylcarnitine   0.60 0.137 
KO Heart trans-2-dodecenoylcarnitine   0.39 0.001 
KO Heart R-3-hydroxy-lauroylcarnitine   0.32 0.000 
KO Heart S-3-hydroxy-lauroylcarnitine   1.14 0.052 
KO Heart myristoylcarnitine   0.73 0.948 
KO Heart myristoleoylcarnitine   0.63 0.195 
KO Heart cis-5-tetradecenoylcarnitine   0.43 0.000 
KO Heart trans-2-tetradecenoylcarnitine   0.74 0.019 
KO Heart 
cis,cis-5,8-
tetradecadienoylcarnitine   0.73 0.163 
KO Heart R-3-hydroxy-myristoylcarnitine   0.79 0.000 
KO Heart S-3-hydroxy-myristoylcarnitine   1.77 0.095 
KO Heart hydroxy-C14:1   1.21 0.081 
KO Heart palmitoylcarnitine   1.87 2.118 
KO Heart palmitoleoylcarnitine   0.44 0.047 
KO Heart trans-2-hexadecenoylcarnitine   1.00 0.042 
KO Heart R-3-hydroxy-palmitoylcarnitine   1.33 0.046 
KO Heart S-3-hydroxy-palmitoylcarnitine   3.10 0.285 
KO Heart hydroxy-C16:1   2.33 0.076 
KO Heart stearoylcarnitine   1.65 2.969 
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 KO Heart oleoylcarnitine   0.14 1.579 
KO Heart linoleoylcarnitine   1.13 1.697 
KO Heart alpha-linolenoylcarnitine   0.42 0.094 
KO Heart gamma-linolenoylcarnitine   0.53 0.040 
KO Heart R-3-hydroxy-stearoylcarnitine   1.08 0.031 
KO Heart S-3-hydroxy-stearoylcarnitine   1.56 0.267 
KO Heart hydroxy-C18:1   3.04 0.591 
KO Heart hydroxy-C18:2   2.42 0.343 
KO Heart hydroxy-C18:3   0.71 0.031 
KO Heart malonylcarnitine   5.24 2.067 
KO Heart succinylcarnitine   8.98 4.625 
KO Heart methyl-malonylcarnitine   1.65 0.747 
KO Heart ethyl-malonylcarnitine   0.15 0.000 
KO Heart glutaroylcarnitine   0.00 0.000 
KO Heart adipoylcarnitine   0.36 0.015 
KO Heart 3-methyl-glutaroylcarnitine   0.39 0.000 
KO Heart suberoylcarnitine   0.52 0.000 
KO Heart sebacoylcarnitine   0.31 0.000 
WT Heart total_carnitine   1271.39 936.466 
WT Heart free_carnitine   699.31 568.849 
WT Heart butyrobetaine   17.85 15.851 
WT Heart acetylcarnitine   510.14 244.638 
WT Heart propionylcarnitine   22.55 22.953 
WT Heart butyrylcarnitine   0.89 11.295 
WT Heart isobutyrylcarnitine   0.27 0.246 
WT Heart R-3-hydroxy-butyrylcarnitine   4.93 2.299 
WT Heart S-3-hydroxy-butyrylcarnitine   16.76 7.270 
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 WT Heart valerylcarnitine   0.74 1.871 
WT Heart isovalerylcarnitine   0.25 0.131 
WT Heart 3-hydroxy-isovalerylcarnitine   1.88 3.114 
WT Heart 2-methyl-butyrylcarnitine   1.27 1.474 
WT Heart tigloylcarnitine   0.46 0.407 
WT Heart 3-methyl-crotonylcarnitine   0.04 0.013 
WT Heart hexanoylcarnitine   0.73 1.115 
WT Heart R-3-hydroxy-hexanoylcarnitine   0.24 0.157 
WT Heart S-3-hydroxy-hexanoylcarnitine   0.67 0.484 
WT Heart phenylacetylcarnitine   0.03 0.000 
WT Heart phenylpropionylcarnitine   0.31   
WT Heart 4-phenyl-butyrylcarnitine   0.07   
WT Heart benzoylcarnitine   0.12 0.073 
WT Heart 4-methyl-hexanoylcarnitine   0.22 0.004 
WT Heart octanoylcarnitine   0.41 0.000 
WT Heart R-3-hydroxy-octanoylcarnitine   0.38 0.063 
WT Heart S-3-hydroxy-octanoylcarnitine   0.74 0.152 
WT Heart branched-chain C8   0.16 0.000 
WT Heart 
cis-3,4-methylene-
heptanoylcarnitine   0.30 0.012 
WT Heart 4-methyl-octanoylcarnitine   0.44 0.009 
WT Heart 2,6-dimethyl-heptanoylcarnitine   0.36 0.006 
WT Heart decanoylcarnitine   0.00 0.216 
WT Heart cis-4-decenoylcarnitine   0.00 0.000 
WT Heart 
cis-3,4-methylene-
nonanoylcarnitine   0.00 0.000 
WT Heart R-3-hydroxy-decanoylcarnitine   0.55 0.007 
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 WT Heart S-3-hydroxy-decanoylcarnitine   1.62 0.068 
WT Heart 5-decynoylcarnitine   0.09 0.000 
WT Heart lauroylcarnitine   0.36 0.000 
WT Heart trans-2-dodecenoylcarnitine   0.26 0.000 
WT Heart R-3-hydroxy-lauroylcarnitine   0.30 0.000 
WT Heart S-3-hydroxy-lauroylcarnitine   0.98 0.042 
WT Heart myristoylcarnitine   0.27 0.217 
WT Heart myristoleoylcarnitine   0.46 0.055 
WT Heart cis-5-tetradecenoylcarnitine   0.08 0.000 
WT Heart trans-2-tetradecenoylcarnitine   0.50 0.031 
WT Heart 
cis,cis-5,8-
tetradecadienoylcarnitine   0.43 0.044 
WT Heart R-3-hydroxy-myristoylcarnitine   0.67 0.000 
WT Heart S-3-hydroxy-myristoylcarnitine   1.40 0.019 
WT Heart hydroxy-C14:1   1.05 0.042 
WT Heart palmitoylcarnitine   0.71 1.151 
WT Heart palmitoleoylcarnitine   0.27 0.003 
WT Heart trans-2-hexadecenoylcarnitine   0.66 0.001 
WT Heart R-3-hydroxy-palmitoylcarnitine   1.03 0.001 
WT Heart S-3-hydroxy-palmitoylcarnitine   1.44 0.106 
WT Heart hydroxy-C16:1   1.94 0.059 
WT Heart stearoylcarnitine   0.44 1.419 
WT Heart oleoylcarnitine   0.03 0.409 
WT Heart linoleoylcarnitine   0.67 0.777 
WT Heart alpha-linolenoylcarnitine   0.27 0.039 
WT Heart gamma-linolenoylcarnitine   0.35 0.037 
WT Heart R-3-hydroxy-stearoylcarnitine   0.77 0.045 
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 SampleID WT/KO SpecimenType CompoundName Value 
15 KO Mouse Blood (Whole) total_carnitine 60.895 
15 KO Mouse Blood (Whole) free_carnitine 30.995 
15 KO Mouse Blood (Whole) calculated_acylcarnitines 29.900 
15 KO Mouse Blood (Whole) acyl/free 0.965 
15 KO Mouse Blood (Whole) butyrobetaine 2.466 
15 KO Mouse Blood (Whole) acetylcarnitine 29.135 
15 KO Mouse Blood (Whole) propionylcarnitine 0.484 
15 KO Mouse Blood (Whole) butyrylcarnitine 0.338 
15 KO Mouse Blood (Whole) isobutyrylcarnitine 0.069 
15 KO Mouse Blood (Whole) R-3-hydroxy-butyrylcarnitine 0.006 
15 KO Mouse Blood (Whole) S-3-hydroxy-butyrylcarnitine 0.024 
15 KO Mouse Blood (Whole) valerylcarnitine 0.003 
15 KO Mouse Blood (Whole) isovalerylcarnitine 0.146 
WT Heart S-3-hydroxy-stearoylcarnitine   0.97 0.089 
WT Heart hydroxy-C18:1   1.60 0.251 
WT Heart hydroxy-C18:2   0.65 0.191 
WT Heart hydroxy-C18:3   0.28 0.051 
WT Heart malonylcarnitine   6.71 3.143 
WT Heart succinylcarnitine   12.99 16.055 
WT Heart methyl-malonylcarnitine   1.52 1.056 
WT Heart ethyl-malonylcarnitine   0.11 0.000 
WT Heart glutaroylcarnitine   0.15 0.000 
WT Heart adipoylcarnitine   0.26 0.031 
WT Heart 3-methyl-glutaroylcarnitine   0.29 0.000 
WT Heart suberoylcarnitine   0.33 0.000 
WT Heart sebacoylcarnitine   0.21 0.000 
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 15 KO Mouse Blood (Whole) 3-hydroxy-isovalerylcarnitine 0.068 
15 KO Mouse Blood (Whole) 2-methyl-butyrylcarnitine 0.085 
15 KO Mouse Blood (Whole) pivaloylcarnitine 0.000 
15 KO Mouse Blood (Whole) tigloylcarnitine 0.002 
15 KO Mouse Blood (Whole) 3-methyl-crotonylcarnitine 0.000 
15 KO Mouse Blood (Whole) hexanoylcarnitine 0.019 
15 KO Mouse Blood (Whole) R-3-hydroxy-hexanoylcarnitine 0.003 
15 KO Mouse Blood (Whole) S-3-hydroxy-hexanoylcarnitine 0.003 
15 KO Mouse Blood (Whole) phenylacetylcarnitine 0.000 
15 KO Mouse Blood (Whole) phenylpropionylcarnitine 0.000 
15 KO Mouse Blood (Whole) 4-phenyl-butyrylcarnitine 0.000 
15 KO Mouse Blood (Whole) benzoylcarnitine 0.001 
15 KO Mouse Blood (Whole) 4-methyl-hexanoylcarnitine 0.000 
15 KO Mouse Blood (Whole) octanoylcarnitine 0.024 
15 KO Mouse Blood (Whole) R-3-hydroxy-octanoylcarnitine 0.001 
15 KO Mouse Blood (Whole) S-3-hydroxy-octanoylcarnitine 0.005 
15 KO Mouse Blood (Whole) valproylcarnitine 0.000 
15 KO Mouse Blood (Whole) branched-chain C8 0.000 
15 KO Mouse Blood (Whole) 
cis-3,4-methylene-
heptanoylcarnitine 0.001 
15 KO Mouse Blood (Whole) 4-methyl-octanoylcarnitine 0.000 
15 KO Mouse Blood (Whole) 2,6-dimethyl-heptanoylcarnitine 0.000 
15 KO Mouse Blood (Whole) decanoylcarnitine 0.022 
15 KO Mouse Blood (Whole) cis-4-decenoylcarnitine 0.022 
15 KO Mouse Blood (Whole) 
cis-3,4-methylene-
nonanoylcarnitine 0.002 
15 KO Mouse Blood (Whole) R-3-hydroxy-decanoylcarnitine 0.004 
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 15 KO Mouse Blood (Whole) S-3-hydroxy-decanoylcarnitine 0.010 
15 KO Mouse Blood (Whole) 5-decynoylcarnitine 0.000 
15 KO Mouse Blood (Whole) lauroylcarnitine 0.018 
15 KO Mouse Blood (Whole) trans-2-dodecenoylcarnitine 0.003 
15 KO Mouse Blood (Whole) R-3-hydroxy-lauroylcarnitine 0.001 
15 KO Mouse Blood (Whole) S-3-hydroxy-lauroylcarnitine 0.004 
15 KO Mouse Blood (Whole) myristoylcarnitine 0.070 
15 KO Mouse Blood (Whole) myristoleoylcarnitine 0.023 
15 KO Mouse Blood (Whole) cis-5-tetradecenoylcarnitine 0.026 
15 KO Mouse Blood (Whole) trans-2-tetradecenoylcarnitine 0.005 
15 KO Mouse Blood (Whole) 
cis,cis-5,8-
tetradecadienoylcarnitine 0.013 
15 KO Mouse Blood (Whole) R-3-hydroxy-myristoylcarnitine 0.002 
15 KO Mouse Blood (Whole) S-3-hydroxy-myristoylcarnitine 0.005 
15 KO Mouse Blood (Whole) hydroxy-C14:1 0.005 
15 KO Mouse Blood (Whole) palmitoylcarnitine 0.597 
15 KO Mouse Blood (Whole) palmitoleoylcarnitine 0.046 
15 KO Mouse Blood (Whole) trans-2-hexadecenoylcarnitine 0.003 
15 KO Mouse Blood (Whole) R-3-hydroxy-palmitoylcarnitine 0.002 
15 KO Mouse Blood (Whole) S-3-hydroxy-palmitoylcarnitine 0.007 
15 KO Mouse Blood (Whole) hydroxy-C16:1 0.001 
15 KO Mouse Blood (Whole) stearoylcarnitine 0.199 
15 KO Mouse Blood (Whole) oleoylcarnitine 0.465 
15 KO Mouse Blood (Whole) linoleoylcarnitine 0.140 
15 KO Mouse Blood (Whole) alpha-linolenoylcarnitine 0.025 
15 KO Mouse Blood (Whole) gamma-linolenoylcarnitine 0.004 
15 KO Mouse Blood (Whole) R-3-hydroxy-stearoylcarnitine 0.008 
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 15 KO Mouse Blood (Whole) S-3-hydroxy-stearoylcarnitine 0.003 
15 KO Mouse Blood (Whole) hydroxy-C18:1 0.010 
15 KO Mouse Blood (Whole) hydroxy-C18:2 0.001 
15 KO Mouse Blood (Whole) hydroxy-C18:3 0.002 
15 KO Mouse Blood (Whole) malonylcarnitine 0.088 
15 KO Mouse Blood (Whole) succinylcarnitine 0.458 
15 KO Mouse Blood (Whole) methyl-malonylcarnitine 0.052 
15 KO Mouse Blood (Whole) ethyl-malonylcarnitine 0.001 
15 KO Mouse Blood (Whole) glutaroylcarnitine 0.003 
15 KO Mouse Blood (Whole) adipoylcarnitine 0.006 
15 KO Mouse Blood (Whole) 3-methyl-glutaroylcarnitine 0.001 
15 KO Mouse Blood (Whole) suberoylcarnitine 0.011 
15 KO Mouse Blood (Whole) sebacoylcarnitine 0.001 
15 KO Mouse Blood (Whole) sum_of_individual_acylcarnitines 32.791 
15 KO Mouse Blood (Whole) ratio:_sum/calculated 1.097 
43 KO Mouse Blood (Whole) total_carnitine 42.126 
43 KO Mouse Blood (Whole) free_carnitine 23.120 
43 KO Mouse Blood (Whole) calculated_acylcarnitines 19.007 
43 KO Mouse Blood (Whole) acyl/free 0.822 
43 KO Mouse Blood (Whole) butyrobetaine 2.064 
43 KO Mouse Blood (Whole) acetylcarnitine 17.998 
43 KO Mouse Blood (Whole) propionylcarnitine 0.340 
43 KO Mouse Blood (Whole) butyrylcarnitine 0.225 
43 KO Mouse Blood (Whole) isobutyrylcarnitine 0.042 
43 KO Mouse Blood (Whole) R-3-hydroxy-butyrylcarnitine 0.003 
43 KO Mouse Blood (Whole) S-3-hydroxy-butyrylcarnitine 0.010 
43 KO Mouse Blood (Whole) valerylcarnitine 0.001 
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 43 KO Mouse Blood (Whole) isovalerylcarnitine 0.069 
43 KO Mouse Blood (Whole) 3-hydroxy-isovalerylcarnitine 0.042 
43 KO Mouse Blood (Whole) 2-methyl-butyrylcarnitine 0.043 
43 KO Mouse Blood (Whole) pivaloylcarnitine 0.000 
43 KO Mouse Blood (Whole) tigloylcarnitine 0.001 
43 KO Mouse Blood (Whole) 3-methyl-crotonylcarnitine 0.000 
43 KO Mouse Blood (Whole) hexanoylcarnitine 0.009 
43 KO Mouse Blood (Whole) R-3-hydroxy-hexanoylcarnitine 0.001 
43 KO Mouse Blood (Whole) S-3-hydroxy-hexanoylcarnitine 0.001 
43 KO Mouse Blood (Whole) phenylacetylcarnitine 0.001 
43 KO Mouse Blood (Whole) phenylpropionylcarnitine 0.000 
43 KO Mouse Blood (Whole) 4-phenyl-butyrylcarnitine 0.000 
43 KO Mouse Blood (Whole) benzoylcarnitine 0.002 
43 KO Mouse Blood (Whole) 4-methyl-hexanoylcarnitine 0.000 
43 KO Mouse Blood (Whole) octanoylcarnitine 0.019 
43 KO Mouse Blood (Whole) R-3-hydroxy-octanoylcarnitine 0.001 
43 KO Mouse Blood (Whole) S-3-hydroxy-octanoylcarnitine 0.002 
43 KO Mouse Blood (Whole) valproylcarnitine 0.000 
43 KO Mouse Blood (Whole) branched-chain C8 0.000 
43 KO Mouse Blood (Whole) 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
43 KO Mouse Blood (Whole) 4-methyl-octanoylcarnitine 0.000 
43 KO Mouse Blood (Whole) 2,6-dimethyl-heptanoylcarnitine 0.000 
43 KO Mouse Blood (Whole) decanoylcarnitine 0.016 
43 KO Mouse Blood (Whole) cis-4-decenoylcarnitine 0.016 
43 KO Mouse Blood (Whole) 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
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 43 KO Mouse Blood (Whole) R-3-hydroxy-decanoylcarnitine 0.002 
43 KO Mouse Blood (Whole) S-3-hydroxy-decanoylcarnitine 0.003 
43 KO Mouse Blood (Whole) 5-decynoylcarnitine 0.000 
43 KO Mouse Blood (Whole) lauroylcarnitine 0.010 
43 KO Mouse Blood (Whole) trans-2-dodecenoylcarnitine 0.000 
43 KO Mouse Blood (Whole) R-3-hydroxy-lauroylcarnitine 0.001 
43 KO Mouse Blood (Whole) S-3-hydroxy-lauroylcarnitine 0.002 
43 KO Mouse Blood (Whole) myristoylcarnitine 0.048 
43 KO Mouse Blood (Whole) myristoleoylcarnitine 0.011 
43 KO Mouse Blood (Whole) cis-5-tetradecenoylcarnitine 0.006 
43 KO Mouse Blood (Whole) trans-2-tetradecenoylcarnitine 0.001 
43 KO Mouse Blood (Whole) 
cis,cis-5,8-
tetradecadienoylcarnitine 0.006 
43 KO Mouse Blood (Whole) R-3-hydroxy-myristoylcarnitine 0.000 
43 KO Mouse Blood (Whole) S-3-hydroxy-myristoylcarnitine 0.002 
43 KO Mouse Blood (Whole) hydroxy-C14:1 0.003 
43 KO Mouse Blood (Whole) palmitoylcarnitine 0.641 
43 KO Mouse Blood (Whole) palmitoleoylcarnitine 0.028 
43 KO Mouse Blood (Whole) trans-2-hexadecenoylcarnitine 0.003 
43 KO Mouse Blood (Whole) R-3-hydroxy-palmitoylcarnitine 0.003 
43 KO Mouse Blood (Whole) S-3-hydroxy-palmitoylcarnitine 0.002 
43 KO Mouse Blood (Whole) hydroxy-C16:1 0.000 
43 KO Mouse Blood (Whole) stearoylcarnitine 0.265 
43 KO Mouse Blood (Whole) oleoylcarnitine 0.389 
43 KO Mouse Blood (Whole) linoleoylcarnitine 0.100 
43 KO Mouse Blood (Whole) alpha-linolenoylcarnitine 0.013 
43 KO Mouse Blood (Whole) gamma-linolenoylcarnitine 0.003 
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 43 KO Mouse Blood (Whole) R-3-hydroxy-stearoylcarnitine 0.007 
43 KO Mouse Blood (Whole) S-3-hydroxy-stearoylcarnitine 0.002 
43 KO Mouse Blood (Whole) hydroxy-C18:1 0.005 
43 KO Mouse Blood (Whole) hydroxy-C18:2 0.002 
43 KO Mouse Blood (Whole) hydroxy-C18:3 0.002 
43 KO Mouse Blood (Whole) malonylcarnitine 0.060 
43 KO Mouse Blood (Whole) succinylcarnitine 0.228 
43 KO Mouse Blood (Whole) methyl-malonylcarnitine 0.044 
43 KO Mouse Blood (Whole) ethyl-malonylcarnitine 0.001 
43 KO Mouse Blood (Whole) glutaroylcarnitine 0.006 
43 KO Mouse Blood (Whole) adipoylcarnitine 0.004 
43 KO Mouse Blood (Whole) 3-methyl-glutaroylcarnitine 0.001 
43 KO Mouse Blood (Whole) suberoylcarnitine 0.006 
43 KO Mouse Blood (Whole) sebacoylcarnitine 0.001 
43 KO Mouse Blood (Whole) sum_of_individual_acylcarnitines 20.753 
43 KO Mouse Blood (Whole) ratio:_sum/calculated 1.092 
70 KO Mouse Blood (Whole) total_carnitine 76.024 
70 KO Mouse Blood (Whole) free_carnitine 34.427 
70 KO Mouse Blood (Whole) calculated_acylcarnitines 41.597 
70 KO Mouse Blood (Whole) acyl/free 1.208 
70 KO Mouse Blood (Whole) butyrobetaine 3.129 
70 KO Mouse Blood (Whole) acetylcarnitine 39.835 
70 KO Mouse Blood (Whole) propionylcarnitine 1.346 
70 KO Mouse Blood (Whole) butyrylcarnitine 0.755 
70 KO Mouse Blood (Whole) isobutyrylcarnitine 0.194 
70 KO Mouse Blood (Whole) R-3-hydroxy-butyrylcarnitine 0.007 
70 KO Mouse Blood (Whole) S-3-hydroxy-butyrylcarnitine 0.046 
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 70 KO Mouse Blood (Whole) valerylcarnitine 0.016 
70 KO Mouse Blood (Whole) isovalerylcarnitine 0.261 
70 KO Mouse Blood (Whole) 3-hydroxy-isovalerylcarnitine 0.136 
70 KO Mouse Blood (Whole) 2-methyl-butyrylcarnitine 0.146 
70 KO Mouse Blood (Whole) pivaloylcarnitine 0.000 
70 KO Mouse Blood (Whole) tigloylcarnitine 0.005 
70 KO Mouse Blood (Whole) 3-methyl-crotonylcarnitine 0.000 
70 KO Mouse Blood (Whole) hexanoylcarnitine 0.018 
70 KO Mouse Blood (Whole) R-3-hydroxy-hexanoylcarnitine 0.002 
70 KO Mouse Blood (Whole) S-3-hydroxy-hexanoylcarnitine 0.001 
70 KO Mouse Blood (Whole) phenylacetylcarnitine 0.005 
70 KO Mouse Blood (Whole) phenylpropionylcarnitine 0.001 
70 KO Mouse Blood (Whole) 4-phenyl-butyrylcarnitine 0.000 
70 KO Mouse Blood (Whole) benzoylcarnitine 0.008 
70 KO Mouse Blood (Whole) 4-methyl-hexanoylcarnitine 0.001 
70 KO Mouse Blood (Whole) octanoylcarnitine 0.017 
70 KO Mouse Blood (Whole) R-3-hydroxy-octanoylcarnitine 0.001 
70 KO Mouse Blood (Whole) S-3-hydroxy-octanoylcarnitine 0.003 
70 KO Mouse Blood (Whole) valproylcarnitine 0.000 
70 KO Mouse Blood (Whole) branched-chain C8 0.000 
70 KO Mouse Blood (Whole) 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
70 KO Mouse Blood (Whole) 4-methyl-octanoylcarnitine 0.000 
70 KO Mouse Blood (Whole) 2,6-dimethyl-heptanoylcarnitine 0.000 
70 KO Mouse Blood (Whole) decanoylcarnitine 0.015 
70 KO Mouse Blood (Whole) cis-4-decenoylcarnitine 0.010 
70 KO Mouse Blood (Whole) cis-3,4-methylene- 0.000 
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 nonanoylcarnitine 
70 KO Mouse Blood (Whole) R-3-hydroxy-decanoylcarnitine 0.002 
70 KO Mouse Blood (Whole) S-3-hydroxy-decanoylcarnitine 0.005 
70 KO Mouse Blood (Whole) 5-decynoylcarnitine 0.000 
70 KO Mouse Blood (Whole) lauroylcarnitine 0.012 
70 KO Mouse Blood (Whole) trans-2-dodecenoylcarnitine 0.001 
70 KO Mouse Blood (Whole) R-3-hydroxy-lauroylcarnitine 0.002 
70 KO Mouse Blood (Whole) S-3-hydroxy-lauroylcarnitine 0.003 
70 KO Mouse Blood (Whole) myristoylcarnitine 0.053 
70 KO Mouse Blood (Whole) myristoleoylcarnitine 0.011 
70 KO Mouse Blood (Whole) cis-5-tetradecenoylcarnitine 0.010 
70 KO Mouse Blood (Whole) trans-2-tetradecenoylcarnitine 0.003 
70 KO Mouse Blood (Whole) 
cis,cis-5,8-
tetradecadienoylcarnitine 0.013 
70 KO Mouse Blood (Whole) R-3-hydroxy-myristoylcarnitine 0.000 
70 KO Mouse Blood (Whole) S-3-hydroxy-myristoylcarnitine 0.004 
70 KO Mouse Blood (Whole) hydroxy-C14:1 0.003 
70 KO Mouse Blood (Whole) palmitoylcarnitine 0.768 
70 KO Mouse Blood (Whole) palmitoleoylcarnitine 0.034 
70 KO Mouse Blood (Whole) trans-2-hexadecenoylcarnitine 0.002 
70 KO Mouse Blood (Whole) R-3-hydroxy-palmitoylcarnitine 0.001 
70 KO Mouse Blood (Whole) S-3-hydroxy-palmitoylcarnitine 0.004 
70 KO Mouse Blood (Whole) hydroxy-C16:1 0.001 
70 KO Mouse Blood (Whole) stearoylcarnitine 0.225 
70 KO Mouse Blood (Whole) oleoylcarnitine 0.325 
70 KO Mouse Blood (Whole) linoleoylcarnitine 0.114 
70 KO Mouse Blood (Whole) alpha-linolenoylcarnitine 0.021 
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 70 KO Mouse Blood (Whole) gamma-linolenoylcarnitine 0.001 
70 KO Mouse Blood (Whole) R-3-hydroxy-stearoylcarnitine 0.008 
70 KO Mouse Blood (Whole) S-3-hydroxy-stearoylcarnitine 0.001 
70 KO Mouse Blood (Whole) hydroxy-C18:1 0.008 
70 KO Mouse Blood (Whole) hydroxy-C18:2 0.002 
70 KO Mouse Blood (Whole) hydroxy-C18:3 0.002 
70 KO Mouse Blood (Whole) malonylcarnitine 0.097 
70 KO Mouse Blood (Whole) succinylcarnitine 0.348 
70 KO Mouse Blood (Whole) methyl-malonylcarnitine 0.074 
70 KO Mouse Blood (Whole) ethyl-malonylcarnitine 0.000 
70 KO Mouse Blood (Whole) glutaroylcarnitine 0.004 
70 KO Mouse Blood (Whole) adipoylcarnitine 0.006 
70 KO Mouse Blood (Whole) 3-methyl-glutaroylcarnitine 0.000 
70 KO Mouse Blood (Whole) suberoylcarnitine 0.009 
70 KO Mouse Blood (Whole) sebacoylcarnitine 0.001 
70 KO Mouse Blood (Whole) sum_of_individual_acylcarnitines 45.006 
70 KO Mouse Blood (Whole) ratio:_sum/calculated 1.082 
96 WT Mouse Blood (Whole) total_carnitine 44.086 
96 WT Mouse Blood (Whole) free_carnitine 22.989 
96 WT Mouse Blood (Whole) calculated_acylcarnitines 21.097 
96 WT Mouse Blood (Whole) acyl/free 0.918 
96 WT Mouse Blood (Whole) butyrobetaine 2.263 
96 WT Mouse Blood (Whole) acetylcarnitine 20.862 
96 WT Mouse Blood (Whole) propionylcarnitine 0.438 
96 WT Mouse Blood (Whole) butyrylcarnitine 0.228 
96 WT Mouse Blood (Whole) isobutyrylcarnitine 0.068 
96 WT Mouse Blood (Whole) R-3-hydroxy-butyrylcarnitine 0.006 
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 96 WT Mouse Blood (Whole) S-3-hydroxy-butyrylcarnitine 0.019 
96 WT Mouse Blood (Whole) valerylcarnitine 0.001 
96 WT Mouse Blood (Whole) isovalerylcarnitine 0.056 
96 WT Mouse Blood (Whole) 3-hydroxy-isovalerylcarnitine 0.063 
96 WT Mouse Blood (Whole) 2-methyl-butyrylcarnitine 0.072 
96 WT Mouse Blood (Whole) pivaloylcarnitine 0.000 
96 WT Mouse Blood (Whole) tigloylcarnitine 0.002 
96 WT Mouse Blood (Whole) 3-methyl-crotonylcarnitine 0.000 
96 WT Mouse Blood (Whole) hexanoylcarnitine 0.016 
96 WT Mouse Blood (Whole) R-3-hydroxy-hexanoylcarnitine 0.002 
96 WT Mouse Blood (Whole) S-3-hydroxy-hexanoylcarnitine 0.002 
96 WT Mouse Blood (Whole) phenylacetylcarnitine 0.001 
96 WT Mouse Blood (Whole) phenylpropionylcarnitine 0.000 
96 WT Mouse Blood (Whole) 4-phenyl-butyrylcarnitine 0.000 
96 WT Mouse Blood (Whole) benzoylcarnitine 0.002 
96 WT Mouse Blood (Whole) 4-methyl-hexanoylcarnitine 0.000 
96 WT Mouse Blood (Whole) octanoylcarnitine 0.030 
96 WT Mouse Blood (Whole) R-3-hydroxy-octanoylcarnitine 0.001 
96 WT Mouse Blood (Whole) S-3-hydroxy-octanoylcarnitine 0.004 
96 WT Mouse Blood (Whole) valproylcarnitine 0.000 
96 WT Mouse Blood (Whole) branched-chain C8 0.000 
96 WT Mouse Blood (Whole) 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
96 WT Mouse Blood (Whole) 4-methyl-octanoylcarnitine 0.000 
96 WT Mouse Blood (Whole) 2,6-dimethyl-heptanoylcarnitine 0.000 
96 WT Mouse Blood (Whole) decanoylcarnitine 0.019 
96 WT Mouse Blood (Whole) cis-4-decenoylcarnitine 0.022 
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 96 WT Mouse Blood (Whole) 
cis-3,4-methylene-
nonanoylcarnitine 0.001 
96 WT Mouse Blood (Whole) R-3-hydroxy-decanoylcarnitine 0.003 
96 WT Mouse Blood (Whole) S-3-hydroxy-decanoylcarnitine 0.005 
96 WT Mouse Blood (Whole) 5-decynoylcarnitine 0.000 
96 WT Mouse Blood (Whole) lauroylcarnitine 0.014 
96 WT Mouse Blood (Whole) trans-2-dodecenoylcarnitine 0.001 
96 WT Mouse Blood (Whole) R-3-hydroxy-lauroylcarnitine 0.001 
96 WT Mouse Blood (Whole) S-3-hydroxy-lauroylcarnitine 0.003 
96 WT Mouse Blood (Whole) myristoylcarnitine 0.060 
96 WT Mouse Blood (Whole) myristoleoylcarnitine 0.015 
96 WT Mouse Blood (Whole) cis-5-tetradecenoylcarnitine 0.011 
96 WT Mouse Blood (Whole) trans-2-tetradecenoylcarnitine 0.002 
96 WT Mouse Blood (Whole) 
cis,cis-5,8-
tetradecadienoylcarnitine 0.009 
96 WT Mouse Blood (Whole) R-3-hydroxy-myristoylcarnitine 0.000 
96 WT Mouse Blood (Whole) S-3-hydroxy-myristoylcarnitine 0.004 
96 WT Mouse Blood (Whole) hydroxy-C14:1 0.002 
96 WT Mouse Blood (Whole) palmitoylcarnitine 0.612 
96 WT Mouse Blood (Whole) palmitoleoylcarnitine 0.029 
96 WT Mouse Blood (Whole) trans-2-hexadecenoylcarnitine 0.002 
96 WT Mouse Blood (Whole) R-3-hydroxy-palmitoylcarnitine 0.001 
96 WT Mouse Blood (Whole) S-3-hydroxy-palmitoylcarnitine 0.006 
96 WT Mouse Blood (Whole) hydroxy-C16:1 0.001 
96 WT Mouse Blood (Whole) stearoylcarnitine 0.238 
96 WT Mouse Blood (Whole) oleoylcarnitine 0.325 
96 WT Mouse Blood (Whole) linoleoylcarnitine 0.101 
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 96 WT Mouse Blood (Whole) alpha-linolenoylcarnitine 0.027 
96 WT Mouse Blood (Whole) gamma-linolenoylcarnitine 0.001 
96 WT Mouse Blood (Whole) R-3-hydroxy-stearoylcarnitine 0.006 
96 WT Mouse Blood (Whole) S-3-hydroxy-stearoylcarnitine 0.001 
96 WT Mouse Blood (Whole) hydroxy-C18:1 0.007 
96 WT Mouse Blood (Whole) hydroxy-C18:2 0.001 
96 WT Mouse Blood (Whole) hydroxy-C18:3 0.002 
96 WT Mouse Blood (Whole) malonylcarnitine 0.054 
96 WT Mouse Blood (Whole) succinylcarnitine 0.303 
96 WT Mouse Blood (Whole) methyl-malonylcarnitine 0.059 
96 WT Mouse Blood (Whole) ethyl-malonylcarnitine 0.001 
96 WT Mouse Blood (Whole) glutaroylcarnitine 0.004 
96 WT Mouse Blood (Whole) adipoylcarnitine 0.005 
96 WT Mouse Blood (Whole) 3-methyl-glutaroylcarnitine 0.001 
96 WT Mouse Blood (Whole) suberoylcarnitine 0.007 
96 WT Mouse Blood (Whole) sebacoylcarnitine 0.001 
96 WT Mouse Blood (Whole) sum_of_individual_acylcarnitines 23.839 
96 WT Mouse Blood (Whole) ratio:_sum/calculated 1.130 
97 WT Mouse Blood (Whole) total_carnitine 66.228 
97 WT Mouse Blood (Whole) free_carnitine 34.389 
97 WT Mouse Blood (Whole) calculated_acylcarnitines 31.839 
97 WT Mouse Blood (Whole) acyl/free 0.926 
97 WT Mouse Blood (Whole) butyrobetaine 2.273 
97 WT Mouse Blood (Whole) acetylcarnitine 28.050 
97 WT Mouse Blood (Whole) propionylcarnitine 0.928 
97 WT Mouse Blood (Whole) butyrylcarnitine 1.067 
97 WT Mouse Blood (Whole) isobutyrylcarnitine 0.197 
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 97 WT Mouse Blood (Whole) R-3-hydroxy-butyrylcarnitine 0.010 
97 WT Mouse Blood (Whole) S-3-hydroxy-butyrylcarnitine 0.045 
97 WT Mouse Blood (Whole) valerylcarnitine 0.009 
97 WT Mouse Blood (Whole) isovalerylcarnitine 0.083 
97 WT Mouse Blood (Whole) 3-hydroxy-isovalerylcarnitine 0.077 
97 WT Mouse Blood (Whole) 2-methyl-butyrylcarnitine 0.099 
97 WT Mouse Blood (Whole) pivaloylcarnitine 0.000 
97 WT Mouse Blood (Whole) tigloylcarnitine 0.004 
97 WT Mouse Blood (Whole) 3-methyl-crotonylcarnitine 0.000 
97 WT Mouse Blood (Whole) hexanoylcarnitine 0.034 
97 WT Mouse Blood (Whole) R-3-hydroxy-hexanoylcarnitine 0.003 
97 WT Mouse Blood (Whole) S-3-hydroxy-hexanoylcarnitine 0.003 
97 WT Mouse Blood (Whole) phenylacetylcarnitine 0.004 
97 WT Mouse Blood (Whole) phenylpropionylcarnitine 0.004 
97 WT Mouse Blood (Whole) 4-phenyl-butyrylcarnitine 0.000 
97 WT Mouse Blood (Whole) benzoylcarnitine 0.003 
97 WT Mouse Blood (Whole) 4-methyl-hexanoylcarnitine 0.001 
97 WT Mouse Blood (Whole) octanoylcarnitine 0.027 
97 WT Mouse Blood (Whole) R-3-hydroxy-octanoylcarnitine 0.001 
97 WT Mouse Blood (Whole) S-3-hydroxy-octanoylcarnitine 0.005 
97 WT Mouse Blood (Whole) valproylcarnitine 0.000 
97 WT Mouse Blood (Whole) branched-chain C8 0.000 
97 WT Mouse Blood (Whole) 
cis-3,4-methylene-
heptanoylcarnitine 0.001 
97 WT Mouse Blood (Whole) 4-methyl-octanoylcarnitine 0.000 
97 WT Mouse Blood (Whole) 2,6-dimethyl-heptanoylcarnitine 0.000 
97 WT Mouse Blood (Whole) decanoylcarnitine 0.022 
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 97 WT Mouse Blood (Whole) cis-4-decenoylcarnitine 0.018 
97 WT Mouse Blood (Whole) 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
97 WT Mouse Blood (Whole) R-3-hydroxy-decanoylcarnitine 0.006 
97 WT Mouse Blood (Whole) S-3-hydroxy-decanoylcarnitine 0.011 
97 WT Mouse Blood (Whole) 5-decynoylcarnitine 0.000 
97 WT Mouse Blood (Whole) lauroylcarnitine 0.018 
97 WT Mouse Blood (Whole) trans-2-dodecenoylcarnitine 0.002 
97 WT Mouse Blood (Whole) R-3-hydroxy-lauroylcarnitine 0.002 
97 WT Mouse Blood (Whole) S-3-hydroxy-lauroylcarnitine 0.005 
97 WT Mouse Blood (Whole) myristoylcarnitine 0.069 
97 WT Mouse Blood (Whole) myristoleoylcarnitine 0.023 
97 WT Mouse Blood (Whole) cis-5-tetradecenoylcarnitine 0.020 
97 WT Mouse Blood (Whole) trans-2-tetradecenoylcarnitine 0.002 
97 WT Mouse Blood (Whole) 
cis,cis-5,8-
tetradecadienoylcarnitine 0.009 
97 WT Mouse Blood (Whole) R-3-hydroxy-myristoylcarnitine 0.002 
97 WT Mouse Blood (Whole) S-3-hydroxy-myristoylcarnitine 0.007 
97 WT Mouse Blood (Whole) hydroxy-C14:1 0.005 
97 WT Mouse Blood (Whole) palmitoylcarnitine 0.760 
97 WT Mouse Blood (Whole) palmitoleoylcarnitine 0.041 
97 WT Mouse Blood (Whole) trans-2-hexadecenoylcarnitine 0.003 
97 WT Mouse Blood (Whole) R-3-hydroxy-palmitoylcarnitine 0.002 
97 WT Mouse Blood (Whole) S-3-hydroxy-palmitoylcarnitine 0.006 
97 WT Mouse Blood (Whole) hydroxy-C16:1 0.000 
97 WT Mouse Blood (Whole) stearoylcarnitine 0.229 
97 WT Mouse Blood (Whole) oleoylcarnitine 0.399 
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 97 WT Mouse Blood (Whole) linoleoylcarnitine 0.121 
97 WT Mouse Blood (Whole) alpha-linolenoylcarnitine 0.018 
97 WT Mouse Blood (Whole) gamma-linolenoylcarnitine 0.001 
97 WT Mouse Blood (Whole) R-3-hydroxy-stearoylcarnitine 0.006 
97 WT Mouse Blood (Whole) S-3-hydroxy-stearoylcarnitine 0.003 
97 WT Mouse Blood (Whole) hydroxy-C18:1 0.011 
97 WT Mouse Blood (Whole) hydroxy-C18:2 0.002 
97 WT Mouse Blood (Whole) hydroxy-C18:3 0.002 
97 WT Mouse Blood (Whole) malonylcarnitine 0.063 
97 WT Mouse Blood (Whole) succinylcarnitine 0.356 
97 WT Mouse Blood (Whole) methyl-malonylcarnitine 0.056 
97 WT Mouse Blood (Whole) ethyl-malonylcarnitine 0.000 
97 WT Mouse Blood (Whole) glutaroylcarnitine 0.003 
97 WT Mouse Blood (Whole) adipoylcarnitine 0.005 
97 WT Mouse Blood (Whole) 3-methyl-glutaroylcarnitine 0.001 
97 WT Mouse Blood (Whole) suberoylcarnitine 0.009 
97 WT Mouse Blood (Whole) sebacoylcarnitine 0.001 
97 WT Mouse Blood (Whole) sum_of_individual_acylcarnitines 32.975 
97 WT Mouse Blood (Whole) ratio:_sum/calculated 1.036 
98 WT Mouse Blood (Whole) total_carnitine 50.582 
98 WT Mouse Blood (Whole) free_carnitine 27.491 
98 WT Mouse Blood (Whole) calculated_acylcarnitines 23.091 
98 WT Mouse Blood (Whole) acyl/free 0.840 
98 WT Mouse Blood (Whole) butyrobetaine 2.276 
98 WT Mouse Blood (Whole) acetylcarnitine 22.528 
98 WT Mouse Blood (Whole) propionylcarnitine 0.531 
98 WT Mouse Blood (Whole) butyrylcarnitine 0.341 
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 98 WT Mouse Blood (Whole) isobutyrylcarnitine 0.105 
98 WT Mouse Blood (Whole) R-3-hydroxy-butyrylcarnitine 0.005 
98 WT Mouse Blood (Whole) S-3-hydroxy-butyrylcarnitine 0.017 
98 WT Mouse Blood (Whole) valerylcarnitine 0.002 
98 WT Mouse Blood (Whole) isovalerylcarnitine 0.072 
98 WT Mouse Blood (Whole) 3-hydroxy-isovalerylcarnitine 0.067 
98 WT Mouse Blood (Whole) 2-methyl-butyrylcarnitine 0.060 
98 WT Mouse Blood (Whole) pivaloylcarnitine 0.000 
98 WT Mouse Blood (Whole) tigloylcarnitine 0.002 
98 WT Mouse Blood (Whole) 3-methyl-crotonylcarnitine 0.000 
98 WT Mouse Blood (Whole) hexanoylcarnitine 0.015 
98 WT Mouse Blood (Whole) R-3-hydroxy-hexanoylcarnitine 0.002 
98 WT Mouse Blood (Whole) S-3-hydroxy-hexanoylcarnitine 0.002 
98 WT Mouse Blood (Whole) phenylacetylcarnitine 0.000 
98 WT Mouse Blood (Whole) phenylpropionylcarnitine 0.001 
98 WT Mouse Blood (Whole) 4-phenyl-butyrylcarnitine 0.000 
98 WT Mouse Blood (Whole) benzoylcarnitine 0.003 
98 WT Mouse Blood (Whole) 4-methyl-hexanoylcarnitine 0.000 
98 WT Mouse Blood (Whole) octanoylcarnitine 0.023 
98 WT Mouse Blood (Whole) R-3-hydroxy-octanoylcarnitine 0.001 
98 WT Mouse Blood (Whole) S-3-hydroxy-octanoylcarnitine 0.004 
98 WT Mouse Blood (Whole) valproylcarnitine 0.000 
98 WT Mouse Blood (Whole) branched-chain C8 0.000 
98 WT Mouse Blood (Whole) 
cis-3,4-methylene-
heptanoylcarnitine 0.001 
98 WT Mouse Blood (Whole) 4-methyl-octanoylcarnitine 0.000 
98 WT Mouse Blood (Whole) 2,6-dimethyl-heptanoylcarnitine 0.000 
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 98 WT Mouse Blood (Whole) decanoylcarnitine 0.017 
98 WT Mouse Blood (Whole) cis-4-decenoylcarnitine 0.019 
98 WT Mouse Blood (Whole) 
cis-3,4-methylene-
nonanoylcarnitine 0.002 
98 WT Mouse Blood (Whole) R-3-hydroxy-decanoylcarnitine 0.002 
98 WT Mouse Blood (Whole) S-3-hydroxy-decanoylcarnitine 0.005 
98 WT Mouse Blood (Whole) 5-decynoylcarnitine 0.000 
98 WT Mouse Blood (Whole) lauroylcarnitine 0.016 
98 WT Mouse Blood (Whole) trans-2-dodecenoylcarnitine 0.001 
98 WT Mouse Blood (Whole) R-3-hydroxy-lauroylcarnitine 0.001 
98 WT Mouse Blood (Whole) S-3-hydroxy-lauroylcarnitine 0.003 
98 WT Mouse Blood (Whole) myristoylcarnitine 0.062 
98 WT Mouse Blood (Whole) myristoleoylcarnitine 0.011 
98 WT Mouse Blood (Whole) cis-5-tetradecenoylcarnitine 0.011 
98 WT Mouse Blood (Whole) trans-2-tetradecenoylcarnitine 0.004 
98 WT Mouse Blood (Whole) 
cis,cis-5,8-
tetradecadienoylcarnitine 0.012 
98 WT Mouse Blood (Whole) R-3-hydroxy-myristoylcarnitine 0.000 
98 WT Mouse Blood (Whole) S-3-hydroxy-myristoylcarnitine 0.001 
98 WT Mouse Blood (Whole) hydroxy-C14:1 0.002 
98 WT Mouse Blood (Whole) palmitoylcarnitine 0.715 
98 WT Mouse Blood (Whole) palmitoleoylcarnitine 0.034 
98 WT Mouse Blood (Whole) trans-2-hexadecenoylcarnitine 0.002 
98 WT Mouse Blood (Whole) R-3-hydroxy-palmitoylcarnitine 0.002 
98 WT Mouse Blood (Whole) S-3-hydroxy-palmitoylcarnitine 0.004 
98 WT Mouse Blood (Whole) hydroxy-C16:1 0.000 
98 WT Mouse Blood (Whole) stearoylcarnitine 0.276 
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 98 WT Mouse Blood (Whole) oleoylcarnitine 0.359 
98 WT Mouse Blood (Whole) linoleoylcarnitine 0.116 
98 WT Mouse Blood (Whole) alpha-linolenoylcarnitine 0.020 
98 WT Mouse Blood (Whole) gamma-linolenoylcarnitine 0.000 
98 WT Mouse Blood (Whole) R-3-hydroxy-stearoylcarnitine 0.007 
98 WT Mouse Blood (Whole) S-3-hydroxy-stearoylcarnitine 0.001 
98 WT Mouse Blood (Whole) hydroxy-C18:1 0.003 
98 WT Mouse Blood (Whole) hydroxy-C18:2 0.001 
98 WT Mouse Blood (Whole) hydroxy-C18:3 0.002 
98 WT Mouse Blood (Whole) malonylcarnitine 0.066 
98 WT Mouse Blood (Whole) succinylcarnitine 0.324 
98 WT Mouse Blood (Whole) methyl-malonylcarnitine 0.047 
98 WT Mouse Blood (Whole) ethyl-malonylcarnitine 0.001 
98 WT Mouse Blood (Whole) glutaroylcarnitine 0.003 
98 WT Mouse Blood (Whole) adipoylcarnitine 0.005 
98 WT Mouse Blood (Whole) 3-methyl-glutaroylcarnitine 0.001 
98 WT Mouse Blood (Whole) suberoylcarnitine 0.005 
98 WT Mouse Blood (Whole) sebacoylcarnitine 0.001 
98 WT Mouse Blood (Whole) sum_of_individual_acylcarnitines 25.943 
98 WT Mouse Blood (Whole) ratio:_sum/calculated 1.124 
15 KO Mouse Plasma total_carnitine 86.203 
15 KO Mouse Plasma free_carnitine 52.836 
15 KO Mouse Plasma calculated_acylcarnitines 33.368 
15 KO Mouse Plasma acyl/free 0.632 
15 KO Mouse Plasma butyrobetaine 1.413 
15 KO Mouse Plasma acetylcarnitine 31.858 
15 KO Mouse Plasma propionylcarnitine 0.633 
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 15 KO Mouse Plasma butyrylcarnitine 0.682 
15 KO Mouse Plasma isobutyrylcarnitine 0.124 
15 KO Mouse Plasma R-3-hydroxy-butyrylcarnitine 0.056 
15 KO Mouse Plasma S-3-hydroxy-butyrylcarnitine 0.121 
15 KO Mouse Plasma valerylcarnitine 0.012 
15 KO Mouse Plasma isovalerylcarnitine 0.246 
15 KO Mouse Plasma 3-hydroxy-isovalerylcarnitine 0.070 
15 KO Mouse Plasma 2-methyl-butyrylcarnitine 0.156 
15 KO Mouse Plasma pivaloylcarnitine 0.000 
15 KO Mouse Plasma tigloylcarnitine 0.004 
15 KO Mouse Plasma 3-methyl-crotonylcarnitine 0.000 
15 KO Mouse Plasma hexanoylcarnitine 0.048 
15 KO Mouse Plasma R-3-hydroxy-hexanoylcarnitine 0.004 
15 KO Mouse Plasma S-3-hydroxy-hexanoylcarnitine 0.006 
15 KO Mouse Plasma phenylacetylcarnitine 0.001 
15 KO Mouse Plasma phenylpropionylcarnitine 0.001 
15 KO Mouse Plasma 4-phenyl-butyrylcarnitine 0.000 
15 KO Mouse Plasma benzoylcarnitine 0.005 
15 KO Mouse Plasma 4-methyl-hexanoylcarnitine 0.000 
15 KO Mouse Plasma octanoylcarnitine 0.015 
15 KO Mouse Plasma R-3-hydroxy-octanoylcarnitine 0.004 
15 KO Mouse Plasma S-3-hydroxy-octanoylcarnitine 0.011 
15 KO Mouse Plasma valproylcarnitine 0.000 
15 KO Mouse Plasma branched-chain C8 0.000 
15 KO Mouse Plasma 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
15 KO Mouse Plasma 4-methyl-octanoylcarnitine 0.000 
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 15 KO Mouse Plasma 2,6-dimethyl-heptanoylcarnitine 0.000 
15 KO Mouse Plasma decanoylcarnitine 0.021 
15 KO Mouse Plasma cis-4-decenoylcarnitine 0.017 
15 KO Mouse Plasma 
cis-3,4-methylene-
nonanoylcarnitine 0.002 
15 KO Mouse Plasma R-3-hydroxy-decanoylcarnitine 0.005 
15 KO Mouse Plasma S-3-hydroxy-decanoylcarnitine 0.016 
15 KO Mouse Plasma 5-decynoylcarnitine 0.000 
15 KO Mouse Plasma lauroylcarnitine 0.023 
15 KO Mouse Plasma trans-2-dodecenoylcarnitine 0.002 
15 KO Mouse Plasma R-3-hydroxy-lauroylcarnitine 0.002 
15 KO Mouse Plasma S-3-hydroxy-lauroylcarnitine 0.005 
15 KO Mouse Plasma myristoylcarnitine 0.062 
15 KO Mouse Plasma myristoleoylcarnitine 0.027 
15 KO Mouse Plasma cis-5-tetradecenoylcarnitine 0.070 
15 KO Mouse Plasma trans-2-tetradecenoylcarnitine 0.012 
15 KO Mouse Plasma 
cis,cis-5,8-
tetradecadienoylcarnitine 0.031 
15 KO Mouse Plasma R-3-hydroxy-myristoylcarnitine 0.005 
15 KO Mouse Plasma S-3-hydroxy-myristoylcarnitine 0.006 
15 KO Mouse Plasma hydroxy-C14:1 0.013 
15 KO Mouse Plasma palmitoylcarnitine 0.182 
15 KO Mouse Plasma palmitoleoylcarnitine 0.049 
15 KO Mouse Plasma trans-2-hexadecenoylcarnitine 0.003 
15 KO Mouse Plasma R-3-hydroxy-palmitoylcarnitine 0.005 
15 KO Mouse Plasma S-3-hydroxy-palmitoylcarnitine 0.009 
15 KO Mouse Plasma hydroxy-C16:1 0.002 
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 15 KO Mouse Plasma stearoylcarnitine 0.048 
15 KO Mouse Plasma oleoylcarnitine 0.283 
15 KO Mouse Plasma linoleoylcarnitine 0.117 
15 KO Mouse Plasma alpha-linolenoylcarnitine 0.011 
15 KO Mouse Plasma gamma-linolenoylcarnitine 0.002 
15 KO Mouse Plasma R-3-hydroxy-stearoylcarnitine 0.007 
15 KO Mouse Plasma S-3-hydroxy-stearoylcarnitine 0.001 
15 KO Mouse Plasma hydroxy-C18:1 0.016 
15 KO Mouse Plasma hydroxy-C18:2 0.002 
15 KO Mouse Plasma hydroxy-C18:3 0.003 
15 KO Mouse Plasma malonylcarnitine 0.027 
15 KO Mouse Plasma succinylcarnitine 0.026 
15 KO Mouse Plasma methyl-malonylcarnitine 0.005 
15 KO Mouse Plasma ethyl-malonylcarnitine 0.000 
15 KO Mouse Plasma glutaroylcarnitine 0.001 
15 KO Mouse Plasma adipoylcarnitine 0.012 
15 KO Mouse Plasma 3-methyl-glutaroylcarnitine 0.002 
15 KO Mouse Plasma suberoylcarnitine 0.017 
15 KO Mouse Plasma sebacoylcarnitine 0.002 
15 KO Mouse Plasma sum_of_individual_acylcarnitines 35.211 
15 KO Mouse Plasma ratio:_sum/calculated 1.055 
43 KO Mouse Plasma total_carnitine 62.694 
43 KO Mouse Plasma free_carnitine 41.110 
43 KO Mouse Plasma calculated_acylcarnitines 21.584 
43 KO Mouse Plasma acyl/free 0.525 
43 KO Mouse Plasma butyrobetaine 1.204 
43 KO Mouse Plasma acetylcarnitine 19.670 
 266 
 43 KO Mouse Plasma propionylcarnitine 0.451 
43 KO Mouse Plasma butyrylcarnitine 0.455 
43 KO Mouse Plasma isobutyrylcarnitine 0.053 
43 KO Mouse Plasma R-3-hydroxy-butyrylcarnitine 0.020 
43 KO Mouse Plasma S-3-hydroxy-butyrylcarnitine 0.024 
43 KO Mouse Plasma valerylcarnitine 0.004 
43 KO Mouse Plasma isovalerylcarnitine 0.093 
43 KO Mouse Plasma 3-hydroxy-isovalerylcarnitine 0.037 
43 KO Mouse Plasma 2-methyl-butyrylcarnitine 0.060 
43 KO Mouse Plasma pivaloylcarnitine 0.000 
43 KO Mouse Plasma tigloylcarnitine 0.003 
43 KO Mouse Plasma 3-methyl-crotonylcarnitine 0.000 
43 KO Mouse Plasma hexanoylcarnitine 0.015 
43 KO Mouse Plasma R-3-hydroxy-hexanoylcarnitine 0.001 
43 KO Mouse Plasma S-3-hydroxy-hexanoylcarnitine 0.003 
43 KO Mouse Plasma phenylacetylcarnitine 0.001 
43 KO Mouse Plasma phenylpropionylcarnitine 0.001 
43 KO Mouse Plasma 4-phenyl-butyrylcarnitine 0.000 
43 KO Mouse Plasma benzoylcarnitine 0.005 
43 KO Mouse Plasma 4-methyl-hexanoylcarnitine 0.000 
43 KO Mouse Plasma octanoylcarnitine 0.005 
43 KO Mouse Plasma R-3-hydroxy-octanoylcarnitine 0.002 
43 KO Mouse Plasma S-3-hydroxy-octanoylcarnitine 0.004 
43 KO Mouse Plasma valproylcarnitine 0.000 
43 KO Mouse Plasma branched-chain C8 0.000 
43 KO Mouse Plasma 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
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 43 KO Mouse Plasma 4-methyl-octanoylcarnitine 0.000 
43 KO Mouse Plasma 2,6-dimethyl-heptanoylcarnitine 0.000 
43 KO Mouse Plasma decanoylcarnitine 0.007 
43 KO Mouse Plasma cis-4-decenoylcarnitine 0.006 
43 KO Mouse Plasma 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
43 KO Mouse Plasma R-3-hydroxy-decanoylcarnitine 0.002 
43 KO Mouse Plasma S-3-hydroxy-decanoylcarnitine 0.004 
43 KO Mouse Plasma 5-decynoylcarnitine 0.000 
43 KO Mouse Plasma lauroylcarnitine 0.005 
43 KO Mouse Plasma trans-2-dodecenoylcarnitine 0.000 
43 KO Mouse Plasma R-3-hydroxy-lauroylcarnitine 0.000 
43 KO Mouse Plasma S-3-hydroxy-lauroylcarnitine 0.001 
43 KO Mouse Plasma myristoylcarnitine 0.024 
43 KO Mouse Plasma myristoleoylcarnitine 0.015 
43 KO Mouse Plasma cis-5-tetradecenoylcarnitine 0.008 
43 KO Mouse Plasma trans-2-tetradecenoylcarnitine 0.001 
43 KO Mouse Plasma 
cis,cis-5,8-
tetradecadienoylcarnitine 0.010 
43 KO Mouse Plasma R-3-hydroxy-myristoylcarnitine 0.000 
43 KO Mouse Plasma S-3-hydroxy-myristoylcarnitine 0.003 
43 KO Mouse Plasma hydroxy-C14:1 0.003 
43 KO Mouse Plasma palmitoylcarnitine 0.122 
43 KO Mouse Plasma palmitoleoylcarnitine 0.014 
43 KO Mouse Plasma trans-2-hexadecenoylcarnitine 0.002 
43 KO Mouse Plasma R-3-hydroxy-palmitoylcarnitine 0.001 
43 KO Mouse Plasma S-3-hydroxy-palmitoylcarnitine 0.003 
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 43 KO Mouse Plasma hydroxy-C16:1 0.001 
43 KO Mouse Plasma stearoylcarnitine 0.052 
43 KO Mouse Plasma oleoylcarnitine 0.138 
43 KO Mouse Plasma linoleoylcarnitine 0.059 
43 KO Mouse Plasma alpha-linolenoylcarnitine 0.002 
43 KO Mouse Plasma gamma-linolenoylcarnitine 0.001 
43 KO Mouse Plasma R-3-hydroxy-stearoylcarnitine 0.006 
43 KO Mouse Plasma S-3-hydroxy-stearoylcarnitine 0.001 
43 KO Mouse Plasma hydroxy-C18:1 0.008 
43 KO Mouse Plasma hydroxy-C18:2 0.001 
43 KO Mouse Plasma hydroxy-C18:3 0.001 
43 KO Mouse Plasma malonylcarnitine 0.013 
43 KO Mouse Plasma succinylcarnitine 0.009 
43 KO Mouse Plasma methyl-malonylcarnitine 0.003 
43 KO Mouse Plasma ethyl-malonylcarnitine 0.000 
43 KO Mouse Plasma glutaroylcarnitine 0.001 
43 KO Mouse Plasma adipoylcarnitine 0.009 
43 KO Mouse Plasma 3-methyl-glutaroylcarnitine 0.000 
43 KO Mouse Plasma suberoylcarnitine 0.008 
43 KO Mouse Plasma sebacoylcarnitine 0.001 
43 KO Mouse Plasma sum_of_individual_acylcarnitines 21.455 
43 KO Mouse Plasma ratio:_sum/calculated 0.994 
70 KO Mouse Plasma total_carnitine 115.697 
70 KO Mouse Plasma free_carnitine 33.199 
70 KO Mouse Plasma calculated_acylcarnitines 82.498 
70 KO Mouse Plasma acyl/free 2.485 
70 KO Mouse Plasma butyrobetaine 0.395 
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 70 KO Mouse Plasma acetylcarnitine 47.872 
70 KO Mouse Plasma propionylcarnitine 2.576 
70 KO Mouse Plasma butyrylcarnitine 1.501 
70 KO Mouse Plasma isobutyrylcarnitine 0.313 
70 KO Mouse Plasma R-3-hydroxy-butyrylcarnitine 0.060 
70 KO Mouse Plasma S-3-hydroxy-butyrylcarnitine 0.256 
70 KO Mouse Plasma valerylcarnitine 0.049 
70 KO Mouse Plasma isovalerylcarnitine 0.509 
70 KO Mouse Plasma 3-hydroxy-isovalerylcarnitine 0.187 
70 KO Mouse Plasma 2-methyl-butyrylcarnitine 0.272 
70 KO Mouse Plasma pivaloylcarnitine 0.000 
70 KO Mouse Plasma tigloylcarnitine 0.011 
70 KO Mouse Plasma 3-methyl-crotonylcarnitine 0.001 
70 KO Mouse Plasma hexanoylcarnitine 0.061 
70 KO Mouse Plasma R-3-hydroxy-hexanoylcarnitine 0.003 
70 KO Mouse Plasma S-3-hydroxy-hexanoylcarnitine 0.004 
70 KO Mouse Plasma phenylacetylcarnitine 0.012 
70 KO Mouse Plasma phenylpropionylcarnitine 0.004 
70 KO Mouse Plasma 4-phenyl-butyrylcarnitine 0.000 
70 KO Mouse Plasma benzoylcarnitine 0.026 
70 KO Mouse Plasma 4-methyl-hexanoylcarnitine 0.001 
70 KO Mouse Plasma octanoylcarnitine 0.016 
70 KO Mouse Plasma R-3-hydroxy-octanoylcarnitine 0.003 
70 KO Mouse Plasma S-3-hydroxy-octanoylcarnitine 0.008 
70 KO Mouse Plasma valproylcarnitine 0.000 
70 KO Mouse Plasma branched-chain C8 0.000 
70 KO Mouse Plasma cis-3,4-methylene- 0.001 
 270 
 heptanoylcarnitine 
70 KO Mouse Plasma 4-methyl-octanoylcarnitine 0.000 
70 KO Mouse Plasma 2,6-dimethyl-heptanoylcarnitine 0.000 
70 KO Mouse Plasma decanoylcarnitine 0.018 
70 KO Mouse Plasma cis-4-decenoylcarnitine 0.010 
70 KO Mouse Plasma 
cis-3,4-methylene-
nonanoylcarnitine 0.001 
70 KO Mouse Plasma R-3-hydroxy-decanoylcarnitine 0.003 
70 KO Mouse Plasma S-3-hydroxy-decanoylcarnitine 0.010 
70 KO Mouse Plasma 5-decynoylcarnitine 0.000 
70 KO Mouse Plasma lauroylcarnitine 0.025 
70 KO Mouse Plasma trans-2-dodecenoylcarnitine 0.003 
70 KO Mouse Plasma R-3-hydroxy-lauroylcarnitine 0.001 
70 KO Mouse Plasma S-3-hydroxy-lauroylcarnitine 0.004 
70 KO Mouse Plasma myristoylcarnitine 0.048 
70 KO Mouse Plasma myristoleoylcarnitine 0.020 
70 KO Mouse Plasma cis-5-tetradecenoylcarnitine 0.030 
70 KO Mouse Plasma trans-2-tetradecenoylcarnitine 0.006 
70 KO Mouse Plasma 
cis,cis-5,8-
tetradecadienoylcarnitine 0.025 
70 KO Mouse Plasma R-3-hydroxy-myristoylcarnitine 0.002 
70 KO Mouse Plasma S-3-hydroxy-myristoylcarnitine 0.008 
70 KO Mouse Plasma hydroxy-C14:1 0.007 
70 KO Mouse Plasma palmitoylcarnitine 0.158 
70 KO Mouse Plasma palmitoleoylcarnitine 0.027 
70 KO Mouse Plasma trans-2-hexadecenoylcarnitine 0.002 
70 KO Mouse Plasma R-3-hydroxy-palmitoylcarnitine 0.001 
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 70 KO Mouse Plasma S-3-hydroxy-palmitoylcarnitine 0.005 
70 KO Mouse Plasma hydroxy-C16:1 0.001 
70 KO Mouse Plasma stearoylcarnitine 0.032 
70 KO Mouse Plasma oleoylcarnitine 0.125 
70 KO Mouse Plasma linoleoylcarnitine 0.091 
70 KO Mouse Plasma alpha-linolenoylcarnitine 0.009 
70 KO Mouse Plasma gamma-linolenoylcarnitine 0.001 
70 KO Mouse Plasma R-3-hydroxy-stearoylcarnitine 0.006 
70 KO Mouse Plasma S-3-hydroxy-stearoylcarnitine 0.001 
70 KO Mouse Plasma hydroxy-C18:1 0.007 
70 KO Mouse Plasma hydroxy-C18:2 0.001 
70 KO Mouse Plasma hydroxy-C18:3 0.002 
70 KO Mouse Plasma malonylcarnitine 0.035 
70 KO Mouse Plasma succinylcarnitine 0.024 
70 KO Mouse Plasma methyl-malonylcarnitine 0.005 
70 KO Mouse Plasma ethyl-malonylcarnitine 0.000 
70 KO Mouse Plasma glutaroylcarnitine 0.012 
70 KO Mouse Plasma adipoylcarnitine 0.019 
70 KO Mouse Plasma 3-methyl-glutaroylcarnitine 0.003 
70 KO Mouse Plasma suberoylcarnitine 0.021 
70 KO Mouse Plasma sebacoylcarnitine 0.003 
70 KO Mouse Plasma sum_of_individual_acylcarnitines 54.557 
70 KO Mouse Plasma ratio:_sum/calculated 0.661 
96 WT Mouse Plasma total_carnitine 65.675 
96 WT Mouse Plasma free_carnitine 47.432 
96 WT Mouse Plasma calculated_acylcarnitines 18.243 
96 WT Mouse Plasma acyl/free 0.385 
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 96 WT Mouse Plasma butyrobetaine 0.829 
96 WT Mouse Plasma acetylcarnitine 23.878 
96 WT Mouse Plasma propionylcarnitine 0.779 
96 WT Mouse Plasma butyrylcarnitine 0.649 
96 WT Mouse Plasma isobutyrylcarnitine 0.107 
96 WT Mouse Plasma R-3-hydroxy-butyrylcarnitine 0.047 
96 WT Mouse Plasma S-3-hydroxy-butyrylcarnitine 0.077 
96 WT Mouse Plasma valerylcarnitine 0.007 
96 WT Mouse Plasma isovalerylcarnitine 0.091 
96 WT Mouse Plasma 3-hydroxy-isovalerylcarnitine 0.059 
96 WT Mouse Plasma 2-methyl-butyrylcarnitine 0.107 
96 WT Mouse Plasma pivaloylcarnitine 0.000 
96 WT Mouse Plasma tigloylcarnitine 0.006 
96 WT Mouse Plasma 3-methyl-crotonylcarnitine 0.000 
96 WT Mouse Plasma hexanoylcarnitine 0.032 
96 WT Mouse Plasma R-3-hydroxy-hexanoylcarnitine 0.002 
96 WT Mouse Plasma S-3-hydroxy-hexanoylcarnitine 0.004 
96 WT Mouse Plasma phenylacetylcarnitine 0.002 
96 WT Mouse Plasma phenylpropionylcarnitine 0.003 
96 WT Mouse Plasma 4-phenyl-butyrylcarnitine 0.000 
96 WT Mouse Plasma benzoylcarnitine 0.008 
96 WT Mouse Plasma 4-methyl-hexanoylcarnitine 0.000 
96 WT Mouse Plasma octanoylcarnitine 0.010 
96 WT Mouse Plasma R-3-hydroxy-octanoylcarnitine 0.003 
96 WT Mouse Plasma S-3-hydroxy-octanoylcarnitine 0.008 
96 WT Mouse Plasma valproylcarnitine 0.000 
96 WT Mouse Plasma branched-chain C8 0.000 
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 96 WT Mouse Plasma 
cis-3,4-methylene-
heptanoylcarnitine 0.001 
96 WT Mouse Plasma 4-methyl-octanoylcarnitine 0.000 
96 WT Mouse Plasma 2,6-dimethyl-heptanoylcarnitine 0.000 
96 WT Mouse Plasma decanoylcarnitine 0.015 
96 WT Mouse Plasma cis-4-decenoylcarnitine 0.010 
96 WT Mouse Plasma 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
96 WT Mouse Plasma R-3-hydroxy-decanoylcarnitine 0.002 
96 WT Mouse Plasma S-3-hydroxy-decanoylcarnitine 0.010 
96 WT Mouse Plasma 5-decynoylcarnitine 0.000 
96 WT Mouse Plasma lauroylcarnitine 0.019 
96 WT Mouse Plasma trans-2-dodecenoylcarnitine 0.001 
96 WT Mouse Plasma R-3-hydroxy-lauroylcarnitine 0.001 
96 WT Mouse Plasma S-3-hydroxy-lauroylcarnitine 0.003 
96 WT Mouse Plasma myristoylcarnitine 0.042 
96 WT Mouse Plasma myristoleoylcarnitine 0.021 
96 WT Mouse Plasma cis-5-tetradecenoylcarnitine 0.035 
96 WT Mouse Plasma trans-2-tetradecenoylcarnitine 0.009 
96 WT Mouse Plasma 
cis,cis-5,8-
tetradecadienoylcarnitine 0.025 
96 WT Mouse Plasma R-3-hydroxy-myristoylcarnitine 0.002 
96 WT Mouse Plasma S-3-hydroxy-myristoylcarnitine 0.011 
96 WT Mouse Plasma hydroxy-C14:1 0.005 
96 WT Mouse Plasma palmitoylcarnitine 0.160 
96 WT Mouse Plasma palmitoleoylcarnitine 0.026 
96 WT Mouse Plasma trans-2-hexadecenoylcarnitine 0.003 
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 96 WT Mouse Plasma R-3-hydroxy-palmitoylcarnitine 0.003 
96 WT Mouse Plasma S-3-hydroxy-palmitoylcarnitine 0.006 
96 WT Mouse Plasma hydroxy-C16:1 0.001 
96 WT Mouse Plasma stearoylcarnitine 0.045 
96 WT Mouse Plasma oleoylcarnitine 0.182 
96 WT Mouse Plasma linoleoylcarnitine 0.086 
96 WT Mouse Plasma alpha-linolenoylcarnitine 0.007 
96 WT Mouse Plasma gamma-linolenoylcarnitine 0.001 
96 WT Mouse Plasma R-3-hydroxy-stearoylcarnitine 0.007 
96 WT Mouse Plasma S-3-hydroxy-stearoylcarnitine 0.001 
96 WT Mouse Plasma hydroxy-C18:1 0.007 
96 WT Mouse Plasma hydroxy-C18:2 0.001 
96 WT Mouse Plasma hydroxy-C18:3 0.002 
96 WT Mouse Plasma malonylcarnitine 0.018 
96 WT Mouse Plasma succinylcarnitine 0.022 
96 WT Mouse Plasma methyl-malonylcarnitine 0.005 
96 WT Mouse Plasma ethyl-malonylcarnitine 0.000 
96 WT Mouse Plasma glutaroylcarnitine 0.010 
96 WT Mouse Plasma adipoylcarnitine 0.013 
96 WT Mouse Plasma 3-methyl-glutaroylcarnitine 0.001 
96 WT Mouse Plasma suberoylcarnitine 0.013 
96 WT Mouse Plasma sebacoylcarnitine 0.002 
96 WT Mouse Plasma sum_of_individual_acylcarnitines 26.717 
96 WT Mouse Plasma ratio:_sum/calculated 1.464 
97 WT Mouse Plasma total_carnitine 92.469 
97 WT Mouse Plasma free_carnitine 55.174 
97 WT Mouse Plasma calculated_acylcarnitines 37.296 
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 97 WT Mouse Plasma acyl/free 0.676 
97 WT Mouse Plasma butyrobetaine 1.440 
97 WT Mouse Plasma acetylcarnitine 33.390 
97 WT Mouse Plasma propionylcarnitine 1.601 
97 WT Mouse Plasma butyrylcarnitine 2.621 
97 WT Mouse Plasma isobutyrylcarnitine 0.277 
97 WT Mouse Plasma R-3-hydroxy-butyrylcarnitine 0.078 
97 WT Mouse Plasma S-3-hydroxy-butyrylcarnitine 0.159 
97 WT Mouse Plasma valerylcarnitine 0.046 
97 WT Mouse Plasma isovalerylcarnitine 0.150 
97 WT Mouse Plasma 3-hydroxy-isovalerylcarnitine 0.080 
97 WT Mouse Plasma 2-methyl-butyrylcarnitine 0.150 
97 WT Mouse Plasma pivaloylcarnitine 0.000 
97 WT Mouse Plasma tigloylcarnitine 0.008 
97 WT Mouse Plasma 3-methyl-crotonylcarnitine 0.001 
97 WT Mouse Plasma hexanoylcarnitine 0.121 
97 WT Mouse Plasma R-3-hydroxy-hexanoylcarnitine 0.003 
97 WT Mouse Plasma S-3-hydroxy-hexanoylcarnitine 0.007 
97 WT Mouse Plasma phenylacetylcarnitine 0.010 
97 WT Mouse Plasma phenylpropionylcarnitine 0.022 
97 WT Mouse Plasma 4-phenyl-butyrylcarnitine 0.000 
97 WT Mouse Plasma benzoylcarnitine 0.009 
97 WT Mouse Plasma 4-methyl-hexanoylcarnitine 0.001 
97 WT Mouse Plasma octanoylcarnitine 0.015 
97 WT Mouse Plasma R-3-hydroxy-octanoylcarnitine 0.004 
97 WT Mouse Plasma S-3-hydroxy-octanoylcarnitine 0.010 
97 WT Mouse Plasma valproylcarnitine 0.000 
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 97 WT Mouse Plasma branched-chain C8 0.000 
97 WT Mouse Plasma 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
97 WT Mouse Plasma 4-methyl-octanoylcarnitine 0.000 
97 WT Mouse Plasma 2,6-dimethyl-heptanoylcarnitine 0.000 
97 WT Mouse Plasma decanoylcarnitine 0.014 
97 WT Mouse Plasma cis-4-decenoylcarnitine 0.009 
97 WT Mouse Plasma 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
97 WT Mouse Plasma R-3-hydroxy-decanoylcarnitine 0.004 
97 WT Mouse Plasma S-3-hydroxy-decanoylcarnitine 0.014 
97 WT Mouse Plasma 5-decynoylcarnitine 0.000 
97 WT Mouse Plasma lauroylcarnitine 0.014 
97 WT Mouse Plasma trans-2-dodecenoylcarnitine 0.002 
97 WT Mouse Plasma R-3-hydroxy-lauroylcarnitine 0.001 
97 WT Mouse Plasma S-3-hydroxy-lauroylcarnitine 0.004 
97 WT Mouse Plasma myristoylcarnitine 0.041 
97 WT Mouse Plasma myristoleoylcarnitine 0.022 
97 WT Mouse Plasma cis-5-tetradecenoylcarnitine 0.025 
97 WT Mouse Plasma trans-2-tetradecenoylcarnitine 0.002 
97 WT Mouse Plasma 
cis,cis-5,8-
tetradecadienoylcarnitine 0.015 
97 WT Mouse Plasma R-3-hydroxy-myristoylcarnitine 0.004 
97 WT Mouse Plasma S-3-hydroxy-myristoylcarnitine 0.007 
97 WT Mouse Plasma hydroxy-C14:1 0.008 
97 WT Mouse Plasma palmitoylcarnitine 0.134 
97 WT Mouse Plasma palmitoleoylcarnitine 0.029 
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 97 WT Mouse Plasma trans-2-hexadecenoylcarnitine 0.002 
97 WT Mouse Plasma R-3-hydroxy-palmitoylcarnitine 0.003 
97 WT Mouse Plasma S-3-hydroxy-palmitoylcarnitine 0.005 
97 WT Mouse Plasma hydroxy-C16:1 0.002 
97 WT Mouse Plasma stearoylcarnitine 0.029 
97 WT Mouse Plasma oleoylcarnitine 0.125 
97 WT Mouse Plasma linoleoylcarnitine 0.054 
97 WT Mouse Plasma alpha-linolenoylcarnitine 0.003 
97 WT Mouse Plasma gamma-linolenoylcarnitine 0.002 
97 WT Mouse Plasma R-3-hydroxy-stearoylcarnitine 0.006 
97 WT Mouse Plasma S-3-hydroxy-stearoylcarnitine 0.001 
97 WT Mouse Plasma hydroxy-C18:1 0.008 
97 WT Mouse Plasma hydroxy-C18:2 0.003 
97 WT Mouse Plasma hydroxy-C18:3 0.003 
97 WT Mouse Plasma malonylcarnitine 0.041 
97 WT Mouse Plasma succinylcarnitine 0.027 
97 WT Mouse Plasma methyl-malonylcarnitine 0.004 
97 WT Mouse Plasma ethyl-malonylcarnitine 0.000 
97 WT Mouse Plasma glutaroylcarnitine 0.007 
97 WT Mouse Plasma adipoylcarnitine 0.015 
97 WT Mouse Plasma 3-methyl-glutaroylcarnitine 0.001 
97 WT Mouse Plasma suberoylcarnitine 0.019 
97 WT Mouse Plasma sebacoylcarnitine 0.003 
97 WT Mouse Plasma sum_of_individual_acylcarnitines 39.471 
97 WT Mouse Plasma ratio:_sum/calculated 1.058 
98 WT Mouse Plasma total_carnitine 81.297 
98 WT Mouse Plasma free_carnitine 49.917 
 278 
 98 WT Mouse Plasma calculated_acylcarnitines 31.381 
98 WT Mouse Plasma acyl/free 0.629 
98 WT Mouse Plasma butyrobetaine 1.603 
98 WT Mouse Plasma acetylcarnitine 28.897 
98 WT Mouse Plasma propionylcarnitine 0.842 
98 WT Mouse Plasma butyrylcarnitine 0.731 
98 WT Mouse Plasma isobutyrylcarnitine 0.154 
98 WT Mouse Plasma R-3-hydroxy-butyrylcarnitine 0.065 
98 WT Mouse Plasma S-3-hydroxy-butyrylcarnitine 0.141 
98 WT Mouse Plasma valerylcarnitine 0.013 
98 WT Mouse Plasma isovalerylcarnitine 0.100 
98 WT Mouse Plasma 3-hydroxy-isovalerylcarnitine 0.077 
98 WT Mouse Plasma 2-methyl-butyrylcarnitine 0.092 
98 WT Mouse Plasma pivaloylcarnitine 0.000 
98 WT Mouse Plasma tigloylcarnitine 0.005 
98 WT Mouse Plasma 3-methyl-crotonylcarnitine 0.000 
98 WT Mouse Plasma hexanoylcarnitine 0.046 
98 WT Mouse Plasma R-3-hydroxy-hexanoylcarnitine 0.003 
98 WT Mouse Plasma S-3-hydroxy-hexanoylcarnitine 0.006 
98 WT Mouse Plasma phenylacetylcarnitine 0.001 
98 WT Mouse Plasma phenylpropionylcarnitine 0.003 
98 WT Mouse Plasma 4-phenyl-butyrylcarnitine 0.000 
98 WT Mouse Plasma benzoylcarnitine 0.007 
98 WT Mouse Plasma 4-methyl-hexanoylcarnitine 0.001 
98 WT Mouse Plasma octanoylcarnitine 0.013 
98 WT Mouse Plasma R-3-hydroxy-octanoylcarnitine 0.002 
98 WT Mouse Plasma S-3-hydroxy-octanoylcarnitine 0.008 
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 98 WT Mouse Plasma valproylcarnitine 0.000 
98 WT Mouse Plasma branched-chain C8 0.000 
98 WT Mouse Plasma 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
98 WT Mouse Plasma 4-methyl-octanoylcarnitine 0.000 
98 WT Mouse Plasma 2,6-dimethyl-heptanoylcarnitine 0.000 
98 WT Mouse Plasma decanoylcarnitine 0.019 
98 WT Mouse Plasma cis-4-decenoylcarnitine 0.011 
98 WT Mouse Plasma 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
98 WT Mouse Plasma R-3-hydroxy-decanoylcarnitine 0.002 
98 WT Mouse Plasma S-3-hydroxy-decanoylcarnitine 0.010 
98 WT Mouse Plasma 5-decynoylcarnitine 0.000 
98 WT Mouse Plasma lauroylcarnitine 0.024 
98 WT Mouse Plasma trans-2-dodecenoylcarnitine 0.002 
98 WT Mouse Plasma R-3-hydroxy-lauroylcarnitine 0.001 
98 WT Mouse Plasma S-3-hydroxy-lauroylcarnitine 0.004 
98 WT Mouse Plasma myristoylcarnitine 0.076 
98 WT Mouse Plasma myristoleoylcarnitine 0.021 
98 WT Mouse Plasma cis-5-tetradecenoylcarnitine 0.045 
98 WT Mouse Plasma trans-2-tetradecenoylcarnitine 0.008 
98 WT Mouse Plasma 
cis,cis-5,8-
tetradecadienoylcarnitine 0.021 
98 WT Mouse Plasma R-3-hydroxy-myristoylcarnitine 0.003 
98 WT Mouse Plasma S-3-hydroxy-myristoylcarnitine 0.008 
98 WT Mouse Plasma hydroxy-C14:1 0.008 
98 WT Mouse Plasma palmitoylcarnitine 0.177 
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 98 WT Mouse Plasma palmitoleoylcarnitine 0.047 
98 WT Mouse Plasma trans-2-hexadecenoylcarnitine 0.003 
98 WT Mouse Plasma R-3-hydroxy-palmitoylcarnitine 0.003 
98 WT Mouse Plasma S-3-hydroxy-palmitoylcarnitine 0.006 
98 WT Mouse Plasma hydroxy-C16:1 0.001 
98 WT Mouse Plasma stearoylcarnitine 0.044 
98 WT Mouse Plasma oleoylcarnitine 0.192 
98 WT Mouse Plasma linoleoylcarnitine 0.092 
98 WT Mouse Plasma alpha-linolenoylcarnitine 0.007 
98 WT Mouse Plasma gamma-linolenoylcarnitine 0.003 
98 WT Mouse Plasma R-3-hydroxy-stearoylcarnitine 0.006 
98 WT Mouse Plasma S-3-hydroxy-stearoylcarnitine 0.001 
98 WT Mouse Plasma hydroxy-C18:1 0.012 
98 WT Mouse Plasma hydroxy-C18:2 0.004 
98 WT Mouse Plasma hydroxy-C18:3 0.001 
98 WT Mouse Plasma malonylcarnitine 0.048 
98 WT Mouse Plasma succinylcarnitine 0.067 
98 WT Mouse Plasma methyl-malonylcarnitine 0.009 
98 WT Mouse Plasma ethyl-malonylcarnitine 0.000 
98 WT Mouse Plasma glutaroylcarnitine 0.009 
98 WT Mouse Plasma adipoylcarnitine 0.013 
98 WT Mouse Plasma 3-methyl-glutaroylcarnitine 0.001 
98 WT Mouse Plasma suberoylcarnitine 0.012 
98 WT Mouse Plasma sebacoylcarnitine 0.001 
98 WT Mouse Plasma sum_of_individual_acylcarnitines 32.231 
98 WT Mouse Plasma ratio:_sum/calculated 1.027 
15 KO Mouse Urine total_carnitine 737.740 
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 15 KO Mouse Urine free_carnitine 598.817 
15 KO Mouse Urine calculated_acylcarnitines 138.923 
15 KO Mouse Urine acyl/free 0.232 
15 KO Mouse Urine butyrobetaine 24.060 
15 KO Mouse Urine acetylcarnitine 36.318 
15 KO Mouse Urine propionylcarnitine 0.626 
15 KO Mouse Urine butyrylcarnitine 0.806 
15 KO Mouse Urine isobutyrylcarnitine 0.124 
15 KO Mouse Urine R-3-hydroxy-butyrylcarnitine 0.012 
15 KO Mouse Urine S-3-hydroxy-butyrylcarnitine 0.064 
15 KO Mouse Urine valerylcarnitine 0.012 
15 KO Mouse Urine isovalerylcarnitine 0.160 
15 KO Mouse Urine 3-hydroxy-isovalerylcarnitine 0.806 
15 KO Mouse Urine 2-methyl-butyrylcarnitine 0.105 
15 KO Mouse Urine pivaloylcarnitine 0.000 
15 KO Mouse Urine tigloylcarnitine 0.015 
15 KO Mouse Urine 3-methyl-crotonylcarnitine 0.001 
15 KO Mouse Urine hexanoylcarnitine 0.041 
15 KO Mouse Urine R-3-hydroxy-hexanoylcarnitine 0.027 
15 KO Mouse Urine S-3-hydroxy-hexanoylcarnitine 0.016 
15 KO Mouse Urine phenylacetylcarnitine 0.002 
15 KO Mouse Urine phenylpropionylcarnitine 0.001 
15 KO Mouse Urine 4-phenyl-butyrylcarnitine 0.000 
15 KO Mouse Urine benzoylcarnitine 0.208 
15 KO Mouse Urine 4-methyl-hexanoylcarnitine 0.001 
15 KO Mouse Urine octanoylcarnitine 0.027 
15 KO Mouse Urine R-3-hydroxy-octanoylcarnitine 0.005 
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 15 KO Mouse Urine S-3-hydroxy-octanoylcarnitine 0.008 
15 KO Mouse Urine valproylcarnitine 0.000 
15 KO Mouse Urine branched-chain C8 0.000 
15 KO Mouse Urine 
cis-3,4-methylene-
heptanoylcarnitine 0.018 
15 KO Mouse Urine 4-methyl-octanoylcarnitine 0.000 
15 KO Mouse Urine 2,6-dimethyl-heptanoylcarnitine 0.002 
15 KO Mouse Urine decanoylcarnitine 0.012 
15 KO Mouse Urine cis-4-decenoylcarnitine 0.020 
15 KO Mouse Urine 
cis-3,4-methylene-
nonanoylcarnitine 0.071 
15 KO Mouse Urine R-3-hydroxy-decanoylcarnitine 0.001 
15 KO Mouse Urine S-3-hydroxy-decanoylcarnitine 0.007 
15 KO Mouse Urine 5-decynoylcarnitine 0.007 
15 KO Mouse Urine malonylcarnitine 6.734 
15 KO Mouse Urine succinylcarnitine 5.151 
15 KO Mouse Urine methyl-malonylcarnitine 2.365 
15 KO Mouse Urine ethyl-malonylcarnitine 0.034 
15 KO Mouse Urine glutaroylcarnitine 3.770 
15 KO Mouse Urine adipoylcarnitine 3.375 
15 KO Mouse Urine 3-methyl-glutaroylcarnitine 0.526 
15 KO Mouse Urine suberoylcarnitine 2.226 
15 KO Mouse Urine sebacoylcarnitine 0.483 
15 KO Mouse Urine sum_of_individual_acylcarnitines 64.198 
15 KO Mouse Urine ratio:_sum/calculated 0.462 
43 KO Mouse Urine total_carnitine 718.844 
43 KO Mouse Urine free_carnitine 560.265 
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 43 KO Mouse Urine calculated_acylcarnitines 158.579 
43 KO Mouse Urine acyl/free 0.283 
43 KO Mouse Urine butyrobetaine 32.649 
43 KO Mouse Urine acetylcarnitine 32.911 
43 KO Mouse Urine propionylcarnitine 0.546 
43 KO Mouse Urine butyrylcarnitine 0.995 
43 KO Mouse Urine isobutyrylcarnitine 0.161 
43 KO Mouse Urine R-3-hydroxy-butyrylcarnitine 0.047 
43 KO Mouse Urine S-3-hydroxy-butyrylcarnitine 0.092 
43 KO Mouse Urine valerylcarnitine 0.017 
43 KO Mouse Urine isovalerylcarnitine 0.060 
43 KO Mouse Urine 3-hydroxy-isovalerylcarnitine 0.926 
43 KO Mouse Urine 2-methyl-butyrylcarnitine 0.090 
43 KO Mouse Urine pivaloylcarnitine 0.000 
43 KO Mouse Urine tigloylcarnitine 0.015 
43 KO Mouse Urine 3-methyl-crotonylcarnitine 0.001 
43 KO Mouse Urine hexanoylcarnitine 0.057 
43 KO Mouse Urine R-3-hydroxy-hexanoylcarnitine 0.018 
43 KO Mouse Urine S-3-hydroxy-hexanoylcarnitine 0.019 
43 KO Mouse Urine phenylacetylcarnitine 0.002 
43 KO Mouse Urine phenylpropionylcarnitine 0.001 
43 KO Mouse Urine 4-phenyl-butyrylcarnitine 0.000 
43 KO Mouse Urine benzoylcarnitine 0.218 
43 KO Mouse Urine 4-methyl-hexanoylcarnitine 0.002 
43 KO Mouse Urine octanoylcarnitine 0.041 
43 KO Mouse Urine R-3-hydroxy-octanoylcarnitine 0.003 
43 KO Mouse Urine S-3-hydroxy-octanoylcarnitine 0.003 
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 43 KO Mouse Urine valproylcarnitine 0.000 
43 KO Mouse Urine branched-chain C8 0.000 
43 KO Mouse Urine 
cis-3,4-methylene-
heptanoylcarnitine 0.034 
43 KO Mouse Urine 4-methyl-octanoylcarnitine 0.002 
43 KO Mouse Urine 2,6-dimethyl-heptanoylcarnitine 0.001 
43 KO Mouse Urine decanoylcarnitine 0.022 
43 KO Mouse Urine cis-4-decenoylcarnitine 0.042 
43 KO Mouse Urine 
cis-3,4-methylene-
nonanoylcarnitine 0.081 
43 KO Mouse Urine R-3-hydroxy-decanoylcarnitine 0.002 
43 KO Mouse Urine S-3-hydroxy-decanoylcarnitine 0.002 
43 KO Mouse Urine 5-decynoylcarnitine 0.019 
43 KO Mouse Urine malonylcarnitine 5.713 
43 KO Mouse Urine succinylcarnitine 3.732 
43 KO Mouse Urine methyl-malonylcarnitine 1.286 
43 KO Mouse Urine ethyl-malonylcarnitine 0.013 
43 KO Mouse Urine glutaroylcarnitine 2.969 
43 KO Mouse Urine adipoylcarnitine 2.680 
43 KO Mouse Urine 3-methyl-glutaroylcarnitine 0.164 
43 KO Mouse Urine suberoylcarnitine 1.136 
43 KO Mouse Urine sebacoylcarnitine 0.196 
43 KO Mouse Urine sum_of_individual_acylcarnitines 54.365 
43 KO Mouse Urine ratio:_sum/calculated 0.343 
70 KO Mouse Urine total_carnitine 248.932 
70 KO Mouse Urine free_carnitine 173.427 
70 KO Mouse Urine calculated_acylcarnitines 75.505 
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 70 KO Mouse Urine acyl/free 0.435 
70 KO Mouse Urine butyrobetaine 6.135 
70 KO Mouse Urine acetylcarnitine 10.753 
70 KO Mouse Urine propionylcarnitine 0.329 
70 KO Mouse Urine butyrylcarnitine 0.245 
70 KO Mouse Urine isobutyrylcarnitine 0.183 
70 KO Mouse Urine R-3-hydroxy-butyrylcarnitine 0.000 
70 KO Mouse Urine S-3-hydroxy-butyrylcarnitine 0.009 
70 KO Mouse Urine valerylcarnitine 0.007 
70 KO Mouse Urine isovalerylcarnitine 0.071 
70 KO Mouse Urine 3-hydroxy-isovalerylcarnitine 0.375 
70 KO Mouse Urine 2-methyl-butyrylcarnitine 0.050 
70 KO Mouse Urine pivaloylcarnitine 0.000 
70 KO Mouse Urine tigloylcarnitine 0.014 
70 KO Mouse Urine 3-methyl-crotonylcarnitine 0.000 
70 KO Mouse Urine hexanoylcarnitine 0.013 
70 KO Mouse Urine R-3-hydroxy-hexanoylcarnitine 0.009 
70 KO Mouse Urine S-3-hydroxy-hexanoylcarnitine 0.005 
70 KO Mouse Urine phenylacetylcarnitine 0.002 
70 KO Mouse Urine phenylpropionylcarnitine 0.000 
70 KO Mouse Urine 4-phenyl-butyrylcarnitine 0.000 
70 KO Mouse Urine benzoylcarnitine 0.085 
70 KO Mouse Urine 4-methyl-hexanoylcarnitine 0.001 
70 KO Mouse Urine octanoylcarnitine 0.009 
70 KO Mouse Urine R-3-hydroxy-octanoylcarnitine 0.001 
70 KO Mouse Urine S-3-hydroxy-octanoylcarnitine 0.002 
70 KO Mouse Urine valproylcarnitine 0.000 
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 70 KO Mouse Urine branched-chain C8 0.000 
70 KO Mouse Urine 
cis-3,4-methylene-
heptanoylcarnitine 0.009 
70 KO Mouse Urine 4-methyl-octanoylcarnitine 0.000 
70 KO Mouse Urine 2,6-dimethyl-heptanoylcarnitine 0.001 
70 KO Mouse Urine decanoylcarnitine 0.007 
70 KO Mouse Urine cis-4-decenoylcarnitine 0.008 
70 KO Mouse Urine 
cis-3,4-methylene-
nonanoylcarnitine 0.048 
70 KO Mouse Urine R-3-hydroxy-decanoylcarnitine 0.001 
70 KO Mouse Urine S-3-hydroxy-decanoylcarnitine 0.002 
70 KO Mouse Urine 5-decynoylcarnitine 0.005 
70 KO Mouse Urine malonylcarnitine 2.372 
70 KO Mouse Urine succinylcarnitine 2.003 
70 KO Mouse Urine methyl-malonylcarnitine 1.123 
70 KO Mouse Urine ethyl-malonylcarnitine 0.021 
70 KO Mouse Urine glutaroylcarnitine 2.872 
70 KO Mouse Urine adipoylcarnitine 2.237 
70 KO Mouse Urine 3-methyl-glutaroylcarnitine 0.144 
70 KO Mouse Urine suberoylcarnitine 1.285 
70 KO Mouse Urine sebacoylcarnitine 0.476 
70 KO Mouse Urine sum_of_individual_acylcarnitines 24.800 
70 KO Mouse Urine ratio:_sum/calculated 0.328 
96 WT Mouse Urine total_carnitine 256.373 
96 WT Mouse Urine free_carnitine 171.935 
96 WT Mouse Urine calculated_acylcarnitines 84.438 
96 WT Mouse Urine acyl/free 0.491 
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 96 WT Mouse Urine butyrobetaine 15.111 
96 WT Mouse Urine acetylcarnitine 9.677 
96 WT Mouse Urine propionylcarnitine 0.219 
96 WT Mouse Urine butyrylcarnitine 0.307 
96 WT Mouse Urine isobutyrylcarnitine 0.066 
96 WT Mouse Urine R-3-hydroxy-butyrylcarnitine 0.000 
96 WT Mouse Urine S-3-hydroxy-butyrylcarnitine 0.005 
96 WT Mouse Urine valerylcarnitine 0.004 
96 WT Mouse Urine isovalerylcarnitine 0.027 
96 WT Mouse Urine 3-hydroxy-isovalerylcarnitine 0.333 
96 WT Mouse Urine 2-methyl-butyrylcarnitine 0.038 
96 WT Mouse Urine pivaloylcarnitine 0.000 
96 WT Mouse Urine tigloylcarnitine 0.009 
96 WT Mouse Urine 3-methyl-crotonylcarnitine 0.000 
96 WT Mouse Urine hexanoylcarnitine 0.016 
96 WT Mouse Urine R-3-hydroxy-hexanoylcarnitine 0.007 
96 WT Mouse Urine S-3-hydroxy-hexanoylcarnitine 0.006 
96 WT Mouse Urine phenylacetylcarnitine 0.002 
96 WT Mouse Urine phenylpropionylcarnitine 0.000 
96 WT Mouse Urine 4-phenyl-butyrylcarnitine 0.000 
96 WT Mouse Urine benzoylcarnitine 0.114 
96 WT Mouse Urine 4-methyl-hexanoylcarnitine 0.000 
96 WT Mouse Urine octanoylcarnitine 0.014 
96 WT Mouse Urine R-3-hydroxy-octanoylcarnitine 0.001 
96 WT Mouse Urine S-3-hydroxy-octanoylcarnitine 0.001 
96 WT Mouse Urine valproylcarnitine 0.000 
96 WT Mouse Urine branched-chain C8 0.000 
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 96 WT Mouse Urine 
cis-3,4-methylene-
heptanoylcarnitine 0.010 
96 WT Mouse Urine 4-methyl-octanoylcarnitine 0.001 
96 WT Mouse Urine 2,6-dimethyl-heptanoylcarnitine 0.001 
96 WT Mouse Urine decanoylcarnitine 0.006 
96 WT Mouse Urine cis-4-decenoylcarnitine 0.008 
96 WT Mouse Urine 
cis-3,4-methylene-
nonanoylcarnitine 0.054 
96 WT Mouse Urine R-3-hydroxy-decanoylcarnitine 0.001 
96 WT Mouse Urine S-3-hydroxy-decanoylcarnitine 0.001 
96 WT Mouse Urine 5-decynoylcarnitine 0.005 
96 WT Mouse Urine malonylcarnitine 2.830 
96 WT Mouse Urine succinylcarnitine 3.622 
96 WT Mouse Urine methyl-malonylcarnitine 1.706 
96 WT Mouse Urine ethyl-malonylcarnitine 0.014 
96 WT Mouse Urine glutaroylcarnitine 2.297 
96 WT Mouse Urine adipoylcarnitine 2.306 
96 WT Mouse Urine 3-methyl-glutaroylcarnitine 0.170 
96 WT Mouse Urine suberoylcarnitine 1.454 
96 WT Mouse Urine sebacoylcarnitine 0.247 
96 WT Mouse Urine sum_of_individual_acylcarnitines 25.591 
96 WT Mouse Urine ratio:_sum/calculated 0.303 
97 WT Mouse Urine total_carnitine 495.455 
97 WT Mouse Urine free_carnitine 409.470 
97 WT Mouse Urine calculated_acylcarnitines 85.985 
97 WT Mouse Urine acyl/free 0.210 
97 WT Mouse Urine butyrobetaine 15.903 
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 97 WT Mouse Urine acetylcarnitine 21.824 
97 WT Mouse Urine propionylcarnitine 0.573 
97 WT Mouse Urine butyrylcarnitine 0.485 
97 WT Mouse Urine isobutyrylcarnitine 0.176 
97 WT Mouse Urine R-3-hydroxy-butyrylcarnitine 0.011 
97 WT Mouse Urine S-3-hydroxy-butyrylcarnitine 0.016 
97 WT Mouse Urine valerylcarnitine 0.006 
97 WT Mouse Urine isovalerylcarnitine 0.053 
97 WT Mouse Urine 3-hydroxy-isovalerylcarnitine 0.899 
97 WT Mouse Urine 2-methyl-butyrylcarnitine 0.060 
97 WT Mouse Urine pivaloylcarnitine 0.000 
97 WT Mouse Urine tigloylcarnitine 0.016 
97 WT Mouse Urine 3-methyl-crotonylcarnitine 0.001 
97 WT Mouse Urine hexanoylcarnitine 0.013 
97 WT Mouse Urine R-3-hydroxy-hexanoylcarnitine 0.012 
97 WT Mouse Urine S-3-hydroxy-hexanoylcarnitine 0.017 
97 WT Mouse Urine phenylacetylcarnitine 0.006 
97 WT Mouse Urine phenylpropionylcarnitine 0.001 
97 WT Mouse Urine 4-phenyl-butyrylcarnitine 0.000 
97 WT Mouse Urine benzoylcarnitine 0.169 
97 WT Mouse Urine 4-methyl-hexanoylcarnitine 0.000 
97 WT Mouse Urine octanoylcarnitine 0.011 
97 WT Mouse Urine R-3-hydroxy-octanoylcarnitine 0.002 
97 WT Mouse Urine S-3-hydroxy-octanoylcarnitine 0.003 
97 WT Mouse Urine valproylcarnitine 0.000 
97 WT Mouse Urine branched-chain C8 0.000 
97 WT Mouse Urine cis-3,4-methylene- 0.013 
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 heptanoylcarnitine 
97 WT Mouse Urine 4-methyl-octanoylcarnitine 0.001 
97 WT Mouse Urine 2,6-dimethyl-heptanoylcarnitine 0.001 
97 WT Mouse Urine decanoylcarnitine 0.005 
97 WT Mouse Urine cis-4-decenoylcarnitine 0.007 
97 WT Mouse Urine 
cis-3,4-methylene-
nonanoylcarnitine 0.050 
97 WT Mouse Urine R-3-hydroxy-decanoylcarnitine 0.001 
97 WT Mouse Urine S-3-hydroxy-decanoylcarnitine 0.003 
97 WT Mouse Urine 5-decynoylcarnitine 0.007 
97 WT Mouse Urine malonylcarnitine 2.765 
97 WT Mouse Urine succinylcarnitine 3.132 
97 WT Mouse Urine methyl-malonylcarnitine 1.281 
97 WT Mouse Urine ethyl-malonylcarnitine 0.014 
97 WT Mouse Urine glutaroylcarnitine 1.766 
97 WT Mouse Urine adipoylcarnitine 2.091 
97 WT Mouse Urine 3-methyl-glutaroylcarnitine 0.213 
97 WT Mouse Urine suberoylcarnitine 1.714 
97 WT Mouse Urine sebacoylcarnitine 0.303 
97 WT Mouse Urine sum_of_individual_acylcarnitines 37.740 
97 WT Mouse Urine ratio:_sum/calculated 0.439 
98 WT Mouse Urine total_carnitine 0.181 
98 WT Mouse Urine free_carnitine 0.522 
98 WT Mouse Urine calculated_acylcarnitines -0.341 
98 WT Mouse Urine acyl/free -0.653 
98 WT Mouse Urine butyrobetaine 0.038 
98 WT Mouse Urine acetylcarnitine 0.000 
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 98 WT Mouse Urine propionylcarnitine 0.000 
98 WT Mouse Urine butyrylcarnitine 0.000 
98 WT Mouse Urine isobutyrylcarnitine 0.000 
98 WT Mouse Urine R-3-hydroxy-butyrylcarnitine 0.000 
98 WT Mouse Urine S-3-hydroxy-butyrylcarnitine 0.000 
98 WT Mouse Urine valerylcarnitine 0.000 
98 WT Mouse Urine isovalerylcarnitine 0.000 
98 WT Mouse Urine 3-hydroxy-isovalerylcarnitine 0.000 
98 WT Mouse Urine 2-methyl-butyrylcarnitine 0.000 
98 WT Mouse Urine pivaloylcarnitine 0.000 
98 WT Mouse Urine tigloylcarnitine 0.000 
98 WT Mouse Urine 3-methyl-crotonylcarnitine 0.000 
98 WT Mouse Urine hexanoylcarnitine 0.000 
98 WT Mouse Urine R-3-hydroxy-hexanoylcarnitine 0.000 
98 WT Mouse Urine S-3-hydroxy-hexanoylcarnitine 0.000 
98 WT Mouse Urine phenylacetylcarnitine 0.000 
98 WT Mouse Urine phenylpropionylcarnitine 0.000 
98 WT Mouse Urine 4-phenyl-butyrylcarnitine 0.000 
98 WT Mouse Urine benzoylcarnitine 0.000 
98 WT Mouse Urine 4-methyl-hexanoylcarnitine 0.000 
98 WT Mouse Urine octanoylcarnitine 0.000 
98 WT Mouse Urine R-3-hydroxy-octanoylcarnitine 0.000 
98 WT Mouse Urine S-3-hydroxy-octanoylcarnitine 0.000 
98 WT Mouse Urine valproylcarnitine 0.000 
98 WT Mouse Urine branched-chain C8 0.000 
98 WT Mouse Urine 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
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 98 WT Mouse Urine 4-methyl-octanoylcarnitine 0.000 
98 WT Mouse Urine 2,6-dimethyl-heptanoylcarnitine 0.000 
98 WT Mouse Urine decanoylcarnitine 0.000 
98 WT Mouse Urine cis-4-decenoylcarnitine 0.000 
98 WT Mouse Urine 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
98 WT Mouse Urine R-3-hydroxy-decanoylcarnitine 0.000 
98 WT Mouse Urine S-3-hydroxy-decanoylcarnitine 0.000 
98 WT Mouse Urine 5-decynoylcarnitine 0.000 
98 WT Mouse Urine malonylcarnitine 0.004 
98 WT Mouse Urine succinylcarnitine 0.000 
98 WT Mouse Urine methyl-malonylcarnitine 0.001 
98 WT Mouse Urine ethyl-malonylcarnitine 0.000 
98 WT Mouse Urine glutaroylcarnitine 0.000 
98 WT Mouse Urine adipoylcarnitine 0.000 
98 WT Mouse Urine 3-methyl-glutaroylcarnitine 0.000 
98 WT Mouse Urine suberoylcarnitine 0.000 
98 WT Mouse Urine sebacoylcarnitine 0.000 
98 WT Mouse Urine sum_of_individual_acylcarnitines 0.008 
15 KO Mouse Brain total_carnitine 252.737 
15 KO Mouse Brain free_carnitine 167.498 
15 KO Mouse Brain calculated_acylcarnitines 85.239 
15 KO Mouse Brain acyl/free 0.509 
15 KO Mouse Brain butyrobetaine 4.071 
15 KO Mouse Brain acetylcarnitine 83.157 
15 KO Mouse Brain propionylcarnitine 2.897 
15 KO Mouse Brain butyrylcarnitine 1.375 
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 15 KO Mouse Brain isobutyrylcarnitine 0.130 
15 KO Mouse Brain R-3-hydroxy-butyrylcarnitine 0.263 
15 KO Mouse Brain S-3-hydroxy-butyrylcarnitine 0.597 
15 KO Mouse Brain valerylcarnitine 0.042 
15 KO Mouse Brain isovalerylcarnitine 0.639 
15 KO Mouse Brain 3-hydroxy-isovalerylcarnitine 0.571 
15 KO Mouse Brain 2-methyl-butyrylcarnitine 0.198 
15 KO Mouse Brain pivaloylcarnitine 0.000 
15 KO Mouse Brain tigloylcarnitine 0.007 
15 KO Mouse Brain 3-methyl-crotonylcarnitine 0.000 
15 KO Mouse Brain hexanoylcarnitine 0.072 
15 KO Mouse Brain R-3-hydroxy-hexanoylcarnitine 0.005 
15 KO Mouse Brain S-3-hydroxy-hexanoylcarnitine 0.011 
15 KO Mouse Brain phenylacetylcarnitine 0.002 
15 KO Mouse Brain phenylpropionylcarnitine 0.000 
15 KO Mouse Brain 4-phenyl-butyrylcarnitine 0.000 
15 KO Mouse Brain benzoylcarnitine 0.000 
15 KO Mouse Brain 4-methyl-hexanoylcarnitine 0.000 
15 KO Mouse Brain octanoylcarnitine 0.018 
15 KO Mouse Brain R-3-hydroxy-octanoylcarnitine 0.001 
15 KO Mouse Brain S-3-hydroxy-octanoylcarnitine 0.006 
15 KO Mouse Brain valproylcarnitine 0.000 
15 KO Mouse Brain branched-chain C8 0.000 
15 KO Mouse Brain 
cis-3,4-methylene-
heptanoylcarnitine 0.002 
15 KO Mouse Brain 4-methyl-octanoylcarnitine 0.001 
15 KO Mouse Brain 2,6-dimethyl-heptanoylcarnitine 0.000 
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 15 KO Mouse Brain decanoylcarnitine 0.029 
15 KO Mouse Brain cis-4-decenoylcarnitine 0.009 
15 KO Mouse Brain 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
15 KO Mouse Brain R-3-hydroxy-decanoylcarnitine 0.000 
15 KO Mouse Brain S-3-hydroxy-decanoylcarnitine 0.009 
15 KO Mouse Brain 5-decynoylcarnitine 0.002 
15 KO Mouse Brain lauroylcarnitine 0.114 
15 KO Mouse Brain trans-2-dodecenoylcarnitine 0.000 
15 KO Mouse Brain R-3-hydroxy-lauroylcarnitine 0.003 
15 KO Mouse Brain S-3-hydroxy-lauroylcarnitine 0.005 
15 KO Mouse Brain myristoylcarnitine 0.676 
15 KO Mouse Brain myristoleoylcarnitine 0.033 
15 KO Mouse Brain cis-5-tetradecenoylcarnitine 0.000 
15 KO Mouse Brain trans-2-tetradecenoylcarnitine 0.000 
15 KO Mouse Brain 
cis,cis-5,8-
tetradecadienoylcarnitine 0.028 
15 KO Mouse Brain R-3-hydroxy-myristoylcarnitine 0.000 
15 KO Mouse Brain S-3-hydroxy-myristoylcarnitine 0.000 
15 KO Mouse Brain hydroxy-C14:1 0.007 
15 KO Mouse Brain palmitoylcarnitine 1.738 
15 KO Mouse Brain palmitoleoylcarnitine 0.138 
15 KO Mouse Brain trans-2-hexadecenoylcarnitine 0.002 
15 KO Mouse Brain R-3-hydroxy-palmitoylcarnitine 0.000 
15 KO Mouse Brain S-3-hydroxy-palmitoylcarnitine 0.026 
15 KO Mouse Brain hydroxy-C16:1 0.028 
15 KO Mouse Brain stearoylcarnitine 1.418 
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 15 KO Mouse Brain oleoylcarnitine 1.703 
15 KO Mouse Brain linoleoylcarnitine 0.120 
15 KO Mouse Brain alpha-linolenoylcarnitine 0.000 
15 KO Mouse Brain gamma-linolenoylcarnitine 0.000 
15 KO Mouse Brain R-3-hydroxy-stearoylcarnitine 0.000 
15 KO Mouse Brain S-3-hydroxy-stearoylcarnitine 0.006 
15 KO Mouse Brain hydroxy-C18:1 0.022 
15 KO Mouse Brain hydroxy-C18:2 0.016 
15 KO Mouse Brain hydroxy-C18:3 0.000 
15 KO Mouse Brain malonylcarnitine 0.461 
15 KO Mouse Brain succinylcarnitine 0.303 
15 KO Mouse Brain methyl-malonylcarnitine 0.089 
15 KO Mouse Brain ethyl-malonylcarnitine 0.001 
15 KO Mouse Brain glutaroylcarnitine 0.168 
15 KO Mouse Brain adipoylcarnitine 0.027 
15 KO Mouse Brain 3-methyl-glutaroylcarnitine 0.047 
15 KO Mouse Brain suberoylcarnitine 0.043 
15 KO Mouse Brain sebacoylcarnitine 0.003 
15 KO Mouse Brain sum_of_individual_acylcarnitines 97.268 
15 KO Mouse Brain ratio:_sum/calculated 1.141 
15 KO Mouse Fat total_carnitine 57.346 
15 KO Mouse Fat free_carnitine 31.845 
15 KO Mouse Fat calculated_acylcarnitines 25.501 
15 KO Mouse Fat acyl/free 0.801 
15 KO Mouse Fat butyrobetaine 2.103 
15 KO Mouse Fat acetylcarnitine 8.308 
15 KO Mouse Fat propionylcarnitine 0.233 
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 15 KO Mouse Fat butyrylcarnitine 0.236 
15 KO Mouse Fat isobutyrylcarnitine 0.069 
15 KO Mouse Fat R-3-hydroxy-butyrylcarnitine 0.152 
15 KO Mouse Fat S-3-hydroxy-butyrylcarnitine 0.127 
15 KO Mouse Fat valerylcarnitine 0.003 
15 KO Mouse Fat isovalerylcarnitine 0.207 
15 KO Mouse Fat 3-hydroxy-isovalerylcarnitine 0.048 
15 KO Mouse Fat 2-methyl-butyrylcarnitine 0.050 
15 KO Mouse Fat pivaloylcarnitine 0.000 
15 KO Mouse Fat tigloylcarnitine 0.000 
15 KO Mouse Fat 3-methyl-crotonylcarnitine 0.000 
15 KO Mouse Fat hexanoylcarnitine 0.022 
15 KO Mouse Fat R-3-hydroxy-hexanoylcarnitine 0.005 
15 KO Mouse Fat S-3-hydroxy-hexanoylcarnitine 0.021 
15 KO Mouse Fat phenylacetylcarnitine 0.003 
15 KO Mouse Fat phenylpropionylcarnitine 0.000 
15 KO Mouse Fat 4-phenyl-butyrylcarnitine 0.000 
15 KO Mouse Fat 4-methyl-hexanoylcarnitine 0.000 
15 KO Mouse Fat octanoylcarnitine 0.010 
15 KO Mouse Fat R-3-hydroxy-octanoylcarnitine 0.003 
15 KO Mouse Fat S-3-hydroxy-octanoylcarnitine 0.004 
15 KO Mouse Fat valproylcarnitine 0.000 
15 KO Mouse Fat branched-chain C8 0.000 
15 KO Mouse Fat 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
15 KO Mouse Fat 4-methyl-octanoylcarnitine 0.000 
15 KO Mouse Fat 2,6-dimethyl-heptanoylcarnitine 0.000 
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 15 KO Mouse Fat decanoylcarnitine 0.004 
15 KO Mouse Fat cis-4-decenoylcarnitine 0.000 
15 KO Mouse Fat 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
15 KO Mouse Fat R-3-hydroxy-decanoylcarnitine 0.000 
15 KO Mouse Fat S-3-hydroxy-decanoylcarnitine 0.012 
15 KO Mouse Fat 5-decynoylcarnitine 0.000 
15 KO Mouse Fat lauroylcarnitine 0.000 
15 KO Mouse Fat trans-2-dodecenoylcarnitine 0.000 
15 KO Mouse Fat R-3-hydroxy-lauroylcarnitine 0.000 
15 KO Mouse Fat S-3-hydroxy-lauroylcarnitine 0.001 
15 KO Mouse Fat myristoylcarnitine 0.064 
15 KO Mouse Fat myristoleoylcarnitine 0.070 
15 KO Mouse Fat cis-5-tetradecenoylcarnitine 0.000 
15 KO Mouse Fat trans-2-tetradecenoylcarnitine 0.000 
15 KO Mouse Fat 
cis,cis-5,8-
tetradecadienoylcarnitine 0.000 
15 KO Mouse Fat R-3-hydroxy-myristoylcarnitine 0.000 
15 KO Mouse Fat S-3-hydroxy-myristoylcarnitine 0.000 
15 KO Mouse Fat hydroxy-C14:1 0.009 
15 KO Mouse Fat palmitoylcarnitine 0.098 
15 KO Mouse Fat palmitoleoylcarnitine 0.000 
15 KO Mouse Fat trans-2-hexadecenoylcarnitine 0.000 
15 KO Mouse Fat R-3-hydroxy-palmitoylcarnitine 0.000 
15 KO Mouse Fat S-3-hydroxy-palmitoylcarnitine 0.016 
15 KO Mouse Fat hydroxy-C16:1 0.046 
15 KO Mouse Fat stearoylcarnitine 0.069 
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 15 KO Mouse Fat oleoylcarnitine 0.004 
15 KO Mouse Fat linoleoylcarnitine 0.123 
15 KO Mouse Fat alpha-linolenoylcarnitine 0.000 
15 KO Mouse Fat gamma-linolenoylcarnitine 0.000 
15 KO Mouse Fat R-3-hydroxy-stearoylcarnitine 0.000 
15 KO Mouse Fat S-3-hydroxy-stearoylcarnitine 0.000 
15 KO Mouse Fat hydroxy-C18:1 0.035 
15 KO Mouse Fat hydroxy-C18:2 0.012 
15 KO Mouse Fat hydroxy-C18:3 0.000 
15 KO Mouse Fat malonylcarnitine 0.000 
15 KO Mouse Fat succinylcarnitine 0.101 
15 KO Mouse Fat methyl-malonylcarnitine 0.003 
15 KO Mouse Fat ethyl-malonylcarnitine 0.001 
15 KO Mouse Fat glutaroylcarnitine 0.000 
15 KO Mouse Fat adipoylcarnitine 0.014 
15 KO Mouse Fat 3-methyl-glutaroylcarnitine 0.005 
15 KO Mouse Fat suberoylcarnitine 0.022 
15 KO Mouse Fat sebacoylcarnitine 0.000 
15 KO Mouse Fat sum_of_individual_acylcarnitines 10.211 
15 KO Mouse Fat ratio:_sum/calculated 0.400 
15 KO Mouse Heart total_carnitine 964.287 
15 KO Mouse Heart free_carnitine 704.870 
15 KO Mouse Heart calculated_acylcarnitines 259.417 
15 KO Mouse Heart acyl/free 0.368 
15 KO Mouse Heart butyrobetaine 12.430 
15 KO Mouse Heart acetylcarnitine 231.944 
15 KO Mouse Heart propionylcarnitine 11.693 
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 15 KO Mouse Heart butyrylcarnitine 8.580 
15 KO Mouse Heart isobutyrylcarnitine 6.083 
15 KO Mouse Heart R-3-hydroxy-butyrylcarnitine 5.067 
15 KO Mouse Heart S-3-hydroxy-butyrylcarnitine 5.077 
15 KO Mouse Heart valerylcarnitine 0.886 
15 KO Mouse Heart isovalerylcarnitine 0.087 
15 KO Mouse Heart 3-hydroxy-isovalerylcarnitine 0.806 
15 KO Mouse Heart 2-methyl-butyrylcarnitine 0.661 
15 KO Mouse Heart pivaloylcarnitine 0.000 
15 KO Mouse Heart tigloylcarnitine 0.173 
15 KO Mouse Heart 3-methyl-crotonylcarnitine 0.000 
15 KO Mouse Heart hexanoylcarnitine 0.794 
15 KO Mouse Heart R-3-hydroxy-hexanoylcarnitine 0.135 
15 KO Mouse Heart S-3-hydroxy-hexanoylcarnitine 0.361 
15 KO Mouse Heart phenylacetylcarnitine 0.012 
15 KO Mouse Heart phenylpropionylcarnitine 0.000 
15 KO Mouse Heart 4-phenyl-butyrylcarnitine 0.000 
15 KO Mouse Heart benzoylcarnitine 0.039 
15 KO Mouse Heart 4-methyl-hexanoylcarnitine 0.004 
15 KO Mouse Heart octanoylcarnitine 0.176 
15 KO Mouse Heart R-3-hydroxy-octanoylcarnitine 0.052 
15 KO Mouse Heart S-3-hydroxy-octanoylcarnitine 0.170 
15 KO Mouse Heart valproylcarnitine 0.000 
15 KO Mouse Heart branched-chain C8 0.000 
15 KO Mouse Heart 
cis-3,4-methylene-
heptanoylcarnitine 0.009 
15 KO Mouse Heart 4-methyl-octanoylcarnitine 0.000 
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 15 KO Mouse Heart 2,6-dimethyl-heptanoylcarnitine 0.000 
15 KO Mouse Heart decanoylcarnitine 0.177 
15 KO Mouse Heart cis-4-decenoylcarnitine 0.035 
15 KO Mouse Heart 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
15 KO Mouse Heart R-3-hydroxy-decanoylcarnitine 0.016 
15 KO Mouse Heart S-3-hydroxy-decanoylcarnitine 0.112 
15 KO Mouse Heart 5-decynoylcarnitine 0.000 
15 KO Mouse Heart lauroylcarnitine 0.231 
15 KO Mouse Heart trans-2-dodecenoylcarnitine 0.000 
15 KO Mouse Heart R-3-hydroxy-lauroylcarnitine 0.011 
15 KO Mouse Heart S-3-hydroxy-lauroylcarnitine 0.051 
15 KO Mouse Heart myristoylcarnitine 0.775 
15 KO Mouse Heart myristoleoylcarnitine 0.272 
15 KO Mouse Heart cis-5-tetradecenoylcarnitine 0.264 
15 KO Mouse Heart trans-2-tetradecenoylcarnitine 0.000 
15 KO Mouse Heart 
cis,cis-5,8-
tetradecadienoylcarnitine 0.100 
15 KO Mouse Heart R-3-hydroxy-myristoylcarnitine 0.003 
15 KO Mouse Heart S-3-hydroxy-myristoylcarnitine 0.062 
15 KO Mouse Heart hydroxy-C14:1 0.108 
15 KO Mouse Heart palmitoylcarnitine 1.465 
15 KO Mouse Heart palmitoleoylcarnitine 0.233 
15 KO Mouse Heart trans-2-hexadecenoylcarnitine 0.034 
15 KO Mouse Heart R-3-hydroxy-palmitoylcarnitine 0.061 
15 KO Mouse Heart S-3-hydroxy-palmitoylcarnitine 0.205 
15 KO Mouse Heart hydroxy-C16:1 0.270 
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 15 KO Mouse Heart stearoylcarnitine 4.086 
15 KO Mouse Heart oleoylcarnitine 2.931 
15 KO Mouse Heart linoleoylcarnitine 1.005 
15 KO Mouse Heart alpha-linolenoylcarnitine 0.009 
15 KO Mouse Heart gamma-linolenoylcarnitine 0.000 
15 KO Mouse Heart R-3-hydroxy-stearoylcarnitine 0.040 
15 KO Mouse Heart S-3-hydroxy-stearoylcarnitine 0.190 
15 KO Mouse Heart hydroxy-C18:1 0.622 
15 KO Mouse Heart hydroxy-C18:2 0.321 
15 KO Mouse Heart hydroxy-C18:3 0.088 
15 KO Mouse Heart malonylcarnitine 5.286 
15 KO Mouse Heart succinylcarnitine 19.812 
15 KO Mouse Heart methyl-malonylcarnitine 0.930 
15 KO Mouse Heart ethyl-malonylcarnitine 0.013 
15 KO Mouse Heart glutaroylcarnitine 0.000 
15 KO Mouse Heart adipoylcarnitine 0.013 
15 KO Mouse Heart 3-methyl-glutaroylcarnitine 0.009 
15 KO Mouse Heart suberoylcarnitine 0.018 
15 KO Mouse Heart sebacoylcarnitine 0.002 
15 KO Mouse Heart sum_of_individual_acylcarnitines 312.672 
15 KO Mouse Heart ratio:_sum/calculated 1.205 
15 KO Mouse Kidney total_carnitine 475.739 
15 KO Mouse Kidney free_carnitine 347.970 
15 KO Mouse Kidney calculated_acylcarnitines 127.769 
15 KO Mouse Kidney acyl/free 0.367 
15 KO Mouse Kidney butyrobetaine 4.727 
15 KO Mouse Kidney acetylcarnitine 62.411 
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 15 KO Mouse Kidney propionylcarnitine 3.744 
15 KO Mouse Kidney butyrylcarnitine 3.433 
15 KO Mouse Kidney isobutyrylcarnitine 0.651 
15 KO Mouse Kidney R-3-hydroxy-butyrylcarnitine 1.525 
15 KO Mouse Kidney S-3-hydroxy-butyrylcarnitine 1.025 
15 KO Mouse Kidney valerylcarnitine 0.207 
15 KO Mouse Kidney isovalerylcarnitine 0.245 
15 KO Mouse Kidney 3-hydroxy-isovalerylcarnitine 1.403 
15 KO Mouse Kidney 2-methyl-butyrylcarnitine 0.803 
15 KO Mouse Kidney pivaloylcarnitine 0.000 
15 KO Mouse Kidney tigloylcarnitine 0.010 
15 KO Mouse Kidney 3-methyl-crotonylcarnitine 0.000 
15 KO Mouse Kidney hexanoylcarnitine 0.394 
15 KO Mouse Kidney R-3-hydroxy-hexanoylcarnitine 0.065 
15 KO Mouse Kidney S-3-hydroxy-hexanoylcarnitine 0.077 
15 KO Mouse Kidney phenylacetylcarnitine 0.005 
15 KO Mouse Kidney phenylpropionylcarnitine 0.000 
15 KO Mouse Kidney 4-phenyl-butyrylcarnitine 0.000 
15 KO Mouse Kidney benzoylcarnitine 0.180 
15 KO Mouse Kidney 4-methyl-hexanoylcarnitine 0.004 
15 KO Mouse Kidney octanoylcarnitine 0.142 
15 KO Mouse Kidney R-3-hydroxy-octanoylcarnitine 0.029 
15 KO Mouse Kidney S-3-hydroxy-octanoylcarnitine 0.112 
15 KO Mouse Kidney valproylcarnitine 0.000 
15 KO Mouse Kidney branched-chain C8 0.000 
15 KO Mouse Kidney 
cis-3,4-methylene-
heptanoylcarnitine 0.001 
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 15 KO Mouse Kidney 4-methyl-octanoylcarnitine 0.005 
15 KO Mouse Kidney 2,6-dimethyl-heptanoylcarnitine 0.000 
15 KO Mouse Kidney decanoylcarnitine 0.171 
15 KO Mouse Kidney cis-4-decenoylcarnitine 0.014 
15 KO Mouse Kidney 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
15 KO Mouse Kidney R-3-hydroxy-decanoylcarnitine 0.040 
15 KO Mouse Kidney S-3-hydroxy-decanoylcarnitine 0.143 
15 KO Mouse Kidney 5-decynoylcarnitine 0.002 
15 KO Mouse Kidney lauroylcarnitine 0.271 
15 KO Mouse Kidney trans-2-dodecenoylcarnitine 0.000 
15 KO Mouse Kidney R-3-hydroxy-lauroylcarnitine 0.023 
15 KO Mouse Kidney S-3-hydroxy-lauroylcarnitine 0.168 
15 KO Mouse Kidney myristoylcarnitine 1.427 
15 KO Mouse Kidney myristoleoylcarnitine 0.149 
15 KO Mouse Kidney cis-5-tetradecenoylcarnitine 0.135 
15 KO Mouse Kidney trans-2-tetradecenoylcarnitine 0.012 
15 KO Mouse Kidney 
cis,cis-5,8-
tetradecadienoylcarnitine 0.080 
15 KO Mouse Kidney R-3-hydroxy-myristoylcarnitine 0.000 
15 KO Mouse Kidney S-3-hydroxy-myristoylcarnitine 0.377 
15 KO Mouse Kidney hydroxy-C14:1 0.254 
15 KO Mouse Kidney palmitoylcarnitine 8.315 
15 KO Mouse Kidney palmitoleoylcarnitine 1.092 
15 KO Mouse Kidney trans-2-hexadecenoylcarnitine 0.079 
15 KO Mouse Kidney R-3-hydroxy-palmitoylcarnitine 0.053 
15 KO Mouse Kidney S-3-hydroxy-palmitoylcarnitine 1.157 
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 15 KO Mouse Kidney hydroxy-C16:1 0.392 
15 KO Mouse Kidney stearoylcarnitine 5.240 
15 KO Mouse Kidney oleoylcarnitine 8.057 
15 KO Mouse Kidney linoleoylcarnitine 4.271 
15 KO Mouse Kidney alpha-linolenoylcarnitine 0.101 
15 KO Mouse Kidney gamma-linolenoylcarnitine 0.043 
15 KO Mouse Kidney R-3-hydroxy-stearoylcarnitine 0.012 
15 KO Mouse Kidney S-3-hydroxy-stearoylcarnitine 0.153 
15 KO Mouse Kidney hydroxy-C18:1 0.955 
15 KO Mouse Kidney hydroxy-C18:2 0.721 
15 KO Mouse Kidney hydroxy-C18:3 0.117 
15 KO Mouse Kidney malonylcarnitine 0.835 
15 KO Mouse Kidney succinylcarnitine 0.332 
15 KO Mouse Kidney methyl-malonylcarnitine 0.124 
15 KO Mouse Kidney ethyl-malonylcarnitine 0.010 
15 KO Mouse Kidney glutaroylcarnitine 1.094 
15 KO Mouse Kidney adipoylcarnitine 1.496 
15 KO Mouse Kidney 3-methyl-glutaroylcarnitine 0.189 
15 KO Mouse Kidney suberoylcarnitine 0.041 
15 KO Mouse Kidney sebacoylcarnitine 0.005 
15 KO Mouse Kidney sum_of_individual_acylcarnitines 114.622 
15 KO Mouse Kidney ratio:_sum/calculated 0.897 
15 KO Mouse Liver total_carnitine 412.023 
15 KO Mouse Liver free_carnitine 297.247 
15 KO Mouse Liver calculated_acylcarnitines 114.776 
15 KO Mouse Liver acyl/free 0.386 
15 KO Mouse Liver butyrobetaine 2.952 
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 15 KO Mouse Liver acetylcarnitine 68.491 
15 KO Mouse Liver propionylcarnitine 9.035 
15 KO Mouse Liver butyrylcarnitine 3.999 
15 KO Mouse Liver isobutyrylcarnitine 2.756 
15 KO Mouse Liver R-3-hydroxy-butyrylcarnitine 8.323 
15 KO Mouse Liver S-3-hydroxy-butyrylcarnitine 2.350 
15 KO Mouse Liver valerylcarnitine 1.402 
15 KO Mouse Liver isovalerylcarnitine 0.605 
15 KO Mouse Liver 3-hydroxy-isovalerylcarnitine 0.468 
15 KO Mouse Liver 2-methyl-butyrylcarnitine 1.300 
15 KO Mouse Liver pivaloylcarnitine 0.000 
15 KO Mouse Liver tigloylcarnitine 0.000 
15 KO Mouse Liver 3-methyl-crotonylcarnitine 0.000 
15 KO Mouse Liver hexanoylcarnitine 0.724 
15 KO Mouse Liver R-3-hydroxy-hexanoylcarnitine 0.045 
15 KO Mouse Liver S-3-hydroxy-hexanoylcarnitine 0.047 
15 KO Mouse Liver phenylacetylcarnitine 0.003 
15 KO Mouse Liver phenylpropionylcarnitine 0.000 
15 KO Mouse Liver 4-phenyl-butyrylcarnitine 0.001 
15 KO Mouse Liver benzoylcarnitine 0.006 
15 KO Mouse Liver 4-methyl-hexanoylcarnitine 0.026 
15 KO Mouse Liver octanoylcarnitine 0.056 
15 KO Mouse Liver R-3-hydroxy-octanoylcarnitine 0.009 
15 KO Mouse Liver S-3-hydroxy-octanoylcarnitine 0.017 
15 KO Mouse Liver valproylcarnitine 0.000 
15 KO Mouse Liver branched-chain C8 0.000 
15 KO Mouse Liver cis-3,4-methylene- 0.000 
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 heptanoylcarnitine 
15 KO Mouse Liver 4-methyl-octanoylcarnitine 0.003 
15 KO Mouse Liver 2,6-dimethyl-heptanoylcarnitine 0.000 
15 KO Mouse Liver decanoylcarnitine 0.006 
15 KO Mouse Liver cis-4-decenoylcarnitine 0.003 
15 KO Mouse Liver 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
15 KO Mouse Liver R-3-hydroxy-decanoylcarnitine 0.001 
15 KO Mouse Liver S-3-hydroxy-decanoylcarnitine 0.018 
15 KO Mouse Liver 5-decynoylcarnitine 0.000 
15 KO Mouse Liver lauroylcarnitine 0.000 
15 KO Mouse Liver trans-2-dodecenoylcarnitine 0.000 
15 KO Mouse Liver R-3-hydroxy-lauroylcarnitine 0.001 
15 KO Mouse Liver S-3-hydroxy-lauroylcarnitine 0.005 
15 KO Mouse Liver myristoylcarnitine 0.193 
15 KO Mouse Liver myristoleoylcarnitine 0.113 
15 KO Mouse Liver cis-5-tetradecenoylcarnitine 0.000 
15 KO Mouse Liver trans-2-tetradecenoylcarnitine 0.000 
15 KO Mouse Liver 
cis,cis-5,8-
tetradecadienoylcarnitine 0.000 
15 KO Mouse Liver R-3-hydroxy-myristoylcarnitine 0.000 
15 KO Mouse Liver S-3-hydroxy-myristoylcarnitine 0.000 
15 KO Mouse Liver hydroxy-C14:1 0.021 
15 KO Mouse Liver palmitoylcarnitine 0.811 
15 KO Mouse Liver palmitoleoylcarnitine 0.154 
15 KO Mouse Liver trans-2-hexadecenoylcarnitine 0.000 
15 KO Mouse Liver R-3-hydroxy-palmitoylcarnitine 0.012 
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 15 KO Mouse Liver S-3-hydroxy-palmitoylcarnitine 0.059 
15 KO Mouse Liver hydroxy-C16:1 0.082 
15 KO Mouse Liver stearoylcarnitine 1.029 
15 KO Mouse Liver oleoylcarnitine 1.281 
15 KO Mouse Liver linoleoylcarnitine 0.603 
15 KO Mouse Liver alpha-linolenoylcarnitine 0.000 
15 KO Mouse Liver gamma-linolenoylcarnitine 0.000 
15 KO Mouse Liver R-3-hydroxy-stearoylcarnitine 0.000 
15 KO Mouse Liver S-3-hydroxy-stearoylcarnitine 0.000 
15 KO Mouse Liver hydroxy-C18:1 0.079 
15 KO Mouse Liver hydroxy-C18:2 0.050 
15 KO Mouse Liver hydroxy-C18:3 0.018 
15 KO Mouse Liver malonylcarnitine 2.031 
15 KO Mouse Liver succinylcarnitine 0.405 
15 KO Mouse Liver methyl-malonylcarnitine 0.108 
15 KO Mouse Liver ethyl-malonylcarnitine 0.000 
15 KO Mouse Liver glutaroylcarnitine 1.166 
15 KO Mouse Liver adipoylcarnitine 0.893 
15 KO Mouse Liver 3-methyl-glutaroylcarnitine 0.061 
15 KO Mouse Liver suberoylcarnitine 0.030 
15 KO Mouse Liver sebacoylcarnitine 0.029 
15 KO Mouse Liver sum_of_individual_acylcarnitines 108.928 
15 KO Mouse Liver ratio:_sum/calculated 0.949 
15 KO Mouse Lung total_carnitine 631.837 
15 KO Mouse Lung free_carnitine 412.819 
15 KO Mouse Lung calculated_acylcarnitines 219.018 
15 KO Mouse Lung acyl/free 0.531 
 308 
 15 KO Mouse Lung butyrobetaine 9.254 
15 KO Mouse Lung acetylcarnitine 223.281 
15 KO Mouse Lung propionylcarnitine 1.457 
15 KO Mouse Lung butyrylcarnitine 5.106 
15 KO Mouse Lung isobutyrylcarnitine 0.182 
15 KO Mouse Lung R-3-hydroxy-butyrylcarnitine 1.738 
15 KO Mouse Lung S-3-hydroxy-butyrylcarnitine 3.214 
15 KO Mouse Lung valerylcarnitine 0.127 
15 KO Mouse Lung isovalerylcarnitine 0.920 
15 KO Mouse Lung 3-hydroxy-isovalerylcarnitine 0.563 
15 KO Mouse Lung 2-methyl-butyrylcarnitine 0.414 
15 KO Mouse Lung pivaloylcarnitine 0.000 
15 KO Mouse Lung tigloylcarnitine 0.006 
15 KO Mouse Lung 3-methyl-crotonylcarnitine 0.000 
15 KO Mouse Lung hexanoylcarnitine 0.390 
15 KO Mouse Lung R-3-hydroxy-hexanoylcarnitine 0.064 
15 KO Mouse Lung S-3-hydroxy-hexanoylcarnitine 0.309 
15 KO Mouse Lung phenylacetylcarnitine 0.001 
15 KO Mouse Lung phenylpropionylcarnitine 0.000 
15 KO Mouse Lung 4-phenyl-butyrylcarnitine 0.000 
15 KO Mouse Lung benzoylcarnitine 0.018 
15 KO Mouse Lung 4-methyl-hexanoylcarnitine 0.000 
15 KO Mouse Lung octanoylcarnitine 0.092 
15 KO Mouse Lung R-3-hydroxy-octanoylcarnitine 0.080 
15 KO Mouse Lung S-3-hydroxy-octanoylcarnitine 0.306 
15 KO Mouse Lung valproylcarnitine 0.000 
15 KO Mouse Lung branched-chain C8 0.000 
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 15 KO Mouse Lung 
cis-3,4-methylene-
heptanoylcarnitine 0.015 
15 KO Mouse Lung 4-methyl-octanoylcarnitine 0.003 
15 KO Mouse Lung 2,6-dimethyl-heptanoylcarnitine 0.000 
15 KO Mouse Lung decanoylcarnitine 0.164 
15 KO Mouse Lung cis-4-decenoylcarnitine 0.049 
15 KO Mouse Lung 
cis-3,4-methylene-
nonanoylcarnitine 0.014 
15 KO Mouse Lung R-3-hydroxy-decanoylcarnitine 0.056 
15 KO Mouse Lung S-3-hydroxy-decanoylcarnitine 0.293 
15 KO Mouse Lung 5-decynoylcarnitine 0.000 
15 KO Mouse Lung lauroylcarnitine 0.406 
15 KO Mouse Lung trans-2-dodecenoylcarnitine 0.009 
15 KO Mouse Lung R-3-hydroxy-lauroylcarnitine 0.041 
15 KO Mouse Lung S-3-hydroxy-lauroylcarnitine 0.187 
15 KO Mouse Lung myristoylcarnitine 1.836 
15 KO Mouse Lung myristoleoylcarnitine 0.157 
15 KO Mouse Lung cis-5-tetradecenoylcarnitine 0.244 
15 KO Mouse Lung trans-2-tetradecenoylcarnitine 0.036 
15 KO Mouse Lung 
cis,cis-5,8-
tetradecadienoylcarnitine 0.059 
15 KO Mouse Lung R-3-hydroxy-myristoylcarnitine 0.140 
15 KO Mouse Lung S-3-hydroxy-myristoylcarnitine 0.333 
15 KO Mouse Lung hydroxy-C14:1 0.300 
15 KO Mouse Lung palmitoylcarnitine 6.425 
15 KO Mouse Lung palmitoleoylcarnitine 0.566 
15 KO Mouse Lung trans-2-hexadecenoylcarnitine 0.112 
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 15 KO Mouse Lung R-3-hydroxy-palmitoylcarnitine 0.234 
15 KO Mouse Lung S-3-hydroxy-palmitoylcarnitine 0.683 
15 KO Mouse Lung hydroxy-C16:1 0.351 
15 KO Mouse Lung stearoylcarnitine 2.550 
15 KO Mouse Lung oleoylcarnitine 3.990 
15 KO Mouse Lung linoleoylcarnitine 1.272 
15 KO Mouse Lung alpha-linolenoylcarnitine 0.044 
15 KO Mouse Lung gamma-linolenoylcarnitine 0.027 
15 KO Mouse Lung R-3-hydroxy-stearoylcarnitine 0.121 
15 KO Mouse Lung S-3-hydroxy-stearoylcarnitine 0.091 
15 KO Mouse Lung hydroxy-C18:1 0.884 
15 KO Mouse Lung hydroxy-C18:2 0.351 
15 KO Mouse Lung hydroxy-C18:3 0.094 
15 KO Mouse Lung malonylcarnitine 0.238 
15 KO Mouse Lung succinylcarnitine 0.469 
15 KO Mouse Lung methyl-malonylcarnitine 0.061 
15 KO Mouse Lung ethyl-malonylcarnitine 0.005 
15 KO Mouse Lung glutaroylcarnitine 0.000 
15 KO Mouse Lung adipoylcarnitine 0.104 
15 KO Mouse Lung 3-methyl-glutaroylcarnitine 0.008 
15 KO Mouse Lung suberoylcarnitine 0.038 
15 KO Mouse Lung sebacoylcarnitine 0.003 
15 KO Mouse Lung sum_of_individual_acylcarnitines 261.333 
15 KO Mouse Lung ratio:_sum/calculated 1.193 
15 KO Mouse Muscle total_carnitine 264.841 
15 KO Mouse Muscle free_carnitine 87.259 
15 KO Mouse Muscle calculated_acylcarnitines 177.582 
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 15 KO Mouse Muscle acyl/free 2.035 
15 KO Mouse Muscle butyrobetaine 6.191 
15 KO Mouse Muscle acetylcarnitine 121.490 
15 KO Mouse Muscle propionylcarnitine 0.563 
15 KO Mouse Muscle butyrylcarnitine 3.500 
15 KO Mouse Muscle isobutyrylcarnitine 0.189 
15 KO Mouse Muscle R-3-hydroxy-butyrylcarnitine 0.647 
15 KO Mouse Muscle S-3-hydroxy-butyrylcarnitine 3.235 
15 KO Mouse Muscle valerylcarnitine 0.022 
15 KO Mouse Muscle isovalerylcarnitine 0.472 
15 KO Mouse Muscle 3-hydroxy-isovalerylcarnitine 0.652 
15 KO Mouse Muscle 2-methyl-butyrylcarnitine 0.192 
15 KO Mouse Muscle pivaloylcarnitine 0.000 
15 KO Mouse Muscle tigloylcarnitine 0.020 
15 KO Mouse Muscle 3-methyl-crotonylcarnitine 0.000 
15 KO Mouse Muscle hexanoylcarnitine 0.338 
15 KO Mouse Muscle R-3-hydroxy-hexanoylcarnitine 0.027 
15 KO Mouse Muscle S-3-hydroxy-hexanoylcarnitine 0.058 
15 KO Mouse Muscle phenylacetylcarnitine 0.000 
15 KO Mouse Muscle phenylpropionylcarnitine 0.000 
15 KO Mouse Muscle 4-phenyl-butyrylcarnitine 0.000 
15 KO Mouse Muscle benzoylcarnitine 0.016 
15 KO Mouse Muscle 4-methyl-hexanoylcarnitine 0.000 
15 KO Mouse Muscle octanoylcarnitine 0.111 
15 KO Mouse Muscle R-3-hydroxy-octanoylcarnitine 0.022 
15 KO Mouse Muscle S-3-hydroxy-octanoylcarnitine 0.082 
15 KO Mouse Muscle valproylcarnitine 0.000 
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 15 KO Mouse Muscle branched-chain C8 0.000 
15 KO Mouse Muscle 
cis-3,4-methylene-
heptanoylcarnitine 0.012 
15 KO Mouse Muscle 4-methyl-octanoylcarnitine 0.000 
15 KO Mouse Muscle 2,6-dimethyl-heptanoylcarnitine 0.000 
15 KO Mouse Muscle decanoylcarnitine 0.137 
15 KO Mouse Muscle cis-4-decenoylcarnitine 0.015 
15 KO Mouse Muscle 
cis-3,4-methylene-
nonanoylcarnitine 0.007 
15 KO Mouse Muscle R-3-hydroxy-decanoylcarnitine 0.039 
15 KO Mouse Muscle S-3-hydroxy-decanoylcarnitine 0.044 
15 KO Mouse Muscle 5-decynoylcarnitine 0.000 
15 KO Mouse Muscle lauroylcarnitine 0.226 
15 KO Mouse Muscle trans-2-dodecenoylcarnitine 0.000 
15 KO Mouse Muscle R-3-hydroxy-lauroylcarnitine 0.006 
15 KO Mouse Muscle S-3-hydroxy-lauroylcarnitine 0.016 
15 KO Mouse Muscle myristoylcarnitine 1.392 
15 KO Mouse Muscle myristoleoylcarnitine 0.349 
15 KO Mouse Muscle cis-5-tetradecenoylcarnitine 0.164 
15 KO Mouse Muscle trans-2-tetradecenoylcarnitine 0.000 
15 KO Mouse Muscle 
cis,cis-5,8-
tetradecadienoylcarnitine 0.058 
15 KO Mouse Muscle R-3-hydroxy-myristoylcarnitine 0.000 
15 KO Mouse Muscle S-3-hydroxy-myristoylcarnitine 0.071 
15 KO Mouse Muscle hydroxy-C14:1 0.029 
15 KO Mouse Muscle palmitoylcarnitine 12.639 
15 KO Mouse Muscle palmitoleoylcarnitine 2.629 
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 15 KO Mouse Muscle trans-2-hexadecenoylcarnitine 0.022 
15 KO Mouse Muscle R-3-hydroxy-palmitoylcarnitine 0.063 
15 KO Mouse Muscle S-3-hydroxy-palmitoylcarnitine 0.438 
15 KO Mouse Muscle hydroxy-C16:1 0.245 
15 KO Mouse Muscle stearoylcarnitine 7.562 
15 KO Mouse Muscle oleoylcarnitine 22.434 
15 KO Mouse Muscle linoleoylcarnitine 6.579 
15 KO Mouse Muscle alpha-linolenoylcarnitine 0.411 
15 KO Mouse Muscle gamma-linolenoylcarnitine 0.062 
15 KO Mouse Muscle R-3-hydroxy-stearoylcarnitine 0.000 
15 KO Mouse Muscle S-3-hydroxy-stearoylcarnitine 0.179 
15 KO Mouse Muscle hydroxy-C18:1 0.831 
15 KO Mouse Muscle hydroxy-C18:2 0.374 
15 KO Mouse Muscle hydroxy-C18:3 0.069 
15 KO Mouse Muscle malonylcarnitine 0.497 
15 KO Mouse Muscle succinylcarnitine 0.371 
15 KO Mouse Muscle methyl-malonylcarnitine 0.106 
15 KO Mouse Muscle ethyl-malonylcarnitine 0.000 
15 KO Mouse Muscle glutaroylcarnitine 0.000 
15 KO Mouse Muscle adipoylcarnitine 0.056 
15 KO Mouse Muscle 3-methyl-glutaroylcarnitine 0.005 
15 KO Mouse Muscle suberoylcarnitine 0.043 
15 KO Mouse Muscle sebacoylcarnitine 0.002 
15 KO Mouse Muscle sum_of_individual_acylcarnitines 189.819 
15 KO Mouse Muscle ratio:_sum/calculated 1.069 
15 KO Mouse Pancreas total_carnitine 184.359 
15 KO Mouse Pancreas free_carnitine 59.215 
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 15 KO Mouse Pancreas calculated_acylcarnitines 125.144 
15 KO Mouse Pancreas acyl/free 2.113 
15 KO Mouse Pancreas butyrobetaine 7.360 
15 KO Mouse Pancreas acetylcarnitine 45.458 
15 KO Mouse Pancreas propionylcarnitine 1.943 
15 KO Mouse Pancreas butyrylcarnitine 6.899 
15 KO Mouse Pancreas isobutyrylcarnitine 2.010 
15 KO Mouse Pancreas R-3-hydroxy-butyrylcarnitine 0.473 
15 KO Mouse Pancreas S-3-hydroxy-butyrylcarnitine 1.547 
15 KO Mouse Pancreas valerylcarnitine 0.185 
15 KO Mouse Pancreas isovalerylcarnitine 2.295 
15 KO Mouse Pancreas 3-hydroxy-isovalerylcarnitine 0.134 
15 KO Mouse Pancreas 2-methyl-butyrylcarnitine 2.316 
15 KO Mouse Pancreas pivaloylcarnitine 0.000 
15 KO Mouse Pancreas tigloylcarnitine 0.004 
15 KO Mouse Pancreas 3-methyl-crotonylcarnitine 0.000 
15 KO Mouse Pancreas hexanoylcarnitine 0.124 
15 KO Mouse Pancreas R-3-hydroxy-hexanoylcarnitine 0.011 
15 KO Mouse Pancreas S-3-hydroxy-hexanoylcarnitine 0.031 
15 KO Mouse Pancreas phenylacetylcarnitine 0.000 
15 KO Mouse Pancreas phenylpropionylcarnitine 0.000 
15 KO Mouse Pancreas 4-phenyl-butyrylcarnitine 0.000 
15 KO Mouse Pancreas benzoylcarnitine 0.000 
15 KO Mouse Pancreas 4-methyl-hexanoylcarnitine 0.002 
15 KO Mouse Pancreas octanoylcarnitine 0.020 
15 KO Mouse Pancreas R-3-hydroxy-octanoylcarnitine 0.012 
15 KO Mouse Pancreas S-3-hydroxy-octanoylcarnitine 0.030 
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 15 KO Mouse Pancreas valproylcarnitine 0.000 
15 KO Mouse Pancreas branched-chain C8 0.000 
15 KO Mouse Pancreas 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
15 KO Mouse Pancreas 4-methyl-octanoylcarnitine 0.000 
15 KO Mouse Pancreas 2,6-dimethyl-heptanoylcarnitine 0.000 
15 KO Mouse Pancreas decanoylcarnitine 0.009 
15 KO Mouse Pancreas cis-4-decenoylcarnitine 0.002 
15 KO Mouse Pancreas 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
15 KO Mouse Pancreas R-3-hydroxy-decanoylcarnitine 0.014 
15 KO Mouse Pancreas S-3-hydroxy-decanoylcarnitine 0.018 
15 KO Mouse Pancreas 5-decynoylcarnitine 0.000 
15 KO Mouse Pancreas lauroylcarnitine 0.003 
15 KO Mouse Pancreas trans-2-dodecenoylcarnitine 0.000 
15 KO Mouse Pancreas R-3-hydroxy-lauroylcarnitine 0.002 
15 KO Mouse Pancreas S-3-hydroxy-lauroylcarnitine 0.020 
15 KO Mouse Pancreas myristoylcarnitine 0.164 
15 KO Mouse Pancreas myristoleoylcarnitine 0.000 
15 KO Mouse Pancreas cis-5-tetradecenoylcarnitine 0.000 
15 KO Mouse Pancreas trans-2-tetradecenoylcarnitine 0.000 
15 KO Mouse Pancreas 
cis,cis-5,8-
tetradecadienoylcarnitine 0.000 
15 KO Mouse Pancreas R-3-hydroxy-myristoylcarnitine 0.000 
15 KO Mouse Pancreas S-3-hydroxy-myristoylcarnitine 0.034 
15 KO Mouse Pancreas hydroxy-C14:1 0.051 
15 KO Mouse Pancreas palmitoylcarnitine 1.788 
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 15 KO Mouse Pancreas palmitoleoylcarnitine 0.056 
15 KO Mouse Pancreas trans-2-hexadecenoylcarnitine 0.006 
15 KO Mouse Pancreas R-3-hydroxy-palmitoylcarnitine 0.004 
15 KO Mouse Pancreas S-3-hydroxy-palmitoylcarnitine 0.167 
15 KO Mouse Pancreas hydroxy-C16:1 0.089 
15 KO Mouse Pancreas stearoylcarnitine 1.799 
15 KO Mouse Pancreas oleoylcarnitine 1.143 
15 KO Mouse Pancreas linoleoylcarnitine 0.453 
15 KO Mouse Pancreas alpha-linolenoylcarnitine 0.009 
15 KO Mouse Pancreas gamma-linolenoylcarnitine 0.000 
15 KO Mouse Pancreas R-3-hydroxy-stearoylcarnitine 0.000 
15 KO Mouse Pancreas S-3-hydroxy-stearoylcarnitine 0.097 
15 KO Mouse Pancreas hydroxy-C18:1 0.127 
15 KO Mouse Pancreas hydroxy-C18:2 0.105 
15 KO Mouse Pancreas hydroxy-C18:3 0.034 
15 KO Mouse Pancreas malonylcarnitine 0.000 
15 KO Mouse Pancreas succinylcarnitine 0.131 
15 KO Mouse Pancreas methyl-malonylcarnitine 0.029 
15 KO Mouse Pancreas ethyl-malonylcarnitine 0.000 
15 KO Mouse Pancreas glutaroylcarnitine 0.000 
15 KO Mouse Pancreas adipoylcarnitine 0.036 
15 KO Mouse Pancreas 3-methyl-glutaroylcarnitine 0.004 
15 KO Mouse Pancreas suberoylcarnitine 0.013 
15 KO Mouse Pancreas sebacoylcarnitine 0.009 
15 KO Mouse Pancreas sum_of_individual_acylcarnitines 69.912 
15 KO Mouse Pancreas ratio:_sum/calculated 0.559 
15 KO Mouse Spleen total_carnitine 516.835 
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 15 KO Mouse Spleen free_carnitine 213.966 
15 KO Mouse Spleen calculated_acylcarnitines 302.870 
15 KO Mouse Spleen acyl/free 1.416 
15 KO Mouse Spleen butyrobetaine 8.085 
15 KO Mouse Spleen acetylcarnitine 221.128 
15 KO Mouse Spleen propionylcarnitine 7.456 
15 KO Mouse Spleen butyrylcarnitine 29.179 
15 KO Mouse Spleen isobutyrylcarnitine 1.620 
15 KO Mouse Spleen R-3-hydroxy-butyrylcarnitine 4.800 
15 KO Mouse Spleen S-3-hydroxy-butyrylcarnitine 7.040 
15 KO Mouse Spleen valerylcarnitine 1.312 
15 KO Mouse Spleen isovalerylcarnitine 2.004 
15 KO Mouse Spleen 3-hydroxy-isovalerylcarnitine 0.573 
15 KO Mouse Spleen 2-methyl-butyrylcarnitine 1.035 
15 KO Mouse Spleen pivaloylcarnitine 0.000 
15 KO Mouse Spleen tigloylcarnitine 0.023 
15 KO Mouse Spleen 3-methyl-crotonylcarnitine 0.000 
15 KO Mouse Spleen hexanoylcarnitine 1.247 
15 KO Mouse Spleen R-3-hydroxy-hexanoylcarnitine 0.080 
15 KO Mouse Spleen S-3-hydroxy-hexanoylcarnitine 0.342 
15 KO Mouse Spleen phenylacetylcarnitine 0.000 
15 KO Mouse Spleen phenylpropionylcarnitine 0.000 
15 KO Mouse Spleen 4-phenyl-butyrylcarnitine 0.000 
15 KO Mouse Spleen benzoylcarnitine 0.011 
15 KO Mouse Spleen 4-methyl-hexanoylcarnitine 0.016 
15 KO Mouse Spleen octanoylcarnitine 0.217 
15 KO Mouse Spleen R-3-hydroxy-octanoylcarnitine 0.085 
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 15 KO Mouse Spleen S-3-hydroxy-octanoylcarnitine 0.328 
15 KO Mouse Spleen valproylcarnitine 0.000 
15 KO Mouse Spleen branched-chain C8 0.000 
15 KO Mouse Spleen 
cis-3,4-methylene-
heptanoylcarnitine 0.029 
15 KO Mouse Spleen 4-methyl-octanoylcarnitine 0.004 
15 KO Mouse Spleen 2,6-dimethyl-heptanoylcarnitine 0.000 
15 KO Mouse Spleen decanoylcarnitine 0.161 
15 KO Mouse Spleen cis-4-decenoylcarnitine 0.034 
15 KO Mouse Spleen 
cis-3,4-methylene-
nonanoylcarnitine 0.009 
15 KO Mouse Spleen R-3-hydroxy-decanoylcarnitine 0.036 
15 KO Mouse Spleen S-3-hydroxy-decanoylcarnitine 0.183 
15 KO Mouse Spleen 5-decynoylcarnitine 0.000 
15 KO Mouse Spleen lauroylcarnitine 0.241 
15 KO Mouse Spleen trans-2-dodecenoylcarnitine 0.003 
15 KO Mouse Spleen R-3-hydroxy-lauroylcarnitine 0.011 
15 KO Mouse Spleen S-3-hydroxy-lauroylcarnitine 0.085 
15 KO Mouse Spleen myristoylcarnitine 1.519 
15 KO Mouse Spleen myristoleoylcarnitine 0.242 
15 KO Mouse Spleen cis-5-tetradecenoylcarnitine 0.091 
15 KO Mouse Spleen trans-2-tetradecenoylcarnitine 0.000 
15 KO Mouse Spleen 
cis,cis-5,8-
tetradecadienoylcarnitine 0.100 
15 KO Mouse Spleen R-3-hydroxy-myristoylcarnitine 0.000 
15 KO Mouse Spleen S-3-hydroxy-myristoylcarnitine 0.127 
15 KO Mouse Spleen hydroxy-C14:1 0.135 
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 15 KO Mouse Spleen palmitoylcarnitine 12.324 
15 KO Mouse Spleen palmitoleoylcarnitine 1.195 
15 KO Mouse Spleen trans-2-hexadecenoylcarnitine 0.017 
15 KO Mouse Spleen R-3-hydroxy-palmitoylcarnitine 0.005 
15 KO Mouse Spleen S-3-hydroxy-palmitoylcarnitine 0.501 
15 KO Mouse Spleen hydroxy-C16:1 0.233 
15 KO Mouse Spleen stearoylcarnitine 5.377 
15 KO Mouse Spleen oleoylcarnitine 15.900 
15 KO Mouse Spleen linoleoylcarnitine 4.756 
15 KO Mouse Spleen alpha-linolenoylcarnitine 0.129 
15 KO Mouse Spleen gamma-linolenoylcarnitine 0.078 
15 KO Mouse Spleen R-3-hydroxy-stearoylcarnitine 0.063 
15 KO Mouse Spleen S-3-hydroxy-stearoylcarnitine 0.316 
15 KO Mouse Spleen hydroxy-C18:1 0.725 
15 KO Mouse Spleen hydroxy-C18:2 0.289 
15 KO Mouse Spleen hydroxy-C18:3 0.056 
15 KO Mouse Spleen malonylcarnitine 0.200 
15 KO Mouse Spleen succinylcarnitine 0.108 
15 KO Mouse Spleen methyl-malonylcarnitine 0.062 
15 KO Mouse Spleen ethyl-malonylcarnitine 0.000 
15 KO Mouse Spleen glutaroylcarnitine 0.000 
15 KO Mouse Spleen adipoylcarnitine 0.034 
15 KO Mouse Spleen 3-methyl-glutaroylcarnitine 0.003 
15 KO Mouse Spleen suberoylcarnitine 0.027 
15 KO Mouse Spleen sebacoylcarnitine 0.000 
15 KO Mouse Spleen sum_of_individual_acylcarnitines 323.903 
15 KO Mouse Spleen ratio:_sum/calculated 1.069 
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 96 WT Mouse Brain total_carnitine 123.794 
96 WT Mouse Brain free_carnitine 103.547 
96 WT Mouse Brain calculated_acylcarnitines 20.247 
96 WT Mouse Brain acyl/free 0.196 
96 WT Mouse Brain butyrobetaine 7.911 
96 WT Mouse Brain acetylcarnitine 33.787 
96 WT Mouse Brain propionylcarnitine 2.840 
96 WT Mouse Brain butyrylcarnitine 1.051 
96 WT Mouse Brain isobutyrylcarnitine 0.150 
96 WT Mouse Brain R-3-hydroxy-butyrylcarnitine 0.082 
96 WT Mouse Brain S-3-hydroxy-butyrylcarnitine 0.209 
96 WT Mouse Brain valerylcarnitine 0.154 
96 WT Mouse Brain isovalerylcarnitine 0.094 
96 WT Mouse Brain 3-hydroxy-isovalerylcarnitine 0.384 
96 WT Mouse Brain 2-methyl-butyrylcarnitine 0.263 
96 WT Mouse Brain pivaloylcarnitine 0.000 
96 WT Mouse Brain tigloylcarnitine 0.001 
96 WT Mouse Brain 3-methyl-crotonylcarnitine 0.000 
96 WT Mouse Brain hexanoylcarnitine 0.059 
96 WT Mouse Brain R-3-hydroxy-hexanoylcarnitine 0.001 
96 WT Mouse Brain S-3-hydroxy-hexanoylcarnitine 0.002 
96 WT Mouse Brain phenylacetylcarnitine 0.000 
96 WT Mouse Brain phenylpropionylcarnitine 0.000 
96 WT Mouse Brain 4-phenyl-butyrylcarnitine 0.000 
96 WT Mouse Brain benzoylcarnitine 0.000 
96 WT Mouse Brain 4-methyl-hexanoylcarnitine 0.000 
96 WT Mouse Brain octanoylcarnitine 0.019 
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 96 WT Mouse Brain R-3-hydroxy-octanoylcarnitine 0.000 
96 WT Mouse Brain S-3-hydroxy-octanoylcarnitine 0.000 
96 WT Mouse Brain valproylcarnitine 0.000 
96 WT Mouse Brain branched-chain C8 0.000 
96 WT Mouse Brain 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
96 WT Mouse Brain 4-methyl-octanoylcarnitine 0.000 
96 WT Mouse Brain 2,6-dimethyl-heptanoylcarnitine 0.000 
96 WT Mouse Brain decanoylcarnitine 0.020 
96 WT Mouse Brain cis-4-decenoylcarnitine 0.002 
96 WT Mouse Brain 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
96 WT Mouse Brain R-3-hydroxy-decanoylcarnitine 0.000 
96 WT Mouse Brain S-3-hydroxy-decanoylcarnitine 0.008 
96 WT Mouse Brain 5-decynoylcarnitine 0.000 
96 WT Mouse Brain lauroylcarnitine 0.123 
96 WT Mouse Brain trans-2-dodecenoylcarnitine 0.000 
96 WT Mouse Brain R-3-hydroxy-lauroylcarnitine 0.001 
96 WT Mouse Brain S-3-hydroxy-lauroylcarnitine 0.001 
96 WT Mouse Brain myristoylcarnitine 0.915 
96 WT Mouse Brain myristoleoylcarnitine 0.000 
96 WT Mouse Brain cis-5-tetradecenoylcarnitine 0.000 
96 WT Mouse Brain trans-2-tetradecenoylcarnitine 0.000 
96 WT Mouse Brain 
cis,cis-5,8-
tetradecadienoylcarnitine 0.000 
96 WT Mouse Brain R-3-hydroxy-myristoylcarnitine 0.000 
96 WT Mouse Brain S-3-hydroxy-myristoylcarnitine 0.000 
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 96 WT Mouse Brain hydroxy-C14:1 0.022 
96 WT Mouse Brain palmitoylcarnitine 1.591 
96 WT Mouse Brain palmitoleoylcarnitine 0.134 
96 WT Mouse Brain trans-2-hexadecenoylcarnitine 0.000 
96 WT Mouse Brain R-3-hydroxy-palmitoylcarnitine 0.000 
96 WT Mouse Brain S-3-hydroxy-palmitoylcarnitine 0.014 
96 WT Mouse Brain hydroxy-C16:1 0.021 
96 WT Mouse Brain stearoylcarnitine 0.630 
96 WT Mouse Brain oleoylcarnitine 1.132 
96 WT Mouse Brain linoleoylcarnitine 0.134 
96 WT Mouse Brain alpha-linolenoylcarnitine 0.000 
96 WT Mouse Brain gamma-linolenoylcarnitine 0.000 
96 WT Mouse Brain R-3-hydroxy-stearoylcarnitine 0.000 
96 WT Mouse Brain S-3-hydroxy-stearoylcarnitine 0.000 
96 WT Mouse Brain hydroxy-C18:1 0.011 
96 WT Mouse Brain hydroxy-C18:2 0.000 
96 WT Mouse Brain hydroxy-C18:3 0.003 
96 WT Mouse Brain malonylcarnitine 0.155 
96 WT Mouse Brain succinylcarnitine 0.213 
96 WT Mouse Brain methyl-malonylcarnitine 0.015 
96 WT Mouse Brain ethyl-malonylcarnitine 0.000 
96 WT Mouse Brain glutaroylcarnitine 0.083 
96 WT Mouse Brain adipoylcarnitine 0.014 
96 WT Mouse Brain 3-methyl-glutaroylcarnitine 0.018 
96 WT Mouse Brain suberoylcarnitine 0.000 
96 WT Mouse Brain sebacoylcarnitine 0.000 
96 WT Mouse Brain sum_of_individual_acylcarnitines 44.358 
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 96 WT Mouse Brain ratio:_sum/calculated 2.191 
96 WT Mouse Fat total_carnitine 59.480 
96 WT Mouse Fat free_carnitine 21.231 
96 WT Mouse Fat calculated_acylcarnitines 38.249 
96 WT Mouse Fat acyl/free 1.802 
96 WT Mouse Fat butyrobetaine 1.774 
96 WT Mouse Fat acetylcarnitine 4.971 
96 WT Mouse Fat propionylcarnitine 0.187 
96 WT Mouse Fat butyrylcarnitine 0.105 
96 WT Mouse Fat isobutyrylcarnitine 0.147 
96 WT Mouse Fat R-3-hydroxy-butyrylcarnitine 0.041 
96 WT Mouse Fat S-3-hydroxy-butyrylcarnitine 0.067 
96 WT Mouse Fat valerylcarnitine 0.002 
96 WT Mouse Fat isovalerylcarnitine 0.127 
96 WT Mouse Fat 3-hydroxy-isovalerylcarnitine 0.040 
96 WT Mouse Fat 2-methyl-butyrylcarnitine 0.111 
96 WT Mouse Fat pivaloylcarnitine 0.000 
96 WT Mouse Fat tigloylcarnitine 0.000 
96 WT Mouse Fat 3-methyl-crotonylcarnitine 0.000 
96 WT Mouse Fat hexanoylcarnitine 0.014 
96 WT Mouse Fat R-3-hydroxy-hexanoylcarnitine 0.003 
96 WT Mouse Fat S-3-hydroxy-hexanoylcarnitine 0.004 
96 WT Mouse Fat phenylacetylcarnitine 0.000 
96 WT Mouse Fat phenylpropionylcarnitine 0.000 
96 WT Mouse Fat 4-phenyl-butyrylcarnitine 0.000 
96 WT Mouse Fat benzoylcarnitine 0.000 
96 WT Mouse Fat 4-methyl-hexanoylcarnitine 0.000 
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 96 WT Mouse Fat octanoylcarnitine 0.002 
96 WT Mouse Fat R-3-hydroxy-octanoylcarnitine 0.004 
96 WT Mouse Fat S-3-hydroxy-octanoylcarnitine 0.002 
96 WT Mouse Fat valproylcarnitine 0.000 
96 WT Mouse Fat branched-chain C8 0.000 
96 WT Mouse Fat 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
96 WT Mouse Fat 4-methyl-octanoylcarnitine 0.000 
96 WT Mouse Fat 2,6-dimethyl-heptanoylcarnitine 0.000 
96 WT Mouse Fat decanoylcarnitine 0.000 
96 WT Mouse Fat cis-4-decenoylcarnitine 0.000 
96 WT Mouse Fat 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
96 WT Mouse Fat R-3-hydroxy-decanoylcarnitine 0.000 
96 WT Mouse Fat S-3-hydroxy-decanoylcarnitine 0.001 
96 WT Mouse Fat 5-decynoylcarnitine 0.000 
96 WT Mouse Fat lauroylcarnitine 0.000 
96 WT Mouse Fat trans-2-dodecenoylcarnitine 0.000 
96 WT Mouse Fat R-3-hydroxy-lauroylcarnitine 0.000 
96 WT Mouse Fat S-3-hydroxy-lauroylcarnitine 0.000 
96 WT Mouse Fat myristoylcarnitine 0.000 
96 WT Mouse Fat myristoleoylcarnitine 0.048 
96 WT Mouse Fat cis-5-tetradecenoylcarnitine 0.000 
96 WT Mouse Fat trans-2-tetradecenoylcarnitine 0.000 
96 WT Mouse Fat 
cis,cis-5,8-
tetradecadienoylcarnitine 0.005 
96 WT Mouse Fat R-3-hydroxy-myristoylcarnitine 0.000 
 325 
 96 WT Mouse Fat S-3-hydroxy-myristoylcarnitine 0.000 
96 WT Mouse Fat hydroxy-C14:1 0.004 
96 WT Mouse Fat palmitoylcarnitine 0.000 
96 WT Mouse Fat palmitoleoylcarnitine 0.019 
96 WT Mouse Fat trans-2-hexadecenoylcarnitine 0.000 
96 WT Mouse Fat R-3-hydroxy-palmitoylcarnitine 0.001 
96 WT Mouse Fat S-3-hydroxy-palmitoylcarnitine 0.022 
96 WT Mouse Fat hydroxy-C16:1 0.019 
96 WT Mouse Fat stearoylcarnitine 0.000 
96 WT Mouse Fat oleoylcarnitine 0.000 
96 WT Mouse Fat linoleoylcarnitine 0.096 
96 WT Mouse Fat alpha-linolenoylcarnitine 0.000 
96 WT Mouse Fat gamma-linolenoylcarnitine 0.000 
96 WT Mouse Fat R-3-hydroxy-stearoylcarnitine 0.000 
96 WT Mouse Fat S-3-hydroxy-stearoylcarnitine 0.000 
96 WT Mouse Fat hydroxy-C18:1 0.006 
96 WT Mouse Fat hydroxy-C18:2 0.012 
96 WT Mouse Fat hydroxy-C18:3 0.005 
96 WT Mouse Fat malonylcarnitine 0.070 
96 WT Mouse Fat succinylcarnitine 0.052 
96 WT Mouse Fat methyl-malonylcarnitine 0.009 
96 WT Mouse Fat ethyl-malonylcarnitine 0.000 
96 WT Mouse Fat glutaroylcarnitine 0.000 
96 WT Mouse Fat adipoylcarnitine 0.000 
96 WT Mouse Fat 3-methyl-glutaroylcarnitine 0.000 
96 WT Mouse Fat suberoylcarnitine 0.000 
96 WT Mouse Fat sebacoylcarnitine 0.002 
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 96 WT Mouse Fat sum_of_individual_acylcarnitines 6.199 
96 WT Mouse Fat ratio:_sum/calculated 0.162 
96 WT Mouse Heart total_carnitine 1360.152 
96 WT Mouse Heart free_carnitine 780.405 
96 WT Mouse Heart calculated_acylcarnitines 579.747 
96 WT Mouse Heart acyl/free 0.743 
96 WT Mouse Heart butyrobetaine 22.150 
96 WT Mouse Heart acetylcarnitine 504.800 
96 WT Mouse Heart propionylcarnitine 8.049 
96 WT Mouse Heart butyrylcarnitine 14.548 
96 WT Mouse Heart isobutyrylcarnitine 10.411 
96 WT Mouse Heart R-3-hydroxy-butyrylcarnitine 6.625 
96 WT Mouse Heart S-3-hydroxy-butyrylcarnitine 17.252 
96 WT Mouse Heart valerylcarnitine 0.653 
96 WT Mouse Heart isovalerylcarnitine 0.079 
96 WT Mouse Heart 3-hydroxy-isovalerylcarnitine 1.498 
96 WT Mouse Heart 2-methyl-butyrylcarnitine 0.557 
96 WT Mouse Heart pivaloylcarnitine 0.000 
96 WT Mouse Heart tigloylcarnitine 0.286 
96 WT Mouse Heart 3-methyl-crotonylcarnitine 0.002 
96 WT Mouse Heart hexanoylcarnitine 1.630 
96 WT Mouse Heart R-3-hydroxy-hexanoylcarnitine 0.184 
96 WT Mouse Heart S-3-hydroxy-hexanoylcarnitine 0.754 
96 WT Mouse Heart phenylacetylcarnitine 0.000 
96 WT Mouse Heart phenylpropionylcarnitine 0.000 
96 WT Mouse Heart 4-phenyl-butyrylcarnitine 0.000 
96 WT Mouse Heart benzoylcarnitine 0.113 
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 96 WT Mouse Heart 4-methyl-hexanoylcarnitine 0.006 
96 WT Mouse Heart octanoylcarnitine 0.431 
96 WT Mouse Heart R-3-hydroxy-octanoylcarnitine 0.055 
96 WT Mouse Heart S-3-hydroxy-octanoylcarnitine 0.289 
96 WT Mouse Heart valproylcarnitine 0.000 
96 WT Mouse Heart branched-chain C8 0.000 
96 WT Mouse Heart 
cis-3,4-methylene-
heptanoylcarnitine 0.007 
96 WT Mouse Heart 4-methyl-octanoylcarnitine 0.005 
96 WT Mouse Heart 2,6-dimethyl-heptanoylcarnitine 0.000 
96 WT Mouse Heart decanoylcarnitine 0.518 
96 WT Mouse Heart cis-4-decenoylcarnitine 0.062 
96 WT Mouse Heart 
cis-3,4-methylene-
nonanoylcarnitine 0.004 
96 WT Mouse Heart R-3-hydroxy-decanoylcarnitine 0.073 
96 WT Mouse Heart S-3-hydroxy-decanoylcarnitine 0.255 
96 WT Mouse Heart 5-decynoylcarnitine 0.000 
96 WT Mouse Heart lauroylcarnitine 0.770 
96 WT Mouse Heart trans-2-dodecenoylcarnitine 0.004 
96 WT Mouse Heart R-3-hydroxy-lauroylcarnitine 0.025 
96 WT Mouse Heart S-3-hydroxy-lauroylcarnitine 0.144 
96 WT Mouse Heart myristoylcarnitine 2.291 
96 WT Mouse Heart myristoleoylcarnitine 0.711 
96 WT Mouse Heart cis-5-tetradecenoylcarnitine 0.740 
96 WT Mouse Heart trans-2-tetradecenoylcarnitine 0.014 
96 WT Mouse Heart 
cis,cis-5,8-
tetradecadienoylcarnitine 0.525 
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 96 WT Mouse Heart R-3-hydroxy-myristoylcarnitine 0.030 
96 WT Mouse Heart S-3-hydroxy-myristoylcarnitine 0.179 
96 WT Mouse Heart hydroxy-C14:1 0.223 
96 WT Mouse Heart palmitoylcarnitine 6.833 
96 WT Mouse Heart palmitoleoylcarnitine 1.107 
96 WT Mouse Heart trans-2-hexadecenoylcarnitine 0.113 
96 WT Mouse Heart R-3-hydroxy-palmitoylcarnitine 0.126 
96 WT Mouse Heart S-3-hydroxy-palmitoylcarnitine 0.645 
96 WT Mouse Heart hydroxy-C16:1 0.435 
96 WT Mouse Heart stearoylcarnitine 5.602 
96 WT Mouse Heart oleoylcarnitine 9.352 
96 WT Mouse Heart linoleoylcarnitine 5.545 
96 WT Mouse Heart alpha-linolenoylcarnitine 0.282 
96 WT Mouse Heart gamma-linolenoylcarnitine 0.072 
96 WT Mouse Heart R-3-hydroxy-stearoylcarnitine 0.113 
96 WT Mouse Heart S-3-hydroxy-stearoylcarnitine 0.532 
96 WT Mouse Heart hydroxy-C18:1 1.097 
96 WT Mouse Heart hydroxy-C18:2 0.840 
96 WT Mouse Heart hydroxy-C18:3 0.179 
96 WT Mouse Heart malonylcarnitine 6.827 
96 WT Mouse Heart succinylcarnitine 21.383 
96 WT Mouse Heart methyl-malonylcarnitine 2.320 
96 WT Mouse Heart ethyl-malonylcarnitine 0.000 
96 WT Mouse Heart glutaroylcarnitine 0.000 
96 WT Mouse Heart adipoylcarnitine 0.009 
96 WT Mouse Heart 3-methyl-glutaroylcarnitine 0.001 
96 WT Mouse Heart suberoylcarnitine 0.002 
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 96 WT Mouse Heart sebacoylcarnitine 0.001 
96 WT Mouse Heart sum_of_individual_acylcarnitines 638.215 
96 WT Mouse Heart ratio:_sum/calculated 1.101 
96 WT Mouse Kidney total_carnitine 386.888 
96 WT Mouse Kidney free_carnitine 270.807 
96 WT Mouse Kidney calculated_acylcarnitines 116.081 
96 WT Mouse Kidney acyl/free 0.429 
96 WT Mouse Kidney butyrobetaine 8.451 
96 WT Mouse Kidney acetylcarnitine 72.331 
96 WT Mouse Kidney propionylcarnitine 3.427 
96 WT Mouse Kidney butyrylcarnitine 4.640 
96 WT Mouse Kidney isobutyrylcarnitine 0.766 
96 WT Mouse Kidney R-3-hydroxy-butyrylcarnitine 0.933 
96 WT Mouse Kidney S-3-hydroxy-butyrylcarnitine 2.040 
96 WT Mouse Kidney valerylcarnitine 0.474 
96 WT Mouse Kidney isovalerylcarnitine 0.224 
96 WT Mouse Kidney 3-hydroxy-isovalerylcarnitine 1.442 
96 WT Mouse Kidney 2-methyl-butyrylcarnitine 0.998 
96 WT Mouse Kidney pivaloylcarnitine 0.000 
96 WT Mouse Kidney tigloylcarnitine 0.033 
96 WT Mouse Kidney 3-methyl-crotonylcarnitine 0.000 
96 WT Mouse Kidney hexanoylcarnitine 0.364 
96 WT Mouse Kidney R-3-hydroxy-hexanoylcarnitine 0.025 
96 WT Mouse Kidney S-3-hydroxy-hexanoylcarnitine 0.071 
96 WT Mouse Kidney phenylacetylcarnitine 0.000 
96 WT Mouse Kidney phenylpropionylcarnitine 0.000 
96 WT Mouse Kidney 4-phenyl-butyrylcarnitine 0.000 
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 96 WT Mouse Kidney benzoylcarnitine 0.062 
96 WT Mouse Kidney 4-methyl-hexanoylcarnitine 0.009 
96 WT Mouse Kidney octanoylcarnitine 0.134 
96 WT Mouse Kidney R-3-hydroxy-octanoylcarnitine 0.011 
96 WT Mouse Kidney S-3-hydroxy-octanoylcarnitine 0.055 
96 WT Mouse Kidney valproylcarnitine 0.000 
96 WT Mouse Kidney branched-chain C8 0.000 
96 WT Mouse Kidney 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
96 WT Mouse Kidney 4-methyl-octanoylcarnitine 0.004 
96 WT Mouse Kidney 2,6-dimethyl-heptanoylcarnitine 0.000 
96 WT Mouse Kidney decanoylcarnitine 0.136 
96 WT Mouse Kidney cis-4-decenoylcarnitine 0.005 
96 WT Mouse Kidney 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
96 WT Mouse Kidney R-3-hydroxy-decanoylcarnitine 0.025 
96 WT Mouse Kidney S-3-hydroxy-decanoylcarnitine 0.068 
96 WT Mouse Kidney 5-decynoylcarnitine 0.003 
96 WT Mouse Kidney lauroylcarnitine 0.195 
96 WT Mouse Kidney trans-2-dodecenoylcarnitine 0.000 
96 WT Mouse Kidney R-3-hydroxy-lauroylcarnitine 0.011 
96 WT Mouse Kidney S-3-hydroxy-lauroylcarnitine 0.043 
96 WT Mouse Kidney myristoylcarnitine 1.128 
96 WT Mouse Kidney myristoleoylcarnitine 0.209 
96 WT Mouse Kidney cis-5-tetradecenoylcarnitine 0.000 
96 WT Mouse Kidney trans-2-tetradecenoylcarnitine 0.000 
96 WT Mouse Kidney cis,cis-5,8- 0.079 
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 tetradecadienoylcarnitine 
96 WT Mouse Kidney R-3-hydroxy-myristoylcarnitine 0.000 
96 WT Mouse Kidney S-3-hydroxy-myristoylcarnitine 0.129 
96 WT Mouse Kidney hydroxy-C14:1 0.066 
96 WT Mouse Kidney palmitoylcarnitine 7.794 
96 WT Mouse Kidney palmitoleoylcarnitine 0.972 
96 WT Mouse Kidney trans-2-hexadecenoylcarnitine 0.047 
96 WT Mouse Kidney R-3-hydroxy-palmitoylcarnitine 0.035 
96 WT Mouse Kidney S-3-hydroxy-palmitoylcarnitine 0.540 
96 WT Mouse Kidney hydroxy-C16:1 0.232 
96 WT Mouse Kidney stearoylcarnitine 5.701 
96 WT Mouse Kidney oleoylcarnitine 6.877 
96 WT Mouse Kidney linoleoylcarnitine 4.979 
96 WT Mouse Kidney alpha-linolenoylcarnitine 0.265 
96 WT Mouse Kidney gamma-linolenoylcarnitine 0.024 
96 WT Mouse Kidney R-3-hydroxy-stearoylcarnitine 0.019 
96 WT Mouse Kidney S-3-hydroxy-stearoylcarnitine 0.131 
96 WT Mouse Kidney hydroxy-C18:1 0.267 
96 WT Mouse Kidney hydroxy-C18:2 0.439 
96 WT Mouse Kidney hydroxy-C18:3 0.097 
96 WT Mouse Kidney malonylcarnitine 0.733 
96 WT Mouse Kidney succinylcarnitine 1.076 
96 WT Mouse Kidney methyl-malonylcarnitine 0.126 
96 WT Mouse Kidney ethyl-malonylcarnitine 0.000 
96 WT Mouse Kidney glutaroylcarnitine 0.687 
96 WT Mouse Kidney adipoylcarnitine 0.550 
96 WT Mouse Kidney 3-methyl-glutaroylcarnitine 0.092 
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 96 WT Mouse Kidney suberoylcarnitine 0.012 
96 WT Mouse Kidney sebacoylcarnitine 0.002 
96 WT Mouse Kidney sum_of_individual_acylcarnitines 121.837 
96 WT Mouse Kidney ratio:_sum/calculated 1.050 
96 WT Mouse Liver total_carnitine 327.240 
96 WT Mouse Liver free_carnitine 184.576 
96 WT Mouse Liver calculated_acylcarnitines 142.664 
96 WT Mouse Liver acyl/free 0.773 
96 WT Mouse Liver butyrobetaine 10.293 
96 WT Mouse Liver acetylcarnitine 111.336 
96 WT Mouse Liver propionylcarnitine 13.528 
96 WT Mouse Liver butyrylcarnitine 6.376 
96 WT Mouse Liver isobutyrylcarnitine 0.522 
96 WT Mouse Liver R-3-hydroxy-butyrylcarnitine 4.112 
96 WT Mouse Liver S-3-hydroxy-butyrylcarnitine 2.470 
96 WT Mouse Liver valerylcarnitine 3.175 
96 WT Mouse Liver isovalerylcarnitine 0.134 
96 WT Mouse Liver 3-hydroxy-isovalerylcarnitine 0.514 
96 WT Mouse Liver 2-methyl-butyrylcarnitine 1.088 
96 WT Mouse Liver pivaloylcarnitine 0.000 
96 WT Mouse Liver tigloylcarnitine 0.004 
96 WT Mouse Liver 3-methyl-crotonylcarnitine 0.000 
96 WT Mouse Liver hexanoylcarnitine 1.428 
96 WT Mouse Liver R-3-hydroxy-hexanoylcarnitine 0.040 
96 WT Mouse Liver S-3-hydroxy-hexanoylcarnitine 0.141 
96 WT Mouse Liver phenylacetylcarnitine 0.000 
96 WT Mouse Liver phenylpropionylcarnitine 0.011 
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 96 WT Mouse Liver 4-phenyl-butyrylcarnitine 0.000 
96 WT Mouse Liver benzoylcarnitine 0.017 
96 WT Mouse Liver 4-methyl-hexanoylcarnitine 0.030 
96 WT Mouse Liver octanoylcarnitine 0.230 
96 WT Mouse Liver R-3-hydroxy-octanoylcarnitine 0.015 
96 WT Mouse Liver S-3-hydroxy-octanoylcarnitine 0.033 
96 WT Mouse Liver valproylcarnitine 0.000 
96 WT Mouse Liver branched-chain C8 0.000 
96 WT Mouse Liver 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
96 WT Mouse Liver 4-methyl-octanoylcarnitine 0.003 
96 WT Mouse Liver 2,6-dimethyl-heptanoylcarnitine 0.000 
96 WT Mouse Liver decanoylcarnitine 0.074 
96 WT Mouse Liver cis-4-decenoylcarnitine 0.000 
96 WT Mouse Liver 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
96 WT Mouse Liver R-3-hydroxy-decanoylcarnitine 0.007 
96 WT Mouse Liver S-3-hydroxy-decanoylcarnitine 0.016 
96 WT Mouse Liver 5-decynoylcarnitine 0.000 
96 WT Mouse Liver lauroylcarnitine 0.000 
96 WT Mouse Liver trans-2-dodecenoylcarnitine 0.000 
96 WT Mouse Liver R-3-hydroxy-lauroylcarnitine 0.000 
96 WT Mouse Liver S-3-hydroxy-lauroylcarnitine 0.000 
96 WT Mouse Liver myristoylcarnitine 0.125 
96 WT Mouse Liver myristoleoylcarnitine 0.029 
96 WT Mouse Liver cis-5-tetradecenoylcarnitine 0.000 
96 WT Mouse Liver trans-2-tetradecenoylcarnitine 0.000 
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 96 WT Mouse Liver 
cis,cis-5,8-
tetradecadienoylcarnitine 0.001 
96 WT Mouse Liver R-3-hydroxy-myristoylcarnitine 0.000 
96 WT Mouse Liver S-3-hydroxy-myristoylcarnitine 0.000 
96 WT Mouse Liver hydroxy-C14:1 0.003 
96 WT Mouse Liver palmitoylcarnitine 0.523 
96 WT Mouse Liver palmitoleoylcarnitine 0.133 
96 WT Mouse Liver trans-2-hexadecenoylcarnitine 0.000 
96 WT Mouse Liver R-3-hydroxy-palmitoylcarnitine 0.000 
96 WT Mouse Liver S-3-hydroxy-palmitoylcarnitine 0.024 
96 WT Mouse Liver hydroxy-C16:1 0.024 
96 WT Mouse Liver stearoylcarnitine 0.729 
96 WT Mouse Liver oleoylcarnitine 0.571 
96 WT Mouse Liver linoleoylcarnitine 0.531 
96 WT Mouse Liver alpha-linolenoylcarnitine 0.024 
96 WT Mouse Liver gamma-linolenoylcarnitine 0.000 
96 WT Mouse Liver R-3-hydroxy-stearoylcarnitine 0.000 
96 WT Mouse Liver S-3-hydroxy-stearoylcarnitine 0.002 
96 WT Mouse Liver hydroxy-C18:1 0.032 
96 WT Mouse Liver hydroxy-C18:2 0.016 
96 WT Mouse Liver hydroxy-C18:3 0.003 
96 WT Mouse Liver malonylcarnitine 1.066 
96 WT Mouse Liver succinylcarnitine 0.653 
96 WT Mouse Liver methyl-malonylcarnitine 0.086 
96 WT Mouse Liver ethyl-malonylcarnitine 0.003 
96 WT Mouse Liver glutaroylcarnitine 2.062 
96 WT Mouse Liver adipoylcarnitine 0.811 
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 96 WT Mouse Liver 3-methyl-glutaroylcarnitine 0.082 
96 WT Mouse Liver suberoylcarnitine 0.030 
96 WT Mouse Liver sebacoylcarnitine 0.012 
96 WT Mouse Liver sum_of_individual_acylcarnitines 152.877 
96 WT Mouse Liver ratio:_sum/calculated 1.072 
96 WT Mouse Lung total_carnitine 827.661 
96 WT Mouse Lung free_carnitine 645.522 
96 WT Mouse Lung calculated_acylcarnitines 182.139 
96 WT Mouse Lung acyl/free 0.282 
96 WT Mouse Lung butyrobetaine 16.292 
96 WT Mouse Lung acetylcarnitine 190.537 
96 WT Mouse Lung propionylcarnitine 1.775 
96 WT Mouse Lung butyrylcarnitine 1.892 
96 WT Mouse Lung isobutyrylcarnitine 0.890 
96 WT Mouse Lung R-3-hydroxy-butyrylcarnitine 0.766 
96 WT Mouse Lung S-3-hydroxy-butyrylcarnitine 1.499 
96 WT Mouse Lung valerylcarnitine 0.076 
96 WT Mouse Lung isovalerylcarnitine 1.214 
96 WT Mouse Lung 3-hydroxy-isovalerylcarnitine 0.815 
96 WT Mouse Lung 2-methyl-butyrylcarnitine 1.221 
96 WT Mouse Lung pivaloylcarnitine 0.000 
96 WT Mouse Lung tigloylcarnitine 0.025 
96 WT Mouse Lung 3-methyl-crotonylcarnitine 0.000 
96 WT Mouse Lung hexanoylcarnitine 0.263 
96 WT Mouse Lung R-3-hydroxy-hexanoylcarnitine 0.050 
96 WT Mouse Lung S-3-hydroxy-hexanoylcarnitine 0.195 
96 WT Mouse Lung phenylacetylcarnitine 0.008 
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 96 WT Mouse Lung phenylpropionylcarnitine 0.000 
96 WT Mouse Lung 4-phenyl-butyrylcarnitine 0.000 
96 WT Mouse Lung benzoylcarnitine 0.040 
96 WT Mouse Lung 4-methyl-hexanoylcarnitine 0.001 
96 WT Mouse Lung octanoylcarnitine 0.047 
96 WT Mouse Lung R-3-hydroxy-octanoylcarnitine 0.089 
96 WT Mouse Lung S-3-hydroxy-octanoylcarnitine 0.092 
96 WT Mouse Lung valproylcarnitine 0.000 
96 WT Mouse Lung branched-chain C8 0.000 
96 WT Mouse Lung 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
96 WT Mouse Lung 4-methyl-octanoylcarnitine 0.000 
96 WT Mouse Lung 2,6-dimethyl-heptanoylcarnitine 0.000 
96 WT Mouse Lung decanoylcarnitine 0.057 
96 WT Mouse Lung cis-4-decenoylcarnitine 0.020 
96 WT Mouse Lung 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
96 WT Mouse Lung R-3-hydroxy-decanoylcarnitine 0.030 
96 WT Mouse Lung S-3-hydroxy-decanoylcarnitine 0.083 
96 WT Mouse Lung 5-decynoylcarnitine 0.000 
96 WT Mouse Lung lauroylcarnitine 0.234 
96 WT Mouse Lung trans-2-dodecenoylcarnitine 0.000 
96 WT Mouse Lung R-3-hydroxy-lauroylcarnitine 0.012 
96 WT Mouse Lung S-3-hydroxy-lauroylcarnitine 0.038 
96 WT Mouse Lung myristoylcarnitine 0.937 
96 WT Mouse Lung myristoleoylcarnitine 0.090 
96 WT Mouse Lung cis-5-tetradecenoylcarnitine 0.012 
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 96 WT Mouse Lung trans-2-tetradecenoylcarnitine 0.003 
96 WT Mouse Lung 
cis,cis-5,8-
tetradecadienoylcarnitine 0.064 
96 WT Mouse Lung R-3-hydroxy-myristoylcarnitine 0.001 
96 WT Mouse Lung S-3-hydroxy-myristoylcarnitine 0.054 
96 WT Mouse Lung hydroxy-C14:1 0.064 
96 WT Mouse Lung palmitoylcarnitine 4.120 
96 WT Mouse Lung palmitoleoylcarnitine 0.318 
96 WT Mouse Lung trans-2-hexadecenoylcarnitine 0.029 
96 WT Mouse Lung R-3-hydroxy-palmitoylcarnitine 0.083 
96 WT Mouse Lung S-3-hydroxy-palmitoylcarnitine 0.249 
96 WT Mouse Lung hydroxy-C16:1 0.094 
96 WT Mouse Lung stearoylcarnitine 1.334 
96 WT Mouse Lung oleoylcarnitine 1.525 
96 WT Mouse Lung linoleoylcarnitine 0.614 
96 WT Mouse Lung alpha-linolenoylcarnitine 0.000 
96 WT Mouse Lung gamma-linolenoylcarnitine 0.019 
96 WT Mouse Lung R-3-hydroxy-stearoylcarnitine 0.169 
96 WT Mouse Lung S-3-hydroxy-stearoylcarnitine 0.034 
96 WT Mouse Lung hydroxy-C18:1 0.475 
96 WT Mouse Lung hydroxy-C18:2 0.122 
96 WT Mouse Lung hydroxy-C18:3 0.012 
96 WT Mouse Lung malonylcarnitine 0.368 
96 WT Mouse Lung succinylcarnitine 0.680 
96 WT Mouse Lung methyl-malonylcarnitine 0.058 
96 WT Mouse Lung ethyl-malonylcarnitine 0.001 
96 WT Mouse Lung glutaroylcarnitine 0.000 
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 96 WT Mouse Lung adipoylcarnitine 0.024 
96 WT Mouse Lung 3-methyl-glutaroylcarnitine 0.001 
96 WT Mouse Lung suberoylcarnitine 0.010 
96 WT Mouse Lung sebacoylcarnitine 0.000 
96 WT Mouse Lung sum_of_individual_acylcarnitines 213.531 
96 WT Mouse Lung ratio:_sum/calculated 1.172 
96 WT Mouse Muscle total_carnitine 298.217 
96 WT Mouse Muscle free_carnitine 131.089 
96 WT Mouse Muscle calculated_acylcarnitines 167.128 
96 WT Mouse Muscle acyl/free 1.275 
96 WT Mouse Muscle butyrobetaine 8.071 
96 WT Mouse Muscle acetylcarnitine 144.902 
96 WT Mouse Muscle propionylcarnitine 0.617 
96 WT Mouse Muscle butyrylcarnitine 3.174 
96 WT Mouse Muscle isobutyrylcarnitine 0.193 
96 WT Mouse Muscle R-3-hydroxy-butyrylcarnitine 0.672 
96 WT Mouse Muscle S-3-hydroxy-butyrylcarnitine 4.603 
96 WT Mouse Muscle valerylcarnitine 0.054 
96 WT Mouse Muscle isovalerylcarnitine 0.074 
96 WT Mouse Muscle 3-hydroxy-isovalerylcarnitine 0.781 
96 WT Mouse Muscle 2-methyl-butyrylcarnitine 0.232 
96 WT Mouse Muscle pivaloylcarnitine 0.000 
96 WT Mouse Muscle tigloylcarnitine 0.083 
96 WT Mouse Muscle 3-methyl-crotonylcarnitine 0.000 
96 WT Mouse Muscle hexanoylcarnitine 0.349 
96 WT Mouse Muscle R-3-hydroxy-hexanoylcarnitine 0.020 
96 WT Mouse Muscle S-3-hydroxy-hexanoylcarnitine 0.053 
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 96 WT Mouse Muscle phenylacetylcarnitine 0.000 
96 WT Mouse Muscle phenylpropionylcarnitine 0.000 
96 WT Mouse Muscle 4-phenyl-butyrylcarnitine 0.000 
96 WT Mouse Muscle benzoylcarnitine 0.022 
96 WT Mouse Muscle 4-methyl-hexanoylcarnitine 0.000 
96 WT Mouse Muscle octanoylcarnitine 0.129 
96 WT Mouse Muscle R-3-hydroxy-octanoylcarnitine 0.008 
96 WT Mouse Muscle S-3-hydroxy-octanoylcarnitine 0.041 
96 WT Mouse Muscle valproylcarnitine 0.000 
96 WT Mouse Muscle branched-chain C8 0.000 
96 WT Mouse Muscle 
cis-3,4-methylene-
heptanoylcarnitine 0.000 
96 WT Mouse Muscle 4-methyl-octanoylcarnitine 0.000 
96 WT Mouse Muscle 2,6-dimethyl-heptanoylcarnitine 0.000 
96 WT Mouse Muscle decanoylcarnitine 0.157 
96 WT Mouse Muscle cis-4-decenoylcarnitine 0.019 
96 WT Mouse Muscle 
cis-3,4-methylene-
nonanoylcarnitine 0.000 
96 WT Mouse Muscle R-3-hydroxy-decanoylcarnitine 0.010 
96 WT Mouse Muscle S-3-hydroxy-decanoylcarnitine 0.059 
96 WT Mouse Muscle 5-decynoylcarnitine 0.001 
96 WT Mouse Muscle lauroylcarnitine 0.318 
96 WT Mouse Muscle trans-2-dodecenoylcarnitine 0.000 
96 WT Mouse Muscle R-3-hydroxy-lauroylcarnitine 0.003 
96 WT Mouse Muscle S-3-hydroxy-lauroylcarnitine 0.025 
96 WT Mouse Muscle myristoylcarnitine 1.431 
96 WT Mouse Muscle myristoleoylcarnitine 0.310 
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 96 WT Mouse Muscle cis-5-tetradecenoylcarnitine 0.231 
96 WT Mouse Muscle trans-2-tetradecenoylcarnitine 0.000 
96 WT Mouse Muscle 
cis,cis-5,8-
tetradecadienoylcarnitine 0.104 
96 WT Mouse Muscle R-3-hydroxy-myristoylcarnitine 0.000 
96 WT Mouse Muscle S-3-hydroxy-myristoylcarnitine 0.078 
96 WT Mouse Muscle hydroxy-C14:1 0.033 
96 WT Mouse Muscle palmitoylcarnitine 10.543 
96 WT Mouse Muscle palmitoleoylcarnitine 1.194 
96 WT Mouse Muscle trans-2-hexadecenoylcarnitine 0.092 
96 WT Mouse Muscle R-3-hydroxy-palmitoylcarnitine 0.093 
96 WT Mouse Muscle S-3-hydroxy-palmitoylcarnitine 0.760 
96 WT Mouse Muscle hydroxy-C16:1 0.156 
96 WT Mouse Muscle stearoylcarnitine 4.789 
96 WT Mouse Muscle oleoylcarnitine 9.539 
96 WT Mouse Muscle linoleoylcarnitine 2.720 
96 WT Mouse Muscle alpha-linolenoylcarnitine 0.204 
96 WT Mouse Muscle gamma-linolenoylcarnitine 0.001 
96 WT Mouse Muscle R-3-hydroxy-stearoylcarnitine 0.000 
96 WT Mouse Muscle S-3-hydroxy-stearoylcarnitine 0.345 
96 WT Mouse Muscle hydroxy-C18:1 0.993 
96 WT Mouse Muscle hydroxy-C18:2 0.373 
96 WT Mouse Muscle hydroxy-C18:3 0.044 
96 WT Mouse Muscle malonylcarnitine 0.424 
96 WT Mouse Muscle succinylcarnitine 0.625 
96 WT Mouse Muscle methyl-malonylcarnitine 0.104 
96 WT Mouse Muscle ethyl-malonylcarnitine 0.000 
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 96 WT Mouse Muscle glutaroylcarnitine 0.000 
96 WT Mouse Muscle adipoylcarnitine 0.005 
96 WT Mouse Muscle 3-methyl-glutaroylcarnitine 0.000 
96 WT Mouse Muscle suberoylcarnitine 0.003 
96 WT Mouse Muscle sebacoylcarnitine 0.000 
96 WT Mouse Muscle sum_of_individual_acylcarnitines 191.790 
96 WT Mouse Muscle ratio:_sum/calculated 1.148 
96 WT Mouse Pancreas total_carnitine 44.823 
96 WT Mouse Pancreas free_carnitine 44.477 
96 WT Mouse Pancreas calculated_acylcarnitines 0.346 
96 WT Mouse Pancreas acyl/free 0.008 
96 WT Mouse Pancreas butyrobetaine 2.693 
96 WT Mouse Pancreas acetylcarnitine 12.440 
96 WT Mouse Pancreas propionylcarnitine 0.789 
96 WT Mouse Pancreas butyrylcarnitine 0.584 
96 WT Mouse Pancreas isobutyrylcarnitine 0.251 
96 WT Mouse Pancreas R-3-hydroxy-butyrylcarnitine 0.087 
96 WT Mouse Pancreas S-3-hydroxy-butyrylcarnitine 0.269 
96 WT Mouse Pancreas valerylcarnitine 0.023 
96 WT Mouse Pancreas isovalerylcarnitine 0.157 
96 WT Mouse Pancreas 3-hydroxy-isovalerylcarnitine 0.075 
96 WT Mouse Pancreas 2-methyl-butyrylcarnitine 0.151 
96 WT Mouse Pancreas pivaloylcarnitine 0.000 
96 WT Mouse Pancreas tigloylcarnitine 0.010 
96 WT Mouse Pancreas 3-methyl-crotonylcarnitine 0.000 
96 WT Mouse Pancreas hexanoylcarnitine 0.042 
96 WT Mouse Pancreas R-3-hydroxy-hexanoylcarnitine 0.002 
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 96 WT Mouse Pancreas S-3-hydroxy-hexanoylcarnitine 0.007 
96 WT Mouse Pancreas phenylacetylcarnitine 0.000 
96 WT Mouse Pancreas phenylpropionylcarnitine 0.000 
96 WT Mouse Pancreas 4-phenyl-butyrylcarnitine 0.000 
96 WT Mouse Pancreas benzoylcarnitine 0.000 
96 WT Mouse Pancreas 4-methyl-hexanoylcarnitine 0.000 
96 WT Mouse Pancreas octanoylcarnitine 0.008 
96 WT Mouse Pancreas R-3-hydroxy-octanoylcarnitine 0.002 
96 WT Mouse Pancreas S-3-hydroxy-octanoylcarnitine 0.001 
96 WT Mouse Pancreas valproylcarnitine 0.000 
96 WT Mouse Pancreas branched-chain C8 0.000 
96 WT Mouse Pancreas 
cis-3,4-methylene-
heptanoylcarnitine 0.002 
96 WT Mouse Pancreas 4-methyl-octanoylcarnitine 0.001 
96 WT Mouse Pancreas 2,6-dimethyl-heptanoylcarnitine 0.000 
96 WT Mouse Pancreas decanoylcarnitine 0.000 
96 WT Mouse Pancreas cis-4-decenoylcarnitine 0.000 
96 WT Mouse Pancreas 
cis-3,4-methylene-
nonanoylcarnitine 0.001 
96 WT Mouse Pancreas R-3-hydroxy-decanoylcarnitine 0.004 
96 WT Mouse Pancreas S-3-hydroxy-decanoylcarnitine 0.009 
96 WT Mouse Pancreas 5-decynoylcarnitine 0.000 
96 WT Mouse Pancreas lauroylcarnitine 0.000 
96 WT Mouse Pancreas trans-2-dodecenoylcarnitine 0.000 
96 WT Mouse Pancreas R-3-hydroxy-lauroylcarnitine 0.000 
96 WT Mouse Pancreas S-3-hydroxy-lauroylcarnitine 0.000 
96 WT Mouse Pancreas myristoylcarnitine 0.084 
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 96 WT Mouse Pancreas myristoleoylcarnitine 0.000 
96 WT Mouse Pancreas cis-5-tetradecenoylcarnitine 0.000 
96 WT Mouse Pancreas trans-2-tetradecenoylcarnitine 0.000 
96 WT Mouse Pancreas 
cis,cis-5,8-
tetradecadienoylcarnitine 0.000 
96 WT Mouse Pancreas R-3-hydroxy-myristoylcarnitine 0.000 
96 WT Mouse Pancreas S-3-hydroxy-myristoylcarnitine 0.000 
96 WT Mouse Pancreas hydroxy-C14:1 0.009 
96 WT Mouse Pancreas palmitoylcarnitine 0.442 
96 WT Mouse Pancreas palmitoleoylcarnitine 0.039 
96 WT Mouse Pancreas trans-2-hexadecenoylcarnitine 0.000 
96 WT Mouse Pancreas R-3-hydroxy-palmitoylcarnitine 0.000 
96 WT Mouse Pancreas S-3-hydroxy-palmitoylcarnitine 0.033 
96 WT Mouse Pancreas hydroxy-C16:1 0.014 
96 WT Mouse Pancreas stearoylcarnitine 0.139 
96 WT Mouse Pancreas oleoylcarnitine 0.236 
96 WT Mouse Pancreas linoleoylcarnitine 0.173 
96 WT Mouse Pancreas alpha-linolenoylcarnitine 0.002 
96 WT Mouse Pancreas gamma-linolenoylcarnitine 0.000 
96 WT Mouse Pancreas R-3-hydroxy-stearoylcarnitine 0.000 
96 WT Mouse Pancreas S-3-hydroxy-stearoylcarnitine 0.000 
96 WT Mouse Pancreas hydroxy-C18:1 0.036 
96 WT Mouse Pancreas hydroxy-C18:2 0.056 
96 WT Mouse Pancreas hydroxy-C18:3 0.015 
96 WT Mouse Pancreas malonylcarnitine 0.121 
96 WT Mouse Pancreas succinylcarnitine 0.189 
96 WT Mouse Pancreas methyl-malonylcarnitine 0.020 
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 96 WT Mouse Pancreas ethyl-malonylcarnitine 0.005 
96 WT Mouse Pancreas glutaroylcarnitine 0.000 
96 WT Mouse Pancreas adipoylcarnitine 0.005 
96 WT Mouse Pancreas 3-methyl-glutaroylcarnitine 0.001 
96 WT Mouse Pancreas suberoylcarnitine 0.006 
96 WT Mouse Pancreas sebacoylcarnitine 0.001 
96 WT Mouse Pancreas sum_of_individual_acylcarnitines 16.546 
96 WT Mouse Pancreas ratio:_sum/calculated 47.791 
96 WT Mouse Spleen total_carnitine 419.610 
96 WT Mouse Spleen free_carnitine 221.620 
96 WT Mouse Spleen calculated_acylcarnitines 197.991 
96 WT Mouse Spleen acyl/free 0.893 
96 WT Mouse Spleen butyrobetaine 7.855 
96 WT Mouse Spleen acetylcarnitine 145.812 
96 WT Mouse Spleen propionylcarnitine 3.569 
96 WT Mouse Spleen butyrylcarnitine 4.258 
96 WT Mouse Spleen isobutyrylcarnitine 1.863 
96 WT Mouse Spleen R-3-hydroxy-butyrylcarnitine 1.720 
96 WT Mouse Spleen S-3-hydroxy-butyrylcarnitine 1.986 
96 WT Mouse Spleen valerylcarnitine 0.268 
96 WT Mouse Spleen isovalerylcarnitine 0.693 
96 WT Mouse Spleen 3-hydroxy-isovalerylcarnitine 0.647 
96 WT Mouse Spleen 2-methyl-butyrylcarnitine 1.217 
96 WT Mouse Spleen pivaloylcarnitine 0.000 
96 WT Mouse Spleen tigloylcarnitine 0.102 
96 WT Mouse Spleen 3-methyl-crotonylcarnitine 0.106 
96 WT Mouse Spleen hexanoylcarnitine 0.690 
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 96 WT Mouse Spleen R-3-hydroxy-hexanoylcarnitine 0.148 
96 WT Mouse Spleen S-3-hydroxy-hexanoylcarnitine 0.220 
96 WT Mouse Spleen phenylacetylcarnitine 0.110 
96 WT Mouse Spleen phenylpropionylcarnitine 0.101 
96 WT Mouse Spleen 4-phenyl-butyrylcarnitine 0.100 
96 WT Mouse Spleen benzoylcarnitine 0.134 
96 WT Mouse Spleen 4-methyl-hexanoylcarnitine 0.114 
96 WT Mouse Spleen octanoylcarnitine 0.324 
96 WT Mouse Spleen R-3-hydroxy-octanoylcarnitine 0.136 
96 WT Mouse Spleen S-3-hydroxy-octanoylcarnitine 0.207 
96 WT Mouse Spleen valproylcarnitine 0.000 
96 WT Mouse Spleen branched-chain C8 0.000 
96 WT Mouse Spleen 
cis-3,4-methylene-
heptanoylcarnitine 0.111 
96 WT Mouse Spleen 4-methyl-octanoylcarnitine 0.114 
96 WT Mouse Spleen 2,6-dimethyl-heptanoylcarnitine 0.112 
96 WT Mouse Spleen decanoylcarnitine 0.303 
96 WT Mouse Spleen cis-4-decenoylcarnitine 0.226 
96 WT Mouse Spleen 
cis-3,4-methylene-
nonanoylcarnitine 0.115 
96 WT Mouse Spleen R-3-hydroxy-decanoylcarnitine 0.171 
96 WT Mouse Spleen S-3-hydroxy-decanoylcarnitine 0.288 
96 WT Mouse Spleen 5-decynoylcarnitine 0.117 
96 WT Mouse Spleen lauroylcarnitine 0.475 
96 WT Mouse Spleen trans-2-dodecenoylcarnitine 0.140 
96 WT Mouse Spleen R-3-hydroxy-lauroylcarnitine 0.128 
96 WT Mouse Spleen S-3-hydroxy-lauroylcarnitine 0.185 
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 96 WT Mouse Spleen myristoylcarnitine 1.815 
96 WT Mouse Spleen myristoleoylcarnitine 0.359 
96 WT Mouse Spleen cis-5-tetradecenoylcarnitine 0.365 
96 WT Mouse Spleen trans-2-tetradecenoylcarnitine 0.119 
96 WT Mouse Spleen 
cis,cis-5,8-
tetradecadienoylcarnitine 0.292 
96 WT Mouse Spleen R-3-hydroxy-myristoylcarnitine 0.126 
96 WT Mouse Spleen S-3-hydroxy-myristoylcarnitine 0.236 
96 WT Mouse Spleen hydroxy-C14:1 0.087 
96 WT Mouse Spleen palmitoylcarnitine 9.201 
96 WT Mouse Spleen palmitoleoylcarnitine 0.846 
96 WT Mouse Spleen trans-2-hexadecenoylcarnitine 0.175 
96 WT Mouse Spleen R-3-hydroxy-palmitoylcarnitine 0.168 
96 WT Mouse Spleen S-3-hydroxy-palmitoylcarnitine 0.509 
96 WT Mouse Spleen hydroxy-C16:1 0.146 
96 WT Mouse Spleen stearoylcarnitine 2.822 
96 WT Mouse Spleen oleoylcarnitine 8.853 
96 WT Mouse Spleen linoleoylcarnitine 5.626 
96 WT Mouse Spleen alpha-linolenoylcarnitine 0.405 
96 WT Mouse Spleen gamma-linolenoylcarnitine 0.172 
96 WT Mouse Spleen R-3-hydroxy-stearoylcarnitine 0.194 
96 WT Mouse Spleen S-3-hydroxy-stearoylcarnitine 0.235 
96 WT Mouse Spleen hydroxy-C18:1 0.351 
96 WT Mouse Spleen hydroxy-C18:2 0.370 
96 WT Mouse Spleen hydroxy-C18:3 0.047 
96 WT Mouse Spleen malonylcarnitine 0.351 
96 WT Mouse Spleen succinylcarnitine 0.242 
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 96 WT Mouse Spleen methyl-malonylcarnitine 0.159 
96 WT Mouse Spleen ethyl-malonylcarnitine 0.099 
96 WT Mouse Spleen glutaroylcarnitine 0.061 
96 WT Mouse Spleen adipoylcarnitine 0.135 
96 WT Mouse Spleen 3-methyl-glutaroylcarnitine 0.125 
96 WT Mouse Spleen suberoylcarnitine 0.131 
96 WT Mouse Spleen sebacoylcarnitine 0.127 
96 WT Mouse Spleen sum_of_individual_acylcarnitines 201.959 
96 WT Mouse Spleen ratio:_sum/calculated 1.020 
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